Access Genetics Pty. Ltd.

ACN 43 091 834 972

Contact: Mr Donald Coles, Managing Director

Phone: +61 3 5797 6203 Fax: +61 3 5797 6307
Email: dcoles@valleyseeds.com
Address: 295 Maroondah Link Highway
Alexandra, VIC, 3714
Australia

Profile: In March 2000, the proprietor of Valley Seeds Proprietary Limited, Mr Donald Coles, formed a new
spin-off company, Access Genetics Pty. Ltd., to specialise in generating cereal grain varieties
using new breeding techniques. Strategic alliances have been established with US and European
breeders to introduce elite varieties to the breeding program.

Access Genetics has licensed to leading German life sciences and chemical company BASF AG a
key technology that was developed by the University of Melbourne - a genetic mechanism (male
gamete specific promoter) for expressing key genes in specific parts of the plant. Access Genetics
is using this technology and others in a research project at the University of Melbourne, with aims
including the production of special purpose wheat varieties for use in healthfoods such as low-
calorie breakfast cereal and biscuits. [See separate entry for Valley Seeds].

Acrux Limited ACN 72 082 001 152

Contact: Dr Igor Gonda, Chief Executive Officer/Managing director

Phone: +61 3 8379 0100 Fax: +61 3 8379 0101
Email: info@acrux.com.au
Internet: www.acrux.com.au
Address: 103-113 Stanley Street
West Melbourne, VIC, 3003
Australia

Profile: Acrux Limited is developing and commercializing a new, superior generation of transdermal, skin
and healthcare products based on technology initially discovered at Monash University,
Melbourne, Australia. The portfolio is developed through investments by Acrux and partnerships
with pharmaceutical and healthcare companies. The Company has a diversified pipeline that
includes a Phase 3 program with estradiol, Phase 2b study on the treatment of low libido
associated with low androgen levels in women, Phase 2 trial on pain management with fentanyl
plus numerous other products at an earlier stage of development.

The technology combines widely used GRAS (generally recognised as safe) status compounds to
aid delivery of drugs topically and across the skin into the bloodstream with an applicator designed
to spray a rapid-drying, metered dose of drug onto the skin. Acrux Ltd licensed the patented
technology from Monash University. Acrux’s technology has a number of features that are
expected to provide an improved form of therapy to patients, including:
• convenience of use (compared with injections, and tablets, patches or gels)
• no skin irritation
• cosmetic acceptability (quick-drying, non-occlusive spray)
• dosage flexibility
• ease of manufacture
• low cost of goods
• control of drug levels within the blood that minimisze potentially toxic peaks or ineffective
troughs; and
• reduction in the frequency of drug administration (resulting from the slow release of the drug
through the skin).

Further research and development (preclinical screening) will be conducted in the company’s
dedicated laboratories. Manufacturing, clinical and regulatory services will be contracted to local
and international contract research organisations. Acrux personnel will manage the delivery of
these services. Acrux is organised as a Pooled Development Fund.

Adipogen Pty Ltd ACN 102 901 397

Contact: Dr Mark Harvey, Group Manager
Phone: +61 7 3365 4037
Email: m.harvey@uniquest.com.au
Internet: www.uniquest.com.au
Address: Melbourne University Postal Edith Cavell Building
Carlton, VIC, 3053 Address: Royal Brisbane Hospital
Australia Herston, Queensland, 4029
Australia

Profile: Adipogen was formed in 2002 by UniQuest, The University of Queensland’s technology
commercialisation company. UniQuest has licensed the intellectual property associated with the
development of the new drug to Adipogen, which has attracted seed funding from Uniseed Pty Ltd,
the $20 million pre-seed fund formed in 2001 by the UQ and Melbourne University.

Advanced Laboratory Solutions Pty Ltd ACN 74 082 016 626

Contact: Mr Peter Robert, Executive Director

Phone: +61 3 9686 5022 Fax: +61 3 9686 5033
Email: peter@advancedlabs.com.au
Internet: www.advancedlabs.com.au
Address: 182 -184 Ferrars Street
South Melbourne, VIC, 3205
Australia

Profile: Advanced Laboratory Solutions Pty. Ltd., trading as Advanced Labs, offers ‘next generation’
platform technology to the Australian scientific and medical research community. Their goal is to
offer this technology in a timely manner so as to maximize the Australian scientific community's
ability to remain globally competitive.

Advanced Labs’ core industry focus is genomics, proteomics, bioinformatics, drug discovery,
pharmaceutical manufacturing, and biotechnology. The company invests significant resources in
the Australian and USA markets, in order to rapidly transfer knowledge from centers of research
excellence (such as Stanford and Harvard Universities and the National Institutes of Health - NIH)
to Australian customers. The company is successfully transferring the skills developed in this
market to other customers within the Pacific Rim.

Advanced Labs’ goal is to be a successful, respected, ‘Technology Partner’ to its target market.
Core components of this vision are a global support network, an educated and dynamic Sales &
Marketing Department, a responsive customer service team, and factory-trained service
engineers.

As an example, Advanced Labs in conjunction with the Peter MacCallum Cancer Institute entered
into a joint 'Technology Evaluation Program' in 1999. The outcome of this relationship was the
rapid integration and knowledge transfer of microarray manufacturing to Australian scientists, the
selection of the most appropriate platform technology for the Australian market, and the
subsequent decision by four additional core research precincts to adopt identical technology, thus
aiding and accelerating Australia's push into the international business of medical genomics.
 Advent Pharmaceuticals Pty Ltd ACN 43 095 494 563

Contact: Dr Jill Snell, General Manager

Phone: +61 3 8562 2235 Fax: +61 3 8562 2288
Email: jsnell@advent-pharma.com
Address: Monash Enterprise Centre
5a Harnett Close
Mulgrave, VIC, 3170
Australia

Profile: Advent Pharmaceuticals is a technology development company specialising in the development of

novel dry powder inhalation delivery platforms. The focus of Advent’s product development is
directed initially at novel platforms for the management of asthma and chronic obstructive
pulmonary disease, with future therapeutic applications in new pulmonary delivered medications.
Established in January 2001, Advent Pharmaceuticals is an Australian-registered, privately owned
company. Advent’s product design, development and preclinical testings are presently conducted
in Victoria, Australia. Clinical, regulatory and manufacturing will be outsourced to local and
international contract organisations.
AgGenomics Pty. Ltd. ACN 16 099 612 423

Contact: Dr Glenn Tong, Managing Director

Phone: +61 3 8412 7066 Fax: +61 3 9417 4076
Email: glenn.tong@aggenomics.com.au
Internet: www.aggenomics.com.au
Address: 60-66 Hanover Street Postal P. O. Box 115
Fitzroy, VIC, 3065 Address: Fitzroy, VIC, 3065
Australia Australia

Profile: AgGenomics Pty. Ltd. was formed in March 2002 as a joint venture between Genetic Technologies
Limited (ASX-GTG) and Agriculture Victoria Services Pty Ltd (the commercial arm of the Victorian
Government's Department of Natural Resources and Environment). This joint venture, the first
ultra high throughput genomics facility in Australasia, will dramatically improve the efficiency of
traditional plant and animal breeding programs via the use of ultra high throughput genomics
technologies.

AgGenomics has unique enabling technologies, expertise and extensive experience in the
identification of genetic markers linked to commercially important traits in a wide variety of plant
species. The same technology is also applicable to animal species. The development of genetic
markers such as SNPs, microsatellites (SSRs) and AFLPs and the application of these markers in
marker assisted selection (MAS) is AgGenomics’ key strength and primary business activity.
AgGenomics has extremely high throughput capabilities, with a capacity of well over 20,000
genotype analyses per day using a suite of state-of-the-art automated technology platforms.
These capabilities allow plant and animal breeders to deliver improved varieties to the market
quicker and more economically through the use of MAS.

AgGenomics also has expertise and experience in cultivar identification, eg for Plant Breeders’
Rights and transgene detection. AgGenomics primarily operates on a fee-for-service basis, with no
participation in the sharing of intellectual property. In certain circumstances, such as genetic
marker discovery programs which are linked to a marker assisted selection program requiring ultra
high throughput genotyping, AgGenomics may also enter into collaborative R&D programs on a
cost and IP sharing basis.
 Agri-Gene Pty. Ltd. ACN 28 006 665 381

Contact: Mr Albert McIlroy, CEO

Phone: +61 3 5722 2666 Fax: +61 3 5722 2777
Email: info@agrigene.com.au
Internet: www.agrigene.com.au
Address: 123-125 Tone Road
Wangaratta, VIC, 3677
Australia

Profile: Agri-Gene is a privately owned artificial breeding and merchandise company based at Wangaratta
in North-East Victoria. Agri-Gene imports and exports bovine artificial breeding semen and
embryos for all beef and dairy cattle breeds. Product is distributed Australia-wide through a
network of over 150 resellers and merchandise outlets, and exported globally. The company has
been operating since 1986 as a separate identity, and of its 14 staff, some have over 25 years’
experience in the cattle genetics industry.

Agri-Gene provides, selects and markets breeding programs and genetics. Agri-Gene is the
Australian representative for Sersia France, the exporter for the French Artificial Breeding Co-
Operatives. Agri-Gene also represents Ag-Link from the USA for coloured breeds and Holsteins,
and Jersey Island Genetics from Jersey Island. Approximately 40% of Agri-Gene’s business is in
beef semen, with suppliers being World Wide Sires, Select Sires, Accelerated Genetics, and
Sersia France. Agri-Gene also has a merchandise division which distributes products such as
KAMAR Heat Detectors, Taylor Wharton LN2 Tanks and a full range of BIO-VET artificial
insemination requisites from France. Agri-Gene is also a licensed veterinary wholesaler
specialising in synchronization and reproduction in both dairy and beef.
Agriculture Victoria Services Pty Ltd ACN 006 598 198

Contact: Mr Bruce Lang, Company Secretary

Phone: +61 3 9217 4139 Fax: +61 3 9217 4161
Email: bruce.lang@nre.vic.gov.au
Address: 475 Mickleham Road
Attwood, VIC, 3049
Australia

Profile: Agriculture Victoria Services Pty Ltd (AVS) commercialises agricultural and natural resource
management R&D from the Victorian Department of Natural Resources and Environment primary
industries(DPI). AVS also provides contract R&D for commercial organisations, performed by NRE
scientists, in areas such as plant and animal improvement; animal and plant production; animal
nutrition; health and welfare; functional foods; disease diagnosis for animals and plants; integrated
farm systems; soil, water and plant analysis; food safety; land suitability assessment; management
and mapping; and pest and weed control; groundwater salinity investigations; waste management;
organic and inorganic analytical chemistry. AVS has specialist expertise in contract management,
marketing and business development and intellectual property. Biotechnology research and
application fields include:

Dairy: applying genomics and marker assisted selection technologies to produce improved dairy
genetics and milk products. Crops and Pastures: engineering forages and grains that offer disease
resistance, drought resistance, longer-lived plants, better tolerance to soil stress, and herbicide
resistance as well as fingerprints and molecular markers to identify elite plants. Functional Foods:
developing plants with amplified levels of bioactive therapeutic compounds; evaluating and testing
active plant-derived molecules; optimising agronomic practices to elevate levels of actives in
plants; extraction and post-harvest protocols; trials and commercialisation of ‘healthy plants’. In
September 2001, AVS was awarded a Biotechnology Innovation Fund grant to help
commercialise, via a spin off company, Phytogene Pty Ltd, a method for the manipulation of
senescence in plants. AVS has, together with Genetic Technologies Ltd, also established a joint
venture company, AgGenomics Pty Ltd, which offers a unique service for plant genomics. See
separate entries.
 AgSeed Research, a Division of Monsanto Australia ACN 61 086 442 435

Contact: Mr David Hudson, Canola Business Manager

Phone: +61 3 9522 7122 Fax: +61 3 9525 2253
Email: david.j.hudson@monsanto.com
Internet: www.monsanto.com.au
Address: Level 12
600 St Kilda Road
Melbourne, VIC, 3000
Australia

Profile: AgSeed Research is a division of Monsanto Australia Limited. The business unit is focused on the
breeding and development of elite canola varieties for commercialization in Australia. The
developed products include conventional canola, triazine-tolerant canola, and canola varieties
incorporating tolerance to Roundup herbicide. The business develops both open-pollinated and
hybrid canola varities. AgSeed owns a significant collection of canola germplasm adapted to
Australian conditions. The business undertakes a full breeding program for its products and
includes full glasshouse and field nursery and trials capacity. Monsanto is investing additional
resources to build AgSeed's capabilities and facilities at Horsham in Western Victoria, to meet the
needs of the growing canola market. The business has access to the global resources of the US
based Monsanto Company, in particular to the Brassica breeding activities in Canada and Europe.
AGT Biosciences Ltd ACN 79 000 248 304

Contact: Prof Greg Collier, Managing Director, CEO

ASX: AGT
Phone: +61 3 9234 1188 Fax: +61 3 9234 1244
Email: autogen@autogenlimited.com.au
Internet: www.autogenlimited.com.au
Address: Pigdon’s Road Postal PO Box 1069
Waurn Ponds, VIC, 3205 Address: Grovedale, VIC, 3216
Australia Australia

Profile: AGT BioSciences (formerly Autogen) is an Australian biotechnology company specializing in the
use of gene discovery approaches to identify novel therapeutic targets for the treatment of
prevalent human diseases. The company's vision is to translate its discoveries into new drug
therapies through partnering with pharmaceutical companies.

AGT Bioscience's diabetes and obesity gene discovery program has been highly successful, with
over 40 novel genes in various stages of patent protection. The company’s first major target,
Beacon, has been granted full patent protection in the US and several other major jurisdictions.
AGT Bioscience's major new initiative in depression and anxiety is progressing well, with an
application for patent protection of an animal model for the disease, and a significant number of
target genes being identified. The company’s Center for Human Statistical Genetics is leading a
program aimed at identifying disease genes in human populations with high prevalence disease
rates.

AGT Bioscience has launched the eXpress Technology Platform as a commercially available
offering for gene discovery and validation. This has attracted significant interest from
biotechnology companies in the US, Europe and Australia.

AGT Bioscience's largest alliance to date is the obesity and gene discovery program with French
pharmaceutical company Merck-Santé, a subsidiary of Merck KGaA. This is a successful long-
term relationship that has been extended through contract until 2006. This partnership has
provided in excess of US$16 million as research funding, milestone payments and equity
purchase. In addition, AGT Bioscience will receive royalties and profit sharing on any drugs
developed from the program.

AGT Bioscience has partnered with Sequenom, giving Sequenom access to AGT Bioscience's
eXpress Technology Platform, resources and expertise to validate and functionally characterize a
number of their selected gene targets.
 Albright & Wilson (Australia) Ltd ACN 36 004 234 137

Contact: Dr Richard Thwaites, Manager, Special Projects

Phone: +61 3 9396 8777 (switch), +61 3 9396 8749 (direct) Fax: +61 3 9396 8729
Email: rthwaites@albright.com.au
Internet: www.albright.com.au
Address: 295 Whitehall Street Postal PO Box 20
Yarraville, VIC, 3013 Address: Yarraville, VIC, 3013
Australia Australia

Profile: In 1994, Albright & Wilson (Australia) Ltd, a large chemical manufacturer, formed a partnership
with Tridan Limited, a small R&D investment company, to establish a state-of-the-art biotech
fermentation scale-up facility at Yarraville and together with the University of Melbourne and Food
Science Australia, became core participants in what has now become the CRC for Bioproducts.
The three groups have an equal share in the intellectual property.

The CRC for Bioproducts has a focus on developing commercially valuable materials produced by
plants and other living organisms - such as natural colours, nutraceuticals including the active
components in herbal remedies, pharmaceutical intermediates, and biopolymers. It aims to
establish new industries based on these novel bioproducts and bioprocesses, and also use the
skills developed by the Centre to improve the efficiency and profitability of existing industries
involved in the production and use of bioproducts.

The research program has three facets: cell culture and fermentation of novel plant cell lines;
extraction of novel and useful compounds from agricultural waste, seaweed and other biomass
sources, including the extraction of pectin from citrus peel; and applied physico-chemical studies
of macromolecules in solutions and gels, relevant to products in a range of industries. The
resources of the Centre include a pilot scale fermentation facility (up to 10,000 litres) used
primarily for production of materials from plant cells, laboratories equipped for functional testing of
biopolymers and food ingredients, and state-of-the-art facilities for carbohydrate chemistry and
plant molecular biology.

Albright & Wilson Australia's core business comprises phosphates and surfactants, used in a
variety of industrial applications including detergents, personal care products, food ingredients,
water treatment, mining & minerals processing, and the building & construction industry.
Alpharma Animal Health Pty Ltd ACN 68 088 526 229

Contact: Dr Colin Peel, Managing Director

Phone: +61 3 9826 4777 Fax: +61 3 9826 4822
Email: colin.peel@alpharma.com.au
Internet: www.alpharma.com.au
Address: Level 10, Trak Centre
443-449 Toorak Road
Toorak, VIC, 3142
Australia

Profile: Alpharma Animal Health Pty Ltd specialises in commercial-scale manufacture of recombinant
porcine somatotropin (growth hormone), Reporcin, used to aid in the production of leaner pork. A
subsidiary of US biopharmaceutical company Alpharma, Inc., Alpharma Animal Health has a
purpose-built fermentation plant for Reporcin production located within the CSL precinct in
Parkville, Melbourne. The plant has the capacity to supply the Australian market and countries in
Asia and South America as registrations are received.

US-based Alpharma Inc. established its Asia Pacific headquarters in Melbourne in mid-2000, along
with plans to expand its existing manufacturing plant and operations at Parkville. Alpharma,
presently active in more than 60 countries, is the largest manufacturer of generic liquid and topical
pharmaceuticals in the USA, and is a major producer of antibiotics, vaccines for farmed fish, and
animal health feed additives. Alpharma acquired Southern Cross Biotech Pty Ltd, developer and
manufacturer of Reporcin, to form Alpharma Animal Health Pty. Ltd. in September 1999.
 AMGEN Australia Pty Limited (Scientific Affairs Office) ACN 31 051 057 428

Contact: Mr Russell Edwards, Regional Director, South East Asia

Phone: +61 2 9870 1333 Fax: +61 2 9870 1344
Email: redwards@amgen.com
Internet: www.amgen.com
Address: Level 7,
123 Epping Road
North Ryde, NSW, 2113
Australia

Profile: Amgen Australia is a subsidiary of Amgen Inc, based in Thousand Oaks, California USA. Amgen,
the world's largest biotechnology company, uses science and innovation in an effort to dramatically
improve people's lives. Amgen aspires to be the world's best human therapeutics company.

With its head office in Sydney, Amgen Australia was established in 1991. Amgen Australia markets
the products of Amgen Inc. and contributes to the global product development program of the
company, through collaborations with Australia's laboratory and clinical researchers. Amgen
Australia's mission is to become Australia's leading biopharmaceutical company, based on the
application of cellular and molecular biology. Amgen Australia's positioning is as pioneers in
biotherapy, committed to bringing the benefits of science to the patient.

Melbourne is home to the Scientific Affairs office of Amgen Australia Pty Limited. Based at
Hawthorn, the Scientific Affairs Office is the principal site for research and development activities
for Amgen Australia. These activities include a large clinical research and registration program.
The clinical research programs involve all of the major hospitals around Australia. The research
and product development programs of Amgen aim to help patients in four critical areas: cancer
and complications of cancer, kidney diseases, inflammatory and bone diseases, and neurological
and endocrine diseases.
 AMRAD Corporation Limited ACN 37 006 614 375

Contact: Mr Bob Moses, CEO (Interim)

ASX: AML
Phone: +61 3 9208 4302 Fax: +61 3 9208 4352
Email: amrad@amrad.com.au
Internet: www.amrad.com.au
Address: 576 Swan Street
Richmond, VIC, 3121
Australia

Profile: Amrad Corporation Limited is an Australian drug discovery and development based biotechnology
company. Amrad's in-house pharmaceutical R&D expertise is focused on five priority status
projects in the areas of allergy and inflammation, anti-infectives and neurological indications.
Amrad is dedicated towards delivering candidate products into clinical development for serious
chronic human diseases, focused on early commercial returns. Amrad continues to expand its
intellectual property either through in-house research programs or with collaborations with
Australian research institutes.

Amrad currently has five key projects in preclinical and clinical development. Amrad's strategy is
to add significant value to its portfolio of candidate pharmaceutical products, to the point where
they can be licensed to international pharmaceutical companies. Amrad aims to progress projects
through either collaborations or licensing agreements with appropriate development partners.
Amrad receives returns from its research and development expenditure from agreements with
these project partners.

Amrad’s key competitive advantages are:

• Drug discovery and development capabilities in virology, oncology, neurology and
allergy/inflammation
• Access to enabling technologies of medicinal and protein chemistry and antibodies
• Validated science with pharma and biotechnology partners
• World wide patent protection.

Amrad's core competencies are in the therapeutic areas of infectious diseases (viral, chronic),
neurology (neuro-protection) and allergy/inflammation (asthma, rheumatoid arthritis) and based
on the following enabling technologies – medicinal chemistry, therapeutic proteins and monoclonal
antibodies. Amrad currently has five key projects in preclinical and clinical development. The lead
clinical projects include AM336 for the treatment of chronic severe pain (Phase I/II completed) and
emfilermin for the treatment of reproductive health in collaboration with Serono (Proof of concept
completed). Preclinical projects include AM132 and AM133 for the treatment of cardiovascular
disease in collaboration with Gencell Inc. (a wholly owned subsidiary of Aventis) and Edwards
Lifesciences respectively; AM36 for the treatment of stroke. Drug discovery activities are focused
on the following targets :- IL-13 receptor, GM-CSF receptor (with Cambridge Antibody
Technology), Hepatitis B virus, HIV integrase and the suppressors of cytokine signalling (SOCS).
 Anadis Limited ACN 80 063 114 045

Contact: Mr Steven Skorobogaty, General Manager

ASX: ANX
Phone: +61 3 9358 6388 Fax: +61 3 9358 6399
Email: steven.s@anadis.com.au
Internet: www.anadis.com.au
Address: No. 4
Capital Link Drive
Campbellfield, VIC, 3061
Australia

Profile: Anadis Limited is a research, development and production company specialising in innovative
biopharmaceutical products and related technologies. Applications are therapeutic, primarily in
humans.

Anadis listed on the Australian Stock Exchange in 1999.

Since 1994, Anadis has developed several products containing antibodies and bioactive factors
derived from bovine colostrum. Taken orally, specific hyperimmune colostral antibodies, coupled
with a key proprietary delivery systems, confer passive immunity to the recipient. This principle
underlies two of the four lead products in development (Travelan & Pyloran).

Key advantages include an excellent association with the dairy industry in Australia and the
predominantly disease-free status of the cattle, as the source of high quality colostrum. Anadis has
in place Standard Operating Procedures for OTC grade products for human use.

Anadis opened its new Melbourne office and manufacturing facility in May 2001. During 2001,
Anadis expanded into three areas: Development of natural bioactive substances from animal and
plant sources, acquisition of new technology for active immunity & vaccine development and
contract packaging & blending of food grade products.

Phase II clinical trials of Travelan, a preventative tablet against traveller’s diarrhoea, were
successfully completed during 2000-2001, and Phase III trials are in consideration for
pharmaceutical level claims. Travelan will be launched as an OTC in 2003.

Osteoporon, a bioactive casein derivative for treatment & prevention of Osteoporosis, is currently
undergoing 2 x Phase II clinical trials at Monash University & Austin Hospital.

Phase II trials are underway for Pyloran, an antibody based therapeutic to deal with Helicobacter
pylori, the bacteria which causes gastritis and gastric ulcers.

Anadis is also working in and developing the following area’s;

A “bioshielding” technology which protects, vaccines, probiotics, enzymes and other delicate
proteins to pass through the harsh stomach environment and into the small intestine intact.

Respiratory protection against airborne viruses. Current work is in the short term protection of
military personnel and emergency workers.

Enterovirus 71 – a joint research & commercial development project with the Taiwanese
government's Development Centre for Biotechnolgy against this important and emerging disease.
 Angiostar Ltd ACN 080 492 404

Contact: Dr John Raff, CEO

Phone: (03) 8532 2700 Fax: (03) 9510 5955
Internet: www.starpharma.com
Address: Level 6 Baker Heart Research Building Postal PO Box 6535
Commercial Road Address: ST KILDA ROAD CENTRAL, VIC,
Melbourne, VIC, 3004 8008
Australia Australia

Animal Reproduction Company Pty Ltd ACN 11 080 648 291

Contact: Dr Richard Fry, CEO

Phone: +61 3 9397 7144 Fax: +61 3 9397 7944
Email: animalreproductionco@bigpond.com
Internet: www.animalreproductionco.com
Address: c/- Victorian Institute of Animal Science Postal PO Box 544
Sneydes Road Address: Newport, VIC, 3015
Werribee, VIC, 3030 Australia
Australia

Profile: The Animal Reproduction Company was formed by Dr Richard Fry and Dr Colin Earl to
commercialise in vitro fertilisation (IVF) technology in the cattle and sheep industries. The ARC is
principally an R&D company that has developed IVF for very young calves and lambs where the
resulting embryos are implanted into recipient mothers. This has resulted in the rapid multiplication
of elite seedstock and the ability to halve the generation interval. The ARC is currently developing
the use of sex-sorted sperm in IVF to preselect the sex of offspring. In addition, the ARC has
recently been awarded an AusIndustry R&D START grant to develop cryopreservation of these
elite IVF embryos to facilitate their storage and shipment world wide.
 Antisense Therapeutics Limited ACN 41 095 060 745

Contact: Mr Mark Diamond, Chief Executive Officer and Managing Director

ASX: ANP
Phone: +61 3 9827 8999 Fax: +61 3 9827 1166
Email: mark.diamond@antisense.com.au
Internet: www.antisense.com.au
Address: Level 1
10 Wallace Avenue
Toorak, VIC, 3142
Australia

Profile: A new Australian company entering the gene-directed therapeutics field is Antisense Therapeutics
Limited (ATL), incorporated on 13 November 2000 and listed on the Australian Stock Exchange in
December 2001. ATL’s mission is to create, develop and commercialise novel antisense
pharmaceuticals for large unmet markets. The company plans to develop several antisense drugs,
with its two most advanced projects targeting multiple sclerosis (ATL 1102) and psoriasis (ATL
1101). The company’s access to these projects is derived from its technology and research
collaborations with Isis Pharmaceuticals Inc. and the Murdoch Children’s Research Institute.
Californian based Isis is the world leader in antisense technology. Through its relationship with
Isis, ATL has access to a broad range of intellectual property which will allow it to develop a
substantial product pipeline. ATL plans to commercialise its pipeline via licensing agreements with
larger biotechnology and pharmaceutical companies. Antisense drugs work by entering cells and
blocking the protein-producing activity of specific genes. Most current drugs act on proteins
directly. Antisense compounds work at an earlier stage, preventing production of disease-causing
proteins. Compared to conventional drugs, antisense aims to provide more efficient and
predictable drug discovery, based on increased specificity of action and uniformity of methods of
manufacture, formulation and delivery. Antisense drugs should also have advantages as
medicines as they can be designed to be more selective than traditional therapy, resulting in more
effective and potentially less toxic drugs. The technology available to ATL under its agreement with
Isis also allows them to develop antisense drugs for a very broad range of diseases and with more
convenient dosing regimens and potentially more acceptable routes of administration.

Antisense Therapeutics has achieved a number of key milestones in a timely manner since listing
in December 2001.

ATL’s primary focus is to progress its two lead compounds, ATL1102 for multiple sclerosis and
ATL1101 for psoriasis, through development into human efficacy trials (Phase IIa) and then on
success look to license the compounds to larger pharmaceutical companies. However, the
company may license out earlier if commercially attractive.

The following key development milestones are expected to be achieved over the next 6-12
months:

• The commencement of Phase I human trial in mid-2003 which is expected to be completed in the
first half of 2004. A Phase IIa trial in multiple sclerosis patients is expected to start in the second
half of 2004;

• On the psoriasis project, pre-clinical efficacy testing is expected to be completed by the end of
this year and the animal toxicology studies commenced in 2004;

• An additional six lead compounds for other disease targets including viral, skin, growth and
inflammatory disorders are in the pipeline. Several of these compounds will be tested in pilot
animal efficacy studies with results expected throughout the period.
 AorTech Biomaterials Pty Ltd ACN 17 079 265 286

Contact: Dr Ian Griffiths, Business Unit Director

Phone: +61 3 9562 2669 Fax: +61 3 9562 2977
Email: iang@aortechbio.com
Internet: www.aortechbio.com
Address: 677 Springvale Road
Mulgrave, VIC, 3170
Australia

Profile: AorTech Biomaterials Pty Ltd was formed in Australia in 1997 to commercialise innovative polymer
technology developed by the Cooperative Research Centre (CRC) for Cardiac Technology. The
polymers are a series of novel polyurethanes that incorporate high levels of silicone in the
molecular structure. The major advance is the discovery that through novel raw materials and a
complex proprietary synthetic process, polymers are produced that retain flexibility and
processability while exhibiting biostability, biocompatability and outstanding mechanical and
physical properties. The technology is covered by a family of 7 patents (granted or pending). The
company offers a family of formulations (Elast-Eons) that span grades from quite flexible to rigid. It
also offers customisation and product/component development services using its capabilities in
the processing of polymers. Recently the company has made the decision to commercially supply
a new grade, Elast-Eon HF. This material combines all of the advantages of Elast-Eon technology
with unparalleled fatigue performance in demanding environments. This allows new device
opportunities for flexible materials, such as replacement heart valves and components in the next
generation of cardiac assist technologies. AorTech Biomaterials' parent company is AorTech
International plc, based in Scotland. AorTech Biomaterials Pty Ltd has its headquarters in
Melbourne, and is specialised in stabilization of biomaterials technologies and pilot scale
manufacturing. The Melbourne facility was launched by the Minister for State and Regional
Development, John Brumby, in 2001. The main objectives for the business are to realize the full
commercial potential for the technologies, while stabilizing new biomaterials inventions from
partner organizations.
Applied Biosystems Pty Ltd ACN 89 004 669 863

Contact: Dr Nick Samaras, General Manager

Phone: +61 3 9730 8600 Fax: +61 3 9730 8799
Email: abozsales@appliedbiosystems.com
Internet: www.appliedbiosystems.com.au
Address: 52 Rocco Drive
Scoresby, VIC, 3179
Australia

Profile: Applied Biosystems provides state-of-the-art instrumentation, reagents, consumables and

bioinformatic solutions to life science researchers. These systems enable scientists to realise new
research possibilities in basic research, pharmaceutical research and development, diagnostics,
forensics and food and environmental testing. The company’s broad portfolio of technologies are
crucial for applications such as DNA sequencing, the polymerase chain reaction (PCR), real-time
PCR, DNA and peptide synthesis, chemiluminescence, mass spectrometry, chromatography and
data management.

Serving over 30,000 laboratories in more than 150 countries, and with over 5,000 employees
worldwide (50 in Australia), Applied Biosystems has had a broad impact on the evolution of biology
over the last 20 years, including the unraveling of the human genome sequence. The company’s
commitment to innovation and investment in research continues to fuel the development of
advanced technologies for the life sciences. Whatever the vision for discovery, Applied Biosystems
is building a scalable integrated applications infrastructure to support it - infrastructure that will
enable scientists to discover the secrets of life and apply this knowledge to improve the human
condition.

Applied Biosystems Pty Ltd commenced activity in Melbourne in the mid-1980s, and the Group
headquarters is in Foster City, California.
 Applied Biotechnologies Pty Ltd ACN 006 669 414

Contact: Miss Linton Staples, Managing Director

Phone: +61 3 9305 2653 Fax: +61 3 9308 9622
Email: appbiotech@bigpond.com
Internet: www.animalcontrol.com.au
Address: 46-50 Freight Drive Postal P O Box 379
Somerton, VIC, 3062 Address: Somerton, Vic, 3062
Australia Australia

Applied Chemicals Pty Ltd ACN 96 082 810 973

Contact: Mr Ed Dwyer, Managing Director (Australia)

Phone: +61 3 8542 5111 Fax: +61 3 8542 5188
Email: edward.dwyer@appliedchemicals.com; applied.aus@appliedchemicals.com
Internet: www.appliedchemicals.com
Address: 92 Fairbank Road
Clayton South, VIC, 3169
Australia

Profile: Applied Chemicals Pty Ltd is a specialist supplier of high quality chemicals products and services
that are technically innovative and environmentally sound. The company’s focus is to improve
process efficiencies and environmental hygiene. Founded in Australia in 1942 and established in
the UK ten years later, Applied Chemicals’ technically innovative and environmentally sound
products are used in over 35 countries.

Applied Chemicals manufactures and develops chemical products for use in the metal processing,
non-road transport (ie aviation and shipping), food and mining sectors. Their chemicals are used in
a wide range of products, such as sanitisers and toilet disinfectants, and in the specific treatment
of metals. Applied Chemicals also supplies imported biotech products to Australian industry, such
as petrochemical products, enzyme products used for cleaning in the dairy industry, and dry
concentrated bacteria used for mining remediation. Applied Chemicals also produces an
automotive product range, which is available through retail outlets. Applied has recently
announced the launch of its new E-commerce web site and is leading the market in providing
comprehensive E-commerce facilities to its global customer base.
 Arkopharma ACN 23 081 455 094

Contact: Mr Alistair Cumming, Managing Director

Phone: +61 3 5973 4888 Fax: +61 3 5973 4188
Email: info@nutrasense-australia.com
Internet: www.arkopharma.com
Address: Unit 30 Postal PO Box 324
1140 Nepean Highway Address: Mt Eliza, VIC, 3931
Mornington, VIC, 3931 Australia
Australia

Profile: Nutrasense Australia Pty Ltd, formed in 1998, is now part of the Arkopharma Laboratories
nutraceuticals group, based in Europe. Nutrasense Australia has its head office based on
Victoria's Mornington Peninsula. Currently, Nutrasense Australia manufactures and markets a
range of arthritis and osteoarthritis treatments, including ARTHRO-AID™ Capsules, for temporary
relief from painful flare ups in the hand, knee, ankle or hip joints, back, or any other localised area
of the body; and ARTHRO-AID DIRECT™ Arthritis Cream, using the Fusome™ delivery system
for enhanced transfer of nutrients through the dermal layer. ARTHRO-AID DIRECT contains
glucosamine, a vital, naturally occurring building block of normal cartilage, and shark cartilage, a
naturally occurring source of glycosaminoglycans. Now, as part of the Arkopharma group,
Nutrasense Australia will be expanding its product range. It is through Arkopharma’s mission to
provide a comprehensive approach to health and well-being that Nutrasense Australia aims to
grow and become a leader in the field of complementary medicine. New products of natural origin
are planned for a range of conditions, including menopause, weight control, headache and stress,
and skin disorders. Products recently launched in Australia include Phyto Soya (for menopause)
based on soy bean, and Exolise (slimming) based on green tea extract, AR25® Catechol.
Arrow Laboratories Limited ACN 15 088 417 403

Contact: Dr Stewart Cheng, Technical Director

Phone: +61 3 9737 4300 Fax: +61 3 9737 4399
Email: scheng@arrowlabs.com
Internet: www.arrowpharma.com
Address: 110 Merrindale Drive
Croydon, VIC, 3136
Australia

Profile: Arrow Pharmaceuticals Ltd was established in January 2000 with Head Office in Sydney and a
Research and Development Centre in Melbourne. The company's business strategy involves the
development of a portfolio of products spanning three separate, but interrelated, segments of the
pharmaceutical market.

1. Non-PBS or Private Prescription Products Arrow has developed a portfolio of licences to

distribute some private prescription products on a non-exclusive basis. In general, Arrow's unique
distribution and promotional program adds value to both the manufacturers and the pharmacists
by eliminating many of the costs that are currently involved in the private prescription market.

2. Generic Products Arrow has licensed a number of generic (or patent expired) products from
other companies, both within Australia and internationally. It has also implemented its own product
development program at its R&D facility (Arrow Laboratories) in Melbourne. This facility currently
employs over 30 scientists and is equipped with state of the art instruments and machinery.

3. Branded Products Arrow has acquired a range of both new and existing patented ('branded')
products that it promotes to doctors. This involves the traditional medical detailing in promoting the
product's qualities to doctors in order to generate prescriptions for the brand.
 Arthron Limited ACN 92 093 947 294

Contact: Mr Marcus Clark, interim CEO and Director

Phone: +61 3 9287 0637 Fax: +61 3 9287 0639
Email: mclark@primabiomed.com.au
Internet: www.primabiomed.com.au
Address: Kronheimer Building A&RMC Studley Postal Kronheimer Building A&RMCStudley
Road Address: Road
Heidelberg, VIC, 3084 Heidelberg, VIC, 3084
Australia Australia

Profile: A leading Melbourne research organisation, the Austin Research Institute, together with the former
Biomolecular Research Institute, in July 2000 established a new company, Arthron Limited, to
develop new biopharmaceuticals to combat the inflammation accompanying devastating
autoimmune diseases. Arthron is using drug design to target a key molecule found on the surface
of blood cells involved in the inflammatory response - neutrophils, monocytes and platelets.

The autoimmune diseases being targeted include rheumatoid arthritis and a severe bleeding
disorder, immune thrombocytopenia purpura (ITP). The strategy is to block certain receptors,
found on most inflammatory white blood cells, and that are involved in key inflammatory pathways.
The target is compounds to control autoimmune disease by blocking these "Fc" receptors, thereby
inhibiting the release of inflammatory chemicals.

In mid-2001, the Austin Research Institute entered into an agreement with ASX-listed company
Prima Biomed Limited [see separate entry] to fund the product development in return for a majority
shareholding in Arthron.

ATO Engineering Services ACN 006 151 202

Contact: Mr Kerrin Chin, Technical Service and Marketing Manager

Phone: (03) 9580 5511 Fax: (03) 9587 6361
Email: kchin@rosecorp.com.au
Internet: www.atoturbines.com
Address: Hangar 59 Postal PO Box 46
Bundorra Parade Address: Mentone, Victoria, 3194
Moorabbin Airport, Victoria, 3194 Australia
Australia

Profile: ATO Engineering Services provides Precision Machining and Welding of High Performance
materials such as Titanium, Stainless Steel, Magnesium, Nickel, Aluminium, and Cobalt alloys,
and High Strength Low Alloy Steels. ATO Engineering Services also has Thermal Spray
equipment (Wire Spray, Powder Spray and Plasma Spray)capable of coating substrates with
metallic or ceramic coatings to impart specialised properties such as corrosion resistance, wear
resistance,etc. Examples of coatings are: Yttria-stabilised Zirconia, Chromium Oxide, Tungsten
Carbide, Aluminium, Zinc, Bronze, Nickel/Aluminium

Manufacturer of prototypes, single units or small runs.

 Aus Bio Limited ACN 64 091 858 114

Contact: Dr Peter Jenkins, Executive Director

Phone: +61 3 9905 9831 Fax: +61 3 9905 5528
Email: ausbio@bigpond.com
Internet: www.ausbio.com.au (reserved)
Address: P.O. Box 13 D
Department of Biochemistry and
Molecular Biology
Monash University, VIC, 3800
Australia

Profile: Aus Bio is a highly focussed, Start Up Biotechnology Company which has identified a number of
areas of clinical need, and as a consequence the research programme is currently centered
around 4 projects in the areas of:

1. Lower limb ulcer and wound healing

2. Diabetes and insulin resistance

3. Anti-infective agents including novel anti-virals against Hepatitis B & C

4. In the agreibusiness area, the development of non absorbable “Growth Promoters”

The Company has been granted a US patent on the novel small molecule wound healing
compounds . Preclinical studies indicate no toxicity, and the company is planning clinical trials
during 2003. Aus Bio is also involved in early-phase development of antiviral agents for hepatitis C
and B. The company has now recruited a strong scientific R & D team and has recently raised
capital to progress pre-clinical and clinical projects. Further strategic alliance, partnership, and
joint venture opportunities exist and are being sought. The company's move to the Department of
Biochemistry and Molecular Biology at Monash University has resulted in a number of scientific
and preclinical relationships being developed which will expedite Aus Bio's R&D program.

Ausgenics Pty Ltd ACN 096 588 395

Contact: Ms Ann Cronin

Phone: +61 3 8341 6200 Fax: +61 3 9348 1391
Email: cronin@cryptic.rch.unimelb.
Internet: http://murdoch.rch.unimelb.edu.au/pages/lab/chromosome_research/overview.html
Address: Murdoch Childrens Research Institute Postal Murdoch Childrens Research Institute
Royal Children's Hospital Address:
Flemington Road PO Box 1100
Parkville, VIC, 3052 Parkville, VIC, 3052
Australia Australia

Profile: Ausgenics Pty Ltd is a subsidiary company of the Murdoch Childrens Research Institute
established during 2001 to commercialise a novel gene therapy delivery system.
 Auspep Pty. Ltd. ACN 86 006 673 347

Contact: Mr Stuart Banks, Buisiness Manager

Phone: +61 3 9328 1211 Fax: +61 3 9326 8810
Email: auspep@auspep.com.au
Internet: www.auspep.com.au
Address: 115 Ireland Street Postal PO Box 806
West Melbourne, VIC, 3003 Address: Parkville, VIC, 3052
Australia Australia

Profile: Auspep Pty. Ltd. is a manufacturer of biologically active peptides supplying the research and
pharmaceutical communities worldwide. For over a decade, Auspep has supplied peptide-based
products to researchers worldwide. Auspep has built up a high degree of technical expertise in
both the protein and DNA areas, enabling technical enquiries to be responded to immediately by
either customer service personnel or by Auspep’s team of scientific staff.

In 1996, as testament to its ongoing commitment to high achievement and continual improvement
in all facets of operation, Auspep was certified to an ISO9002 quality system. This has taken
Auspep to new levels of customer service and product consistency and quality.

Austin Research Institute

Contact: Prof Mark Hogarth, Professor/Director

Phone: +61 3 9287 0666 Fax: +61 3 9287 0601
Email: pm.hogarth@ari.unimelb.edu.au
Internet: www.ari.unimelb.edu.au
Address: Kronheimer Building Austin &
Repatriation
Medical Centre Studley Road
Heidelberg, VIC, 3084
Australia

Profile: The AUSTIN RESEARCH INSTITUTE (ARI) is a world leader in developing vaccines for cancer,
improving organ transplantation and understanding the nature of inflammatory diseases. The ARI
also now has a major commitment to develop vaccines for infectious diseases. Established in
1991, the Austin Research Institute (ARI) is located in the grounds of the Austin and Repatriation
Medical Centre (A&RMC) Heidelberg, Melbourne Victoria. It grew from the Research Centre for
Cancer and Transplantation, a “Centre of Excellence” funded by the Federal Government and
established at The University of Melbourne in 1982.
Both the ARI and the Research Centre were formed around research groups established by
Professor Ian McKenzie upon his return to Australia in 1974 from the USA, where he worked at the
Massachusetts General Hospital, the Harvard Medical School and at the Jackson Laboratories
with Nobel Laureate, Dr George Snell. Under the direction of Professor Ian McKenzie, the ARI has
assembled a world-recognised team of researchers. The Austin Research Institute is a centre of
excellence and has the status of a world-class research institute. ARI has a major mission to
develop new therapeutics for the treatment of diseases including autoimmunity, rheumatoid
arthritis, lupus, breast cancer, transplantation rejection and infectious diseases such as malaria.
This is evident from over 128 patents (14 families) that encompass a broad range of platform and
specific technologies. These include immunoconjugates (drug: antibody) for cancer and
transplantation and structure based design of inflammatory drugs; targeted vaccines for infection
and cancer, mucosal vaccines; transgenic pigs, gene discovery, complement regulation. In
addition, many cutting edge technologies are used i.e. gene discovery, X-ray crystallography,
combinatorial chemistry, animal transgenesis.
 Australian Animal Health Laboratory - CSIRO

Contact: Dr Jack Malecki, Commercial Manager

Phone: +61 3 5227 5000 Fax: +61 3 5227 5555
Email: Jack.Malecki@csiro.au
Internet: www.csiro.au/aahl
Address: 5 Portarlington Road Postal Private Bag 24
Geelong, VIC, 3220 Address: Geelong, VIC, 3220
Australia Australia

Profile: The Australian Animal Health Laboratory (AAHL) opened in 1985 and is one of the most
sophisticated laboratories in the world for the safe handling and containment of exotic animal
diseases. The Australian Animal Health Laboratory (AAHL) plays a vital role in maintaining
Australia's capability to quickly diagnose exotic (foreign) and emerging animal diseases. This is
achieved through ongoing research programs to develop the most sensitive, accurate and timely
diagnostic tests, which are critical to the success of any eradication campaign in the event of a
disease outbreak. AAHL also undertakes research to develop new diagnostic tests, vaccines and
therapeutics for endemic and emergency animal diseases of national importance. Major diseases
of livestock, aquaculture animals, and wildlife, are studied.

Australian Botanical Products Pty. Ltd. ACN 45 006 782 529

Contact: Mr Tim Smith, Chief Operating Officer

Phone: +61 3 9796 4833 Fax: +61 3 9796 4966
Email: ausbot@ozemail.com.au
Internet: www.essentialoils.com.au
Address: 39 Melverton Drive
Hallam, VIC, 3803
Australia

Profile: Australian Botanical Products (ABP), together with its subsidiary company Auroma, was
established in 1982 and offers an extensive range of essential oils, fragrance oils, perfumes,
cosmetics, and raw materials for use in the flavour, fragrance, pharmaceutical, and cosmetic
industry.

ABP’s research and development facility is one of the most sophisticated private laboratories of its
kind in Australia. Using the latest gas chromatography and mass spectrometry equipment in
conjunction with an on-line computer that has the largest essential oil database in Australia, ABP
can accurately analyse essential oils, identify their constituent parts and confirm their purity and
origin. The laboratory is staffed with expert pharmacologists and chemists who are dedicated to
quality assurance. The Australian Federal Government regulates the handling of essential oils
through the Therapeutic Goods Administration (TGA). ABP has been granted a TGA licence to
manufacture and contract pack essential oils and other related products.

ABP was the first essential oil company in Australia to set up an in-house analysis facility
comprising GC-MS and multi-dimensional chiral chromatography. The company has also
established Australia's most extensive private collection of essential oils and their components,
their mass spectra and retention indices, physico-chemical and organoleptic properties.

ABP is in the process of establishing an Australian distillation facility for the production of essential
oils from local and imported materials; refining and fractionation for the production of natural
isolates and molecules. The company is seeking to establish agencies for international raw
material suppliers into the cosmetic and pharmaceutical industries.
 Australian Genome Research Facility

Contact: Dr Susan Forrest, Director

Phone: 03 9345 2449 Fax: 03 9345 2678
Email: sue.forrest@agrf.org.au
Internet: www.agrf.org.au
Address: 7th Floor, Walter & Eliza Hall Institute of
Medical Research
1G Royal Parade
Parkville, VIC, 3050
Australia

Profile: The Australian Genome Research Facility, funded by a Major National Research Facility grant, is
an established well managed and effective fee for service genomics facility that serves hundreds
of researchers all around Victoria and Australia. The facility has over 40 staff who are all well
trained in high throughput genomics services. The core services that the AGRF supplies include
DNA sequencing, genotyping and microarray production. The AGRF has contributed to large
microbial, plant, animal and human genome as well as EST sequencing projects, and large gene
mapping projects throughout Australia with a documented level of quality and satisfaction by its
many users. AGRF is highly recognised and well appreciated both nationally and internationally,
for its quality and throughput. The facility has nodes in Brisbane, Melbourne and Adelaide to
access its suite of genomics technologies. We also support an active research and technology
group, the major aim of which is to introduce new cost-effective genetic tools to enhance the
scientific discoveries of the research community. Collaborative efforts when developing and
trialling such methods is encouraged.

Australian Mint Oils Pty Ltd

Contact: Mr Leo Cahill, Managing Director

Phone: +61 3 9310 3271 Fax: +61 3 9310 3432
Email: cahillhl@ocean.com.au
Address: 5 Ovata Drive
Tullamarine, VIC, 3043
Australia

Profile: Australian Mint Oils Pty Ltd grows peppermint, and processes it into peppermint oil at its
Tullamarine facility. The product is customised as an ingredient for manufacturers of toothpaste,
confectionery, and oral hygiene products.
 Australian Starter Culture Research Centre Limited ACN 69 053 927 003

Contact: Dr Guy Limsowtin, CEO

Phone: +61 3 9974 8900 Fax: +61 3 9742 4233
Email: admin@ascrc.com.au
Internet: www.ascrc.com.au
Address: 180 Princes Highway
Werribee, VIC, 3030
Australia

Profile: Australian Starter Culture Research Centre Limited is a non-profit research and development
organization supported by subscriptions from Australian dairy processing companies. ASCRC
subscriber companies are among Australia's leading dairy processors, manufacturers and
exporters.

This special relationship with the Australian dairy industry puts ASCRC in a unique position to
introduce its subscribers to the fruits of basic and applied research, to foster the adoption of new
technologies, to provide assistance in microbiological aspects of process and product
development, and to provide starter-related products and services.

The ASCRC laboratories are located within the Werribee Agriculture and Food Technology
Precinct. Werribee is on the western suburban fringe of Melbourne, in the southern Australian
state of Victoria.

An additional link between subscriber cheese manufacturers and ASCRC's primary research and
development functions is provided by the ASCRC Commercial Business Unit (CBU). The goal of
the CBU is to facilitate transfer of starter strains and other technologies that have been developed
from ASCRC to its subscriber companies, primarily via reliable supply of frozen cultures derived
and characterized by ASCRC.

After nearly two years of laboratory development and trials, the CBU and its production facility
were established at ASCRC to make frozen bulk-set cheese starters available to subscribers on a
commercial basis.

ASCRC CBU is certified to HACCP-9000 for quality management. This certification covers all
aspects of production, microbiological quality control, performance testing and supply.
 Axon Instruments, Inc. ACN 59 090 106 844

Contact: Dr Alan Finkel, Chief Executive Officer

ASX: AXN
Phone: +61 3 9804 6800
Email: maryannk@axonet.com.au
Internet: www.axon.com
Address: 405 Tooronga Road
Hawthorn East, VIC, 3123
Australia

Profile: Axon Instruments, Inc. is the world's pre-eminent manufacturer of hardware and software products
for cellular neurosciences and biophysical research. Axon was founded by Victorian, Dr Alan
Finkel, in 1983 in Silicon Valley, California. Much of Axon’s software engineering development is
done in Melbourne by its wholly owned subsidiary Axon Research Pty. Ltd. US parent Axon
Instruments, Inc. listed on the Australian Stock Exchange in March 2000. Axon's corporate goal is
to produce a range of superior yet affordable products for drug discovery and diagnostics, aimed
at the pharmaceutical industry, biotechnology companies and academic researchers.

Axon has long been a world leader in the design and manufacture of instrumentation and software
for analysing electrical impulses within and between cells. One important new application of its
core technology is in high throughput drug screening systems using the methods of cellular
electrophysiology to screen an important class of pharmaceutical drug targets known as ion
channels.

Another of Axon’s new high throughput screening systems for drug discovery is based on
fluorescence visualisation of the effects of drugs on cell shape, protein trafficking from the cell
membrane to the nucleus, neurite outgrowth, changes in adhesion and other cellular changes.
Axon is collaborating with CSIRO Mathematical & Information Sciences to write the complex
imaging algorithms required.

Axon is an important world supplier of instrumentation and software for genomics and proteomics.
The company has a range of instruments for scanning content from DNA and protein microarrays.
Axon’s software for genomics and proteomics ranges from image processing software to extract
information from gene and protein chips, through to bioinformatics software to store, analyse and
visualize the massive amounts of data generated in microarray studies. Uses include investigation
of the complex relationships between genetic makeup, disease susceptibilities, and differing
responses to drugs. Such devices may improve disease diagnosis and permit individually tailored
medical treatments.
 Baker Medical Research Institute / Baker Heart Research
Institute

Contact: Ms Louisa Garone, Commercialisation Manager

Phone: +61 3 8532 1111 Fax: +61 3 8532 1100
Email: louisa.garone@baker.edu.au
Internet: www.baker.edu.au
Address: Commercial Road Postal PO Box 6492
Melbourne, VIC, 3004 Address: St. Kilda Road Central
Australia Melbourne, Victoria, 8008
Australia

Profile: The Baker Medical Research Institute was founded in 1926 by Thomas Baker and has developed
into one of the world’s leading cardiovascular research centres. The Baker Institute has made a
series of internationally recognised contributions to understanding the causes of high blood
pressure and atherosclerosis. This research has helped establish the Alfred Hospital as a major
world centre for the care of heart patients.

The Institute is affiliated with both Monash University (since 1965) and the Alfred Hospital. The
Baker Institute - Alfred partnership started the first clinic in Australia for the treatment of
hypertension and established open heart surgery in Australia.

The Institute is principally funded by both the Commonwealth and State Governments, through its
own ability to contract research activities, commercialise intellectual property and through various
donor support mechanisms. The Baker has also been a World Health Organisation collaborating
centre since 1989.

The current Director is Professor Garry Jennings and he has led one of the major research groups
in the world studying the translation of basic research findings to clinical practice in cardiology. The
Institute has in excess of 240 staff members, including 34 postgraduate research students and 24
research fellows. The Institute relocated in November 2001 into a new state of the art research
facility enabling enhanced development of core research capabilities and increased opportunity for
external collaboration.
 BALTECH Pty Ltd ACN 29 071 789 850

Contact: Mr Peter Moon, CEO

Phone: +61 3 5330 3552 Fax: +61 3 5330 2542
Email: baltech@baltel.com.au
Address: Suite 16. ICV Ballarat GHEC Postal PO Box 57W
Technology Park UoB University Drive Address: Ballarat West Post Office, VIC, 3350
Mt Helen, VIC, 3353 Australia
Australia

Profile: Ballarat-based BALTECH Pty Ltd and its business partner Animated BioMedical Products of
Sydney have procured full access to a significant US technology that has been under development
by Dynoverse Corporation. Dynoverse has agreed to transfer the total business opportunity and
technology to Australia. The technology is called Virtual Interactive Anatomy (VIA), which
integrates the precise structure and functionality of any individual with advanced devices to collect
those data, and innovative technologies to visualise and analyse them. The technology is based
on, and a significant extension of, the outcomes of the US National Library of Medicine's “Visible
Human Project”. This VIA methodology will impact on/in sectors including defence, medicine, road
safety health care, rehabilitation, sports fitness, education and entertainment, to name a few.
BALTECH and Animated BioMedical Products plan to develop a range of biomedical and defence
simulation and visualisation outcomes, applications and products. The VIA technology offers the
creation of design, engineering and production simulations in which unique people react, interact
and interface with their environment. In healthcare, this affords for the first time individualised
analyses of patient diagnosis, therapy and outcomes. The VIA Technology is intended to be multi-
sensory, creating a highly realistic interactive experience. In addition, the VIA Technology allows
simulation of abnormalities and challenges to the body from its surroundings. Lacerate the skin
and the body bleeds; suture the virtual skin and close the wound; produce a spinal cord lesion that
removes nerve supply to a body segment; then evaluate what mobility would remain and how best
to rehabilitate the patient. The partners are pursuing a total body approach, combined with tissue
level resolution, physiologic, biomechanical and biophysical realism, tactile interaction with the
models, and extensive provision for customization.
 Baxter Laboratories Pty. Ltd. ACN 42 093 625 435

Contact: Mr Brent Baxter, Director

Phone: +61 3 9763 3711 Fax: +61 3 9763 3722
Email: bbaxter@baxterlaboratories.com
Internet: www.baxterlaboratories.com
Address: 22 Kingsley Close
Rowville, VIC, 3178
Australia

Profile: Baxter Laboratories Pty. Ltd. is a family-based Australian-owned contract manufacturer,

specialising in the development, manufacturing and packaging of cosmetic and therapeutic
products, with a particular emphasis on short to medium-sized production runs.

Established in 1995, Baxter Laboratories has grown quickly to become a market leader in low
volume quality products. Goods manufactured by Baxter Laboratories are sold in all corners of the
globe, including Asia, Europe, USA and the Middle East. Over 65% of the products Baxter
Laboratories manufactures are exported to these markets.

All manufacturing and packaging is conducted within cleanroom environments. The company is
registered with the Therapeutic Goods Administration and the National Registration Authority, and
its quality systems ensure full traceability. Baxter Laboratories is based at Rowville, Melbourne.

Bayer Australia Ltd (Healthcare Operations Centre) ACN 22 000 138 714

Contact: Dr Karl-Hine Timer, Operations Manager

Phone: +61 3 9263 2222 Fax: +61 3 9263 2200
Email: george.nearchou.gn@bayer-ag.de
Internet: www.bayer.com.au
Address: 500 Wellington Road Postal PO Box 158
Mulgave, VIC, 0 Address: Ferntree Gully, VIC, 3156
Australia Australia

Profile: Bayer Australia Ltd, the Australian arm of German-based multinational pharmaceutical company
Bayer AG, has several important functions based in Victoria. The Bayer Healthcare Operations
Centre in Wellington Road, Mulgrave, is the manufacturing site for several Bayer pharmaceutical
and "over-the-counter" products. It also provides warehousing and distribution functions for these
products, as well as those imported, for both domestic and international destinations in the
Australia-Pacific region.

The Diagnostics Business Group activities of Bayer in Australian and New Zealand are
headquartered in the Scoresby facility. Management, marketing, sales and distribution are
coordinated from this location.

Bayer Australia is a provider of a broad range of biotechnology and pharmaceutical products for
markets including pharmacy, crop protection, and veterinary. Human diagnostics cover a broad
range, including laboratory diagnostics and automation solutions; amplification products for viral
serology, especially hepatitis and retroviruses; "near patient testing" diagnostics solutions,
especially for blood gas, electrolytes, diabetes and urinalysis; and "self testing" diagnostics
solutions, especially for diabetes and renal disease.
 Bayer CropScience Pty Ltd ACN 87 000 226 022

Contact: Mr Olivier Duroni, CEO

Phone: +61 3 9248 6888 Fax: +61 3 9248 6800
Email: max.cowie@aventis.com
Internet: www.bayercropscience.com.au
Address: 391-393 Tooronga Road
East Hawthorn, VIC, 3123
Australia

Profile: Bayer CropScience (formerly Aventis CropScience) is a major crop protection and crop production
company which is also involved in top-ranking environmental and public health activities.
Committed to developing sustainable agriculture worldwide, Bayer CropScience focuses on
researching, developing and marketing innovative solutions that meet the needs of today's farming
- healthy crops, increased yields, improved crop and food quality - whilst constantly striving to
meet the needs of the environment.

Bayer CropScience devotes a significant proportion of its turnover to the research and
development of new chemicals, biotechnology and plant varieties.

Bayer CropScience's Australian headquarters are located in Melbourne, Victoria, and the company
has over 200 employees Australia-wide. Biotechnology research and development and seed
breeding activities are coordinated from regional offices in Horsham (Victoria), Mount Gambier
(SA), Wagga Wagga (NSW), Canberra (ACT) and Toowomba (Qld).
 Bernard O'Brien Institute of Microsurgery

Contact: Prof Wayne Morrison, Director

Phone: +61 3 9288 4018 Fax: +61 3 9416 0926
Email: morriswa@svhm.org.au
Internet: www.bobim.org
Address: 42 Fitzroy Street
Fitzroy, VIC, 3065
Australia

Profile: The Bernard O’Brien Institute of Microsurgery is a surgical research centre with general surgical
interests but with a special focus on reconstructive plastic surgery, in particular the management of
soft tissue and limb trauma. The Director of the Institute, Wayne Morrison, is also the University of
Melbourne Professor of Surgery and Head of Department of Surgery at St Vincent’s Hospital
Melbourne. The Institute has many collaborations within the hospital and university and with other
institutes, including overseas, and has full affiliation with the University of Melbourne.
The Bernard O’Brien Institute of Microsurgery has been instrumental in its team of surgeons and
scientists developing some innovative procedures over the last decade, particularly in
microsurgery, hand surgery and tissue engineering. Our mission is to undertake clinical and
experimental research in the field of reconstructive surgery, and especially microsurgery, for the
betterment of the health of those afflicted by injury, disease or abnormality. The Institute has not
only pioneered reconstructive microsurgery in this country but has been responsible for the great
majority of microsurgery research in Australia. The Institute has made striking advances in
replantation surgery and the transfer by microsurgical techniques of skin, fat, bone, tendon, joint,
nerve and muscle. It is working actively in the field of foetal microsurgery.
The staff of the Institute consists of a core of clinical microsurgeons as well as a group of
international research fellows. At any one time the Institute supports several postgraduate
students from surgical disciplines and basic science. They average five microsurgical fellows each
year. They learn to assist consultant surgeons and treat all age groups covering: trauma (motor
vehicle, farm and industrial); limb and digit replantation; cancer (skin, breast, face, neck, etc);
nerve and muscle; vascular biology and pain management. In addition to the clinical staff and
research fellows, there is a strong presence of multidisciplinary scientists including the Director of
Research, Associate Professor Erik Thompson, who brings a career of connective tissue/matrix
biology research in cancer to the Institute. The Director of the Institute, Professor Wayne Morrison,
is the Professor of Surgery of the University of Melbourne, the first occasion on which a plastic
surgeon has been appointed to the Chair of Surgery in Australia. This is recognition of the
excellence of microsurgery research and its clinical applications.
Clinically, the Bernard O’Brien Institute of Microsurgery has established itself as a world leader in
the delivery of care to patients suffering complex trauma or disfigurement. New reconstructive
techniques involving transfer of tissue, facial reanimation and the treatment of lymphoedema, have
been pioneered. Recently the Institute has done new work in the fundamental processes of wound
healing, new vessel growth, the effect of injury on tissues and the transplantation of tissues
between species. The Institute has begun pioneering work in the development of tissue banks
whereby donated tissue can be stored for future use in microsurgical transfers and will begin to
interface with cancer research issues brought to the Institute by the new Director of Research.
Also, since breast cancer is a major focus, an emphasis on mammary gland reconstruction is
being developed. A novel method for producing vascularised tissues and organs has been recently
patented and the commercial consequences of this development are now being explored.
 Biacore International Limited ACN 103 121 731

Contact: Mr Rick Filonzi, Branch Office Manager

Phone: +61 3 9897 4900 Fax: +61 3 9897 4944
Email: rfilonzi@ozemail.com.
Internet: www.biacore.com
Address: 3/ 26 Rutland Road
Box Hill, VIC, 3128
Australia

Profile: Biacore International Limited is the world leader in SPR-based technology. Biacore develops,
manufactures and markets innovative and unique products using Surface Plasmon Resonance
(SPR) to detect and monitor biomolecular binding. Biacore® systems are used in the drug
discovery industry, life science and food analysis markets. The company pioneered the
development of the SPR-based technology underlying all Biacore's products, introducing the first
Biacore® system in 1990. Continuous improvements have established Biacore® systems as the
most advanced, easy to use, systems of their kind, with the highest performance standards. Highly
successful promotion and sales, through its own marketing companies in the United States,
Europe, Japan, New Zealand and distributors in Asia-Pacific, have established Biacore as the
clear market leader in this field. In the last few years Biacore has further demonstrated its
commitment to the Australian market, by establishing a Biacore International Limited Branch Office
in Melbourne to handle all aspects of sales, marketing and service for the Biacore Range of
instruments.

The company’s headquarters is in Uppsala, Sweden. Biacore is concentrating on the life science
research, pharmaceutical and biotechnology markets in order to capitalize on SPR technology’s
ability to improve the economics of drug discovery and developments. The company has also
been extending its franchise with leading life science laboratories around the globe by highlighting
the ability of its systems to solve research problems in the increasingly important fields of
proteomics, cancer and neuroscience. The company has also signed several collaboration
agreements with companies in the drug discovery and development industry, such as Millennium
Pharmaceuticals Inc. The aim is to develop new instrumentation targeted specifically towards
solving problems for this customer group.

BigPharma Limited ACN 102 456 048

Contact: Mr Patrick Volpe, Chairman and Executive Director

Phone: +61 3 9854 6138 Fax: +61 3 9817 7137
Email: cardia@bigpond.com.au
Address: Level 1
89 High Street
Kew, VIC, 3101
Australia

Profile: Cardia Technologies Limited has wrapped its medical biotechnology projects into a new wholly-
owned subsidiary company, BigPharma Limited, focused on diabetes and obesity. BigPharma will
take on Cardia's diabetes projects. One is a type 1 diabetes project focused on food toxins, and
the other is a type 2 diabetes collaboration, testing a compound called ISF402, with the
International Diabetes Institute and Monash University.

Cardia, which will subscribe to shares in Big Pharma, expects the result to be an autonomous,
fully-focused medical biotechnology company with the power to attract specialist board members,
raise capital outside Cardia, and explore new R&D options. Cardia [see separate entry] plans to
list the new company on the Australian Stock Exchange (ASX) in 2003.
 Bio 21 Australia Limited ACN 096 058 025

Contact: Dr Stella Clark, Chief Executive Officer

Phone: +61 3 8344 1937 Fax: +61 3 9347 9823
Email: stella.clark@unimelb.edu.au
Internet: www.bio21.com.au
Address: 157 Barry Street
Carlton, VIC, 3053
Australia

Profile: Bio21 Australia Ltd is a company, limited by guarantee, founded by Melbourne Health, The
University of Melbourne and The Walter and Eliza Hall Institute of Medical Research (Founding
Members). It is the governing body of a collaborative cluster of vigorous research institutions. Its
purpose is to develop and enhance the reputation of Victoria as a leading academic centre for the
advancement of knowledge in fundamental areas of biology, medicine, science and technology. A
number of other leading research organisations have joined Bio21 as Members. Bio21 Australia
Ltd is committed to the advancement of, basic biomedical science, translational clinical research
and biotechnology; training in research of the highest order; science communication and education
and; commercialisation of biotechnology discoveries.

Bio Electronics Pty. Limited

Contact: Mr William J (Jim) Lamers, Managing Director

Phone: +61 3 9370 6729 Fax: +61 3 9370 0619
Email: j.lamers@bioelectronics.com.au
Internet: www.bioelectronics.com.au or www.EziStim.com
Address: 964a Mt Alexander Road Postal PO Box 87
Essendon, VIC, 3040 Address: Essendon, VIC, 3040
Australia Australia

Profile: Bio Electronics Pty. Limited manufactures and supplies a range of electrical nerve and muscle
stimulators. The BIOSTIM® ,EziStim™ and PainEze plus™ ranges are designed for personal use
electrotherapy, and incorporate unique pulse generation circuitry to provide equal stimulation at
every electrode.

These products are used to control chronic pain, provide relief from stress, stimulate healing after
physical injury, and promote the rehabilitation of weakened muscles. BIOSTIM® is listed with
Australia's Therapeutic Goods Administration (Therapeutic Devices Branch).

The products have been used by Australian athletes at every Olympic Games since 1976
(excluding Moscow) and at dozens of other international sporting events. Other users include
physiotherapists, masseurs, doctors, pain specialists and individuals.
 Bio Nova International Pty Ltd ACN 29 068 699 338

Contact: Mr Hugh McCormack, Chief Executive Officer

Phone: +61 3 9326 6955 Fax: +61 3 9329 8071
Email: bni@bionova.com.au
Internet: www.bionova.com.au
Address: 36 Munster Terrace Postal PO Box 359
North Melbourne, VIC, 3051 Address: North Melbourne, VIC, 3051
Australia Australia

Profile: Bio Nova International Pty Ltd produces implantable tissue structures for the treatment of defective
tissues and organs. A world leader and pioneer in tissue engineering, Bio Nova has developed
methods to grow tissue structures in animals and safely transplant the engineered structures into
humans. The technology is already used to produce replacement blood vessels that are exported
to many European, Middle Eastern and Asian countries.

Current research is targeted at developing a patient-specific coronary artery bypass graft. Other
applications, which are at various stages from concept through to initial prototypes, include heart
valves, stents, ligaments, hernia repair patches, nerve regeneration tubes, dural patches,
bioartificial skin, wound dressings, endovascular grafts, bone grafting materials, surgical sealant,
and other constructs to enable grafting of pancreatic islet cells for the treatment of diabetes.

Bio Nova’s patented technology for engineering tissues combines synthetic materials with animal
and human tissue and cells, and is expected to provide the basis for generating spare parts for
many future surgical and therapeutic treatments. Bio Nova has Good Manufacturing Practice
(GMP) manufacturing facilities and laboratories and ISO 9001 accreditation.

Bio-Rad Laboratories Pty Ltd

Contact: Mr Glen Costin, Manager

Phone: +1800 224 354 Fax: + 61 3 9899 1121
Email: glen_costin@bio-rad.com
Internet: www.bio-rad.com
Address: 10 Arcade Road Postal PO BOX 210
Box Hill North, VIC, 3129 Address: Regents Park NSW 2143
Australia Australia

Profile: Bio-Rad Laboratories has remained at the center of scientific discovery for more than 50 years by
providing a broad range of innovative tools and services to the clinical diagnostics and life science
research markets. The company is world renowned among hospitals, universities, major research
institutions, biotechnology and pharmaceutical firms for its commitment to quality and customer
service. It has built strong customer relationships that advance research and development efforts
and support the commercialization of new technology, especially in the high-growth fields of
genomics, proteomics, biopharmaceutical discovery, food safety and biotechnology education.
Throughout the past four decades, the company's product portfolio has increased substantially, as
has its expanding customer base and global reach. Bio-Rad now manufactures and distributes
thousands of products that incorporate a wide range of technologies including electrophoresis,
imaging, immunoassay, chromatography, microbiology, bioinformatics, and transfection. By
capitalizing on its expertise and quality reputation, Bio-Rad Laboratories will continue to
strengthen its leading roles in both existing and niche markets, and maintain its position at the
center of scientific discovery. BusinessWeek USA recently ranked Bio-Rad as one of the top 100
Growth Companies in the USA.
 Biocomm Services Pty Ltd ACN 17 094 476 212

Contact: Mr Lawrence Bremner, COO

Phone: +61 3 9660 2400 Fax: +61 3 9660 2444
Email: info@biocomm.com.au
Internet: www.biocomm.com.au
Address: 1 Collins Street
Melbourne, VIC, 3000
Australia

Profile: Biocomm is a biotechnology business development company based in Melbourne, Australia,

providing commercialization services. Biocomm has direct relationships with Australian research
institutions, and assists in developing international connectivity and commercialization of research
for its members and clients. Biocomm has assembled a team of international and Australian
science and business professionals to develop or bring biotechnology opportunities to commercial
reality. Biocomm provides its services for business company development and licensing outcomes.
New company formation is assisted by sector specific seed capital from Biocomm’s capital pool.
Biodiem Ltd ACN 20 096 845 993

Contact: Mr Tom Williams, Managing Director

Phone: +61 3 9613 4100 Fax: +61 3 9613 4111
Email: info@biodiem.com
Internet: www.biodiem.com
Address: Level 10 Atrium Building
459 Collins Street
Melbourne, VIC, 3000
Australia

Profile: Biodiem Ltd is an Australian unlisted company based in Melbourne, with an international focus on
finding, adding value and commercializing world-class research for vaccines, infectious diseases
and other therapeutic areas. The company’s strategy is to accelerate development of new
technologies through collaborations and sponsored research programs with university medical
departments, research companies, and institutions like the Institute of Experimental Medicine
(IEM) in St. Petersburg, Russia. BioDiem has three projects currently underway:

(i) Live Attenuated Influenza Vaccine (LAIV)

(ii) Animal Growth Promoter (BDM-I)
(iii) Post Myocardial Infarction Treatment (BDM-K).

Biodiem is also in late stage negotiations for a new product aimed at treating retinal eye diseases,
in particular diabetic retinopathy and macular degeneration, which are leading causes of blindness
in people over 50.

In addition, BioDiem has an early stage program, based on a potential platform technology for
developing other vaccines, for which the first target is a malaria vaccine.
Live Attenuated Influenza Vaccine.

BioDiem has a licence from the IEM to commercialise the LAIV technology outside of Russia and
the Commonwealth of Independent States (CIS). The LAIV has been approved for public use in
Russia and the CIS and has been used to vaccinate tens of millions of people over the past
decade. Biodiem considers that the live attenuated influenza vaccine has several characteristics,
which make it appealing:

1. It is delivered by a single dose, intranasal spray rather than hypodermic syringe as the current
“killed” vaccine is.
2. As approved and used in Russia, and according to published clinical trials, it has been shown to
be safe and effective in children, adults and the elderly.
3. No evidence of a tendency to induce asthma has been seen in clinical trials in Russia of healthy
children as young as one year old.

4. It has been shown in clinical trials to be 93% effective against influenza in children after a single
dose delivered by nasal spray. It is also significantly effective in reducing the incidence of all acute
respiratory diseases.
5. Clinical trials in 33 schools in Russia demonstrated what is known as “herd immunity” wherein
the use of the live flu vaccine in more than 40% of a school population led to markedly reduced
levels of flu in the unvaccinated control group of children, thereby reducing the spread of flu
through the group.

Retinal eye diseases (BDM-E).

Biodiem is currently in late stage commercial negotiations for another promising project with
evidence of success. This particular project involves a novel synthetic compound relating to the
treatment of age-related retinal eye diseases. The lead indications in this case are age-related
macular degeneration and diabetic retinopathy, some of the leading causes of loss of vision in
people over 55, and for both of which there is currently a significant unmet medical need. The
market for such a compound is estimated to be in excess of US$2 billion per year. In early stage
human studies in Russia in 63 patients with macular degeneration, 88% of patients showed an
improved ophthalmoscopic picture of the eye fundus, and 85% of patients had some improvement
in visual acuity.

Animal Growth Promoter (BDM-I).

Laboratory in vitro preliminary testing has revealed an important feature of the antimicrobial
characteristics of BDM-I. In systems where major existing antibiotics show the development of
resistance by bacteria, no resistance has so far developed with BDM-I.

Potential animal growth promoter. The apparent lack of developed resistance (in tests to date) and
the low oral absorption properties of BDM-I from the gut have suggested a potentially valuable
area of use for BDM-I as a medicated feed additive, particularly for use in the poultry and swine
intensive growing industries, to replace the existing use of antibiotics that have lead to concerns
about the spread of antibiotic resistance.

In early stage trials at a Melbourne university, BDM-I produced significant weight gain in chicks,
relative to control groups. Further studies are continuing to define the potential for BDM-I as an
effective growth promoter in poultry, to replace the increasingly proscribed use of antibiotic growth
promoters.

Post Myocardial Infarction Treatment (BDM-K).

BDM-K is a tissue resolution agent that has also been acquired from the St Petersburg Institute of
Experimental Medicine (IEM). It will be aimed at assisting the recovery of cardiac function after a
heart attack.

In early human studies, conducted in four Russian cardiac clinics, BDM-K has shown the potential
to be useful in assisting the restoration of the contractile function of cardiac muscle, with 3 weeks
oral treatment beginning a week after a heart attack. For patients treated with BDM-K, decreases
were reported in shortness of breath, tachycardia, and oedema in the lower extremities associated
with the cardiac insufficiency. BDM-K also had a positive effect on the contractile function of
myocardium, as shown by a significant increase in the ejection fraction. BDM-K has the potential
to assist the quality and speed of restoring some types of damaged tissue to an improved state,
structure and function, with less scarring.
 Bioglobal Pty Ltd ACN 94 091 488 505

Contact: Mr Pat Volpe, Chairman

Phone: +61 3 9854 6138 Fax: +61 3 9854 6399
Email: ken.i@bioglobal.com.au
Internet: bioglobal.com.au
Address: 437 Joseph Street Postal Level 1, 89 High Street, Kew. Victoria
Ballarat, VIC, 3350 Address: 3101.
Australia P.O.Box 361, Corinda. 4075
Kew, Victoria, 3101
Australia

Profile: Bioglobal has been established to develop and market green, naturally based chemical products
for the annual $100 billion agricultural, animal health and environmental insecticide market.
Over the past two decades research has confirmed that many “hard” agricultural and pest
management chemicals, from DDT and CCA to organophosphates, cause major environmental
and health damage. This research has substantiated strong consumer concerns about serious
chemical contamination of the environment and the food we eat.
Also fuelling this drive for clean and green products is the fact that agricultural producers face
substantial production problems because crop and livestock pests develop chemical resistance i.e.
they become immune to the “hard” broad-spectrum chemicals used.

The Business Model.

The objective of Bioglobal is to create environmentally safe agricultural, animal health and
environmental insecticides from the commercialisation of intellectual property either generated by
its research and development programmes, or by acquisition.
The company then seeks to penetrate these global market segments through strategic
partnerships with major agro-chemical companies who already have the appropriate marketing
and distribution infrastructure in place.

Product Development Strategy.

Bioglobal’s product development involves projects with short, medium and long-term timelines to
balance the need for revenue generation with research and development of major category
products that require longer timeframes. The product selection criteria are as follows:

1. Products are biorational – which means they use green chemicals and/or natural ingredients
that are GRAS (generally recognised as safe) or tier 1 toxicology only.
2. Unique intellectual property can be developed, owned and/or acquired by Bioglobal to provide a
competitive advantage (patent, trademark, PVR and copywrite protection strategy).
3. The products must have global market potential to attract large agro-chemical companies to
partner Bioglobal in commercialisation, marketing and distribution arrangements with significant
commercial returns.
In most instances, Biorational products may not be required to undergo long-term toxicology trials.
This reduces the product lead-time to market, with obvious benefits for capital deployed and
revenue generated.Bioglobal’s Product Portfolio.

The portfolio contains a mix of products, some of which are market-ready, and others still under
development. The major products fall into three market segments of the insecticide industry: crop
protection, animal health and environmental.

1. Crop protection
a. attract and kill technology for moths in cotton, legumes and vegetables
b. attract and kill technology for corn-root worm (major pest in corn and soy beans in the mid-west
of the U.S.A.
2. Animal Health
a. Lucilure trap and lure for blowflies for both sheep and landfill markets
b. extension of the Lucilure technology to screw-worm fly (old and new world).
3. Environmental
a. natural killing agents for termites
b. wood preservative treatment to replace CCA
c. fire-ant bomb: green fumigant and colony control agent
d. rodent repellant (for domestic and commercial plastic cabling).
 Biogreen Ltd ACN 37 066 056 620

Contact: Mr Brent Davey, General Manager

Phone: +61 3 9866 2305 Fax: +61 3 9866 2306
Email: Brent.Davey@biogreen.info
Internet: www.biogreen.info
Address: Level 6
499 St Kilda Road
Melbourne, VIC, 3004
Australia

Profile: Biogreen Ltd is a public, unlisted company with over 1000 shareholders and three operating
subsidiaries - Peat Operations Pty Limited, BioRemediation Pty Ltd and Grotech Australia Pty Ltd.
The group’s focus is to deliver intelligent solutions for the environment in the areas of soil
restoration, fertiliser and insecticide delivery, and environmental containment and protection.

This is achieved by active research and development into the properties and applications of reed-
sedge peat harvested by Peat Operations from the group’s resource at Swan Marsh, near Colac in
south-western Victoria. Biogreen peat is a stable, 100% organic pest-free material that binds
water, nutrients and pollutants, and sustains a vigorous flora of beneficial micro-organisms. The
group’s marketing arm (Biogreen Products) sells substrates that have widespread application in
agriculture, horticulture, broad-acre farming, viticulture, mushroom growing and commercial and
domestic gardening, as soil improvers, potting and growing media, and natural plant growth
stimulants, for improving crop yield and plant vigour, and for minimising water and fertiliser
consumption.

BioRemediation develops and markets biofilters and other products for wastewater treatment,
stormwater management, contamination remediation and environmental protection, while Grotech
is developing and marketing worldwide a radical new technology for the controlled delivery and
targeted release of pesticides and fertilisers.

Biological Therapies ACN 99 006 897 856

Contact: Dr Ian Dettman, CEO

Phone: +61 3 9587 3948 Fax: +61 3 9587 1720
Email: biol@biol.com.au
Internet: www.biologicaltherapies.com
Address: Unit 5
20-30 Malcolm Road
Braeside, VIC, 3195
Australia
Profile: Biological Therapies is an Australian owned company licensed with the Australian Therapeutic
Goods Administration to manufacture a comprehensive range of sterile injectable and non sterile
oral nutritional supplements.

Biological Therapies occupies a total of 1,000 square metres of factory space which includes
separate sterile and non sterile manufacturing facilities, chemical, microbiological and research
and development laboratories, dispatch area, warehousing and administration offices. The
company currently employs around 20 staff.

The early history of Biological Therapies dates back to 1972, when its founder commenced
manufacture of injectable vitamins in his pathology premises. This was followed by a range of
injectable vitamin products, along with several patents concerning their production.

In 1988, the manufacturing facilities were substantially expanded for sterile manufacture of a
range of injectable nutritional supplements and also manufacture of oral powders, tablets and
liquids.

Biological Therapies produces a range of sterile and non sterile products including:·vitamin C
products for injection; vitamin B products for injection; disodium edetate products for injection; oral
nutritional products including tablets, powders and liquids; a range of test strips; and a range of
herbal products. Biological Therapies also specialises in contract manufacturing.

Biomedtech Australia Pty. Ltd. ACN 65 081 459 770

Contact: Ms Juliette Moran, Marketing Assistant
Phone: +61 3 9553 7200 Fax: +61 3 9553 7299
Email: info@go2altitude.com
Internet: www.go2altitude.com
Address: 17 Roberna Street
Moorabbin, VIC, 3189
Australia

Profile: Biomedtech Australia Pty. Ltd. specialises in development, manufacturing and distribution of
equipment for hypoxic stimulation (high altitude conditioning). Biomedtech’s trademarks are
GO2Altitude® and AltiPower®.
BioMelbourne Network

Contact: Mr Tim Murphy, Executive Director

Phone: +61 3 9650 8800 Fax: +61 3 9650 6066
Email: tmurphy@biomelbourne.org
Internet: www.biomelbourne.org
Address: Level 2
25 Flinders Lane
Melbourne, VIC, 3000
Australia

Profile: BioMelbourne Network is an industry development and promotion organisation representing the
leaders of research institutions, biotech companies and service providers in Melbourne – the
leading biotechnology centre in the Asia Pacific.

The Network is the first point of contact for local and international companies looking to do
business in Melbourne and Victoria.

BioMelbourne Network offers access to research and business specialists in Victoria’s health care,
agricultural, industrial and environmental biotechnology sectors.

The Network’s activities include:

•national and international marketing of Victoria’s biotechnology capabilities,

•high level State and Federal lobbying, and
•industry development and education support programs.

More than 250 organisations and over 750 individuals participate in the Network’s initiatives to
position Melbourne as the key biotechnology centre for the Asia Pacific region.

The Network benefits its members by

•Exclusively focusing on growing the Victorian biotechnology industry

•Representing leaders in the science and business community
•Linking business, science and government
•Providing access across all sectors of the Victorian industry
•Providing access to international business links
 Bionic Ear Institute

Contact: Mr John Huigen, General Manager and Associate Director

Phone: +61 3 9667 7500 Fax: +61 3 9667 7505
Email: j.huigen@unimelb.edu.au
Internet: www.bionicearinstitute.com.au
Address: 384-388 Albert St
East Melbourne, VIC, 3002
Australia

Profile: Neurophysiological investigation of the hearing system; safety studies of auditory prostheses,
including biocompatibility studies; electroneural interface design, development and testing; in vitro
and in vivo testing of the affect of trophic factors on the auditory system; psychophysical
evaluation of acoustic and electric stimulation; mathematical modelling of neural activity; signal
processing; development of speech processing algorithms; design, development and construction
of digital signal processor (DSP)-based portable speech processors (electric and acoustic); clinical
evaluation of aids to hearing.
Bioproperties (Australia) Pty. Ltd. ACN 49 007 303 728

Contact: Mr David Tinworth, Managing Director

Phone: +61 3 9879 0039 Fax: +61 3 9879 0713
Email: david.tinworth@bioproperties.com.au
Internet: www.bioproperties.com.au
Address: 36 Charter St Postal Level 28
Ringwood North, VIC, 3134 Address: 200 Queen St
Australia Melbourne, VIC, 3000
Australia

Profile: Bioproperties (Australia) Pty. Ltd. focuses on R&D, scale up and large scale GMP manufacture of
live viral, bacterial and protozoal veterinary vaccines for intensively farmed food animals. It is also
involved in a JV company Nippon Medical Research developing a novel human antibiotic for
resistant Staphylococci and Mycobacterium. During the past ten years Bioproperties has
developed and introduced four Victorian-developed veterinary live vaccines for the poultry industry,
both in Australia and globally, to combat various infectious diseases caused by two Mycoplasma
strains (MG and MS), Salmonella, and the protozoan Eimeria (coccidiosis). The company also
manufactures and markets high-potency vaccines that have controlled Marek’s Disease in
Australia. Two other chicken vaccines (Pasturella and IBDV) are in late-stage development, with
further vaccines for the cattle (Salmonella and toxigenic E.coli) and pig industries (M.
hyopneumoniae) in the pipeline. Most of this work has been done in conjunction with the
University of Melbourne and RMIT University, with contributions also by Monash University and
Sydney University. Bioproperties, together with joint venture partner Nippon Medical Research,
has also identified a new class of narrow-spectrum peptide antibiotic to kill Staphylococcus and
Mycobacteria, currently completed its preclinical stage and entering Phase 1 clinicals in the USA.
Bioproperties has established a multi-million dollar GMP Category 1 biological manufacturing
facility in Glenorie, NSW. The facility has large-scale capabilities in egg and cell culture based viral
production, bacterial fermentation, large-scale sterile filling and freeze drying downstream
capacities. A new laboratory for large-scale production of Eimeria vaccines is also being
established on the site.
 BioRevive Pty Ltd ACN 58 097 360 417

Contact: Mr William Crothers, Chief Executive Officer

Phone: +61 3 8416 0399 Fax: +61 3 8416 0355
Email: biorevive@pacificmedical.com.au
Internet: www.biorevive.biz
Address: Level 1
263 Mary Street
Richmond, VIC, 3121
Australia

Profile: BioRevive Pty Ltd (bioRevive) was established in 2001 in Victoria to manufacture and distribute
natural targeted therapeutic products for people with metabolic imbalances to enable longer and
healthier lives. The product range is 100 % natural and includes individually customised amino
acids, Alcodol – a hangover preventation and treatment capsule, Orul – an aphthous ulcer
treatment capsule, Probiotics - Anaerobic and Facultative microorganisms and other products
targeted at specific cellular and GIT imbalances. The head office is in Melbourne, with distribution
channels currently being established globally. Research and clinical trials are being conducted at
several hospitals in Australia and overseas.
Bioscreen Pty Ltd ACN 69 066 120 796

Contact: Mr William Crothers, Chief Executive Officer

Phone: +61 3 9899 4900 Fax: +61 3 9899 4988
Email: Bioscreen@bioscreen.com.au
Internet: www.bioscreen.com.au
Address: Level 1 Postal Level 1
263 Mary Street Address: 901 White Horse Road
Richmond, VIC, 3121 Box Hill, VIC, 3128
Australia Australia

Profile: Bioscreen Pty Ltd is a Melbourne-based biotechnology company dedicated to the analysis,
diagnosis and prescription of therapeutics for people with metabolic imbalances and cellular
malnutrition. Its main focus is diagnosing imbalances due to both metabolic and pathogen
associated mechanisms. Cellular malnutrition as a result of both cytokine and pathogen
associated changes can cause chronic illness.

Bioscreen was established by the Collaborative Pain Research Unit (CPRU) and the tests arose
as a result of their research into the pathogen and immune responses resulting in the development
of chronic fatigue and chronic pain disorders. The tests highlight changes in both metabolic and
pathogen-associated mechanisms, and offer the health professional a focus for designating
management and treatment programmes.

Bioscreen's approach challenges some traditional approaches as they are purely evidence based
and not driven by the existing clinical paradigms. Bioscreen believes that many chronic illnesses
and developmental disorders are treatable diseases, based on distinct biochemical anomalies.
Bioscreen has examined many thousands of patients with a wide range of symptoms; however,
they have had a particular research interest in chronic pain and fatigue associated disorders,
autism, attention deficit disorder, irritable bowel syndrome and gastrointestinal disorders.

The role of the tests is to determine whether there is an organic basis to a patient's illness, and to
compare the patient's metabolic patterns with those observed in Bioscreen's studies of over
13,000 patients with various chronic diseases imbalances.
 Biota Holdings Limited ACN 28 006 479 081

Contact: Mr Peter Molloy, CEO & Managing Director

ASX: BTA
Phone: +61 3 9529 2311 Fax: +61 3 9529 2261
Email: info@biota.com.au
Internet: www.biota-inc.com
Address: Level 4
616 St. Kilda Road
Melbourne, VIC, 3004
Australia

Profile: Biota Holdings Limited is an Australian, publicly listed, biotech company engaged in R&D of new
pharmaceuticals, with a focus on respiratory infectious diseases. Biota has developed two
products marketed worldwide: Relenza, an antiviral treatment for influenza; and FLU OIA, a rapid
point-of-care influenza A/B diagnostic kit. Biota’s US subsidiary Biota Inc, based in Carlsbad,
California, is focused on improving existing nucleotide drugs to treat important viral, bacterial and
fungal diseases, and cancer.

Biota has two fully operational R&D facilities in Australia and the USA, with strong virology,
medicinal chemistry and structural biology competencies in Australia, and strong nucleoside
chemistry skills in the US.

The Biota Group has three drug discovery platforms. In Australian R&D, Biota utilises its MUCO
(multivalent coupling) technology and structure based drug design. MUCO is aimed at developing
higher potency therapies against diseases such as influenza, bacterial infections and
inflammation. In the US, Biota Inc uses novel N-MAX technology developed by Biota Inc’s Chief
Scientific Officer, Dr P Dan Cook. N-MAX is aimed at improving existing nucleoside drugs with a
superior side effect profile.

Biota has key management in place with outstanding industry experience and commercial
partnering skills. Peter Molloy (CEO) and Sterling Johnson (VP, Business Development) are based
in the US to optimise and capture greater value from business development activities.

Biotech Ventures Pty Ltd ACN 61 094 171 007

Contact: Mr Michael Furzer, Director

Phone: +61 3 9866 7511 Fax: +61 3 9867 1219
Address: Suite 2, Level 4
450 St Kilda Road
Melbourne, VIC, 3004
Australia

Profile: Biotech Ventures Pty Ltd funds research and development into the use of micro-organisms for the
control of pathogens. Biotech Ventures was established in Melbourne in 2000.
 Biotechnic Pty Ltd ACN 26 853 050 837

Contact: Mr Nick Sestito, Managing Director

Phone: +61 3 5277 0910 Fax: +61 3 5277 1061
Email: biotechnic@datafast.net.au
Internet: www.biotechnic.com.au (under construction)
Address: Unit 3 Postal PO Box 1215
2a Backwell Street Address: Geelong, VIC, 3220
North Geelong, VIC, 3215 Australia
Australia

Profile: Biotechnic is a designer and manufacturer of sanitary equipment for the biopharmaceutical
industry.

Biotechnic manufactures equipment that meets the most stringent requirements of the US Food
and Drug Administration (FDA) and the ASME BPE (biopharmaceutical engineering) standard.
Currently, Biotechnic supplies the biopharmaceutical market with USP Class VI compliant hoses
and sanitary fittings. They have designed and manufactured fittings for several US companies,
and at present export revenue represents 80% of total sales.

Included among other items that Biotechnic manufactures are Bioports, which are sanitary access
hatch assemblies. These are machined from Gr 316L stainless steel forgings and can be supplied
in materials such as 904L and Hastelloy. These hatches comply with AS 1210 ( Australian
pressure vessel code) as well as ASME VIII Div. 1. The company believes these to be the most
sanitary in the world as there are no crevices in the seal due to the unique design. Currently,
Biotechnic exports them to New Zealand, Singapore and the USA.

Other items which the company will be manufacturing in the near future are polysulfone flow
indicators, stainless steel filter housings and sanitary check valves.

Biotechnic is continually researching and manufacturing new items that meet the requirements of
the rapidly expanding biotech industry, and have the latest computer numeric control (CNC)
equipment to ensure quality in manufacture. New products can be viewed in the future on the
company's web site, currently under construction.

BMG Labtechnologies Pty Ltd ACN 91 081 087 201

Contact: Mr James Balmer, Managing Director

Phone: +61 3 5973 4744 Fax: +61 3 5973 4711
Email: australia@bmglabtech.com
Internet: www.bmglabtech.com
Address: 2/24 Carbine Way Postal PO Box 469
Mornington, VIC, 3931 Address: Mount Eliza, VIC, 3930
Australia Australia

Profile: BMG Labtechnologies GmbH is a manufacturing company based in Germany specialising in all
aspects of analysis of samples in microplate formats. BMG Labtechnologies Pty Ltd is the regional
office covering Australia, New Zealand and the Pacific region for the sales and support of the
equipment.

Instruments are available to read fluorescence, polarised fluorescence, luminescence, UV-VIS

absorbance and nephelometric analysis. BMG Labtechnologies is a specialist in this field and
strives towards excellence in supporting its customers.

Customer types include those involved in drug discovery, biotechnology, medical research, clinical
diagnostics, food, forensics, environmental technologies, and toxicology.
 Bonlac Foods Limited ACN 52 006 483 665

Contact: Mr Peter Myers, Managing Director & CEO

ASX: BFL
Phone: +61 3 9270 0922 Fax: +61 3 9270 0911
Email: Peter.myers@bonlac.com.au
Internet: www.bonlacfoods.com
Address: Level 7 Postal PO Box 4313
636 St Kilda Road Address: Melbourne, VIC, 3001
Melbourne, VIC, 3004 Australia
Australia

Profile: Bonlac Foods Limited is an Australian-based manufacturer of quality dairy products and speciality
dairy ingredients. It produces butter, cheese and milk powder at factories in Victoria, Tasmania and
New South Wales. Bonlac's leading consumer brands, including Western Star, Allowrie and Girgar
spreads, Bodalla and Perfect Italiano cheeses and Diploma milk powder, are marketed through its
50%-owned joint venture company Bonland Dairies Pty Ltd. Its dairy ingredients products are
exported to more than 50 countries.

Through its Bioscience Division, Bonlac Foods is leading the way in developing specialist health
care products from cows’ milk. The first of these new generation products to be launched on the
market is Recaldent™, a revolutionary additive that can help to prevent early stages of tooth
decay. This new and exciting remineralisation technology is a complex of casein phosphopeptides
and amorphous calcium phosphate (CPP - ACP) which was identified and patented by the
University of Melbourne and developed through collaboration between the University and Bonlac
Foods. The phosphopeptides are derived from the casein protein naturally found in milk. When
used as an ingredient in oral care products, Recaldent promotes the remineralisation, or repair, of
tooth enamel. Sugarless chewing gum containing Recaldent™ is now on sale in the United States,
Europe and Japan. New markets and other products containing Recaldent are planned for the
future. The Bioscience Division has ongoing research into the identification of components of milk
with biological activity, with a view to isolation, purification and commercialisation.

Bonlac Foods was formed in 1986 through the amalgamation of several dairy enterprises with co-
operative histories dating back to the 1880s. Bonlac Foods is 75% owned by its dairy farmer
suppliers and 25% by New Zealand’s Fonterra Cooperative Group, and has its headquarters in
Melbourne. Bonlac’s Perpetual Notes were listed on the ASX (BFL) in 1998.
 Boron Molecular Pty Ltd ACN 76 092 480 674

Contact: Dr Phil Reece, Managing Director, CEO

Phone: +61 3 8558 8000 Fax: +61 3 8558 8004
Email: info@boronmolecular.com
Internet: www.boronmolecular.com
Address: 500 Princes Highway Postal PO Box 756
Noble Park, VIC, 3174 Address: Noble Park, VIC, 3174
Australia Australia

Profile: Boron Molecular Pty Ltd (BM) is a research, development and manufacturing company, servicing
the world’s pharmaceutical and other industries through the supply of specialist chemical products
and services. BM’s core expertise is based on its staff’s knowledge of medicinal chemistry and the
making of organoborons and related compounds as reflected in patents and patent applications
licensed to BM. The technology is designed to achieve substantial cost reductions and technical
improvements in the drug development process as well as the ability to explore novel compounds.

BM is currently the only Australian owned and operated fine chemical manufacturer in this area
and develops and produces a range of innovative organoboron and related products on both small
and large scales for use across a broad range of markets including thepharmaceutical,
agricultural, veterinary, food, cosmetic and the electronics industries.

The advantage of the technology over the prior art is that it allows the production of complex and
novel organoboron compounds that were either too difficult or too expensive to make when
synthesized by other methodologies. Through R&D, BM will expand the compounds presently
available and develop higher value-added products and technical services to the industry.
Boulevarde Nurseries Mildura Pty Ltd ACN 60 082 909 653

Contact: Mr Paul Croxton, Joint Managing Director

Phone: +61 3 5024 6312 Fax: +61 3 5024 6692
Email: info@boulevarde.com.au
Internet: www.boulevarde.com.au
Address: Lot 18 Postal PO Box 816
Newton Avenue Address: Irymple, VIC, 3498
Irymple, VIC, 3498 Australia
Australia

Profile: In north-western Victoria, Boulevarde Nurseries Mildura Pty Ltd uses a synergistic combination of
technologies to short-circuit the process of generating new plant varieties by up to two years, and
to produce healthier plants. The main focus at present is new varieties of table and wine grapes,
and the sophisticated technologies used include licensed internationally patented micrografting
technology; micropropagation in tissue culture; and "embryo rescue", to allow the use of seedless
varieties in the breeding program. Recently, Boulevarde Nurseries Mildura has developed a local
and global export market in hybrid Zantedeschia (Calla Lily), for both cut flowers and rhizomes.
Boulevarde Nurseries Mildura is a large wholesale plant nursery, and is one of the leading
enterprises in the Sunraysia district. Facilities include a sophisticated tissue culture laboratory,
hydroponics systems for gowing grapevines, and AQIS approved premises for performance of
quarantine for medium risk crops. Through the implementation of quality systems and utilisation of
leading edge technology, the nursery has attained growth in the excess of 500% over the past four
years. It is Boulevarde Nurseries' aim to achieve solid growth, further establishing itself as a
limited category specialist in the areas of viticulture and commercial crops such as grafted citrus
and avocadoes, olives, passion fruit, kiwi fruit, and ornamental lines including Zantedeschia,
Daphne, Ornithogalum, chrysanthemums, and others.
 Bovogen Biologicals Pty. Ltd. ACN 16 096 634 927

Contact: Mr Rick Clements, Managing Director

Phone: +61 3 9336 3622 Fax: +61 3 9336 3644
Email: info@bovogen.com
Internet: www.bovogen.com
Address: 71 Ogilvie Street
Essendon, VIC, 3040
Australia

Profile: Bovogen Biologicals is an Australian bio-processing company manufacturing highly purified animal
derived biologicals, including bulk quantities of bovine serum albumin. Bovogen Biologicals can
also supply various animal sera and organs in addition to large quantities of bovine plasma as a
raw material for the pharmaceutical and biotechnology industries. Bovogen Biologicals’
manufacturing premises are located in Keilor East, Melbourne, at 12 Williams Avenue.
Brain Research Institute

Contact: Ms Jewell Gardner, Research Administrative Officer

Phone: +61 3 9496 4076 Fax: +61 3 9496 2980
Email: bri@brain.org.au
Internet: www.brain.org.au
Address: Neurosciences Building Austin &
Repatriation Medical Centre
Banksia Street
Heidelberg West, VIC, 3081
Australia

Profile: The Brain Research Institute (BRI) was established at the Austin and Repatriation Medical Centre,
Melbourne, Australia in 1996. The Institute was created as a platform of high-standard brain
research. The targeted research topics were the brain function in health and disease. The BRI first
dedicated major energy into fundraising efforts towards the acquisition and commissioning of a
world-class Magnetic Resonance Imaging (MRI) System.

The installation of a cutting-edge 3 Tesla GE MRI system took place in early 2000. Software
development, hardware designing and validation studies were priorities during the first year after
the installment of the new scanner. Simultaneously, brain research started and has created some
stunning results, which are about to be published.

The BRI has brought together a growing group of researchers with the enthusiasm, vision and
talent to tackle and overcome difficult clinical questions in brain disorders. Amongst them are
neurologists, neurophysiologists, physicists, radiographers, radiologists, neuropsychologists,
psychiatrists and scientists from Australia and overseas. The BRI employs over 40 researchers full
time and part time on staff and 25 visiting honorary staff. BRI is an affiliated institution of the
University of Melbourne and an administering institution of the National Health and Medical
Research Council.
 Brain Sciences Institute

Contact: Assoc Prof David Crewther, Director

Phone: +61 3 9214 8822 Fax: +61 3 9214 5525
Email: dcrewther@bsi.swin.edu.au
Internet: www.bsi.swin.edu.au
Address: Swinburne University of Technology Postal Swinburne University of Technology
400 Burwood Road Address: PO Box 218
Hawthorn, VIC, 3122 Hawthorn, Victoria, 3122
Australia Australia

Profile: The Brain Sciences Institute is a major research and postgraduate teaching facility within
Swinburne University. Its primary purpose is to facilitate research into the relationship between
human behavioural states and measured brain activity to understand the neural basis of cognition
and emotion in the normal and disordered brain. BSI also undertakes contract research in areas
consistent with its primary purpose.
Bristol-Myers Squibb Australia Pty Ltd ACN 33 004 333 322

Contact: Mr John Kilborn, Managing Director

Phone: +61 3 9213 4000 Fax: +61 3 9701 1526
Internet: www.bms.com
Address: 556 Princes Highway Postal PO Box 39
Noble Park, VIC, 3174 Address: Noble Park, VIC, 3174
Australia Australia

Profile: Bristol-Myers Squibb Australia Pty Ltd is the Australian division of the Bristol-Myers Squibb
Company - a global leader in the research, development, manufacturing and marketing of
innovative ethical medicines. The company, which has a mission to extend and enhance human
life, has a history of excellence in Australia. Preceding a major global merger in 1989, the Bristol-
Myers Company and ER Squibb and Sons had operated in Australia since 1930 and 1955
respectively.

Today, Bristol-Myers Squibb is among Australia’s leading producers of ethical pharmaceutical

products. Based at Noble Park in Victoria, the Australian division manufactures and markets
medicines in a number of therapeutic areas, including cancer, cardiovascular disease and
infectious diseases. Australia is one of the top 10 international markets for the global corporation,
representing a strategic manufacturing location, an important research and development site and
a key employer of highly skilled people. In Australia, the company is able to draw upon its global
strengths to achieve local benefits - both in terms of the new and innovative products it brings to
market, as well as local employment and training opportunities.

Bristol-Myers Squibb’s commitment to Australia has been acknowledged by the Australian

Government, which selected the company as one of only nine to receive grants under the
Pharmaceutical Industry Investment Program. As a grant recipient, Bristol-Myers Squibb has
committed to increasing R&D and manufacturing levels in Australia over a period of five years from
1999.
 Burnet Institute

Contact: Mr Stephan Swadzba, PR and development

Phone: +61 3 9282 2135 Fax: +61 3 9282 2100
Email: stephan@burnet.edu.au
Internet: www.burnet.edu.au
Address: Alfred Medical Research and Education Postal GPO Box 2284
Precinct (AMREP) Address: Melbourne, Victoria, 3001
Commercial Road Australia
Prahan, VIC, 3181
Australia

Profile: The Macfarlane Burnet Institute for Medical Research and Public Health (Burnet Institute) was
established in 1986 as a research arm of the Virology Department of the former Fairfield Infectious
Diseases Hospital in Melbourne. Incorporated as an independent entity in 1989, the Burnet
Institute has grown rapidly into an internationally-recognised and influential communicable
diseases research institute, distinguished by its broad, multi-disciplinary approach to diseases of
national and global importance, with a major focus on HIV/AIDS, viral hepatitis and infectious
respiratory diseases.

The Burnet Institute's overall focus is directed at controlling the spread of serious infectious
diseases and at reducing both direct and indirect harm caused to individuals and communities by
these diseases. Its strategy encompasses two major, complementary approaches: discovery and
development of new vaccines and drugs to combat infectious diseases; and interventions to
implement changes in policy, management and behaviour to reduce the risks of disease and to
deal more effectively and equitably with the consequences of disease.

Approximately half of the Burnet Institute’s 120 staff and research students are engaged in
laboratory-based experimental virology research programs, the other half are engaged in
Institute’s innovative field-based research and public health programs in Australia and in many
developing nations, particularly in the Asia-Pacific region.

In July 2002, the Burnet Institute will relocate from its present research facilities on the campus of
the former Fairfield Hospital, which was closed in 1996, to become one of the founding partners in
the Alfred Medical Research and Education Precinct (AMREP) which is currently being
constructed on the campus of the Alfred Hospital in Prahran in inner-suburban Melbourne.

The Burnet Institute will occupy new, state-of-the-art purpose-built facilities within this new
research complex in which more than A$90 M will have been invested by the end of 2001. The
Burnet Institute’s partners in this development are the Alfred Hospital, Monash University, and the
Baker Medical Research Institute.
 Calibre Biotechnology Pty Limited ACN 51 101 665 945

Contact: Dr Tony Hughes, Director

Phone: +61 3 8344 8604 Fax: +61 3 8344 0241
Email: rahughes@unimelb.edu.au
Address: 215 Grattan Street
Parkville, VIC, 3052
Australia

Profile: Calibre Biotechnology is a drug development company based on designing candidate therapeutic
molecules which mimic the action of naturally occurring agents. Its initial development program is
aimed at mimics of brain-derived neurotrophic factor (BDNF), for the treatment of major
neurodegenerative diseases such as Parkinson’s and motor neurone disease.

The design techniques also have wider application as a platform technology for the future
development of drug targets across a range of therapeutic areas.
Cancer Vac Limited ACN 64 096 859 513

Contact: Mr Mark Clark, CEO

Phone: +61 3 9287 0637 Fax: +61 3 9287 0639
Email: mclark@primabiomed.com.au
Internet: www.primabiomed.com.au
Address: Kronheimer Building A&RMC
Studley Road
Heidelberg, VIC, 3084
Australia

Profile: Formed in mid-2001 by Prima Biomed Ltd and Ilexus Pty. Ltd., Cancer Vac Limited is continuing
the development of a therapeutic process for treating solid tumours. The Austin Research Institute
research has discovered that stimulation of cells "ex vivo" (temporarily removed from the patient)
may generate potent immune responses that will eliminate, arrest or retard the growth of tumours.
The cell type of interest is the dendritic cell. Reintroduction of primed dendritic cells into the body
may lead to the eradication of tumours through killing of tumour cells by cytotoxic T cells.

Cancer Vac’s process involves (a) isolation of the immune system cells (dendritic cells) from the
blood of a cancer patient; (b) stimulation of those dendritic cells by hormones (cytokines) of the
immune system to activate the dendritic cells; (c) exposure of the dendritic cells to the
immunostimulant combined with the tumour antigen to generate antigen-specific dendritic cells;
and (d) introduction of these antigen-specific dendritic cells into the cancer patient to activate
cancer-specific killer cells. The killer cells then seek out and eradicate the cancer cells they have
been primed to recognise.

The cancers being targeted for this type of therapy are breast, colon, lung, prostate, ovarian and
pancreatic. A phase I clinical trial in cancer patients is in progress, with patient recruitment
expected to be complete by the end of June 2002.

Cancer Vac’s technology originated at the Austin Research Institute, and was exclusively
sublicensed worldwide to Cancer Vac by Ilexus.
 CancerProbe Pty Ltd ACN 83 095 341 183

Contact: Mr Graeme Kaufman, Managing Director

Phone: +61 3 9826 0399 Fax: +61 3 9824 0083
Email: graeme.kaufman@circadian.com.au
Internet: www.circadian.com.au/cancerprobe.htm
Address: Level 1 Postal PO Box 23
10 Wallace Avenue Address: Toorak, VIC, 3142
Toorak, VIC, 3142 Australia
Australia

Profile: CancerProbe Pty Ltd, formed in December 2000, is developing applications of a novel method for
rapid identification and detection of cancer-specific antigens. The methodology may have
applications for a broad range of cancers, including breast, ovarian, colorectal and prostate
cancers. CancerProbe holds the rights to the early stage research and development, and a
provisional patent application covering the technology has been lodged. Researchers have been
appointed for the development of new blood tests for cancer detection, which may also have
potential for new therapeutic products. Circadian Technologies Limited, an Australian Stock
Exchange (ASX)-listed company [see separate profile], holds a 30% interest in CancerProbe.
Cardia Technologies Limited ACN 89 064 755 237

Contact: Mr Patrick Volpe, Executive Chairman

ASX: CNN
Phone: 0412 088 858 Fax: +61 3 9620 3452
Email: cardia@bigpond.com
Address: Level 1
89 High Street
Kew, VIC, 3101
Australia

Profile: Cardia Technologies Limited is a diversified biotechnology company with interests in medical
biotechnology, agricultural biotechnology and natural pharmaceuticals. Cardia is funding a
diabetes type 2 research and development project with the International Diabetes Institute in
Caulfield, Victoria. From this research, it is hoped that a new drug treatment programme for
diabetes type 2 will be developed, and preliminary work to date is encouraging. Cardia has a
further 18 months of the project to run before final animal model testing, toxicology studies and
efficacy data are complete.
 Carlton and United Breweries Limited ACN 76 004 056 106

Contact: Dr Peter Rogers, Manager, Manager New Technology

Phone: +61 3 9420 6522 Fax: +61 3 9420 6932
Email: peter.rogers@fostersgroup.com
Address: 4-6 Southampton Crescent Postal GPO Box 753F
Abbotsford, VIC, 3067 Address: Melbourne, VIC, 3001
Australia Australia

Profile: Carlton and United Breweries (CUB) maintains a strong technical capability in all aspects of the
brewing process, and carries out strategic work in raw material science - including hop and malt
chemistry and processing, yeast management and physiology, chemosensory science, packaging
engineering, and alcoholic and non alcoholic beverage development.

CUB is involved in value adding end-products from brewing. CUB pioneered the application of
liquid carbon dioxide extraction of hop acids and the use of isomerised hop acid extracts for
brewing; it was the first brewing company to introduce sterile membrane filtration of beer. The
company produces tailored yeast for the food industry; various malt extracts, brewer's grain
products for the diary industry, and markets a glucan immunostimulant for aquaculture and the
health and wholesomeness marketplacem. CUB is expert in large scale fermentations, and the
management of secondary or attenuated pathways in yeasts. This includes the analysis of brewing
yeast gene expression. The company supports the Malting Barley Quality Improvement program
for the developmentof new barley varieties, is a member of the Malting Barley Quality
Improvement Technical Committee, and also the Western Australian Malting Quality Committee.

The company is a member of the Australian Association of Brewers, which supports medical
research in Australia and is a member of the subscription research organisation Brewing Research
International. Several projects with Universities are supported by Australian Research Council
funding. CUB commissioned a new laboratory, pilot brewery and large scale plant at the
Abbotsford site in 2000, which provides over 1000 square metres of floor space for experimental
work.
Cell Therapies Pty Ltd ACN 15 100 285 916

Contact: Mr Ray Wood, Managing Director

Phone: +61 3 8665 5270 Fax: +61 3 9639 8255
Email: rayjwood@bigpond.com
Address: Level 4
257 Collins Street
Melbourne, VIC, 3000
Australia

Profile: Cell Therapies provides clinical trials and TGA licensed contract cell manipulation services to
organisations developing new treatments based on advanced stem cell (autologous) therapies for
a range of disorders, including cancer.
 Cellestis Limited ACN 86 094 962 133

Contact: Dr Anthony Radford, CEO

ASX: CST
Phone: +61 3 9571 3500 Fax: +61 3 9571 3544
Email: quantiferon@cellestis.com
Internet: www.cellestis.com
Address: Level 1 Postal 1046A Dandenong Road
1046a Dandenong Road Address: Carnegie, VIC, 3163
Carnegie, VIC, 3163 Australia
Australia

Profile: Cellestis Limited manufactures and markets QuantiFERON products for medical diagnosis and
scientific research. The QuantiFERON technology is a patented whole blood method for detecting
cell-mediated immune responses using whole blood samples. Cellestis currently manufactures
and markets two QuantiFERON products, QuantiFERON-CMI and QuantiFERON-TB. Cellestis'
platform technology, the QuantiFERON system, is applicable to monitoring a number of infectious
diseases and medical conditions, and other products are under development. Cellestis licensed
the Quantiferon technology from Australia's largest biotechnology company, CSL Limited, in
December 2000. CSL was focusing its activities and no longer saw the Quantiferon diagnostic
technology as core to its business strategy. Cellestis subsequently listed on the Australian Stock
Exchange on 24 April 2001.

Cellestis specializes in TB diagnosis and has developed a new and highly sensitive TB diagnostic,
with high specificity as it is immune to cross-reactive effects from BCG vaccination or other
kindred mycobacteria.
Centre for Animal Biotechnology

Contact: Dr Els Meeusen, Director

Phone: +61 3 8344 7345 Fax: +61 3 9347 4083
Email: e.meeusen@unimelb.edu.au
Internet: www.cab.unimelb.edu.au
Address: School of Veterinary Science, The
University of Melbourne
Cnr Flemington Road and Park Drive
Parkville, VIC, 3010
Australia

Profile: The Centre for Animal Biotechnology (CAB) is an international Centre of excellence for basic and
applied immunology and molecular biology research in sheep. The major goal of CAB is to
promote and conduct high quality research in large animal species that will contribute significantly
to the development of improved methods for livestock management and disease control as well as
serving as useful models for human disease processes.
 Centre for Developmental Cancer Therapeutics Inc.

Contact: Assoc Prof Mark Rosenthal, Director

Phone: +61 3 9342 7306 Fax: +61 3 9347 7508
Email: mark.rosenthal@mh.org.au
Internet: www.cdct.org
Address: Royal Melbourne Hospital Postal Level 6, CCB Post Office
Grattan Street Address: Royal Melbourne Hospital
Parkville, VIC, 3052 Parkville, Victoria, 3052
Australia Australia

Profile: The Centre for Developmental Cancer Therapeutics (CDCT) is a cooperative venture of six
Melbourne institutions with international reputations for first class cancer research and treatment.
The aim of the CDCT collaboration is to improve cancer treatment through clinical and scientific
research. The group has a strong focus on early drug development in oncology and haematology,
with a particular emphasis on strategy to proof of concept. The CDCT also places great
importance on the integration of biological endpoints to clinical trials.
Centre for Environmental Stress and Adaptation Research

Contact: Mr Ary Hoffmann, Director

Phone: +61 3 9479 2769 Fax: +61 3 9479 2361
Email: A.Hoffmann@latrobe.edu.au
Internet: www.latrobe.edu.au/cesar
Address: La Trobe University
Bundoora, VIC, 3086
Australia

Profile: The Centre for Environmental Stress Adaptation Research (CESAR) was established in 2000 with
funding from the Australian Research Council via its Special Research Centre scheme. CESAR
operates across nodes at La Trobe, Melbourne and Monash Universities and has a number of
connections to agricultural industries. There are now more than 50 postdocs, research assistants,
postgraduate students and other CESAR personnel located across the three nodes. The main aim
of CESAR is to understand the main issues and mechanisms involved with adaptation of
organisms to stress using experimental model systems, and to disseminate this information to
industry and the community. The Centre has a major program in developing methods for predicting
and minimizing the development of resistance to chemical pesticides. The Centre also has a large
program in assessing the impact of stressful inputs on organisms in natural environments.
 Centre for Equine Virology

Contact: Prof Michael Studdert, Director

Phone: +61 3 8344 7373 Fax: +61 3 8344 7374
Email: m.studdert@unimelb.edu.au
Internet: www.vet.unimelb.edu.au/research/CEV.html
Address: School of Veterinary Science The Postal School of Veterinary Science
University of Melbourne Address: The University of Melbourne
Cnr Flemington Road and Park Drive Parkville, Victoria, 3010
Parkville, VIC, 3050 Australia
Australia

Profile: The Centre for Equine Virology was established by a decision of University Council in 1991. The
major purposes of the CEV are: (i) to conduct research into virus diseases of horses, (ii) to provide
diagnostic services to industry and (iii) to develop and provide policy advice to various industry
and government agencies.

The CEV and its antecedent, the Virus Laboratory, have made many notable contributions to
equine virus disease research including the development of a combined inactivated vaccine for the
control of respiratory disease and abortion caused by equine herpesvirus 1 (EHV1) and EHV4 and
the development of a blood test to differentiate antibodies to EHV1 and EHV4. Other
herpesviruses including, EHV2, EHV5 and EHV3 as well as equine adenoviruses and equine
rhinoviruses are also subjects of research.

A major theme of the research effort is concerned with improved diagnosis and control of viruses
that cause respiratory disease in horses. The CEV provides diagnostic services nationally for all
endemic equine virus diseases for which fees are charged. Policy advice is provided to many
individuals, to commercial companies and to various state and federal governmental agencies.

Funding for the CEV comes from a significant grant from Racing Victoria, from competitive grants
currently including Rural Industries Research and Development Corporation and the Australian
Research Council and from other industry bodies.
 Cerylid Biosciences Ltd ACN 95 090 898 025

Contact: Dr Jackie Fairley, Chief Executive Officer

Phone: +61 3 9208 4444 Fax: +61 3 9208 4030
Email: info@cerylid.com.au
Internet: www.cerylid.com.au
Address: 576 Swan Street
Richmond, VIC, 3121
Australia

Profile: Cerylid Biosciences Ltd (Cerylid) was founded in January 2000 by a consortium of venture capital
investors and has become one of Australia's leading unlisted public Australian biotechnology
companies. Cerylid is focused on the discovery and development of novel small molecule
pharmaceuticals from naturally occurring compounds which, historically, have provided the
chemical foundation for over 40% of the drugs in the market and have been the origin of almost all
therapeutic breakthroughs.

Cerylid has assembled one of the world's largest collections of biotic samples for drug discovery;
containing over 600,000 natural product extracts from over 60,000 samples of plants, marine
organisms and microbes from the Australasian region.

Cerylid has built a high-throughput screening (HTS) capability that incorporates several proprietary
systems: a miniaturised, semi-automated dereplication process for identifying lead compounds,
and disease discovery libraries that are enriched for therapeutically important bioactive
compounds.

Cerylid’s internal discovery program primarily focuses on anticancer drugs. The lead molecule,
CBL316, is in preclinical development at the National Cancer Institute (USA) and appears to have
a new mechanism of action. In addition, Cerylid has a further three exploratory leads, has
identified over 2,800 natural product sample extracts which demonstrate anticancer bioactivity, and
has developed a series of screens for the identification of new anticancer lead molecules.

Partnerships, including with Aventis, Anadys Pharmaceuticals, Chiron and Chugai

Pharmaceuticals, currently generate annual revenues of over A$5 m.

Cerylid's Head Office and research laboratories are located in Melbourne, Australia where it
employs over 35 staff including an established highly experienced team of research scientists with
expertise in all aspects of natural products drug discovery and chemistry.
 Chem Eng Contracts Pty Ltd

Contact: Mr George Wild, Sales and Marketing Manager

Phone: +61 3 9553 3788 Fax: +61 3 9555 7951
Email: sales@chemeng.com.au
Internet: www.chemeng.com.au
Address: 8 Simpson Street
Moorabbin, VIC, 3189
Australia

Profile: Chem Eng Contracts (CEC) has extensive experience and capabilities in the pharmaceutical and
biotech industries.
CEC has worked for over 30 different companies in this sector.
CEC experience and capabilities includes:
-Process scale up
-Pilot Plants
-Materials handling
-GMP facilities
-Plant Services
-Process problem solving
-Concept development
-Project construction and management

Chemicon Australia Pty Ltd ACN 95 090 655 824

Contact: Ms Tina Sansotta, Operations Manager

Phone: +61 3 9839 2000 Fax: +61 3 9887 3912
Email: custserv@chemicon.com.au
Internet: www.chemicon.com.au
Address: 34 Wadhurst Drive
Boronia, VIC, 3155
Australia

Profile: Chemicon Australia supplies high quality immunological reagents and molecular biology to the life
science research and diagnostic industries.

Based on previous experience as a manufacturer of quality research and diagnostic products,

Chemicon offers a contract manufacturing service, including the manufacture, purification and
conjugation of monoclonal and polyclonal antibodies. Other services available include diagnostic
kit production and recombinant protein expression and bulk purification. The Chemicon site in
Melbourne is approved under the Australian Therapeutic Goods Act, 1989, for the manufacture of
in vitro diagnostic reagents and kits and is ISO9001 quality accredited.

The Chemicon Australia product range (known as the SILENUS® range) forms an integral part of
their manufactured products portfolio. The range includes monoclonal antibodies to human tissue
antigens, human receptors, and miscellaneous antigens; and polyclonal antibodies to human
immunoglobulins, animal immunoglobulins, human serum proteins and miscellaneous antigens.
Miscellaneous products include flow cytometry products, gastroenterology products, and assay
development. Other focus areas are cell biology, molecular biology, epitope tagging, and contract
manufacturing.

Chemicon Australia distributes and supports a range of imported agency lines to the domestic
market, which are complementary and synergistic to their core product range.

Chemicon Australia was formerly known as Silenus Labs Pty Ltd and Amrad Biotech. Silenus Labs
Pty Ltd became a subsidiary of Chemicon International, Inc. in 1999, and began trading as
Chemicon Australia Pty Ltd in May 2001.
 Chirogen Pty Ltd ACN 36 094 253 531

Contact: Mr Justus Hombuirg, CEO and President

Phone: +61 405 499 905 Fax: +61 3 5227 1040
Email: j.homburg@chirogen.com
Internet: www.chirogen.com.au
Address: 215 Grattan St
Parkville, VIC, 3052
Australia

Profile: Chiral compounds are key ingredients for many chemical syntheses, including pharmaceuticals,
plastics, fine chemicals and veterinary drugs. Chirality is the property of a compound in which a
percentage of molecules are chemically identical but differ in the orientation of some key atomic
groups. The chemical and biological properties of these two types of molecules are often
profoundly different, necessitating separation of the two chiral isomers during production to ensure
quality and minimum toxicity.

Chirogen is developing technology that offers a breakthrough method of designing and

synthesising chiral compounds of very high purity. The approach uses catalysts and other
processes to directly produce a single chiral isomer, eliminating the requirement for a costly
separation step. This offers the potential to yield larger quantities of pure chiral compounds at a
much reduced cost with the potential to eliminate toxic side effects inherent in current
technologies.

Chr. Hansen Proprietary Limited ACN 33 007 624 811

Contact: Mr Roy Con Foo, Chief Executive Officer

Phone: +61 3 9762 9600 Fax: +61 3 9762 9700
Email: Roy.ConFoo@au.chr-hansen.com
Internet: www.chr-hansen.com
Address: 49 Barry Street Postal PO Box 591
Bayswater, VIC, 3153 Address: Bayswater, VIC, 3153
Australia Australia

Profile: Chr. Hansen Proprietary Limited, with headquarters located in Bayswater, Victoria, is the
Australian arm of a large Danish multinational group Chr. Hansen Holding A/S, one of the world's
leading suppliers of natural ingredients for cheese, yoghurts, beverages, snacks, processed
meats, confectionery, wine, and probiotics for human and animal health.

Chr. Hansen's operations in Australia began in 1951 in Adelaide, South Australia, where the
company's enzyme factory is situated. The Australian operations employ 43 highly qualified
personnel in production, sales, administration, warehousing and customer service. The
headquarters also supports the New Zealand office located in Hamilton.

Australian-manufactured products include calf rennet and animal lipases.

To promote human health, Chr. Hansen's large range of probiotics, imported from its production
site in Denmark, are used in yoghurts, infant formulas and over-the-counter (OTC) capsules.

An animal probiotic range is also available, and the natural feed additive BioPlus 2B was the first
probiotic to achieve European Union (EU) approval. Its growth promotant properties have been
well documented.

Other products supplied include: cheese coagulants; lipase; cultures for dairy products; cultures
for processed meats and wine; natural colours; flavours; spices and oleoresins; anti-oxidants;
functional ingredients and growth promoters for animal nutrition.
 Circadian Technologies Limited ACN 006 340 567

Contact: Mr Leon Serry, Managing Director

ASX: CIR
Phone: +61 3 9826 0399 Fax: +61 3 9824 0083
Internet: www.circadian.com.au
Address: 10 Wallace Avenue
Toorak, VIC, 3142
Australia

Profile: Provides funding and management expertise in biotechnology research and development.

Clean TeQ Pty Ltd ACN 36 089 076 022

Contact: Mr Greg Toll, Director

Phone: +61 3 9706 4122 Fax: +61 3 9706 4050
Email: info@cleanteq.com
Internet: www.cleanteq.com
Address: 38 Kimberly Road
Dandenong South, VIC, 3175
Australia

Profile: Over the past ten years, Victorian-based Clean TeQ Pty Ltd has established itself globally as a
leading company in the environmental engineering and biotechnology sector. Using the latest
scientific and engineering principles, it provides innovative solutions in air pollution control, water
treatment, wastewater treatment and resource recovery and provides solutions for a number of
diverse industry sectors, such as the mining, food, petrochemical, plastics and printing industries.

The company’s focus is on biological treatment (live organisms) for odour control, wastewater
treatment and remediation and advanced separation technology. Clean TeQ has developed
technology based on the use of naturally occurring bacteria for the treatment of air, water and
wastewater, and in resource recovery schemes for waste processing and mining. The Clean TeQ
approach is to use the inherent ability of natural bacteria to provide cost-effective, environmentally
sound solutions in the processing industries.

Clean TeQ has designed, manufactured and installed over forty bioreactors (biological air and
water pollution control systems) for the sewage treatment industry to reduce odour and toxic
emissions, for the pharmaceutical and printing industries to reduce emissions of volatile organic
compounds, and for the food industry to reduce odour emissions. Clean TeQ’s current focus is the
use of biological augmentation to provide solutions for wastewater treatment and mining
applications (when coupled to the Clean-iX® Advanced Separation Process, valuable resources
can be separated and value-added products produced).
 Clear Cut Solutions Pty Ltd ACN 24 070 758 244

Contact: Mr Ian Mellier, Analyst

Phone: +61 3 9787 6456 Fax: +61 3 9787 6567
Email: ianm@clearcut.com.au
Internet: www.clearcut.com.au
Address: PO Box 865
Mount Eliza, VIC, 3930
Australia

Profile: Clear Cut Solutions Pty. Ltd. provides tests and testing services for alcohol and drugs of
dependency.

Clear Cut Solutions offers a variety of drug-testing methods. Tests are available for analysing
alcohol - passive and active breathalysers - and drugs of dependence - hair-based tests for
detecting long-term or past drug use, and urine-based immunodiagnostic tests.

Hair analysis for drugs of dependency is carried out by Clear Cut Solutions' US partner American
Medical Laboratories, with Clear Cut Solutions providing a confidential link to that service. Unlike
urine testing, hair testing can detect drug use for months or years, depending on the length of the
sample. Clearcut Solutions can detect drug use in the previous 60-90 days. Hair testing has a
major advantage arising from the fact that hair becomes a permanent record of drug use, whereas
urine is quickly excreted from the body.

Urine tests cover amphetamines, opiates (heroin), cocaine, THC (marijuana), methadone, and
benzodiazepines. Saliva tests will be available soon.

Clone International Pty Ltd ACN 81 091 414 283

Contact: Dr Richard Fry, Chief Executive Officer

Phone: +61 3 9397 7144 Fax: +61 3 9397 7944
Email: rfry@cloneinter.com.au
Internet: www.cloneinternational.com.au
Address: c/- Victorian Institute of Animal Science Postal PO Box 544
Sneydes Road Address: Newport, VIC, 3015
Werribee, VIC, 3030 Australia
Australia

Profile: Clone International was founded by Dr Mal Brandon and Dr Richard Fry in 2000 to commercialise
nuclear transfer or "cloning" technology in the Australasian livestock industry. Clone International
has been granted the world's first licence from the USA-based Geron Corporation to use the
"Dolly" nuclear transfer technology; the licence is to commercially produce cloned cattle and sheep
for agricultural purposes in Australia, New Zealand and China. Clone International also has the
rights to clone horses in Australia and New Zealand and to genetically modify cattle and sheep for
agricultural application.
 CobaltNiche Design ACN 074 499 371

Contact: Mr Steve Martinuzzo, Managing Director

Phone: +61 3 93263277 Fax: +61 3 93264399
Email: steve@cobaltniche.com
Internet: www.cobaltniche.com
Address: 114 Capel St
North Melbourne, VIC, 3051
Australia

Profile: CobaltNiche is a product development group operating across a range of industry sectors
including biotech, scientific & medical instruments as well as IT electronics, transport, and
consumer products. The group also offers manufacturing where required, especially for high-
quality, low volume quantities.

The group is made up of consultant industrial designers and engineers using leading computer
aided design (CAD) systems and unique creative thinking techniques. Our process ensures
innovative designs and technically precise specifications or parts.

Technologies and tools include:

CAD systems (Pro/Engineer, Pro/Engineer Surfaces, Solidworks, CDRS)

Rapid prototyping (incl. SLS, SLA, LOM) management, assembly and testing
Finite Element Analysis (Strand7)
Unique, ‘Lateral-3D’ creative thinking process

Cognis Australia Pty Ltd ACN 87 006 374 456

Contact: Mr Tony Popper, Managing Director

Phone: +61 3 9301 9900 Fax: +61 3 9309 9492
Email: tony.popper@cognis.com
Internet: www.cognis.com
Address: 83 Maffra Street
Broadmeadows, VIC, 3042
Australia

Profile: Cognis Australia Pty Ltd produces natural beta carotene from a salt water alga and markets a
range of betacarotene formulations for sale to the food supplement and food colour and specialty
chemicals for a variety of industries. As an independent firm in specialty chemicals, Cognis will
continue to expand the core businesses and make targeted investments in new markets.

Cognis products draw on the powers of nature. The Oleochemicals business offers the largest and
most complete spectrum of chemical products made from natural raw materials to customers all
over the world. Cognis Oleochemicals are the environmentally friendly alternative to many other
chemicals still being used in industry and are based upon oils from coconut, palm, palm kernel,
and soybean. The oleochemicals are converted in Victoria into speciality chemicals used in the
agricultural, personal care, paint, ink, textile and lubricant industries.

Cognis utilizes a highly efficient worldwide operating network with subsidiaries in close to 50
countries and with almost 10,000 employees. Its Australian headquarters is in Broadmeadows,
Victoria, with the betacarotene production factory in Cheltenham, utilising algae farmed from Hutt
Lagoon (Western Australia) and Whyalla (South Australia).
 CogState Ltd ACN 80 090 975 723

Contact: Dr Peter Bick, Chief Executive Officer

Phone: +61 3 9349 1300 Fax: +61 3 9348 2689
Email: pbick@cogstate.com
Internet: www.cogstate.com
Address: 51 Leicester Street
Carlton South, VIC, 3053
Australia

Profile: CogState Ltd is a Melbourne based neuroscience company with a focus on the development of
diagnostics and therapeutics for early Alzheimer’s disease or mild cognitive impairment (MCI).
CogState is developing a small molecule for MCI licensed from a Japanese pharmaceutical
company and is also commercialising a simple computerised cognitive performance test
developed by researchers from Australian universities. The computerized test takes about 15
minutes, and has found several uses in measuring the restoration of brain function in athletes who
have been concussed (CogSport), and in testing pharmaceutical drug-related cognitive impairment
(CogState). The test is unique in that it allows repeated measurements to be taken, so that
cognitive changes can be detected and monitored. Several international pharmaceutical
companies, including Pfizer, are already using the test. All 10 Melbourne-based Australian Football
League teams, as well as a number of high-profile international rugby teams and other sporting
organisations around the world, use the test to help make decisions about player fitness after head
injuries. A product aimed at use by General Practitioners to monitor elderly patients cognitive
health (CogHealth) is being developed and will be in trials by mid-2003.

The company's therapeutic drug development strategy is to in-license promising candidates, take
them through preclinical and early-stage clinical trials, and then out-license them for further
commercialisation. The company licensed a series of small molecule drugs with agonist activity for
brain angiotensin receptors from a Japanese biopharmaceutical company. These drugs target the
hippocampus and appear to improve learning and memory in rats. Preclinical trials were underway
in Melbourne by September 2002, and the company hopes to move this first drug product into
clinical trials in 12-18 months. CogState has been backed by GBS Ventures (formerly Rothschild
Bioscience) and a consortium of private investment funds.
Compumedics Limited ACN 95 006 854 897

Contact: Mr David Lawson, Chief Financial Officer

ASX: CMP
Phone: +61 3 8420 7300 Fax: +61 3 8420 7399
Email: dlawson@compumedics.com.au
Internet: www.compumedics.com
Address: 1 Marine Parade
Abbotsford, VIC, 3067
Australia

Profile: ASX-listed Compumedics Limited designs, manufactures and markets computer-based medical
monitoring and diagnostic equipment and is the supplier of choice for an increasing number of
leading sleep researchers, universities and hospitals around the world. In 1987, Compumedics
was the first company to install computer-based sleep centres in Australasia, and its equipment is
now in a number of highly acclaimed sleep centres in Australia, New Zealand, USA, Germany,
Italy, Spain, France, Netherlands, Belgium, England, Scotland, India, China, Singapore, Malaysia
and Japan. The majority of Compumedics' income is from export sales, although the company still
has a 70% share of the Australian sleep market. All products are developed, designed,
manufactured and marketed from the company's Australian headquarters in Melbourne.

Products include systems for sleep disorder monitoring and analysis, neurophysiological and
cardiology monitoring and analysis, telemedicine and imaging and electromyography. The
Compumedics Voyager imaging system includes image viewing, image archiving and integrated
physiology with video conferencing facilities.

Connetics Australia Pty Ltd ACN 78 006 363 891

Contact: Mr Ross Macdonald, Vice President, Business Development, Connetics Corporation

 Phone: +61 3 9763 0022 Fax: +61 3 9763 0354
Email: rmacdonald@connetics.com
Internet: www.connetics.com
Address: 8 Macro Court
Rowville, VIC, 3178
Australia

Profile: Connetics Australia Pty Ltd (formerly known as Soltec Research Pty Ltd) has a wide range of
innovative, proprietary technologies for topical and transdermal drug delivery. Products developed
using Connetics Australia’s delivery technologies are sold in major markets around the world and
the company has commercial alliances with many major global pharmaceutical companies.
Connetics Australia’s four key technologies are: a gel delivery system for transdermal and topical
delivery; dermal penetration enhancers for transdermal delivery of certain drugs; emulsion
technologies for topical delivery; and aerosol mousse technologies for topical delivery. Formerly a
subsidiary of Adelaide-based pharmaceutical company F.H. Faulding & Co. Limited, Connetics
Australia was acquired in 2001 by Connetics Corporation, a dermatology pharmaceutical company
based in Palo Alto, California.
Cooperative Research Centre for Discovery of Genes for
Common Human Diseases (Gene CRC)

Contact: Ms Linda Peterson, Business Manager

Phone: +61 3 9208 4444 Fax: +61 3 9208 4030
Email: genecrc@cerylid.com.au
Internet: www.genecrc.org
Address: 576 Swan Street
Richmond, VIC, 3121
Australia

Profile: The Cooperative Research Centre for Discovery of Genes for Common Human Diseases (the
"Gene CRC"), an unincorporated joint venture established under the Federal Government’s
Cooperative Research Centres scheme, was established in July 1997. Its core participants include
the University of Queensland’s Institute for Molecular Bioscience, the Queensland Institute of
Medical Research, the Murdoch Childrens Research Institute, the Walter and Eliza Hall Institute of
Medical Research, and Cerylid Biosciences Ltd. The Menzies Centre for Population Health
Research is an associate participant.

The Gene CRC has developed an exciting and highly competitive research portfolio, with major
projects directed towards endometriosis, insulin dependent diabetes mellitus and multiple
sclerosis. In addition, the Gene CRC also aims to identify genes contributing to Non-Insulin
Dependent Mellitus (Type 2 diabetes), Basal Cell Carcinoma, Attention Deficit Hyperactivity
Disorder (ADHD), predisposition to Melanoma and propensity for multiple ovulation/dizygotic
twinning.

The Gene CRC also provides post-graduate and post-qualification education for clinicians,
scientists and technologists. Further, in recognition of the need for continuing education with
regard to the ethical and social implications of genetic research, the Gene CRC has developed an
innovative educational program, that provides accurate and topical information and discussion of
the results of human genetic research.
 Cooperative Research Centre for Innovative Dairy Products

Contact: Dr Paul Donnelly, Chief Executive Officer

Phone: +61 3 9607 8607 Fax: +61 3 9600 2044
Email: service@dairycrc.com
Internet: www.dairycrc.com
Address: Level 1
84 William Street
Melbourne, VIC, 3000
Australia

Profile: The Cooperative Research Centre for Innovative Dairy Products is a joint venture funded under
the Federal Government’s Cooperative Research Centre’s program. The joint venture brings six
research organisations which are leaders in the genetics and reproduction of lactation into the joint
venture arrangement with milk processors, commercial genetics groups and IP managers.
CopyRat Pty Ltd ACN 71 094 240 776

Contact: Mr Martin Gore, CEO

Phone: +61 3 9544 0033 Fax: +61 3 9594 7111
Email: mgore@copyrat.com.au
Internet: www.copyrat.com.au
Address: C/- Monash IRD27-31 Wright Street Postal C/- Monash IRD Monash Medical
Clayton, VIC, 3168 Address: Centre
Australia 246 Clayton Road
Clayton, VIC, 3168
Australia

Profile: CopyRat Pty Ltd was established in August 2000 with the aim of becoming a world leading
supplier of rat models of human disease to the biomedical industry and the academic community
for medical research. CopyRat, located in Melbourne, Australia, is a spin out of Monash University,
one of the world’s leading research institutions in embryology and stem cell research. CopyRat
has exclusive rights to intellectual property and know-how developed by Monash University in the
areas of rat embryology and rat stem cells.

The rat is a small, low-cost animal with a short gestation period. The size of the animal allows for
measurement of many physiological parameters that are not possible in its smaller relative, the
mouse. As such, the rat has long been the model of choice for the biomedical industry, as well as
being extensively studied by scientists for a wide range of complex diseases. Currently, a serious
limitation to the use of the rat model for research has been the lack of technology to enable its
genetic modification. CopyRat recognises the development of this technology is essential to
produce rat models of human diseases such as diabetes, cardiovascular disease, respiratory and
neurological disorders. Once developed, the rat models will play a critical role in the future
development of improved treatments for these diseases.

The Company’s business strategy is aimed at generating significant future revenues from products
now being developed in its R&D drive to develop the first genetically modified rat.
 Corryong Essential Oils Pty. Limited

Contact: Mr Peter Nankervis, Managing Director

Phone: +61 2 6076 1460 Fax: +61 2 6076 2360
Email: oils@corryongcec.net.au
Address: Waters Lane Postal PO Box 8
Colac Address: Colac
Corryong, VIC, 3707 Corryong, VIC, 3707
Australia Australia

Profile: Corryong Essential Oils Pty Limited started testing small trial plots of peppermint in 1988, and
started commercial production of peppermint oil in 1990. The company has levelled its 97-hectare
property on the Murray River to plant enough peppermint to meet domestic and world demand.
They are currently in the process of expanding their other property on the Nariel Creek.

The extracted peppermint oil is of the highest quality, and 99% of the production is sold to the
American market. The oil is mainly used as food flavouring, and in products such as biscuits,
toothpaste and chewing gum, with small amounts being used for aromatherapy and beauty
treatments.

Cottee International Pty. Limited ACN 11 085 855 803

Contact: Mr Doug Parrish, CEO

Phone: +61 3 9278 7555 Fax: +61 3 9369 6730
Email: dougp@pharmaction.com.au
Internet: www.cotteehealth.com.au
Address: 73-83 Cherry Lane
Laverton North, VIC, 3026
Australia

Profile: Cottee International operates in purpose designed facilities in Melbourne, Australia. All activities
and manufacturing are consistent with the international standards of Good Manufacturing Practice
(GMP). The company offers a comprehensive range of services to the pharmaceutical and health
industries. These include:

(1) Contract manufacturing and packaging to a world class standard:

Cottee has a Therapeutic Goods Administration (TGA) licence to manufacture sterile or pack non-
sterile therapeutic goods and complementary and alternate medicines for human use. The
company has an extensive portfolio of formulations that are available and ready to take to market
in value-added finished product form;

(2) Sourcing and supply of complementary and alternate medicines:

Cottee is able to supply formulations in bulk. Cottee is also a primary source of supply for many
high demand raw materials such as shark cartilage, glucosamine and BSE-free chondroitin;

(3) A complete range of technical services to manufacturing and packaging:

Cottee has a primary responsibility to ensure that all aspects of new and changed products are
successfully transferred to operations from Cottee Product Development or, as a contract
manufacturer, from other complementary and alternate medicines companies. The Technical
Services/Quality Assurance Group performs the full service quality control and quality assurance
function for Cottee;
(4) Product Development:
This involves the formulation, process development, and stability testing of therapeutic products
from pre-formulation to marketing, including the development, validation and registration or listing
of all formulations. It also involves analytical development, which supports the pharmaceutical
development and manufacturing activities, including the selection, development and validation of
methods for drug products.
Other services include clinical trials, formulation, pilot batch manufacture and stability testing to
support registration of products.
 CRC for Cellular Growth Factors

Contact: Ms Roslyn Clark, Executive Officer

Phone: (03) 9345 2559 Fax: (03) 9345 2616
Email: crccgf@wehi.edu.au
Internet: www.ludwig.edu.au/CRC-CGF/
Address: The Walter and Eliza Hall Institute
1G Royal Parade
Parkville, VIC, 3050
Australia

Profile: The Cooperative Research Centre for Cochlear Implant and Hearing Aid Innovation conducts
innovative research leading to new hearing technology such as cochlear implants with increased
capabilities and improved cosmesis, totally-implantable neuroelectric and acoustic hearing
prostheses, intelligent digital hearing aids for those with mild and moderate hearing losses, and
advances in speech intelligibility and noise reduction algorithms and techniques for use in hearing
prosthetics or communications applications.In addition, the Centre also provides a range of
postgraduate research programs in hearing and communication science. It is actively developing
new approaches to expand professional training in the field and to make this accessible to
geographically isolated regions.A comprehensive technology transfer strategy ensures that
research and educational outcomes result in improved communication benefits for hearing-
impaired people and increased skills in the Australian workforce.

CRC for Cochlear Implant and Hearing Aid Innovation

Contact: Dr Robert Cowan, Director/Chief Executive Officer

Phone: +61 3 9667 7500 Fax: +61 3 9667 7518
Email: r.cowan@unimelb.edu.au
Internet: www.bionicear.com.au/crc
Address: 384 Albert St
East Melbourne, VIC, 3002
Australia

Profile: The CRC has Federal Government funding of $14.2 million over seven years from July 1999, with
commitments of a further $57 million from other participants.

Research is focussed in several major disciplines:

Bioengineering – aimed at determining how to structure new electrode arrays with improved
control and higher capacity using new materials and fabrication techniques;

Electrochemistry – aimed at understanding the electroneural environment in the auditory organs,

and how to best utilise and manage the electrochemical tissue interface;

Electrophysiology – investigation of objective means of programming hearing devices in infants

and young children;BioSafety and Surgery – investigating the biosafety of electrical stimulus
parameters and new materials, and surgical technique for placing advanced miniature devices.

Advanced Habilitation and Training Programs – aimed at improving the performance of children
using the cochlear implant or hearing aids through integration of new information into their speech
and language repertoires.

Clinical Procedures – aimed at improving the efficiency and effectiveness with which clinicians
provide rehabilitation and habilitation using hearing aids and cochlear implants.
 CRC for MicroTechnology

Contact: Mr Clive Davenport, Chief Executive Officer

Phone: +61 3 9214 8557 Fax: +61 3 9214 8008
Email: clive.d@microtechnologycrc.com
Internet: www.microtechnologycrc.com
Address: Level 5 Postal PO BOX 218
60 William Street Address: Hawthorn, Victoria, 3122
Hawthorn, VIC, 3122 Australia
Australia

Profile: The CRC for MicroTechnology was formed in 1999. The CRC for microTechnology has a total
budget of A$64 million, A$17 million of which is core Federal government funding. Through its
participants, it has access to existing top-class research facilities, a pool of talented staff, built-in
international networks and both industrial and academic background IP.

The management structure is designed to encourage commercial outcomes by maximising

support for the R&D programs, business development and technology transfer. Protective
mechanisms exist for the participant’s IP through a bare trust company. Feedback from
independent technical and advisory panels is built into the Centre management structure. The
CRC has a governing board to oversee all aspects of its activities and a full-time Chief Executive
Officer.
CryoLogic Pty. Ltd.

Contact: Dr Willem Lindemans, Research Director

Phone: +61 3 9574 7200 Fax: +61 3 9574 7300
Email: enquiry@cryologic.com
Internet: www.cryologic.com
Address: 54 Geddes Street
Mulgrave, VIC, 3170
Australia

Profile: A Victorian based company, CryoLogic Pty. Ltd. is located in the South Eastern Melbourne
metropolitan region, where it develops and manufactures biomedical instruments for a world-wide
market.

CryoLogic is dedicated to providing innovative solutions to instrumentation, measurement and

control problems in medical, veterinary and biological sciences. Its goal is to deliver functional,
reliable, and affordable equipment.

Its FREEZE CONTROL® range of portable, controlled-rate cryo-preservation systems have been
in use since 1985. They make a significant contribution to assisted reproduction (human IVF,
domestic animal ET), and to conservation and gene banking, and facilitate research in
microbiology, oncology, endocrinology, plant breeding, and aquaculture.

Other controlled temperature products have been developed for specific applications and are
supplied under the name BioTherm™. These include portable incubators for long distance
transport of biological material, and microscope warm stages.

Cryologic has also developed a cell fusion system, the Voltain™ EP-1. This equipment is used for
the cloning of embryos, propagation of stem cells, production of hybridomas, and transgenic
perfusion.

The company maintains an active research and development program, provides customisation
services, and develops new products in consultation with clients. A recent development was an
incubator used for transportation of cells to, and for use in, the International Space Station.

CryoLogic actively markets its products world wide and has representatives in 30 countries. All
equipment is backed by a two-year warranty.
 Cryptopharma Pty Ltd ACN 77 094 788 897

Contact: Mr Charlie Day, Company Secretary

Phone: +61 3 8344 5675 Fax: +61 3 8344 0241
Email: astew@clyde.its.unimelb.edu.au
Internet: www.pharmacology.unimelb.edu.au/pharmwww/LungInflamm.html
Address: c/- Melbourne University Private
215 Grattan Street
Parkville, VIC, 3052
Australia

Profile: Cryptopharma was established in 2000 to focus on targeted delivery of novel pro-drugs for cancer
and inflammation. The underlying concept is that Cryptopharma’s pro-drug remains inactive until in
the vicinity of the target cancer or inflammatory site, where an enzyme there cleaves the link
between the drug and the protective carrier, releasing the active drug at the site where it is
needed. Normal tissues do not produce enough of the enzyme to release the drug - it is only
released at the diseased site. Cryptopharma has coined the term ‘homeokinetics’ for this concept.

In the first instance, Cryptopharma is developing pro-drugs of novel steroid analogues for
therapeutic use to treat solid tumours and chronic inflammatory diseases. This class of estrogen-
related agents has demonstrated efficacy in extensive preclinical studies of three separate
conditions: solid tumour growth, collagen-induced arthritis, and chronic asthma pathology. An
active compound related to those being used by Cryptopharma, 2-methoxyestradiol, has been
approved by the US Food and Drug Administration (FDA) for trial in breast cancer. Cryptopharma
filed a PCT patent application 14 October 2000.

Cryptopharma’s senior investigators have an established track record of collaboration on projects

with commercial focus. They work extensively with industry and have succeeded in bringing
products to clinical use. Expertise includes project management, organic chemistry, preclinical
pharmacology and medicinal chemistry. The infrastructure available is world class.

CSIRO Health Sciences and Nutrition

Contact: Dr Megan Fisher, Business Development Manager

Phone: +61 3 9662 7100 Fax: +61 3 9662 7101
Email: megan.fisher@csiro.au info@hsn.csiro.au
Internet: www.hsn.csiro.au
Address: 343 Royal Parade
Parkville, VIC, 3052
Australia

Profile: Our focus is on the improvement of human well-being and community health, whilst enhancing the
competitiveness of the Australian food, food-related pharmaceutical and pharmaceutical
industries. Our research addresses the prevention of disease, treatments and diagnosis. Current
programs are: Gastrointestinal Health and colon cancer, Consumer Science, Diagnostic and
Therapeutic Technologies, Protein and Pharmaceutical Sciences, Structural Biology, Nutrition
Clinic.
 CSL Limited ACN 99 051 588 348

Contact: Mr Brian McNamee, Managing Director

ASX: CSL
Phone: +61 3 9389 1911 Fax: +61 3 9389 1434
Email: brian_mcnamee@csl.com.au
Internet: www.csl.com.au
Address: 45 Poplar Road
Parkville, VIC, 3052
Australia

Profile: Australia’s largest biotechnology company, CSL Limited, was established in 1916 to produce
vaccines and sera for diseases such as diphtheria, smallpox, tetanus, cholera, plague, whooping
cough and influenza. CSL develops, manufactures and markets pharmaceutical products of
biological origin. Operating in the field of health care, CSL focuses on three main areas:

- Life-saving products derived from human plasma

- Pharmaceuticals and diagnostics essential to community health
- Animal health vaccines and diagnostics to protect livestock and companion animals
CSL's operations are divided into four business divisions:
- CSL Pharmaceuticals
- CSL/ZLB Bioplasma
- CSL Animal Health
- JRH Biosciences, Inc. (based in Kansas USA)

In 2000, CSL completed the A$696-million acquisition of the plasma fractionation assets and
business (ZLB) of Rotkreuzstiftung Zentrallaboratorium Blutspendedienst SRK, a foundation of the
Swiss Red Cross. ZLB has the only FDA-approved plasma products plant outside the USA, and
provides CSL access to the US plasma products market. The deal places CSL among the top four
plasma processors globally. CSL has begun to build a new US subsidiary, ZLB Bioplasma Inc.,
based in Los Angeles.

CSL is the largest investor in Australian pharmaceutical research and development, and one of the
largest employers in Australia's pharmaceutical manufacturing industry.

Products from CSL’s state-of-the-art blood plasma processing facility are used to treat bleeding
disorders, for emergency trauma situations such as shock due to acute blood loss, and for
preventing severe infections. Uniquely, CSL can process plasma from a country, and return it as
finished products to the country of origin.
 Cytopia Pty Ltd ACN 14 082 492 680

Contact: Dr Kevin Healy, Interim CEO

Phone: +61 3 9522 6900 Fax: +61 3 9510 9292
Email: cytopia@cytopia.com.au
Internet: www.cytopia.com.au
Address: Level 5, Baker Heart Research Institute Postal PO Box 6492, St Kilda Road Central
Building Address: Melbourne, VIC, 8008
Commercial Road Australia
Melbourne, VIC, 3004
Australia

Profile: Cytopia is a privately-held Australian drug discovery company with a focus on cancer and
inflammatory diseases such as asthma, rheumatoid arthritis, allergic rhinitis (hay fever), food
allergy, and inflammatory bowel disease. As an adjunct to its high throughput screening facility and
its medicinal chemistry capability, Cytopia is developing proprietary computer-based technology
which allows large chemical collections to be tested for their ability to bind to any drug discovery
target. Chemicals which are specifically active may be able to prevent certain inflammatory
diseases.

Cytopia has recruited a core group of highly qualified and experienced scientists and established a
well-equipped laboratory in Melbourne. Cytopia has worked predominantly on the protein kinase
family, with particular focus on members of the JAK family of protein tyrosine kinases. Cytopia has
obtained worldwide exclusive rights to develop and commercialise technology relating to this
family of kinases. Members of the JAK family of PTKs are critical for important cellular control
mechanisms downstream of all cytokine receptors, and are excellent targets for drug discovery for
diseases of the immune system and cancer.

The goal of the Cytopia drug discovery program is to discover novel bioactive compounds from
chemical libraries generated by means of intelligent use of combinatorial chemistry. In addition to
the five granted US and Australian patents on the drug targets, Cytopia has filed five additional
patents relating to new drug-like molecules that can be used to treat cancer and immune disease.

Cytopia was established in 1998, and is 79% owned by Medica Holdings Limited, a Pooled
Development Fund specialising in investments in the biotechnology sector.

Cytoscreen Pty Ltd ACN 47 100 286 486

Contact: Dr Labrini Nassis, Consultant

Phone: +61 3 8665 5274 Fax: +61 3 9639 8255
Email: labrini@berthold.com.au
Address: Level 4
257 Collins Street
Melbourne, VIC, 3000
Australia

Profile: Cytoscreen offers a new screening service for pharmaceutical companies seeking more timely and
cost-efficient ways to screen chemical compounds that may be used in the treatment of cancer.
Intellectual know-how and expertise from the Peter MacCallum Cancer Institute provides a
competitive advantage to pharmaceutical companies, who currently spend at least US$350 million
to successfully produce one new drug. The screening technology is a new approach in elucidating
drug functionality that can reduce this cost of drug development by reducing time cycles or
increasing the stringency of selection.
 Deakin University

Contact: Ms Alison Hadfield, Director Research Services

Phone: 03-52272835 Fax: 03-52271275
Email: Alison.Hadfield@deakin.edu.au
Internet: www.deakin.edu.au
Address: Pigdons Road
Waurn Ponds, VIC, 3217
Australia

Dendritic Nanotechnologies, Inc. ACN 87 097 725 927

Contact: Mr Tim Grogan, Director

Phone: +61 3 9522 4391 Fax: +61 3 9521 1433
Email: grogan@dnanotech.com
Internet: www.dnanotech.com
Address: Level 1, Old Baker Building Postal PO Box 6535
Prahran, VIC, 3081 Address: St Kilda Road Central, VIC, 8008
Australia Australia

Profile: Dendritic Nanotechnologies Limited (DNT) was established in a venture between Starpharma
Limited and Donald A. Tomalia, Ph.D., the President and Chief Technical Officer of DNT and
pioneer of dendrimer technologies [see Starpharma entry]. DNT has a head office in Melbourne,
Australia, and a laboratory and manufacturing facility in the Center for Applied Research and
Technology at Central Michigan University (CMU), Mt Pleasant, Michigan, USA. DNT was
established:

- to design, manufacture and consistently supply a range of high quality dendrimers to

customers/partners interested in the use of dendrimers for a broad range of research and
commercial applications; and

- to conduct research into novel dendrimer types and architectures.

Dendritic compounds are a unique new class of synthetic nanostructure that allow for precise
control of size, shape and functionality. Dendrimers may be used as macromolecular platforms
suitable for a wide range of applications in nanotechnology (eg nano-drugs, drug delivery,
diagnostics, nano-optics and electronics).
 Dendy Pharmaceuticals Pty. Ltd. ACN 32 007 180 985

Contact: Mr Avi Jaworowski, Managing Director

Phone: +61 3 9591 0202 Fax: +61 3 9592 5335
Email: dendyok@aol.com
Address: 752 Hampton Street
Brighton, VIC, 3186
Australia

Profile: Dendy Pharmaceuticals Pty. Ltd. supplies a range of laxatives and dental products to hospitals
and gastroenterologists, surgeons, radiologists and dentists. Products are manufactured in Victoria
and NSW under contract.

Diagnostic Solutions Pty Ltd ACN 13 081 347 319

Contact: Ms Elly de Gooyer, Managing Director

Phone: +61 3 9817 7222 Fax: +61 3 9817 7200
Email: Info@diagsolns.com.au
Internet: www.diagsolns.com.au
Address: 74 Whitehorse Road Postal P.O. Box 702
Balwyn, VIC, 3103 Address: Balwyn, VIC, 3103
Australia Australia

Profile: Diagnostic Solutions Pty Ltd imports and distributes diagnostic kits and reagents for the pathology
laboratory market. Products distributed include kits and reagents for the diagnosis of a wide range
of autoimmune diseases and quality control products for the haematology, immunology and flow
cytometry markets. Suppliers include Immuno Concepts Inc., Aesku Diagnostics, Biomedical
Diagnostics (BMD) and Streck Laboratories. Established in 1998, the company is based in
Balwyn, in the eastern part of Melbourne.

Diamed Pty Ltd ACN 050 104 875

Contact: Ms Carol Braussard, PA to CEO

Phone: (03) 8532 2700
Address: 14 Palmer Court
Mt Waverley, VIC, 3149
Australia
 DNA Solutions Pty. Ltd. ACN 37 085 282 855

Contact: Mr Vern Muir, Managing Director

Phone: +61 3 9800 1550 Fax: +61 3 9800 1792
Email: dnanow@dnanow.com
Internet: www.dnanow.com
Address: 2 / 23 Wadhurst Drive
Boronia, VIC, 3155
Australia

Profile: DNA Solutions offers:

- Paternity testing services

- Human relationship testing

- Veterinary pathology

DNA Solutions has assisted a third-world government in DNA laboratory set-up, design and
training.

The company’s DNA profiling systems are designed to be the most cost-effective system, with the
lowest cost to implement, without loss of accuracy or reliability.

DNA Solutions at mid-2002 is researching new fast diagnostic DNA tests.

Dornier MedTech

Contact: Mr Michael Fehrmann, Managing Director

Phone: +61 (0)418 354 626
Email: fehrmann@ozemail.com.au
Internet: www.dornier.com.au
Address: 3 Molan Street Postal PO Box 4230
Ringwood, VIC, 3134 Address: Ringwood, VIC, 3134
Australia Australia

Profile: Dornier MedTech supplies therapeutic equipment, especially litotripsy and shockwave equipment
for urology and orthopaedics. Other product areas include ultrasound equipment for urology,
radiology and cardiology. Furthermore, the company supplies a range of surgical lasers for general
surgery, urology and cosmetics. Equipment includes the Lithotripter S, Compact Alpha, Compact
Delta, Epos, Medilas D, Medilas H and Fibertom Yag Laser. The company has a strong technical
service background and offers coverage Australia wide.
 Dynamic Hearing Pty Ltd ACN 16 098 878 212

Contact: Dr Elaine Saunders, Chief Executive Officer

Phone: +61 3 8420 8500 Fax: +61 3 8420 8599
Email: esaunders@dynamichearing.com.au
Internet: www.dynamichearing.com
Address: 2 Chapel Street
Richmond, VIC, 3121
Australia

Profile: Dynamic Hearing is a start-up company that aims to be a market leader in the development of
advanced technology software applications for the emerging digital hearing aid industry. The
company's first product is called ADRO™; advanced digital signal processing software, which
produces improved speech perception for hearing aid users.

Dynamic Hearing is a spin off from the CRC for Cochlear Implant and Hearing Aid Innovation, the
core parties of which are the Bionic Ear Institute, University of Melbourne, Cochlear Ltd and
Australian Hearing Services.

Some of the brightest minds in audiological research and engineering have joined the Dynamic
Hearing team. The company is dedicated to the pursuit of simple, innovative and highly effective
solutions to the many challenges presented in interpreting the world of sound.

Nanyang Ventures and GBS Ventures have both invested $2 million in Dynamic Hearing

E.M.L. Consulting Services Proprietary Limited ACN 71 006 308 774

Contact: Mr Peter Ogier, Victorian State Manager

Phone: +61 3 9836 1999 Fax: +61 3 9836 0808
Email: peter.ogier@eml.com.au
Internet: www.eml.com.au
Address: 431 Canterbury Road
Surrey Hills, VIC, 3127
Australia

Profile: EML Consulting Services is an industrial microbiological laboratory specialising in testing and
consultancy services for the pharmaceutical, medical devices, cosmetics, food and water
industries. The laboratory is accredited by the National Association of Testing Authorities (NATA).

EML Consulting Services’ key expertise includes the regulated testing of pharmaceuticals,
including antibiotic assays and LAL bacterial endotoxin testing. EML Consulting Services has
Therapeutic Goods Administration (TGA) registration for testing pharmaceuticals and medical
devices and is quality system certified to ISO 9002. The company’s aim is to provide quality
microbiology in a cost-effective manner by tailoring services to meet the client’s microbiological
needs.
 EcoEarth Technologies ACN 56 069 788 030

Contact: Mr Michael Burton, Managing Director

Phone: +61 3 5265 6009 Fax: +61 3 5265 621
Email: bwgroup@datafast.net.au
Internet: www.ecoearthtechnologies.com.au
Address: 1565 Barrabool Road
Gnarwarre, VIC, 3221
Australia

Profile: EcoEarth Technologies is in the business of developing, manufacturing and marketing of naturally
biodegradable polymer products as alternatives to plastics.

The company can offer commercially viable environmentally sound biodegradable compostable
alternatives to most disposable plastic products used in society today, such as plastic bags, and
disposable packaging of any kind in the fields of commercial domestic use, agriculture,
horticulture, medical and pharmaceutical.

EcoEarth Technologies specialises in realising a new biodegradable plastic product or application

envisioned by the customer. The new product can be processed using the same machines
currently used to produce conventional plastics. The only difference is that the EcoEarth
Technologies product biodegrades and composts after use, leaving no ecotoxicological effect on
terrestial or aquatic life.

Some examples of biodegradable disposable products are: all types of bags, plant pots, meat
trays, cutlery and crockery, nappies (diapers), sanitary ware, bottles, jars and tubs, cups, food and
packaging wrap, tree guards, snack and sweet wrappers, bale twine and strings, and mesh sacks.

In fact, anything made as blown film, injection moulded, thermoformed, extruded or expanded may
be created in biodegradable polymer products.

The company’s marketing objective is to permanently replace plastics in all areas of use in society,
with EcoEarth Biodegradable environmentally sustainable products.
 Eiffel Technologies Limited ACN 96 072 178 977

Contact: Ms Christine Cussen, Chief Executive Officer

ASX: EIF
Phone: +61 3 9629 8022 Fax: +61 3 9629 8077
Email: c.cussen@eiffeltechnologies.com.au
Internet: www.eiffeltechnologies.com.au
Address: Level 14
50 Market Street
Melbourne, VIC, 3000
Australia

Profile: Eiffel Technologies Limited, is listed on the Australian Stock Exchange. Its research and
commercilisation activities are conducted by its' wholly owned subsidiary company Eiffel Research
& Development Pty Ltd. which specialises in pharmaceutical particle architecture and drug re-
engineering. This involves the development and commercialization of a range of internationally
competitive drug re-engineering and delivery technology platforms in conjunction with the
international pharmaceutical and biotechnology industries. This technology can be used to modify
pharmaceuticals to improve their effect and absorption, and to administer them in a more
convenient way, such as once a day, long-acting sustained release formulations, and replacement
of injections by inhalational drug delivery. The technologies can also be used to re-engineer
biopharmaceuticals to improve absorption, bioavailability, and mode of administration.

Eiffel Technologies’ suite of supercritical fluid technology platforms offers lifecycle management to
the pharmaceutical and biotechnology industries by reformulating new drugs and extending the
patent life of currently marketed drugs. For pharmaceuticals that are due to experience generic
competition, Eiffel Technologies’ proprietary technology platforms includes particle sizing and
engineering; drug encapsulation; implantation; and separation of optical isomers. Eiffel's research
facilities are based at the Department of Chemical Engineering at the University of New South
Wales.
Emeritus Research Pty Ltd ACN 34 091 996 575

Contact: Mrs Gail Grant, Clinical Project Manager

Phone: +61 3 9832 0700 Fax: +61 3 9832 0701
Email: gailgrant@emeritusresearch.com
Internet: www.emeritusresearch.com
Address: Suite 210
19 Milton Parade
Malvern, VIC, 3144
Australia

Profile: Emeritus Research is a Site Management Organisation (SMO) managing a network of clinical
investigators in the primary care and private specialist setting, focusing on improving the quality,
uniformity and efficiency of clinical trial conduct through centralised site management and the
provision of staff and services. The principal objective of Emeritus Research's business model is
to accelerate drug and medical device development by quickly identifying investigator sites that
have access to an adequate number of the desired patients and rapidly initiating studies at these
sites.
Emeritus Research, through its central organisation, provides a 'one stop shop' for companies
wishing to conduct clinical trials. Emeritus Research offers to clients:
• Standard Operating Procedures (SOPs)
• Multiple sites
• Patient database numbering 350,000
• Single budget
• Single contract
• Single HREC submission
• Central project management
• Enhanced site management
• Trained Clinical Research coordinators (CRCs)
• Quality data
 Enecon Pty. Ltd. ACN 34 006 087 494

Contact: Mr Colin Stucley, Managing Director

Phone: +61 3 9817 6255 Fax: +61 3 9817 6455
Email: mail@enecon.com.au
Internet: www.enecon.com.au
Address: Level 2 Postal PO Box 555
35 Whitehorse Road Address: Deepdene DC, VIC, 3103
Deepdene, VIC, 3103 Australia
Australia

Profile: Enecon Pty Ltd (Enecon) is involved in project development through the provision of innovative
technology and engineering, with a particular focus on the utilisation of biomass such as plantation
grown trees and timber industry wastes:

- to provide renewable energy, as an alternative to energy from fossil fuels

- to manufacture value-added products from biomass - principally activated carbons for

applications such as water treatment, and charcoal for energy or for industry.

Enecon offers state-of-the-art technology for recovery of carbon products and energy. This
technology has been developed by the CSIRO in Australia and is now licensed exclusively to
Enecon for commercialisation worldwide. Enecon offers practical engineering skills and
commercial experience for the development of sustainable projects and industries in Australia and
overseas, and its engineers are familiar with a wide range of technologies for energy and for
biomass co-products. Services to help develop new projects range from pre-feasibility studies
through to design, construction, commissioning and product marketing.

Enecon is based in the Eastern suburbs of Melbourne in the State of Victoria, Australia,
approximately 10 km east of Melbourne's central business district.
Ensign Laboratories Proprietary Limited ACN 11 004 395 242

Contact: Mr Peter Thornborrow, Managing Director

Phone: +61 3 9550 1500 Fax: +61 3 9560 5545
Email: ensignlab@ensignlab.com.au
Internet: www.ensignlab.com.au
Address: 490 Wellington Road Postal PO Box 268
Mulgrave, VIC, 3170 Address: Glenways MDC
Australia Mulgrave, VIC, 3170
Australia

Profile: Ensign Laboratories is a wholly owned private Australian company operating as custom and
contract manufacturing chemists. It employs around 260 people, and operates from three sites in
the Melbourne area. The head office is located on a 3.5-hectare site at Mulgrave. It has been
operating since 1955.

Ensign Laboratories is involved in the formulating and filling of a complete range of aerosol
products, including therapeutics, personal care, sunscreen and suncare, veterinary, household,
home garden, automotive, and industrial products. The company is TGA-licensed for non-sterile
therapeutic goods and devices; is US FDA registered; is NRA-licensed to produce veterinary
preparations; and holds a Dairy Food Safety Victoria licence covering the manufacture of dairy
foods. It is also ISO 9002 certified.

Ensign Laboratories operates a substantial product research and development facility involved in
the development of a wide range of products: personal care, sunscreen, household (including
detergents), and topical therapeutics. The customer base includes multinational and national
brand owners, including leading supermarket chains, for which Ensign provides product
development services such as product registration, stability testing and validations as necessary.
During almost 50 years of activity, Ensign Laboratories has achieved international recognition for
technical competence and service.

Environmental and Resource Technology Holdings (EARTH) ACN 40 052 326 744
Pty. Ltd.
Contact: Mr Howard Mitchell, Chief Executive Officer
Phone: 1300 301 691 Fax: +61 3 9551 2030
Email: info@enviromix.com.au
Internet: www.enviromix.com.au
Address: Lot 2
Grange Road
Dingley Village, VIC, 3172
Australia

Profile: EARTH is a biotechnology company that produces horticultural growing media and allied products
from waste vegetation using a patented microbiological process.

EARTH solves the waste disposal problems and costs involved with a substantial component of
the solid waste stream by recovering waste vegetation and producing quality topsoil equivalents,
potting mixtures, mulches and allied products for home garden, landscaping and horticultural use.

EARTH has developed its first regional bioconversion facility at Dingley in Southern Melbourne
(ENVIROMIX™ Southern Melbourne) under licence and intends to establish other regional
licensed facilities throughout Australia and internationally.
Environmental Biotech (Systems) Pty. Limited ACN 14 069 201 752

Contact: Mr Ted Fritz, Managing Director

Phone: +61 3 9318 0996 Fax: +61 3 9318 0702
Email: ebsaustralia@hotmail.com
Internet: www.environmentalbiotech.com.au
Address: 32 Westside Drive
North Laverton, VIC, 3026
Australia

Profile: Environmental Biotech is a bioremediation company that manufactures and distributes proprietary
non-pathogenic bacteria that have been isolated and developed to eradicate grease, fats, oils,
starches and gelatin, especially the kind found in restaurants, hotels, hospitals, and other food-
processing facilities.

Environmental Biotech solves the operation problems experienced in these facilities due to these
waste products. These problems include grease-related drain-line blockages which are endemic in
the industry, rancid odour problems from smelly drains, disposal of waste, and the reduction of
high strength waste water which often attracts government fines and surcharges. As the micro-
organisms eat the waste and convert much of it into carbon dioxide and water, these problems are
reduced. Less waste means less landfill application and that is also good for the environment.

Environmental Biotech is a complete services company that has trained service technicians who
regularly service customers' drain systems, including the replenishment of the active bacteria.
 Enzyme Solutions Pty. Ltd. ACN 75 847 896 228

Contact: Mr Geoff Bearzatto, Chief Executive Officer

Phone: +61 3 9761 7999 Fax: +61 3 9761 7899
Email: geoff@enzymesolutions.com.autom@enzymesolutions.com.au
Internet: www.enzymesolutions.com.au
Address: 26 Research Drive
Croydon South, VIC, 3136
Australia

Profile: Enzyme Solutions Pty Ltd was established in 1997 in Melbourne.

Enzyme Solutions is the Australia-based representative for both Genencor International, Inc. and
Valley Research, Inc., and exports to six other countries.

Enzyme Solutions is ISO 9001-2000 certified and is involved in sales and distribution of enzymes
for many industries including grain processing, dairy, cleaning, wine and fruit juice production,
brewing, baking, pharmaceutical, feed, paper, and waste treatment.

The cornerstone of the business philosophy of Enzyme Solutions is technical support, which
involves helping customers with enzyme selection, trials and process optimisation.

Enzyme Solutions develops products locally to suit the market requirements and has registered
the trademarks Optivin, Optibrew, Solvabrew and StarClear.
EpiTan Limited ACN 88 089 644 119

Contact: Dr Wayne Millen, CEO / Managing Director

ASX: EPT
Phone: +61 3 9662 4688 Fax: +61 3 9662 4788
Email: mail@epitan.com.au
Internet: www.epitan.com.au
Address: Level 10
52 Collins Street
Melbourne, VIC, 3000
Australia

Profile: EpiTan Limited is an emerging biotechnology company with a pre-eminent position on the
prevention of DNA & skin damage from ultra-violet (UV) radiation exposure. Based in Melbourne,
Australia, EpiTan holds a unique technology platform centred on its leading drug candidate
Melanotan. The company has the exclusive worldwide rights to develop Melanotan, which, like
sunlight, stimulates the production of melanin in the skin resulting in a tan. It allows a tan to
develop without exposure to harmful levels of UV light.

Melanotan is currently in Phase IIb clinical trials at two sites – the Royal Prince Alfred Hospital in
Sydney and the Royal Adelaide Hospital. These trials are designed to demonstrate that Melanotan
can reduce the incidence of skin damage resulting from harmful exposure is ultra-violet light.

EpiTan has now successfully developed a more user-friendly drug delivery formulation of
Melanotan in the form of a slow release implant. This will be used in the remaining clinical
programme and the commercialized product. EpiTan is also investigating Melanotan as a
therapeutic agent for other indications such as vitiligo, albinism, psoriasis and various recognised
sun allergies such as polymorphous light eruptions and solar urticaria.

Potential markets worldwide for Melanotan for dermatology purposes are estimated at US$1.5
billion. An even greater market (more than US$5 billion) exists for Melanotan as a new safe
(sunless) tanning drug. EpiTan’s commercialization strategy recognizes the need for strategic
partnerships with other larger pharmaceutical companies and drug delivery companies. By
entering licensing agreements at the appropriate times, EpiTan aims to maximize its potential for
developing novel products in a wide variety of prophylactic and therapeutic areas.
 Epitope Technologies Pty. Ltd. ACN 88 075 293 775

Contact: Mr Stephen Wilson, Business Development Manager

Phone: +61 3 9315 6035 Fax: +61 3 9315 6006
Email: epitope@office.net.au
Address: Level 3 IBM Centre
60 City Road
Southbank, VIC, 3006
Australia

Profile: Epitope Technologies Pty Ltd is developing products for the immunodiagnostic reagents industry -
manufacturing, custom production and distribution. Epitope is working with various institutions to
produce and market several sheep cytokine products that can be used in immunoassays (ELISA).
Epitope is marketing these products through OEM (original equipment manufacture) arrangements
in Europe and the USA. The company also markets a number of monoclonal and polyclonal
antibodies for flow cytometry for clinical and research applications.

Epitope has recently entered into the rapid test area and is currently marketing a range of
infectious disease tests. The company also markets a rapid test for the cardiac marker Troponin I.

Epitope benchmarks potential products and carries out market research through its extensive
international network. Within Australia, Epitope distributes imported niche products.

ES Cell International Pte Ltd ACN 32 097 482 632

Contact: Ms Jane Halprin, Executive Officer

Phone: +61 3 8532 1777 Fax: +61 3 8532 1771
Email: jhalprin@escellinternational.com, contactus@escellinternational.com
Internet: www.escellinternational.com
Address: 4th Floor, Baker Medical Research Postal PO Box 6492
Institute Address: St Kilda Road Central
Commercial Road Melbourne, VIC, 8008
Prahran, VIC, 3181 Australia
Australia

Profile: ES Cell International Pte Ltd (ESI) is a regenerative medicine company and a leading provider of
products and technologies derived from human embryonic stem (hES) cells.

ESI is developing a robust hES cell technology platform and an extensive intellectual property
portfolio, building on established expertise in the area of hES cells and their directed
differentiation.

ESI is maintaining a pre-eminent position through the development, protection and dominance of
manufacturing processes for hES cells and their progeny. ESI is achieving early commercial
returns through the provision of cell lines and technologies to global research and therapeutic
markets.

ESI owns six of the hES cell lines listed on the USA's National Institutes of Health (NIH) Stem Cell
Registry, and distributes its cell lines throughout the world, including the NIH's considerable
network of stem cell researchers.

SI is concentrating its therapeutic development resources on generating cell replacement

therapies for insulin-dependent Diabetes and Parkinson's disease sufferers. In both cases there is
a significant unmet clinical need, and a considerable commercial opportunity.

ESI aims to be in clinical trials with its first therapeutic development candidate by 2006.
 EvoGenix Pty Limited ACN 33 097 483 068

Contact: Dr Merilyn Sleigh, Chief Executive Officer

Phone: +61 3 9662 7170 Fax: +61 3 9662 7171
Email: business@evogenix.com.au; m.sleigh@evogenix.com.au
Internet: www.evogenix.com.
Address: 343 Royal Parade
Parkville, VIC, 3052
Australia

Profile: EvoGenix Pty Limited is developing platform technologies for optimising the value of proteins as
pharmaceuticals and diagnostic agents. EvoGenix has laboratories in Melbourne and an
administrative office in Sydney.

EvoGenix operates within the rapidly growing biopharmaceutical sector, with a focus on protein
therapeutics. There is an increasing number of highly successful products in this area, with
markets exceeding US$ 1 billion annually. Current annual growth in the protein therapeutics
market is around 15%, driven by introduction of new products as well as increased sales of
existing products. Each new product in development is a candidate for optimisation via the
EvoGenix technology platform.

EvoGeneTM Technology developed by EvoGenix provides a method for protein drug developers
to rapidly assess many variants of a natural protein, to find the ideal product candidate which
combines high activity and specificity with capacity for efficient production, without damaging the
inherent benefits of the starting protein. The technology thus provides the potential to overcome
key disadvantages which have previously deterred many companies, particularly the larger
pharmaceutical companies, from developing protein products. EvoGene is a process of “directed
evolution”, an iterative process where at each step, protein variants (mutants) are created. Those
with an improvement in the desired properties are selected as the starting point for the next round
of mutation and selection until the required profile of properties for a product candidate is
achieved.

The competitive advantage of EvoGeneTM Technology lies in its speed in both generating and
then selecting from an enormous range of protein variants. By combining efficiency and
effectiveness, it can enhance the potential for clinical and commercial success of a product without
a major additional burden in time and resources. The EvoGenix technology package is patent
protected, and does not infringe patents held by other parties.

As a process for directed evolution of proteins, EvoGene technology will be most effective for fine
tuning of protein properties, used alone, or in combination with other protein evolution approaches.
The technology has demonstrated impressive results in the improvement of antibody affinity and
enzyme activity in model systems.

EvoGenix is now applying its technology for protein improvement via two different avenues

• In commissioned projects from biotechnology and pharmaceutical companies, where EvoGenix

will identify improved versions of product candidates, for example an anticancer antibody with
increased binding to its target cell, the greater activity resulting in a lower dose requirement (and
hence lower cost per dose) as well as increased clinical effect. The first such project with a
significant European antibody development company will commence in April.

• In internal projects that may be undertaken in collaboration with academic research groups or
with other biotechnology companies. EvoGenix will retain substantial ownership in these projects
with the intention of licensing on to a major pharmaceutical company as the products enter clinical
testing. EvoGenix has identified two such projects which offer very attractive potential for products
to address large markets in areas of clinical need.

Of course, EvoGeneTM technology is applicable, not only in the pharmaceutical sector, but also in
the industrial and agricultural sectors for improvement in the properties of enzymes and other
proteins used in paper or chemical manufacture, to generate food ingredients, in household
products or as components of animal feeds. Because of the broad potential of its technology,
EvoGenix will seek opportunities to work with companies outside of the pharmaceutical sector
either by collaboration or via technology licensing.
 Farm Pride Foods Limited ACN 42 080 590 030

Contact: Mr Glenn Abbott, National Business Manager-Egg Products

ASX: FRM
Phone: +61 3 9798 7077 Fax: +61 3 9701 5729
Email: glenn@farmpride.com.au
Internet: www.farmpride.com.au
Address: 551 Chandler Road Postal PO Box 141
Keysborough, VIC, 3173 Address: Noble Park, VIC, 3174
Australia Australia

Profile: Farm Pride Foods Ltd is a publicly listed company (ASX: FRM), producing and marketing shell
eggs and a range of egg products.

Farm Pride Foods is a supplier of eggs and egg products to the biotechnology industry for raw
material and specialty ingredient applications.

Farm Pride Foods operates an export approved plant, and can offer caged, barn laid and free
range eggs. The product range includes fresh, frozen and dried whole egg and egg yolk, fresh and
frozen egg white, fresh and frozen salted egg yolk, hard boiled, poached and fried eggs,
scrambled egg, crepes, low cholesterol egg and chicken powder.
Felton Grimwade & Bickford Pty. Ltd. ACN 13 004 809 161

Contact: Mr Kerrin Michael, Research and Development Manager General Manager

Phone: +61 3 9562 7711 Fax: +61 3 9562 7291
Email: mail@fgb.com.au
Internet: www.fgb.com.au
Address: 61-69 Clarinda Road Postal PO Box 74
Oakleigh South, VIC, 3167 Address: Oakleigh South, VIC, 3167
Australia Australia

Profile: Felton, Grimwade & Bickford Pty Ltd has a company history which can be traced back to the
1860s. Today it is a Melbourne based independent private company wholly Australian owned and
operated. The company manufactures and markets a range of proprietary products which are
distributed through pharmacies and supermarkets throughout Australia and in a growing number of
export markets.

The company manufactures a range of pharmaceutical and non-pharmaceutical grades of

eucalyptus oil for use in pharmaceuticals, toiletries, confectionery and industrial products. As
Victoria's largest producer of eucalyptus oil, Felton, Grimwade & Bickford incorporates its oil into
its own products as well as selling in bulk to other manufacturers in Australia and overseas.
Medicinal eucalyptus oil produced from E. polybractea is extensively used as a raw material and
active ingredient of cough lozenges, inhalation sprays and drops, gargles, mouth washes,
toothpastes, embrocation balms and ointments, liniments and soaps.

Eucalyptus oil is also used in antiseptics and germicidal disinfectants because of its pleasant
odour and its effectiveness in killing bacteria. Industrial eucalyptus oils are used in the
manufacture of household disinfectants and as an industrial solvent. Other products manufactured
and marketed by the company include over-the-counter pharmaceuticals, herbal & nutritional
supplements, medical devices, personal care and household products.

The company is also working closely with The Mallee Oil Company in Western Australia, on a
project to grow and harvest eucalyptus to reduce dry land salinity. Felton, Grimwade & Bickford
expects this to become a new source of raw material for oil. The spent leaves after the eucalyptus
oil has been extracted are marketed as a mulch and ground cover. Sold under the trade-name
Bosisto's Euca-Mulch, it has been successfully tested by the Department of Agriculture. More work
is being undertaken as it is believed the spent leaves could be an ideal addition to potting mixes.
 Fisher & Paykel Healthcare Corporation Limited ACN 52 005 484 999

Contact: Mr David Boyle, General Manager

ASX: FPH
Phone: +61 3 9879 5022 Fax: +61 3 9879 1598
Email: david.boyle@fphcare.com.au
Internet: www.fphcare.com
Address: 36 New Street Postal P.O. Box 167
Ringwood, VIC, 3134 Address: Ringwood, VIC, 3134
Australia Australia

Profile: Fisher & Paykel Healthcare's lead product is used to treat sleep apnea (apnoea), a condition
causing temporary cessation in breathing during sleep. The New Zealand based parent company
claims a 6% market share of the A$500 million world market for sleep apnea products. Fisher &
Paykel Healthcare also makes respiratory humidifiers, infant resuscitators, and patient warmers.
The parent company listed on the ASX in November 2001.
Florigene Limited ACN 36 006 455 616

Contact: Dr John Mason, R&D Manager

Phone: +61 3 9419 9844 Fax: +61 3 9416 1761
Email: florigene@florigene.com.au
Internet: www.florigene.com.au or www.florigene.com
Address: 16 Gipps Street
Collingwood, VIC, 3066
Australia

Profile: Improvements to flowers - whether in shape, colour, vase life, disease resistance or other
characteristics - have historically been achieved by cross-breeding of existing varieties. This is
typically a long and unpredictable process that might lead to only small improvements and cannot
span the basic gaps imposed by the species' gene pool, e.g. the absence of the gene responsible
for the producing the blue colour.

Florigene is the world's first successful "molecular breeder" in the flower industry. Florigene uses
genetic engineering technology to bridge genetic gaps and rapidly deliver valuable improvements
to flower species. The company now has two proven core technologies - Blue Gene Technology
and Long Vase Life (LVL) Gene Technology. The first commercial products from these
technologies are now on the market.

Florigene was founded in Melbourne, Australia in 1986. Since then, the company has developed,
patented and refined an impressive portfolio of technology, and Florigene is now regarded as a
world-leader in the genetic engineering of flowers. The company's research center and corporate
headquarters are still located in Melbourne.

Carnations were used as a model for research and in 1994, Florigene scientists succeeded in
implanting the Blue Gene into carnations and were able to generate the first carnation to express
colour in the blue range. This flower was called Moondust™ and was an important breakthrough.
Other successes followed in Blue Gene research, and new technologies have since been added to
Florigene's stable.

In the meantime, Florigene's scientists continue to refine the Blue Gene Technology and plan to
extend it to gerberas, chrysanthemums and, of course, the blue rose.
 Fluid System Technologies (ES) Pty Ltd

Contact: Mr Dugald Mackenzie, Business Development Manager

Phone: +61 3 9387 6477 Fax: +61 3 9387 4528
Email: dugaldm@fstau.com.au
Address: 4/1 Wilson Avenue
P.O. Box 319
Brunswick, Victoria, 3056
Australia

Profile: Fluid System Technologies (ES) was formerly known as North Melbourne Valve & Fitting Pty Ltd.
Under new ownership we now offer specialist componentry to the Biotechnology, Pharmaceutical,
Medical and Research industries. These products include valves, fittings, pumps, filters, sight
glasses, tubing and many other components required to build production facilities whether they be
pilot plants or full scale production facilities.

With branches in Queensland and New South Wales and New Zealand, we service the Eastern
States, New Zealand, the Pacific Islands and Papua New Guinea. Key brand names are Jensen
and Swagelok.
FMPR Communications ACN 092379890

Contact: Ms Marnie Firipis, Director

Phone: +61 3 96539650 Fax: +61 3 96539307
Email: inquiry@fmpr.com.au
Internet: http://www.fmpr.com.au
Address: Level 50 - 101 Collins Street
Melbourne, Victoria, 3134
Australia

Profile: FMPR Communications provides medical writing and media communications services to the
biotechnology and pharmaceutical industry.

G.B.C. Scientific Equipment Pty. Ltd. ACN 30 005 472 686

Contact: Mr Ross Grey, Managing Director

Phone: +61 3 9213 3666 Fax: +61 3 9213 3677
Email: gbc@gbcsci.com
Internet: www.gbcsci.com
Address: 12 Monterey Road
Dandenong, VIC, 3175
Australia

Profile: G.B.C. Scientific Equipment designs, manufactures and markets a range of scientific instruments
and is now leading the world in development of instruments such as the most technically
advanced inductively coupled plasma time of flight mass spectrometers (ICP-TOF MS), the new
micro Fourier rheometer (MFR 2100), and x-ray diffraction (XRD) instrumentation. Atomic
absorption spectrometers (AAS), UV-visible spectrometers (UV-Vis), inductively coupled plasma -
optical emission spectrometers (ICP-OES), high performance liquid chromatographs (HPLC) and
rheological analysis equipment are also manufactured and marketed by G.B.C.

Since its inception in 1978, G.B.C. has become renowned in the elemental analysis field as a
result of its successful AAS and ICP portfolio. Endorsed by the international quality standard, ISO
9001, the company prides itself on developing products which exceed market expectations. G.B.C.
has been the recipient of many international export awards. The company's head office is based in
Melbourne and it has a USA subsidiary office in Illinois. Worldwide, G.B.C. is represented an
extensive distribution network covering over 85 countries.
 Genera Biosystems Pty Limited ACN 098 063 837

Contact: Dr Suzanne Lipe, CEO

Phone: +61 3 9345 2248 Fax: +61 3 9345 2242
Email: suzanne.lipe@generabiosystems.com
Internet: www.generabiosystems.com
Address: WEHI Biotechnology Centre
4 Research Avenue, La Trobe R&D
Park
Bundoora, VIC, 3086
Australia

Profile: Genera Biosystems is an early stage Australian biotechnology company established to further
develop and commercialise DNA analysis technology originally developed by the Walter and Eliza
Hall Institute of Medical Research (WEHI) and the Australian Genome Research Facility (AGRF).

Genera's proprietary platform technologies, together, provide a fully integrated test system for
rapid DNA analysis, for the medical research, biopharmaceutical and agricultural industries, which
includes:

- single nucleotide polymorphism (SNP) analysis,

- novel mutation scanning, and
- gene expression.
Genera's AmpaSand™ Beads consist of silica beads which have been covalently coupled to a
unique linker DNA sequence. The Universal Anchoring System™ provides a simple ligation
procedure to link DNA of interest onto AmpaSand™ Beads, thereby customizing it for users’ own
specific applications. The use of Genera's SiFT™ (Sequence Identification by Flow Test)
technology, an ultra-sensitive form of competitive hybridization, allows genetic analysis of results
by standard flow cytometry instrumentation. Software under development will allow accurate and
rapid interpretation of this flow data, producing an integrated DNA analysis system which is gel-
free, high-throughput, multiplexing capable and cost effective..

Genetic Science Services Pty Ltd ACN 34 097 626 885

Contact: Mr George Sofronidis, Managing Director

Phone: +61 3 8412 7077 Fax: +61 3 9416 4076
Email: George@geneticscienceservices.com
Internet: www.geneticscienceservices.com
Address: 60-66 Hanover Street Postal P.O. Box 115
Fitzroy, Vic, 3065 Address: Fitzroy, Vic, 3065
Australia Australia

Profile: Genetic Science Services Pty Ltd commenced during May 2002, offering animal paternity and
endangered species genetic testing.

Genetic Science Services’ vision is to become a leading animal biotechnology service provider. It
provides genetically based identity, parentage, disease and productivity tests for farmers,
breeders, collectors and animal lovers.

Its range of genetically based tests provides managers with a source of certainty in the uncertain
world of inherited animal traits causing illness or affecting productivity.

Its staff are qualified genetic scientists with long-term experience and first class qualifications.
Coupled with a commitment to ongoing training and active research and development, Genetic
Science Services is poised to provide superior service for animal managers. Genetic Science
Services has established a unique partnership with Box Hill Institute, a leading Victorian vocational
institute. It is thus equipped to perform its services in secure, state-of-the-art facilities.
 Genetic Technologies Corporation Pty Limited ACN 92 075 962 800

Contact: Mr Ian Smith, Director

Phone: +61 3 9415 7688 Fax: +61 3 9416 4076
Email: gtc@genetictechnologies.com.au
Internet: www.genetictechnologies.com.au
Address: 60-66 Hanover Street Postal PO Box 115
Fitzroy, VIC, 3065 Address: Fitzroy, VIC, 3065
Australia Australia

Profile: Genetic Technologies Corporation Pty Limited (GTCPL) is the largest DNA parentage testing
laboratory in Australia, and is part of the listed Melbourne-based group Genetic Technologies
Limited. Established in 1988 to undertake DNA identity testing, GTCPL was the first commercial
organisation in Australia to perform DNA parentage testing. Since then GTCPL has continued to
rate on this market and has expanded to provide other DNA-based services.

In the last two years GTCPL has built a new DNA laboratory and invested heavily in state-of-the-
art DNA typing equipment. This equipment allows the company to perform very accurate DNA
typing. In Australia, the Family Court, and the Registry of Births, Deaths & Marriages, only
recognise reports performed by laboratories authorised by the Federal Attorney General and
accredited by the National Association of Testing Authorities (NATA). GTCPL has the necessary
authorisation and accreditation to perform these tests.

GTCPL offers a range of DNA tests for parentage, immigration, forensic investigation, twins
analysis, resolution of deceased estates, and sibship analysis.
 Genetic Technologies Limited ACN 17 009 212 328

Contact: Dr Mervyn Jacobson, Executive Chairman

ASX: GTG
Phone: +61 3 9415 1135 Fax: +61 3 9417 2987
Email: info@gtg.com.au
Internet: www.gtg.com.au
Address: 60-66 Hanover Street Postal PO Box 115
Fitzroy, VIC, 3065 Address: Fitzroy, Victoria, 3065
Australia Australia

Profile: Genetic Technologies Limited, listed on the Australian Stock Exchange (ASX: GTG), heads a
group of 11 companies, 8 of which are based in Australia: four DNA testing and analysis
companies (Genetic Technologies Corporation Pty Limited, GeneType Pty. Ltd., Silbase Scientific
Services Pty. Ltd.,Simons GeneType Diagnostics Pty. Ltd.)and Genetic Science Services Pty Ltd
and two recently formed companies branching out into major new biotechnology areas (ImmunAid
Pty Ltd, and RareCellect Ltd.) [See separate Directory entries]. In 2001, Genetic Technologies
acquired the eighth, Perth-based DNA-ID Labs. The Group’s overseas companies are GeneType
AG (Switzerland), Gtech International Resources (Vancouver Stock Exchange) and GeneType
Corp. (USA). GTG operates Australia’s largest DNA paternity testing service.

The original GeneType group was formed in 1989 in Melbourne. The group’s strong intellectual
property portfolio includes two key DNA-related patents: the first on DNA analysis, covering non-
coding regions of DNA from any species (misleadingly known until recently as "junk DNA"); and
the second on an innovative method for gene mapping, also based on non-coding information.
These broad-ranging patents potentially have wide application, initially in areas such as tissue
matching for organ transplantation, DNA-based forensic work, detection of disease-causing
organisms, and human, animal and plant diagnostics. Gene mapping applications include
diagnostic tests for human genetic diseases such as nasopharangeal cancer, hemochromatosis
and diabetes. Mapping in other species will be applied to breeding programs for cattle, sheep and
pigs.

GTG has recently entered into licence agreements with Genetic Solutions Pty Limited, Nanogen
Inc,Sequenom Inc., Perelegen,, Myriad Genetics,Pyrosequencing, Orchid Biosciences, ARUP,
Inguran LP and The University of Sydney for its non coding intron patents. GTG also owns 51% of
AgGenomics Pty. Ltd., a new Victorian venture for DNA testing of plants [See separate entry]. A
separate GeneType technology is the non-invasive recovery of foetal cells for prenatal genetic
testing [see RareCellect Ltd. entry].
 Genetics Australia Co-operative Limited ACN 64 822 392 303

Contact: Mr Bernie Harford, Chief Executive Officer

Phone: +61 3 5367 3888 Fax: +61 3 5367 5100
Email: bharford@genaust.com.au
Internet: www.genaust.com.au
Address: Woolpack Road Postal PO Box 195
Bacchus Marsh, VIC, 3340 Address: Bacchus Marsh, VIC, 3340
Australia Australia

Profile: Genetics Australia Co-operative Limited is Australia's largest artificial breeding organization. It
provides over half of the Australian dairy industry's requirements for elite genetics. Genetics
Australia invests in R&D in partnership with leading research institutes and the Dairy Research
and Development Corporation. R&D covers dairy herd fertility and reproductive management;
semen processing, bull fertility and semen production; the use of genetic markers; and cloning and
genetic modification technologies. Genetics Australia maintains a large embryo recipient herd and
a modern laboratory for in-vitro production to support cloning and genetic modification research.
The research has produced advances in the technology, including Australia's first calves cloned
from adult somatic cells in early 2000. ; Australia’s first cloned elite dairy bull (Rameses II) .
Genetics Australia is a member of the Cooperative Research Centre (CRC) for Innovative Dairy
Products, which commenced on 1 July 2001. The CRC is pursuing R&D and commercialisation of
genetic and reproductive technologies of relevance to the dairy industry.

GeneType Pty. Ltd. ACN 60 050 029 279

Contact: Mr Ian Goudie, Chief Executive Officer

Phone: +61 3 9417 5711 Fax: +61 3 9417 2987
Email: info@gtg.com.au
Internet: www.gtg.com.au
Address: 60-66 Hanover Street Postal PO Box 115
Fitzroy, VIC, 3065 Address: Fitzroy, VIC, 3065
Australia Australia

Profile: GeneType Pty. Ltd. is part of the ASX-listed Melbourne-based group Genetic Technologies Limited
(GTG). GeneType was founded 1989 when Dr. Malcolm Simons (an immunogeneticist) and Dr.
Mervyn Jacobson (a medical practitioner) met in Melbourne, Australia, and resolved to prove the
non-coding ("junk" DNA) region of the human HLA gene complex on chromosome 6 is in reality
not "junk", but in fact a valuable and highly ordered reservoir of useful genetic information, largely
overlooked by the rest of the world. GeneType offers a DNA-based human identity testing service
(see separate listings for Genetic Technologies Corporation and Simons GeneType Diagnostics)
and conducts applied research programs, principally in human foetal cell recovery and animal
parasitology. GeneType staff also support other priority research projects, including newly formed
companies ImmunAid and RareCellect, and new opportunities in animal and plant genetics and
genomics. [See separate entries for Genetic Technologies Limited, ImmunAid and RareCellect].
 Genomic Disorders Research Centre

Contact: Prof Richard Cotton, Director

Phone: +61 3 9288 2980 Fax: +61 3 9288 2989
Email: cotton@medstv.unimelb.edu.au
Internet: www.genomic.unimelb.edu.au
Address: 7th Floor, Daly Wing St Vincent’s Postal PO Box 2900
Hospital Address: Fitzroy, Victoria, 3065
35 Victoria Parade Australia
Fitzroy, VIC, 3065
Australia

Profile: The Centre was established in 1996 as the Mutation Research Centre and was the first and
remains the only organization, world wide, to focus exclusively on gene mutation, its measurement
and documentation and its linkage to inherited genetic disease, neurological, heart, cancer and
other common diseases. The Human Genome Variation Society and the HUGO Mutation
Database Initiative are administered from the Centre together with editorial responsibility for
Human Mutation journal. The Centre continues to develop its programme in the areas of gene
mutation detection research and has developed cutting edge technologies for the detection of
genetic mutations.

Gilead Sciences Pty Limited ACN 71 072 611 708

Contact: Ms Fiona Palmer, Associate Director Marketing

Phone: +61 3 9563 0433 Fax: +61 3 9567 2522
Email: fpalmer@gilead.com
Internet: www.gilead.com/wt/sec/australia
Address: 41 Stamford Road
Oakleigh, VIC, 3166
Australia

Profile: Gilead Sciences is a biopharmaceutical company that discovers, develops and commercialises
therapeutics to advance the care of patients suffering from life threatening diseases worldwide.
The company focuses its research and clinical programs on anti-infectives, including antivirals,
antifungals and antibacterials. Headquartered in Foster City, California, Gilead has operations in
the United States, Europe and Australia. Gilead Sciences Pty Limited, based in Victoria, is
responsible for sales and marketing activities throughout Australia and New Zealand. The New
Zealand activities are conducted in conjunction with Baxter Healthcare.
 GlaxoSmithKline Australia Pty Ltd ACN 73 004 148 065

Contact: Mr Daniel Tasse, Managing Director

Phone: +61 3 9721 6000 Fax: +61 3 9729 5319
Email: catherine.c.mcgovern@gsk.com
Internet: www.gsk.com.au/home/Home.asp
Address: 1061 Mountain Highway
Boronia, VIC, 3155
Australia

Profile: GlaxoSmithKline Australia Pty Ltd (GSK), one of the largest and most highly resourced
pharmaceutical companies in the country, was created in 2000 by the merger of Glaxo Wellcome
and SmithKline Beecham. GSK employs more than 1500 highly skilled professionals engaged in
research and development, medical, regulatory and clinical research, manufacturing, distribution,
sales and marketing. Products are exported to more than 65 countries around the globe. Total
export earnings in 2001 reached A$197 million.

GSK Australia contributed over A$25 million to Australian research and development funding in
2001. Its product portfolio is closely aligned with the country’s key health priorities in asthma,
immunisation, depression, diabetes, indigenous health, and antibiotic resistance. GSK’s Australian
headquarters in outer eastern Melbourne undertakes pharmaceutical manufacturing, commercial,
and administration functions.

Boronia is the principal production site for all prescription products including tablets, capsules,
aerosols, sterile liquids and creams. It also houses the Blow Fill Seal (BFS) facility, an innovative
delivery system for medicines that allows glass ampoules to be replaced with safer, more
convenient plastic ampoules. Built at an investment of A$50 million, this is GSK’s global
development and manufacturing site for BFS technology. It has been utilised to deliver innovative
medicines for the treatment of asthma and of the nausea and vomiting associated with
chemotherapy and radiotherapy. Over the next four years, GSK Australia plans to invest in capital
equipment and buildings and create new jobs in manufacturing.

With plants in Latrobe, Tasmania and Port Fairy, Victoria, GSK’s Chemicals Division produces
medicinal alkaloids. GSK produces 25% of global supplies and exports over 90% of finished
product. In addition, GSK exports poppy seed for culinary purposes to 12 countries.

Consumer health products are produced in Ermington, New South Wales.

 Glutagen Pty Ltd ACN 096 990 868

Contact: Dr Ted Stelmasiak, Managing Director

Phone: +61 3 9317 0122 Fax: +61 3 9317 0122
Email: glutagen@bigpond.com
Address: 64 The Esplanade
Maribyrnong, VIC, 3032
Australia

Profile: Start-up pharmaceutical and nutritional supplement developer Glutagen Pty Ltd was established in
Melbourne in 2001.

Glutagen specialises in development of treatments for gluten intolerance and Coeliac Disease
(CD). This genetically based condition affects about 1 in 300 people in Europe and the US. CD is
a condition in which abnormalities in the small bowel are produced by gluten present in cereals
such as wheat, rye and barley. At present, the only effective therapy for CD is a life-long gluten-
free diet.

The company has two products under development: Glutazyme – an enzyme supplement which
might be an adjunct to a gluten-free diet; and Glutaren – a pharmaceutical product designed to
prevent intestinal damage caused by gluten-derived toxic peptides. Glutagen’s lead product,
Glutazyme, is to undergo clinical trials in 2003 at a Melbourne hospital.

Grale Scientific Pty. Ltd.

Contact: Mr David Gray, Director

Phone: +61 3 9874 8577 Fax: +61 3 9874 8040
Email: enquiries@grale.com.au
Internet: www.grale.com.au
Address: Unit 18 / 107-113 Heatherdale Road Postal PO Box 5063
Ringwood, VIC, 3134 Address: Ringwood, VIC, 3134
Australia Australia

Profile: The core business of Grale Scientific Pty Ltd is medical instruments to support the pathology
sector. Grale supplies equipment and provides service and consumables to pathology and
diagnostic laboratories, with particular emphasis on histology. As well as designing, manufacturing,
selling and servicing its own brand of products, the company also sells and services a wide range
of instruments from other manufacturers. A key instrument, designed and manufactured by Grale,
is the Grale Cell Counter, used for performing differential white cell counts. This apparatus is used
in many areas of the health sector, including hospitals and pathology and diagnostic laboratories.
Grale is currently negotiating to add to its licensed range of products available from other
manufacturers.

Grale also makes fermenters with associated plant design and construction. A fermenter is a
controlled-environment vessel for growing large-scale cultures of micro-organisms, and Grale
custom-makes this equipment to order, from research bench/laboratory requirement up to large
production machines. While it services and modifies other brands, Grale primarily designs,
services and modifies its own equipment to order. Grale Scientific was established in 1984.
 Halcyon Proteins Pty. Ltd.

Contact: Mr Phillip Strong, Managing Director

Phone: +61 3 9768 2021 Fax: +61 3 9768 2291
Email: halcyonproteins@iprimus.com.au
Internet: www.halcyonproteins.com.au
Address: 430 Hammond Road
Dandenong, VIC, 3175
Australia

Profile: Halcyon Proteins Pty. Ltd. is a Melbourne-based manufacturer and wholesaler of food ingredients:
enzymes, flavouring and colouring, food additives, and food ingredients, under the Flavex trade
name. Established in 1946 to manufacture protein extracts, Halcyon Proteins Pty. Ltd. is
Australia’s leading manufacturer of hydrolysed vegetable proteins. Halcyon Proteins Pty. Ltd. is a
100% family owned and operated company. This family involvement gives the company its
strength, flexibility and versatility.

Products include: hydrolysed vegetable proteins, soy sauce, yeast extract and fish sauce (flavour
enhancers), enzymes, and natural enzyme formulations (papain, bromelain, ficin). Products can
made to the customer’s specifications. The company designs and constructs process equipment,
provides technical advice, and supplies tailor-made products to meet the customer’s specific
requirements. Halcyon Proteins also provides contract drying services for selected food
ingredients.

The purpose-built, state-of-the-art manufacturing plant is located in Dandenong, Victoria, south of

the city of Melbourne. Strict quality control and automation have been the keys to developing high-
quality products at economical prices.

Hatchtech Pty Limited ACN 84 098 559 409

Contact: Dr Vern Bowles, Chief Scientific Officer

Phone: +61 3 8344 4439 Fax: +61 3 9347 5888
Email: vmb@unimelb.edu.au
Address: 215 Grattan Street
Parkville, VIC, 3052
Australia

Profile: Hatchtech Pty Limited is developing a new generation of low-toxicity insecticides for controlling
human ecto parasites, initially focusing on head lice. Head lice are a persistent problem
throughout the world, particularly in younger school-aged children. The problem is becoming
increasingly difficult to treat as head lice continue to develop resistance to conventional
treatments. Hatchtech has applied its novel technology to successfully identify potential new
targets for controlling head lice. In addition, the company has identified several compounds with
strong ovicidal properties. These ovicides stop lice eggs from hatching, inhibiting the rapid spread
of the parasite that is characteristic of infestations in humans. When combined with effective
pesticidal treatments, this innovative approach will lead to a new generation of highly effective,
low-toxicity treatments that target both the eggs and lice, overcoming the problems associated
with resistance.
 Hepatope Pty Ltd

Contact: Dr David Anderson

Phone: (03) 9282 2111 Fax: (03) 9282 2100
Email: anderson@burnet.edu.au
Internet: www.burnet.edu.au
Address: McFarlane Burnet Institute for Medical Postal GPO Box 2284
Research Address: Melbourne, Victoria, 3001
Melbourne, VIC, 3001 Australia
Australia

Profile:

Herbworx International Pty Ltd ACN 25 094 160 326

Contact: Mr Paul Sumner, Chief Executive Officer

Phone: +61 3 9819 1370 Fax: +61 3 9819 1043
Email: psumner@bigpond.net.au
Internet: www.herbworx.com ; www.phytomedicine.com.au ; www.phytotherapies.org
Address: 14 Atkins Street Postal PO Box 3099
Kew, VIC, 3101 Address: Cotham, VIC, 3101
Australia Australia

Profile: Herbworx International Pty Ltd is an international company with a commitment to supplying the
world market with high quality, innovative and clinically effective herbal products. Based in
Australia with strategic partners in Europe, Asia and the USA, Herbworx International is well
positioned to make a significant contribution in the production and marketing of herbal products
worldwide.
 Hexima Limited ACN 64 079 319 314

Contact: Mr Dan O'Brein, Executive Director

Phone: +61 3 8629 2929 Fax: +61 3 8629 2990
Email: dan.obrien@dromolandcapital.com
Address: Level 17
200 Queen Street
Melbourne, VIC, 3000
Australia

Profile: Hexima Limited was launched in 1998 as a joint venture between the University of Melbourne, key
researchers, and Pivot Limited, Australia's largest farmer-owned company. For the first three
years, it was funded by Pivot Ltd, which invested a total of A$1.3 million.

In August 1999, Hexima Ltd won a $750,000 Federal Government R&D START grant to research
and develop gene technology that can create natural insect resistance in plants.

The novel gene, identified and developed by researchers in the University of Melbourne's Plant
Cell Biology Research Centre and La Trobe University's Department of Biochemistry, is being used
to develop insect-resistant varieties of cotton. Based on research on the Nicotiana alata proteinase
inhibitor (NaPI) gene, patents on the gene have been issued in Australia, New Zealand and USA,
and are pending in Japan and Europe. The gene encodes a proteinase inhibitor that inhibits
digestion of proteins in the insect gut. There are six "individual units" of inhibitor. Each of these
could potentially inhibit a different enzyme in the insect gut. The gene has been expressed in
cotton and is effective in inhibiting growth of insects feeding on transgenic cotton leaves.

In November 2001, ownership of Hexima Limited was transferred to private investors and the
intellectual property was transferred from the University of Melbourne to Hexima.

A Biotechnology Innovation Fund (BIF) grant ($250,000) was announced in March 2002. The
project involves greenhouse and field trials of transgenic plants in combination with a topical spray
(technology owned by Nufarm Limited) to control pests in cotton.
 Howard Florey Institute of Experimental Physiology and
Medicine

Contact: Dr Henry DeAizpurua, Research Development Manager

Phone: +61 3 8344 5654 Fax: +61 3 9348 1707
Email: h.deaizpurua@hfi.unimelb.edu.au
Internet: www.hfi.unimelb.edu.au
Address: The University of Melbourne Postal The University of Melbourne
Royal Parade Address: Parkville, Victoria, 3010
Parkville, VIC, 3010 Australia
Australia

Profile: The Howard Florey Institute is known throughout the world as one of Australia’s leading medical
research institutes. Under the direction of Professor Frederick Mendelsohn it undertakes leading
edge research primarily into the brain and the cardiovascular system. The Institute has state-of-the
art equipment for neuroimaging with facilities and skills encompassing genomics,
electrophysiology, cell biology, neural development, whole animal physiology and functional brain
imaging.

The Florey’s mandate is to: advance the understanding of the detailed workings of the body,
especially the brain; use this knowledge to discover the nature, origins and causes of disease; and
prevent, diagnose and treat these diseases in humans and animals. In 1947 a young Melbourne
doctor, Derek Denton was caring for a sick boy with a serious surgical complication. This led to an
investigation into the control of salt and water balance in health and disease. The success of this
research led to increasing international interest. This prompted Kenneth and Baillieu Myer, Sir Ian
Potter and Dr H.C. Coombs along with the Rockefeller Foundation and the National Institutes of
Health in the USA, to set about the development of outstanding laboratories to support the
research effort. The laboratories were incorporated by an Act of the State Parliament in 1971 as
the Howard Florey Institute of Experimental Physiology and Medicine. Professor Denton was its
founding Director. Howard Florey, a brilliant Australian scientist who developed penicillin, gave his
name to the Institute. In addition to research into hypertension and salt appetite, and
endocrinology, peptide chemistry, molecular biology and biotechnology were also developed. New
horizons and expertise in hormone research (relaxin) resulted in the delivery of a portfolio of
patents. The Institute was expanded in 1975 and 1995 with funds from the State and Federal
Governments and significant benefactions from the private sector.

In recent years the Florey has focussed its research on deciphering how the brain develops and
functions. The implications for community health are substantial when you consider that
Alzheimer's disease, depression, stroke, Parkinson's disease or other brain disorders will directly
or indirectly affect over 75% of all Australians at some time. In-depth programs now investigate
how: the brain regulates most body function; the diversity of chemical messengers activate brain
cells which enable us to behave, think, learn and remember; the enormously complex structure of
the brain is developed; and specific areas of the brain become active in response to stimuli and
tasks. The Florey plays a vital role in encouraging and nurturing potential scientists through the
research training of postgraduates from leading universities. Currently there are over 45 PhD
students at the Florey and some 100 research and support staff. Outstanding international
scientists are invited to spend from three months to two years in our laboratories.

The Institute also encourages participation in international symposia. The Florey’s annual research
budget of about $10 million is mainly provided by the Federal Government’s National Health and
Medical Research Council, with significant contributions from Philanthropic Foundations, Industry,
the University of Melbourne, the State Government and private donors. Research at the highest
levels is heavily dependent on financial support. The Institute, to reduce dependence on
government funding, has initiated a major strategy of seeking partnerships with the corporate and
other research institutes.
 IATIA Limited

Contact: Mr Felix Thiang, Director of Marketing

ASX: IAT
Phone: +61 3 9898 6388 Fax: +61 3 9899 6388
Email: iatia@iatia.com.au
Internet: www.iatia.com.au
Address: 46 Rutland Road
Box Hill, VIC, 3128
Australia

Profile: Leaders in Vision Sciences, IATIA is an Australian based organisation actively involved in the
development and marketing of breakthrough optical technologies in the scientific and medical
fields. IATIA has exclusive worldwide rights to platform technology to quantify phase, known as
QPI, that is the subject of international patents.

Its first product, QPm, was launched in November 2001. QPm represents a breakthrough in
microsocopy imaging technology, allowing for the digital phase imaging of samples and the
measurement of physical thickness and refractive index. QPm can be attached to existing as well
as new research-grade microscopes. This phase technology is being applied to electron
microcopy (QPe), optometry (QPr) and ophthalmology (QPa), with these products being released
in the next 2 years.

IATIA also has an instrument division which has developed a wide range of revolutionary medical
and surgical optical instruments based on technology originally developed by the Ophthalmology
Department of the University of Melbourne. This product range is currently the subject of several
granted patents and further pending international patents.

IATIA has developed key strategic alliances and established an international distribution network
for the sale of its products.

IATIA has a strong commitment to staying at the leading edge of technology, providing high
precision, technologically progressive and innovative solutions for the global market.
 Ilexus Pty. Ltd. ACN 70 064 772 103

Contact: Prof Mark Hogarth, Director

Phone: +61 3 9287 0666 Fax: +61 3 9287 0601
Email: l.priest@ari.unimelb.edu.au
Internet: www.ilexus.com.au
Address: Kronheimer Building A&RMC Studley
Road
Heidelberg, VIC, 3084
Australia

Profile: Since its incorporation in 1994, Ilexus Pty Ltd has managed intellectual property created by the
Austin Research Institute (ARI), especially in the fields of inflammation and cancer.

Ilexus is focused on developing technology platforms from the following projects: a portfolio of
antibodies from ARI; CD46 complement regulator; and transferase enzymes (involved in organ
transplantation). Therapeutic and diagnostic applications can be developed from these platforms.

Ilexus’ technology portfolio includes research into cancer immunotherapy, some innovative
compounds for tumour imaging and targeting, and the development of a test for faecal occult
blood that overcomes many of the drawbacks of existing tests.

Other aspects of the technology portfolio include research into the prevention of rejection in organ
transplantation, inflamation and infectious disease.

Under a mid-2001 deal with ASX-listed Prima Biomed Ltd, Prima gained first rights to
commercialise other technology platforms arising from the ARI. This work will be pursued through
three companies: Arthron Limited, for research into rheumatoid arthritis; Cancer Vac Limited,
research involving clinical trials of a cancer vaccine; and Panvax Limited, research into areas of
cancer and infectious disease using a protein carrier (DCtag) that leads to the production of T cells
and antibodies. Ilexus has sublicensed the intellectual property rights to Arthron, Cancer Vac and
Panvax, and Ilexus’ staff have joined Prima Biomed. [See separate entries].
 Iliad Chemicals Pty Ltd ACN 17 099 125 612

Contact: Dr Bernard Flynn, Chief Executive Officer

Phone: +61 3 9903 9673 Fax: +61 3 9903 9582
Email: b.flynn@iliad.com.au
Internet: www.iliad.com.au
Address: c/- Victorian College of Pharmacy
381 Royal Parade
Parkville, VIC, 3052
Australia

Profile: Iliad Chemicals Pty Ltd is a biotechnology start-up company operating in two related areas:
building novel chemical libraries for high-throughput screening; and the commercial development
of a class of novel compounds as potential anticancer agents.

Iliad Chemicals Pty Ltd has developed a series of synthetic protocols that give efficient and direct
access to important structural classes of molecules that are recognized for their capacity to act as
biomolecule inhibitors and that exhibit other important drug-like properties. These methods can be
utilised in providing compound libraries for high-throughput screening programs in drug dicovery.
The design features of this library are such that any bioactive compound discovered from it will
have an increased likelihood of being easily administered to patients and a decreased likelihood of
side effects.

In collaboration with the National Cancer Institute (USA), the Iliad group has utilized its synthesis
techniques in the development of a series of novel and very potent anticancer agents. These
compounds have the potential to operate as dual purpose anticancer agents that are able to
directly target both the cancerous tissue and the vascular system of tumours.

ImmunAid Pty Ltd ACN 68 096 281 542

Contact: Mr Ian Goudie, CEO

Phone: +61 3 9417 5711 Fax: +61 3 9417 2987
Email: info@gtg.com.au
Internet: www.gtg.com.au
Address: 60 - 66 Hanover Street Postal PO Box 115
Fitzroy, VIC, 3065 Address: Fitzroy, VIC, 3065
Australia Australia

Profile: A member of the Genetic Technologies Limited group, ImmunAid Pty Ltd was formed to pursue
opportunities in biotechnology and is funding Australian scientists who are researching novel areas
relevant to the AIDS virus.

ImmunAid Pty Ltd has taken over the project and owns all intellectual property arising from this
project.

ImmunAid is owned 60% by Genetic Technologies [see separate entry] and 40% by the scientists
who developed the original concepts and who continue to work on the project. The original pilot
study was undertaken at University of Western Australia, and with the formation of ImmunAid, it is
intended that this work will be expanded in 2002, both at the University of Western Australia and at
other leading institutes in Australia and USA.
 Increasing Returns Pty Ltd ACN 70 086 139 157

Contact: Mr John Perry, Chief Executive Officer

Phone: +61 3 9226 6289 Fax: +61 3 9343 5281
Email: johnperry@increasingreturns.com
Address: 276 Walsh Street
South Yarra, VIC, 3141
Australia
Profile: Increasing Returns Pty Ltd established a marine biotechnology division in 1999, to further develop
university technology in terms of breeding and land-based grow-out of flounder and other flat fish.
Work has been ongoing and parties to finance and take the breeding program further have been
identified.

The company intends to move forward into commercialisation phase during 2002-03 with private
capital, and is currently completing investment and tax planning with a view to possibly including
Commonwealth R & D funding in 2003 in the finance mix for the expansion and development of
the technology. Other ventures, including the development of a seafood-derived food supplement,
based on a synergistic mix of various forms of sea life, are currently on hold with the possibility of
furthering the projects in the next 2-3 years.

IngenKO Pty Ltd ACN 32 095 313 803

Contact: Mr Martin Gore, Chief Executive Officer

Phone: +61 3 9544 2526 Fax: +61 3 9594 7111
Email: mgore@ingenko.com.au
Internet: www.ingenko.com.au
Address: 27-31 Wright Street
Clayton, VIC, 3168
Australia

Profile: IngenKO Pty Ltd was established in June 2001 as a commercial supplier of gene targeted mice on
a fee for service basis to customers in the pharmaceutical, biotechnology and medical research
industries. The company was established to commercialise intellectual property, know-how and
existing contracts of The Monash Institute of Reproduction and Development through the Centre
for Functional Genomics and Human Disease.

The Centre has 10 years of experience in the generation of transgenically modified mouse lines
and over 7 years in specifically generating gene targeted mice. Mice modified in this way
represent a valuable step in identifying those genes which are potential targets for the
development of therapeutic and diagnostic products. In addition to the receipt of contract income
for the generation of client-specified mouse knock-outs, IngenKO aims to generate royalty income
on intellectual property rights received by IngenKO as part of a discounted fee for contract
services.
 Institute of Drug Technology Australia Limited ACN 66 006 522 970

Contact: Dr Graeme Blackman, Managing Director

ASX: IDT
Phone: +61 3 9801 8888 Fax: +61 3 9801 8773
Email: gblackman@idtaus.com.au
Internet: www.idtaus.com.au
Address: 45 Wadhurst Drive
Boronia, VIC, 3155
Australia

Profile: Melbourne’s Institute of Drug Technology Australia Limited (IDT) is a vital player in the Australian
biomedical industry, being the country’s only fully integrated and accredited contract research,
development and manufacturing firm. Established in 1975, IDT is an Australian-owned public
company, listed on the ASX since 1988. The company has a number of modern manufacturing
facilities and laboratories in Melbourne, and is licensed by the Australian Therapeutic Goods
Administration (TGA) and the US Food and Drug Administration (FDA) for production of active
pharmaceutical ingredients. The company has become especially well known internationally for its
dedicated facilities for the production and testing of anticancer drugs.

The company is a leading manufacturer of active pharmaceutical ingredients for local and
international markets in its FDA inspected containment facilities located in Melbourne and also
provides a comprehensive range of consultancy, analytical and research and development
services to the pharmaceutical, chemical, biotechnology and allied industries. IDT also specialises
in the entire post-discovery pharmaceutical life cycle. Their expertise in the development of new
chemical entities from laboratory-scale to full-scale production, combined with the ability to
conduct phase I-IV clinical trials, uniquely positions IDT to assist companies at many stages from
synthesis to market level production.

In April 2000, the FDA approved for sale a major anticancer product made from an active
pharmaceutical ingredient produced by IDT. IDT is the sole supplier of this anticancer active
ingredient for worldwide distribution by one of the largest multinational pharmaceutical
manufacturers in the USA. In addition, in association with Virax Holdings Limited [see separate
entry], IDT is responsible for undertaking vaccine manufacture in compliance with strict
international quality standards. Other portfolio products include anti-psychotics, antibiotics,
narcotics and anti-inflammatory drugs.

In May 2002, IDT announced the acquisition of Adelaide-based clinical trials research company
CMAX Pty Ltd from the Mayne group.
 International Diabetes Institute

Contact: Mrs Shirley Murray, Public Relations and Project Manager

Phone: +61 3 9258 5050
Email: smurray@idi.org.au
Internet: www.diabetes.com.au
Address: 260 Kooyong Road
Caulfield, VIC, 3162
Australia

Profile: Professor Paul Zimmet's commitment to the study of lifestyle effects on health in developing
countries in the 1970s was the catalyst for the establishment of the Institute. Since its conception
in 1976 the Institute has developed into a world renowned organisation offering a unique program
of integrated diabetes health management coupled with an extensive research program
undertaken by its 80 dedicated staff. In 2000 the clinic registered its thousandth client, making it by
far the largest Diabetes clinic in Australia.

The development and implementation of innovative diabetes management practices through

evidence based research are core activities of the Institute. Professor Zimmet has lead the
Institute during its twenty years of continuous community service. In 1998 Malcolm Kinloch was
appointed Chief Executive Officer. Governance of the Institute is in cooperation with a dedicated
Board of community leaders. The Institute relies on philanthropy, sponsorship and fee for service
to maintain its programs.
Intervet Australia Pty Limited ACN 79 008 467 034

Contact: Dr John McNally, General Manager

Phone: +61 3 5442 5011 Fax: +61 3 5442 3162
Email: sales@intervet.com
Internet: www.intervet.com
Address: 91-105 Harpin Street Postal Box 2800
Bendigo East, VIC, 3550 Address: Bendigo Delivery Centre, VIC, 3554
Australia Australia

Profile: Intervet Australia Pty Limited, based at Bendigo in central Victoria, is engaged in the research and
development, production and marketing of veterinary products. Intervet’s product range consists of
vaccines, reproductive hormones, anti-infectives, anti-parasitics, feed additives, and productivity
enhancers for a wide variety of animal species.

One of the most costly disease problems facing Australia’s feedlot cattle is Bovine Respiratory
Disease (BRD), also known as Shipping Fever. BRD usually arises when cattle are stressed and
then exposed to harmful bacteria such as Mannheimia haemolytica (M h), which in turn decreases
their resistance to infection by respiratory viruses.

CSIRO Livestock Industries discovered that vaccines able to stimulate antibody responses against
a M h toxin significantly protected cattle from BRD. CSIRO, through the former Meat Quality
Cooperative Research Centre, developed and improved a cost-effective 'bacterin' vaccine. This
killed whole-cell vaccine was transferred to Intervet Australia's Bendigo operation for Mh vaccine
commercialisation. Pre-registration vaccine trials conducted in commercial feedlots were very
successful in reducing the costs associated with M h infection. Registration of the new vaccine is
expected by early to mid 2003. Intervet Australia has launched a vaccine to guard against cattle
ticks. TickGARD vaccine, which was previously available in Queensland, was included as part of
Intervet Australia's product range by late 2002.

Intervet Australia took over the Bendigo facilities from the former AusVac Pty Ltd. Intervet Australia
is a business unit of Intervet International BV, headquartered in The Netherlands and part of the
Akzo Nobel Pharma Group. Intervet is one of the world’s leading animal health companies, active
in 120 countries and employing some 5,000 people.
 Invetech Pty Ltd ACN 45 004 301 839

Contact: Mr Paul Wright, CEO

Phone: +61 3 9211 7712 Fax: +61 3 9211 7703
Email: instDevelopment@invetech.com.au
Internet: www.invetech-idd.com
Address: 495 Blackburn Road Postal Private Bag 44
Mount Waverley, VIC, 3149 Address: Mount Waverley, VIC, 3149
Australia Australia

Profile: Invetech Pty Ltd focuses on contract instrumentation development and manufacture. Since 1988,
Invetech has worked with start-ups, multinationals and strategic partners to develop market-
leading instruments for the healthcare industry.

Invetech's core capability is design and development of integrated systems and advanced
technologies for analysis and laboratory automation. The company has a proven record of more
than 15 successful instrument developments, undertaken collaboratively with clients (detailed at .

Many of these developments involve automating medical laboratory processes, where reliable,
repeatable instrument performance is essential to market success. Invetech offers a complete
idea-to-market outsourcing solution, with the option for contract instrument manufacturing
supported by sister company Vision BioSystems. Both companies are part of the publicly listed
Vision Systems group [see separate entries]. Invetech is also active in developing new
manufacturing processes and developing consumer and industrial products.

Invetech has a US Food and Drug Administration (FDA) registered manufacturing facility, and
QSR-compliant ISO9001 accredited design and development.

Invitrogen Australia Pty Limited ACN 72 053 997 194

Contact: Mr Peter Waterman, Senior Director of AustralAsian Research Products

Phone: +61 3 9545 5522 Fax: +61 3 9544 5622
Email: aumail@invitrogen.com
Internet: www.invitrogen.com
Address: 2A / 14 Lionel Road Postal PO Box 4296
Mt Waverley, VIC, 3149 Address: Mulgrave, VIC, 3170
Australia Australia

Profile: Invitrogen Corporation, Carlsbad, USA, develops, manufactures and markets research tools in kit
form and provides other research products and services to biotechnology and biopharmaceutical
researchers and companies worldwide. The company manufactures and markets products and
services that simplify and improve gene cloning, gene expression, and gene analysis techniques
for corporate, academic and government entities. The company also engages in technology
licensing, research services, large-scale production, and life science technical expertise and
support.

Invitrogen Australasia provides a range of molecular biology and cell culture reagents to the
Australian and New Zealand markets from operations based in Melbourne and Auckland. New
Zealand is a premier source of animal sera and protein products. Invitrogen’s Auckland and
Christchurch facilities manufacture and supply animal-derived products.
 Joint Centre for Crop Improvement

Contact: Prof Jim Kollmorgen, Director

Phone: +61 3 5362 2111 Fax: +61 3 5362 2187
Email: jim.kollmorgen@nre.vic.gov.au
Internet: www.jcci.unimelb.edu.au
Address: The University of Melbourne Parkville Postal Private Bag 260
Victoria Australia Address: Horsham, VIC, 3401
and Victorian Institute for Dryland Australia
Agriculture Natimuk Road Horsham
Victoria Australia
Horsham, VIC, 3401
Australia

Profile: The Joint Centre for Crop Improvement (JCCI) is a collaborative venture between The University
of Melbourne and the Department of Natural Resources and Environment. The Centre undertakes
research for the benefit of Australia's grains industries and trains postgraduate students and
research fellows. Members of the Centre are located at campuses of the University and at NRE
Institutes. Biotechnology research in the JCCI is undertaken in the Centre's variety development
program and is located at both the Parkville campus of the University and at the Victorian Institute
for Dryland Agriculture, Horsham. The Molecular Plant Genetics and Germplasm Development
Group is part of the JCCI and is located in the Crop Production Department at The University of
Melbourne. The group is focused on the application of biotechnology to crop production; and
research outputs are directed into the pulse and oilseed Brassica plant breeding programs at
VIDA. Biotechnology research in the JCCI at Horsham focuses on the production of transgenic
wheat and barley for Australia's breeding programs; and there is some work on molecular analysis
of agronomic traits and disease resistance.

Kendle Pty Limited ACN 81 379 182 044

Contact: Dr George Mihaly, Managing Director

Phone: +61 3 9564 8090 Fax: +61 3 9564 8336
Email: mihaly.george@kendle.com
Internet: www.kendle.com
Address: 156 Drummond Street
Oakleigh, VIC, 3166
Australia

Profile: Globally, Kendle is the fifth largest pharmaceutical development organisation, servicing the
pharmaceutical, medical device and biotechnology industries, with a presence in eleven countries.
Kendle’s Australian business originated in 1994, and, following a merger with Synermedica Pty Ltd
in March 2000, now has 40 staff with offices in Melbourne and Sydney as well as a presence in
New Zealand. Kendle offers services in four related areas: Development and Commercialisation;
Clinical; Regulatory; and Health Outcomes. Kendle can plan and manage clinical trials at all
stages of drug development. With access to an international network, Kendle has available a
broad base of physicians and therapeutic areas. With a comprehensive understanding of global
drug development, Kendle integrates preclinical, regulatory, clinical, health economic and
marketing imperatives. It provides strategic planning, project planning and management, technical
appraisals and valuations, and business planning. Kendle offers a full range of regulatory services
for drugs and devices. In addition, the company provides comprehensive health-economic and
pharmacoeconomic services, including defining strategies in drug development, retrospective cost
effectiveness analysis, and health economic studies.
 Kinacia Pty Ltd ACN 82 052 205 848

Contact: Mr Ken Windle, Chairman and Chief Executive Officer

Phone: +61 3 9899 9588 Fax: +61 3 9899 9872
Email: pam.wade@kinacia.com.au
Internet: www.kinacia.com.au
Address: Suite 4
899 Whitehorse Road
Box Hill, VIC, 3128
Australia

Profile: Kinacia Pty Ltd is a leading, privately owned, Australian bioscience company with a primary
research focus on blood clotting and kinases. Kinacia scientists first became interested in a
particular target kinase after discovering its importance in shear induced platelet adhesion,
aggregation, and subsequent clot formation.

Further work has now identified that there are several different isoforms of the kinase and that
these have specialised functions within specific cells: cells not only involved in blood clotting, but
also in tumour cell proliferation and inflammation. A very successful ongoing chemistry effort has
produced over 300 patented novel compounds with mixed isoform selectivity.

Clinical studies are currently being undertaken on the lead anti-clotting compound. Potential
markets for the anti-clotting compound include unstable angina, heart attack and stroke. Lead
compounds in other areas, including restenosis, inflammation and cancers, are also under
investigation. The company is also developing a diagnostic instrument which may assist in
identifying patients at risk of a blood clotting event. A laboratory version of the instrument is being
tested using blood from patients.

Kinacia's research and development program continues to be underpinned by a strong alliance

between the company and researchers from the Australian Centre for Blood Diseases (ACBD) at
Monash University in Melbourne. Kinacia commenced operation in July 1997 and has secured
investment funds from venture capital and private investors, including Australian Technology
Group Limited, Macquarie Technology Funds Management, Momentum Ventures, GBS Venture
Partners (formerly Rothschild Bioscience Fund), the Thorney Group (a division of the Pratt Group),
Macquarie PRISM and Macquarie Investment Managers. In addition, the company has secured
two Australian Government R&D Start Grants totalling $3.5m.
 Kryocor Pty Ltd ACN 46 071 858 387

Contact: Mr Hugh McCormack, Chief Executive Officer

Phone: +61 3 9326 6955 Fax: +61 3 9329 8071
Email: bni@bionova.com.au
Internet: www.bionova.com.au
Address: 36 Munster Terrace Postal PO Box 359
North Melbourne, VIC, 3051 Address: North Melbourne, VIC, 3051
Australia Australia

Profile: Kryocor Pty Ltd was established in 1995 as the R & D arm of Bio Nova International Pty Ltd. It was
awarded an R & D Start grant in June 1997 to develop a coronary bypass prosthesis. This will
enable a unique patented technology, currently used in the manufacture of a range of vascular
prostheses, combined with specific aspects of cell biology, to be the basis for the development of
the world's first "off the shelf" dedicated coronary artery prosthesis which is patient specific.

Coronary artery bypass grafting (CABG) continues to be one of the most commonly performed
surgical procedures in the developed world. The patient's own vessels are currently used for this
procedure. Secondary harvesting of vessels in redo surgery imposes added surgical morbidity and
mortality. An "off the shelf" coronary artery prosthesis which can match the performance of the
patient's natural vessel would be of great benefit by reducing the surgical risk to the patient and
reduce the costs associated with operating time and hospital stay. Testing for the coronary bypass
prosthesis is in the preclinical stage, with research work being conducted in Kryocor’s labs and
certain requirements contracted out to other companies and institutions.

Kryocor Pty Ltd is a wholly owned subsidiary of Bio Nova International Pty Ltd [see separate
entry].
 Ludwig Institute for Cancer Research

Contact: Dr Cassandra Thumwood, Scientific Administrative Officer

Phone: +61 3 9341 3155 Fax: +61 3 9341 3104
Email: Cassandra.Thumwood@ludwig.edu.au
Internet: www.ludwig.edu.au
Address: Level 6, Centre for Medical Research Postal PO Box 2008
Entrance 5, Royal Parade Address: Royal Melbourne Hospital
Royal Melbourne Hospital Parkville, Victoria, 3050
Melbourne, VIC, 3050 Australia
Australia

Profile: The Ludwig Institute for Cancer Research consists of an international network of ten branches
specialising in basic and clinical cancer research. The Melbourne Branch of the Institute was
established in 1980 in collaboration with the Royal Melbourne Hospital, the University of
Melbourne and the Walter and Eliza Hall Institute. The Ludwig Institute extended its affiliations in
1990 by establishing a clinical program at the Austin Campus of the Austin & Repatriation Medical
Centre in 1990. The Director of the Melbourne Branch is Professor Tony Burgess.

The Branch’s aims in basic and clinical cancer research are to identify and characterise molecules
that contribute to the tumourigenic state. This information is used as a starting point for identifying
agents that might be able to be incorporated into new and innovative treatments to improve cancer
outcomes.

In addition to cell signalling based strategies, the research and clinical staff at Ludwig Institute are
actively involved in identifying molecules that can serve as specific cancer markers for imaging
analysis and also as targets for immune based approaches, including the stimulation of host
immune responses to cancer. Currently, the Branch employs 180 staff, including 20 postgraduate
students.

In the laboratories there is a strong theme of research into the mechanisms governing the
regulation of cellular proliferation, movement and control with respect to growth factors and signal
transduction. Areas of particular interest clinically are colon cancer, leukaemia, breast cancer,
melanoma, tumour targeting, cancer immunotherapy and the molecular pathology of cancer.

Austin Campus - Ludwig Joint Oncology Unit & Tumour Targeting Program Harold Stokes Building,
Austin & Repatriation Medical Centre, Heidelberg, Victoria Ludwig Joint Oncology Unit - Phone: 61
3 9457 6933 Fax: 61 3 9457 6698 Tumour Targeting Program - Phone: 61 3 9496 5876 Fax: 61 3
9496 5892
 M 7 Pty. Ltd. ACN 74 088 964 989

Contact: Dr Christine Hirst, Managing Director

Phone: +61 3 9866 5024 Fax: +61 3 9821 5047
Email: chirst@magnet.com.au
Address: 86 Caroline Street
South Yarra, VIC, 3141
Australia

Profile: M7 Pty Ltd is developing an implantable medical device to provide a patient with control over
urinary incontinence. A surgical procedure has been identified in which a small piece of a patient's
existing muscle is taken from another part of the body and transplanted around the urethra. An
electronic device will then be inserted in the area of the muscle. With the aid of a small transmitter
worn by the patient, the muscle can be activated to constrict or relax, thereby enabling the control
of the flow of urine at will.

The company was awarded a Commonwealth Government Biotechnology Innovation Fund grant
of A$250,000 in August 2001 to assist in developing this device. The grant was used to
demonstrate the concept in rabbits rendered incontinent surgically, and with isolated muscle
preparations. The general characteristics of the implantable device were also determined. Work is
continuing to demonstrate the longevity of the transplant and technology in rabbits, and in a larger
animal, to ultimately gain approval to trial the technology and the implantable medical device in
man. It is expected the technology will be applicable to males and females.

Mabtech Limited ACN 99 062 965 619

Contact: Prof Anthony Linnane, Director

Phone: +61 3 9426 4200 Fax: +61 3 9426 4201
Email: tlinnane@cmbm.com.au
Internet: www.mabtech.com.au
Address: 2nd Floor
185/187 Hoddle Street
Richmond, VIC, 3121
Australia

Profile: Mabtech Limited is a Victorian biotechnology company offering high quality immunological
reagents and services at competitive prices. The company was established in 1993, and adopted
the Mabtech name in 1994. It is the commercialisation arm of the Centre for Molecular Biology and
Medicine, a non-profit research institute working on cancer and aging and funded almost entirely
from commercial sources.

Mabtech has been working on tumour diagnostics as its primary product and has developed a
gastrointestinal cancer diagnostic kit to detect stomach and colon cancers, providing an
overlapping but not identical detection of cancers to CEA (carcinoembryonic antigen) detection.
Current research shows that together with CEA, the diagnostic kit can detect over 50% of cancers.
The kit is now being sold on the international market, with Mabtech working hard to get the product
listed on the Pharmaceutical Benefits List to make it more widely available to the domestic market.
 Mayne Health Dorevitch Pathology ACN 84 007 190 043

Contact: Ms Rachelle Michie, Clinical Trials Manager

Phone: +61 3 9244 0421 Fax: +61 3 9244 0432
Email: michie@maynegroup.com
Internet: www.maynegroup.com
Address: Main Laboratory
16-18 Banksia Street
Heidelberg, VIC, 3084
Australia

Profile: Mayne Health Dorevitch Pathology is a leading provider of pathology and medical diagnostic
services to doctors, specialists and hospitals throughout Victoria. The company’s focus is on world
leading diagnostic technology.

Mayne Health Dorevitch Pathology is part of one of the largest private pathology groups in
Australia, including Mayne Health Laverty Pathology in New South Wales and Mayne Health
Western Diagnostic Pathology in Western Australia. Mayne Health Pathology comprises a network
of specialist pathologists with more than 4000 staff, in 41 laboratories.

Mayne Health Dorevitch Pathology provides services to over 70 private and public hospitals in
Melbourne, regional Victoria, and New South Wales. Services to community-based patients are
provided through more than 100 collection centres, and a network of 16 laboratories spread
throughout these regions.

Mayne Pharma Pty Ltd ACN 58 097 064 330

Contact: Mr Alex Bell, Vice President - Technical Operations

Phone: +61 3 8541 5474 Fax: +61 3 8541 5788
Email: alex.bell@au.maynepharma.com
Internet: www.maynegroup.com
Address: 1-23 Lexia Place Postal PO Box 394
Mulgrave, VIC, 3170 Address: Mulgrave, VIC, 3170
Australia Australia

Profile: Mayne Pharma is a leading international pharmaceutical organisation, built on a heritage of 150
years of pharmaceutical excellence. With products marketed in more than 50 countries, our
intimate knowledge of local markets allows us to provide tailored pharmaceutical solutions to
hospital pharmacy and to health professionals.

Our global manufacturing infrastructure operates across 145,000 square feet (13,500m2),
producing more than 44 million ampoules and 26 million vials annually, in addition to the
production of specialised modified release oral pharmaceuticals. Mayne Pharma’s facilities are
world-class and have been cGMP certified by the major authorities, including the FDA (USA), the
MCA (United Kingdom), the HPFB (Canada) and the TGA (Australia).

Our Australian research and development centres and manufacturing plants are located in
Adelaide, South Australia, for capsule and tablet oral pharmaceuticals, and Melbourne, Victoria,
for injectable products. Mayne Pharma has established and proven injectable contract
manufacturing expertise - developing projects from clinical trial stage, through validation and
registration, to commercial manufacture.

Based on our core manufacturing competencies and more than ten years experience, we offer full
contract services, from formulation through to final packaging, and clinical trial quantities to full-
scale production.
 McFarlane Laboratories Pty. Ltd. ACN 54 064 190 003

Contact: Mr Andrew Broadbent, -

Phone: +61 3 8415 1099 Fax: +61 3 8415 1799
Email: mail@maclab.net
Address: 18 Harper Street
Abbotsford, VIC, 3067
Australia

Profile: McFarlane Laboratories, registered in 1973, markets and manufactures over-the-counter

pharmaceutical products to benefit arthritis sufferers and those with excessively oily skin. The
majority of the company's products are exported.

Seatone, an anti-inflammatory agent extracted from New Zealand greenlipped mussels, was
developed in collaboration with Victoria's RMIT University. Concentrated mussel was used
originally as a natural food supplement for the prevention of pain normally associated with arthritis,
swelling and muscle discomfort. After critical review by researchers at the Universities of Adelaide
and Queensland, it was found that persons with a diet which included concentrated mussel
seemed to have less discomfort as they aged. These compounds were patented and named
Lyprinol. Lyprinol was approved and released for sale in 2000. Seatone and Lyprinol have been
used all over the world and have also been used to treat arthritis in animals.

Another product, Ketsugo, contains Isolutrol, a cosmetic ingredient developed in collaboration with
RMIT University and CSIRO which is used for treatment of excessively oily skin. It eliminates the
cause of shiny skin, open pores, blackheads, whiteheads, pimples and acne by gently reducing
the skin's overproduction of oil, keeps pores free from clogging, even under make-up. Ketsugo has
successfully undergone a number of safety and efficacy tests. Among these were the independent
trials conducted by a French dermatologist on 40 men and women with severely oily skin. Within
21 days of using Ketsugo, 85% of the group had skin within the normal oiliness range. All showed
an improvement in the tone and texture of their skin. The active ingredient, Isolutrol, is used in the
product range of one of the world’s leading cosmetic companies.

Both products are manufactured in Melbourne and are available from pharmacies and health food
stores.
 Medical Developments Australia Pty. Ltd. ACN 43 004 903 682

Contact: Mr Allan Eagle, CEO

Phone: +61 3 9547 1888 Fax: +61 3 9547 0262
Email: mda@bigpond.com
Address: Facility 7
56 Smith Road
Springvale, VIC, 3171
Australia

Profile: Medical Developments Australia Pty. Ltd. develops and manufactures medical and surgical
equipment, mainly for aiding respiration. The company commenced activity in 1972, assisted by a
Victorian Government grant to develop the OXI-saver, an oxygen resuscitation system. In Victoria
today, every ambulance is equipped with the OXI-saver.

Since 1972, the company, based in Springvale, Melbourne, has expanded dramatically. By April
2002, Medical Developments Australia was employing 12 people and producing over 80 products,
including asthma devices, human and veterinary anaesthesia machines, emergency oxygen
equipment for diving accidents, pre-hospital pain relief devices, oxygen resuscitators and oxygen
therapy equipment.

The company has also developed the Clare Anaesthetic Ventilator (CAV) in a joint venture with
Melbourne’s Royal Children’s Hospital. The CAV automatically ventilates patients while they are
under anaesthesia.

The company has a strong focus on research and development, and is diversifying its activities
into pharmaceuticals, as a result of a major collaborative project with the CSIRO, now completed.
The company intends to establish a pharmaceutical division.

Medical Developments Australia has a burgeoning export base, which accounts for about 33% of
its current turnover. It has major distributors in United States, New Zealand, South Korea,
Singapore, Europe and Canada.
 MediClin Pty Ltd ACN 88 633 054 548

Contact: Mr John Varigos, Managing Director

Phone: +61 3 9822 9215 Fax: +61 3 9822 7395
Email: jvarigos@mediclin.com.au
Internet: www.mediclin.com.au (under construction)
Address: 1022 Malvern Road
Armadale, VIC, 3143
Australia

Profile: MediClin is a clinical trial management organisation servicing the pharmaceutical and
biotechnology industries to assist with all facets of clinical trial management.

As patient recruitment is often the rate-limiting step in the clinical development of pharmaceuticals,
MediClin utilises a network of physicians, in both primary care and hospital settings, to facilitate
the rapid recruitment of patients into clinical trials.

Each study is custom managed to meet the requirements of the sponsor. Utilising both in-house
and contract staff, MediClin can act as a Site Management Organisation or as a Contract
Research Organisation, depending on the study requirements.

MediClin ensures that all clinical investigative sites have been evaluated for suitability and
commitment to the study, and staff are trained on the requirements of ICH - GCP to ensure all
studies meet the rigid international regulatory standards. With a staff of experienced Clinical
Research Coordinators (CRC) working with company standard operating procedures (SOPs),
MediClin ensures that the busy primary health care physicians are provided with the support
required to ensure speedy and precise recruitment of patients and accurate completion of case
report forms. All CRCs receive in-house training on the therapeutic specifics for each study before
commencement of the study.

Utilising the combination of custom management of each project, therapeutically experienced staff
and a network of primary care and hospital physicians, MediClin ensures that each study is
performed accurately, in the minimum of time, and cost effectively. MediClin approaches clinical
trial management by partnering with the investigative site and the sponsor to ensure that the study
time lines are achieved through effective site management.
 Meditech Research Limited ACN 60 058 390 953

Contact: Mr Chris Carter, CEO

ASX: MTR
Phone: +61 3 9296 2026 Fax: +61 3 9296 2192
Email: mrl@mrl.com.au
Internet: www.mrl.com.au
Address: TOK Corporate CentreLevel 1
459 Toorak Road
Toorak, VIC, 3142
Australia

Profile: Meditech Research Limited (MTR ) is a publicly listed company on the Australian Stock Exchange
engaged in the development of human pharmaceuticals based on naturally occurring
carbohydrates. Meditech aims to develop its two platform technologies, HyACT™ and GAGs, with
a view to multiple licensing of each to major pharmaceutical companies:

1. Hyaluronic Acid Chemosensitising Transport or HyACT™: involves the use of hyaluronan or

hyaluronic acid (HA) as a drug delivery vehicle for anticancer agents. MTR has been able to
demonstrate that hyaluronan binds several receptors including the CD44 receptor, which is
overexpressed on cancer cells. MTR’s technology combines anticancer drugs with hyaluronan to
produce a drug delivery mechanism that delivers anticancer drugs directly and preferentially to
cancer cells. MTR holds several patents covering the HyACT™ technology. Encouraging animal
and preclinical studies prompted MTR to conduct and successfully complete two Phase I human
trials at Royal Melbourne Hospital. MTR intends to continue with clinical development of the
HyACT™ technology in a Phase II clinical trial in 2003.

2. Glycosaminoglycans (GAGs) Project: GAGs is a new pharmaceutical development project

centred on naturally occurring sugar-based polymers, GAGs. GAG fragments attach themselves to
a number of important proteins that are associated with asthma, melanoma and HIV infection. The
identified sugars form the basis for developing drugs to treat the aforementioned diseases. The
project is based at Curtin University in new, well-equipped facilities at the Royal Perth Hospital.

In addition to the two platform technologies, Meditech has also completed a licensing deal with
SkyePharma in the UK that will see MTR gaining royalties from SkyePharma’s sales of Solarase in
S-E Asia.
 Melbourne IVF Pty. Ltd. ACN 007 243 352

Contact: Ms Donna King, Administration Manager

Phone: +61 3 9473 4444 Fax: +61 3 9473 4454
Email: peterh@mivf.com.au
Internet: www.mivf.com.au
Address: Suite 10
320 Victoria Parade
East Melbourne, VIC, 3002
Australia

Profile: Melbourne IVF was established in 1989 for couples experiencing fertility problems, and has made
many significant advances in assisted reproductive technology.

It is now possible to detect some genetic diseases in very early embryos by a procedure known as
preimplantation genetic diagnosis (PGD). To achieve this, the couple has a cycle of in vitro
fertilisation (IVF) treatment to produce embryos in the laboratory. Each embryo is tested for the
disease the parents carry and unaffected embryos are selected for transfer back to the woman's
uterus. To perform the genetic test, embryos are grown to the 8-cell stage (about 3 days) and then
two cells are carefully removed using a fine glass needle. The two biopsied cells are used for the
genetic diagnosis.

PGD has primarily been used to determine the sex of embryos for couples who carry a sex-linked
disease, such as haemophilia or muscular dystrophy (which affect only boys). An increasing
number of diseases can be diagnosed in early embryos by PGD including cystic fibrosis and
thalassaemia, and other chromosomal errors such as Down Syndrome. This test is currently being
used at Melbourne IVF to detect genetic disorders in very early embryos.

Future research efforts will focus on the use of this technology for couples with recurrent
miscarriage or repeated implantation failure with IVF. In both these conditions there is thought to
be a high rate of chromosomal abnormality, and PGD could be used in conjunction with IVF to
determine a normal karyotype (chromosome complement) before embryo replacement. Melbourne
IVF has also been testing a new technique which makes it possible to identify chromosomes in
embryos.
 Merck Pty. Limited ACN 25 005 064 791

Contact: Dr Gail-Eller Roswitha, Divisional Manager - Laboratory Products

Phone: +61 3 9728 5855 Fax: +61 3 9728 1351
Email: roswitha@merck.com.au
Internet: www.merck.com.au
Address: 207 Colchester Road
Kilsyth, VIC, 3137
Australia

Profile: Merck Pty. Limited, part of the 330-year-old global Merck group with headquarters in Germany,
operates two core businesses: Laboratory Products, serving the scientific market with analytical
reagents, test kits and equipment; and Specialty Fine Chemicals, a unique range of high purity fine
chemicals and pearl lustre pigments for manufacturing industries.

Merck sells a range of products in areas such as bioprocessing and bioseparation, cell signalling;
cloning, expression & purification systems; apoptosis & cell cycle, peptide chemistry and
combinatorial chemistry, microbiology and microscopy. Specialised niche catalogues for these
areas are available. The brands include Calbiochem®, Oncogene Research Products®,
Novagen®, Novabiochem® and Clinalfa®.

Merck also sells the BDH, Merck and EM Science range of analytical reagents and solvents. In
addition, there is a range of standards for instrumental analysis.

In the environmental testing equipment area, Merck carries the WTW range and the Brand liquid
handling range.

Merck Pty. Limited is headquartered in Kilsyth, Melbourne, and employs 60 staff located around
Australia.

Mercy Tissue Engineering Limited ACN 77 082 345 953

Contact: Dr Steven Mercer, Managing Director

Phone: +61 3 9928 6030 Fax: +61 3 9928 6033
Email: info@mercytissue.com.au
Internet: www.mercytissue.com.au
Address: 159 Grey Street
East Melbourne, VIC, 3002
Australia

Profile: Mercy Tissue Engineering Pty Ltd is a human tissue culture facility, established by Mercy Health
and Aged Care (Sisters of Mercy) in Melbourne, to offer cell culture treatments and implants for
Australian patients, using the patient’s own tissues ('autologous'). The company has ISO
certification and a Therapeutic Goods Administration (TGA) GMP licence. The initial biologic
implant product is autologous cultured cartilage for repair of articular cartilage defects. The
technology used incorporates proprietary methods developed by the company. Further R&D is
directed at the production of other autologous human tissue implants.
 Metabolic Pharmaceuticals Limited ACN 96 083 866 862

Contact: Dr Chris Belyea, Managing Director

ASX: MBP
Phone: +61 3 9824 0083 Fax: +61 3 9826 0949
Email: info@metabolic.com.au
Internet: www.metabolic.com.au
Address: Level 1 Postal PO Box 23
10 Wallace Avenue Address: Toorak, VIC, 3142
Toorak, VIC, 3142 Australia
Australia

Profile: Metabolic Pharmaceuticals Limited has the mission of developing therapies for metabolic
diseases. Metabolic listed on the Australian Stock Exchange (MBP) in 1998, and major
shareholders are Circadian Technologies Ltd and Monash University. Adopting a "virtual" structure,
it focuses on clinical development of purchased or in-licensed drugs.

Metabolic’s major project is to develop Advanced Obesity Drug 9604 (AOD9604), an orally
administered anti-obesity drug. AOD9604 is the most potent of a series of anti-obesity compounds
modelled on a fat-reducing region of the human growth hormone molecule. Growth hormone
occurs naturally in the body and, along with its growth-promoting function, also acts directly to
reduce stored body fat. Animal studies indicate that AOD9604 may reduce fat in humans, without
the other unwanted effects of growth hormone. A successful Phase I clinical trial was followed by a
Phase 2A trial in obese patients in February 2002 that gave positive results in respect of safety, fat
metabolic activity and indications of weight reduction. An oral Phase 2A trial is scheduled for May
2002.

This technology also has potential veterinary applications. Pig feed containing AOD9604 could be
used to safely reduce back fat in pigs. Domestic pets may also benefit from this technology.

Metabolic’s candidate drugs for type II diabetes act via a novel mechanism to potentiate the action
of the body’s own insulin, and in animal experiments have been shown to normalise diabetic
symptoms. Lead selection is nearly complete.

MBP0201 is an orally-available iron chelator, recently licensed from Sydney’s Heart Research
Institute to treat iron overload. MBP0250 and MBP0260 are fragments of amylin and
adrenomedullin, respectively, discovered by the Auckland University, for treatment of osteoporosis.
Both projects will enter preclinical toxicity studies in 2003 if animal efficacy experiments confirm
promise.

Micronized Foods Pty Ltd ACN 17 071 914 013

Contact: Mr Philip Delacretaz

Phone: +61 3 9338 3911 Fax: +61 3 9330 3748
Email: phildel@e-merch.com.au
Internet: www.e-merch.com.au
Address: 15 Catalina Drive
Tullamarine, VIC, 3043
Australia

Profile: Micronized Foods Pty Ltd is a grower and producer of wild rice and amaranth. With assistance
from a Commonwealth Government R&D START grant, the company has developed a new food
additive from amaranth with elevated levels of tocotrienol compounds (vitamin E).
 Mimotopes Pty Ltd ACN 90 090 841 286

Contact: Dr Andrew Milner, Managing Director

Phone: +61 3 9565 1111 Fax: +61 3 9565 1199
Email: andrew_milner@mimotopes.com
Internet: www.mimotopes.com
Address: 11 Duerdin Street Postal PO Box 1415
Clayton, VIC, 3168 Address: Clayton South MDC, VIC, 3169
Australia Australia

Profile: Mimotopes is an internationally focused biotechnology company formed in 1988 with headquarters
in Melbourne. Since late 2002, Mimotopes has been a subsidiary of Fisher Scientific International
Inc. Fisher serves as a one-stop source of products, services and global solutions for its
customers. The company's primary target markets are scientific research and healthcare. Fisher's
drug discovery chemistry products and services span the drug discovery and development
process from manufacture of compound libraries for identification of hits in biological screening
assays, through lead optimisation, to large-scale GMP manufacture of actives.

Mimotopes develops, markets and distributes products for proteomics (eg peptide libraries, cyclic
peptides and custom peptides), small molecule drug discovery (eg SynPhase™ solid phase
products for combinatorial chemistry, custom small molecule libraries, and lead optimisation
services), and partners small to large pharmaceutical companies in novel drug discovery.
Mimotopes has developed a powerful platform of technology and know-how by combining its
unique solid phase technology (grafted polymers) with expertise in solid phase chemistry,
medicinal chemistry and biological applications.

MiniFab (Aust) Pty Ltd ACN 100 768 474

Contact: Prof Erol Harvey, CEO

Phone: 03 9764 2241 Fax: 03 9763 9867
Email: erolharvey@minifab.com.au
Internet: www.minifab.com.au
Address: 1 Dalmore Drive
Scoresby, VIC, 3179
Australia

Profile:
 MNT Innovation Pty Ltd ACN 16 101 074 855

Contact: Mr Damian Lismore

Phone: +61 3 9214 4414 Fax: +61 3 9214 8008
Email: damian.l@microtechnologycrc.com
Internet: www.microtechnologycrc.com
Address: Level 5 Postal PO Box 218
60 William Street Address: Hawthorn, VIC, 3122
Hawthorn, VIC, 3122 Australia
Australia

Profile: MNT Innovation Pty Ltd is the commercialisation agent for the Cooperative Research Centre
(CRC) for microTechnology.

This CRC focuses on microtechnology – the convergence of technologies and disciplines such as
nanotechnology, materials sciences, microelectronics, biotechnology, life sciences, medicine,
lithography, information technology, physics, chemistry and engineering – deployed in structures
and devices with features in the micron domain.

Microtechnology is a combination of many different technologies. Its significance is that it offers an

alternative to conventional technologies, and it has already made great contributions to the areas
of computer peripherals, sensors, bioscience systems and small actuators.

The CRC for microTechnology combines the ability to make things smaller and inventing new
ways and new products that add to the quality of everyday life.

MNT Innovation Pty Ltd is headquartered in Melbourne. CRC participants are Swinburne
University of Technology, RMIT University, Griffith University, CSIRO, Bioproperties (Australia) Pty.
Ltd. [see separate entry], Motorola (Australia) Pty. Limited, Robert Bosch (Australia) Proprietary
Limited, Alcatel (Australia) Limited, the Department of Defence, the Australian Institute of Sport,
the Victorian Department of Innovation, Industry and Regional Development (DIIRD), and the
Queensland Department of State Development.
 Monash Institute of Reproduction and Development

Contact: Ms Kat Hodgins, Public Relations Co-ordinator

Phone: +61 3 9594 7138 Fax: +61 3 9594 7111
Email: Kat.Hodgins@med.monash.edu.au
Internet: www.monashinstitute.org
Address: 27-31 Wright Street Postal Monash Medical Centre
Clayton, VIC, 3168 Address: 246 Clayton Road
Australia Clayton, Victoria, 3168
Australia

Profile: The Monash Institute of Reproduction and Development was established in 1991. It brought
together scientists and clinicians undertaking research into conception, birth and development at
the (then) Centre for Early Human Development with scientists working in the field of male
reproductive health in the Department of Anatomy at Monash University. The Institute is part of
Monash University’s Faculty of Medicine. Located at the Monash Medical Centre, the Institute has
close links with clinical units including newborn services. A Management Advisory Board
comprising members of the community and the education and health sectors has been appointed
to support the Director of the Institute and the Institute’s Executive Team.

In 1993, the Monash Research Foundation for Reproduction and Development was established to
raise and manage funds for the Institute’s research into reproduction, development and growth. An
Executive Board and Board of Trustees manage these functions and are subordinate to the
Management Advisory Board. The Monash Institute of Reproduction and Development is
committed to excellence in the performance of medical and biological research into the science of
reproduction, development and growth. The Institute promotes the applications of its research for
the benefit of the reproductive health of women and men, the growth and development of the
foetus, infants and children; the development of Australia’s agricultural industry and the
preservation of the Australia’s and the world’s endangered species. The Institute employs its
research knowledge to enhance the education of students, the professional advancement of
medical practitioners and scientists as well as educating members of the community. Key
Research Areas (Keywords):

embryonic adult stem cell biology, genetics of infertility, immunocontraception, cell-based therapies
and transgene/gene knockout technology, prostate development, prostate cancer and disease,
early human development, human infertility and IVF, fertilisation and embryogenesis, nuclear
transfer, cloning and transgenesis in animals, gene expression in oogenesis and development,
primate reproductive biology, mammalian developmental biology, molecular embryology and birth
defects, fetal physiology, neonatal physiology, neonatal intensive care, sleep physiology and
medicine, functional genomics, genetics and human disease, Down Syndrome, cancer biology and
genetics, tumour immunity, cytokine signalling, transcription factors, apoptosis and inflammatory
diseases
 Monash Institutes of Health (MIH)

Contact: Ms Kat Hodgins, Public Relations Co-ordinator

Phone: +61 3 9594 7138 Fax: +61 3 9594 7111
Email: Kat.Hodgins@med.monash.edu.au
Internet: www.monashinstitutes.org
Address: Monash Institutes of Health (MIH)
Monash Medical Centre
246 Clayton Road
Clayton, VIC, 3168
Australia

Profile: The MIH is one of Australia's leading medical and biomedical science research complexes located
less than 30 minutes from the centre of Melbourne. With state of the art facilities for health and
medical research, MIH provides both incubator space for new companies and allows existing
companies access to a research environment with a proven commitment to excellence.

MIH is a full service biotechnology facility taking research from the molecule through to the clinical
stage and ultimately benefiting the broader population through commercialisation. It combines
Australia's largest university, three of Melbourne's most prominent hospitals and three of the
nation's leading independent research institutes.

Major research programs of MIH include embryonic stem cell research, diabetes and cancer
research, functional genomics and cell biology, drug discovery, cardiovascular disease,
haemostasis, reproductive medicine, prostate disease, bioinformatics, infectious disease and
neuroscience.
 Monash IVF Pty Ltd ACN 63 006 942 990

Contact: Ms Donna Howlett, Managing Director

Phone: +61 3 9429 9188 Fax: +61 3 9428 2715
Email: info@monashivf.edu.au
Internet: www.monashivf.edu.au
Address: Epworth Hospital, Level 4
89 Bridge Road
Richmond, VIC, 3121
Australia

Profile: Monash IVF has made many significant advances in assisted reproductive technology since its
establishment in 1971, and the company continues to be a global leader in this field.

Since the early 70’s Monash IVF has helped many families achieve their goal of having a healthy
baby. More than 7000 children have been born as a result of successful treatment in our
programs. Twelve out of the first fifteen IVF babies born in the world are Monash IVF babies.
Some of our team’s groundbreaking achievements include:

• First frozen embryo birth in the world

• First donor egg baby in the world

• World’s first pregnancy and birth from a sperm retrieval operation

• Australia’s first surrogate birth

• Australia’s first open testicular biopsy twins

• Australia’s first Blastocyst baby

In vitro fertilisation (IVF) research began in 1971 at Queen Victoria Medical Centre and Royal
Women's Hospital as a joint venture between Monash and Melbourne Universities, and the first
IVF birth in Australia occurred in 1980. The company diversified in the second half of the 1980s to
provide diagnostic services in pathology (andrology and hormone assays) and ultrasound. One
central location was expanded into several permanent sites plus regional programs throughout
Victoria, in Bairnsdale, Ballarat, Bendigo, Casterton, Geelong, and Sale. In Queensland there are
clinics in Southport and Brisbane, and a regional program in Ipswich. An active research and
development arm ensures couples receive world-class care using the latest technology in
reproductive medicine. The company also offers a DNA Genetics Service. In the field of assisted
reproduction, Monash IVF, through both technology transfer arrangements and ongoing
partnerships, continues to assist numerous programs internationally.

Monash Mouseworks ACN 12 377 614 012

Contact: Ms Tim Ambrose, Manager

Phone: +61 3 9905 5466 Fax: +61 3 9905 2547
Email: Tina.Ambrose@med.monash.edu.au
Internet: www.med.monash.edu.au/mouseworks
Address: c/- Monash UniversityDepartment of
Physiology
Clayton, VIC, 3168
Australia

Profile: Monash Mouseworks provides a specialist facility to produce and house highest quality, germ-free,
genetically modified mice for cutting edge research into genetic disease and cancer.
 Monash Reproductive Pathology and Genetics Pty Ltd ACN 74 067 416 786

Contact: Dr Adrianne Pope, Director of Laboratory Services

Phone: +61 3 9429 9188 Fax: +61 3 9427 8545
Email: info@monashivf.edu.au
Internet: www.monashivf.edu.au
Address: 4th Floor, Epworth Hospital
89 Bridge Road
Richmond, VIC, 3121
Australia

Profile: Monash Reproductive Pathology and Genetics Pty Ltd (MRPG) was established in 1988, as a
wholly owned subsidiary of Monash IVF. MRPG is a NATA-RCPA accredited laboratory,
specializing in diagnostic services for reproductive medicine. All profits generated by Monash
Reproductive Pathology and Genetics are donated to Monash University for research and
development in reproductive medicine. MRPG has two laboratory sites located in Melbourne.
Monash Reproductive Pathology and Genetics is one of a few laboratories to specialise in
reproductive medicine and to comply with stricter international standards for semen assessments.
The range of tests available include reproductive endocrinology, serology, semen analysis, and
specialised andrology procedures, such as retrograde ejaculation assessments. MRPG also
carries out Y chromosome deletion testing, a specialised blood test for those patients with low
sperm counts who are considering assisted reproductive technologies to determine whether a
genetic cause for male infertility exists. Other services provided include a referral service for
sperm antibody assessments from other major diagnostic laboratories within Victoria; genetic
testing, including cystic fibrosis screening and semen cryopreservation, for patients who are
undergoing a procedure that may impair fertility, such as chemotherapy, radiotherapy or
vasectomy. This large cryostorage service has been in operation for 20 years and complies with
Infertility Treatment Authority requirements. Additional tests are continually being evaluated and
added to the reproductive range, and all tests are carried out according to World Health
Organisation guidelines.

Monash Research Cluster for Biomedicine

Contact: Prof Warwick Anderson, Head of School of Biomedical Sciences

Phone: +61 3 9905 2355 Fax: +61 3 9905 2566
Email: warwick.anderson@med.monash.edu.au
Internet: www.med.monash.edu.au
Address: Monash University Faculty of Medicine Postal PO Box 13F
Wellington Road Address: Monash University
Clayton, VIC, Clayton, VIC, 3800
Australia Australia

Profile: The Monash Research Cluster for Biomedicine (MRCB), formed by the Monash University School
of Biomedical Sciences (SOBS); The cluster encompasses the Departments of Anatomy & Cell
Biology, Biochemistry & Molecular Biology, Microbiology, Pharmacology, Physiology, and
Radiography & Medical Imaging, together with the Faculty of Medicine, and Nursing & Health
Sciences. The organisational structure brings together a unique combination of outstanding
academics, researchers, students, state-or-the-art technologies, industry collaboration, and
expertise. The objective of the Cluster to provide excellent facilities and services for academic and
industry researchers whilst encouraging collaboration in multidisciplinary research (for the
commercialisation of biotechnology research in Victoria).
 Mondo Medical Ltd. ACN 66 074 294 072

Contact: Mr Peter Taylor, Chief Executive Officer

Phone: +61 3 9887 7066 Fax: +61 3 9887 7044
Email: ptaylor@mondo.com.au
Internet: www.mondo.com.au
Address: 9 Leicester Avenue
Glen Waverley, VIC, 3150
Australia

Profile: The Mondo Medical objective is to establish partnerships with Australian medical institutions to
further their research and development objectives by commercialising their scientific discoveries,
particularly in the area of medical instruments and devices. Mondo Medical was originally
established in 1996 to bring to the market science that had been developed jointly between
Melbourne University and The Royal Melbourne Hospital. Mondo Medical was awarded Victorian
Start up company of the year in 1999.

Mondo’s first major research project was the Mondo Adaptive Patient Controlled Analgesia (APCA)
system, which interacts with the physiology of the patient by non-invasive electronic means. The
aim of the research is to overcome the uncertainty and risk that could lead to such consequences
as overdose, patient sensitivity, and mis-prescription. Applications are in hospitals where there is
an acute postoperative need for the control of blood pressure - in intensive care, cardiac care,
neurosurgery, recovery wards or other high-dependency bed areas.

Other research projects under development include a non-invasive cardiac output monitor, which
at May 2002 is at the beta prototype stage, and a muscle relaxant controller, which has been
proved in principle and clinically trialled. A blood pressure controller is presently at alpha prototype
stage.

Mondo is also jointly developing biosensor technology, to monitor heart rate, temperature,
respiratory rate, oxygen saturation and blood pressure. A reusable transmitter with a range of 2-5
metres is attached to the biosensor, and signals can be received in a mobile phone and analysed
according to preset instructions from a clinician. If readings are outside of the parameter, the
signal is immediately relayed to a monitoring bureau where appropriate responses are
coordinated. Working prototypes were available by May 2002.
 Monsanto Australia Limited ACN 86 006 725 560

Contact: Mr Terry Bunn, Managing Director

Phone: +61 3 9522 7122 Fax: +61 3 9525 2253
Email: Terry.j.bunn@monsanto.com
Internet: www.monsanto.com.au
Address: 12th Floor Postal PO Box 6051
600 St Kilda Road Address: St Kilda Road Central
Melbourne, VIC, 3004 Melbourne, VIC, 3008
Australia Australia

Profile: Monsanto is a leading provider of agricultural products for farmers. Monsanto's operations in
Australia commenced in 1928 with a focus on the commodity chemicals business before
expanding into agricultural products in the 1950s. Monsanto has developed products that have
become indispensable for Australian agriculture. Roundup® herbicide was introduced in the
1970’s and today the Roundup brand and other glyphosate herbicides produced by Monsanto are
among the world’s most widely used herbicides.

To meet the increasing demand for the Roundup family of products, a glyphosate technical plant
was built at West Footscray which became operational in 1987. In 1990, amination, formulation
and packout equipment were transferred from Sydney.

After more than 20 years of directly supplying Roundup branded products to distribution in
Australia and New Zealand, Monsanto has recently entered into an agreement to give exclusive
distribution rights to the locally based, but globally operating, crop chemical company Nufarm.
Monsanto will continue to support the marketing and regulatory compliance of these brands.

Monsanto is proud to be a world leader in plant biotechnology. Biotechnology enables researchers

to develop improved crop plants, such as crops naturally protected from diseases and insects. The
new direction for Monsanto Australia Ltd will allow the company to concentrate on its
biotechnology crops and seeds business which began here with the commercialisation of
INGARD® cotton in 1996. INGARD cotton contains a gene derived from a naturally occurring soil
bacterium, Bacillus thuringiensis (Bt). The gene enables cotton to produce a specific insecticidal
protein that controls the most serious insect pests for cotton growers, Heliothis. During the
2000/2001 growing season in Australia, the use of INGARD cotton led to reduction in over 40% of
insecticide sprays needed to control this pest. INGARD cotton is one of a combination of tools
within an overall Integrated Pest Management strategy and reduces the environmental impact
from pesticides and pesticide application.

Monsanto’s second generation insect protected cotton, Bollgard II™, approved by the Office of the
Gene Technology Regulator (OGTR) in 2002 will be launched in Australia in 2003. Bollgard II
cotton expresses two insecticidal Bt proteins and provides additional insect protection compared
with INGARD. It also offers an improvement in the management of potential insect resistance.

Monsanto has also developed crops that can tolerate the application of Roundup herbicide over
the top of the crop. Roundup Ready® cotton was commercialised in Australia in 2001. Roundup
Ready cotton provides cost effective and more environmentally benign control of a broad spectrum
of weeds compared to conventional weed control practices.

Monsanto has applied for regulatory approval for Roundup Ready® canola. Roundup Ready
canola provides farmers with a new weed management option, offering greater productivity, more
effective weed control and a more environmentally sustainable farming system compared with
current canola farming systems such as triazine tolerant (TT) canola.
 Murdoch Childrens Research Institute

Contact: Ms Anne Cronin, Director - Operations

Phone: +61 3 8341 6200 Fax: +61 3 9348 1391
Email: cronin@cryptic.rch.unimelb.edu.au
Internet: www.murdoch.rch.unimelb.edu.au
Address: Royal Children's Hospital Flemington Postal PO Box 1100
Road Address: Parkville, Victoria, 3052
Parkville, VIC, 3052 Australia
Australia

Profile: (MCRI) is a medical research institute of more than 540 staff and associates with an operating
budget for 2002 of $35 million. The Institute is a world leader in infant, child and adolescent health
research and is distinguished by its innovative and integrative approach to research. It
encompasses laboratory, clinical and public health approaches, with an emphasis on application of
advances in functional genomics to child health, and an awareness of the importance of ethics and
community education. It is located at the Royal Children's Hospital, Parkville, Victoria and is
affiliated with the University of Melbourne. It has a strong focus on Biotechnology
Commercialisation and has established three startup companies to support commercial initiatives.

MuriGen Pty Ltd ACN 80 089 736 434

Contact: Dr Simon Foote

Phone: +61 3 9345 2611 Fax: +61 3 9347 0852
Email: foote@murigen.com.au
Internet: www.murigen.com.au
Address: c/- Walter and Eliza Hall Institute Postal Post Office
Parkville, VIC, 3050 Address: Royal Melbourne Hospital, VIC, 3050
Australia Australia

Profile: Melbourne’s Walter and Eliza Hall Institute of Medical Research in 1999 established a spin-off
company focusing on genetics for identifying new pharmaceutical targets, MuriGen Pty Ltd.
MuriGen’s innovative approach relies on large-scale mutagenesis screens for genes that suppress
disease in mice.

The Walter and Eliza Hall Institute during 2001 is completing the construction of a new
biotechnology centre for start-up companies. MuriGen will be the first occupant. The centre,
located at Bundoora in the north of Melbourne, houses a large, specialised mouse facility, 60% of
which will be occupied by MuriGen. The facility is expected to be opened in July 2001.
 Nanotechnology Victoria Ltd

Contact: Dr Peter Binks, CEO

Phone: +61 3 9532 3177 Fax: +61 3 9532 2512
Email: enquiries@nanovic.com.au
Internet: www.nanovic.com.au
Address: Kingston Trade Centre Postal PO Box 229
479 Warrigal Road Address: Dingley, Vic, 3172
Moorabbin, Vic, 3189 Australia
Australia

Profile: Nanotechnology Victoria was established in September 2002 as a vehicle for facilitating
investment in Victorian nanoscience and commercialisation of nanotechnologies for benefits to
Victorian and Australian industry. It is an incorporated company in which Monash University,
Swinburne University of Technology, RMIT University, and the CSIRO are founding Members. Its
funding consists of a $12 million Grant from the Victorian Government and matching contributions
from the founding Members. Other Members are expected to join over time to strengthen the
research and commercialisation capabilities of the company.Nanotechnology Victoria's three main
Program activities will be in Nanofabrication and Characterisation, production of Nanostructured
Materials, and Biomolecular Nanotechnology. Its commercial objective is to become self-sustaining
within three years. It will commence with a portfolio of around 30 technologies from its founding
Members.

National Ageing Research Institute Inc.

Contact: Prof Allan McLean, Director

Phone: +61 3 8387 2148 Fax: +61 3 9387 4030
Email: a.mclean@nari.unimelb.edu.au
Internet: www.nari.unimelb.edu.au
Address: Poplar Road Postal PO Box 31
Parkville, VIC, 3052 Address: Parkville, Victoria, 3052
Australia Australia

Profile: The National Ageing Research Institute (NARI) has developed as a centre of excellence in
biomedical research in ageing, health service evaluation and delivery of quality aged care
education programs for health professionals and undergraduate education in Geriatric Medicine
for 4th year medical students of the University of Melbourne. NARI is affiliated with Melbourne
Extended Care and Rehabilitation Service and the University of Melbourne, and comprises three
divisions: Biomedical Research Division, Public Health Division and the Education division. NARI’s
aims are to enhance quality of life, help older people live independently and ensure ageing well for
all. NARI is equipped to deal with age related issues from cell biology to service delivery. We
undertake high quality biomedical, clinical, public health research and educational activities in a
unique multidisciplinary approach to ageing.
 Natraherbal Pty Ltd ACN 31 085 968 547

Contact: Mr Steve Friedmann, Investor Relations Manager, Vital Capital Limited

Phone: +61 3 9605 5900 Fax: +61 3 9605 5999
Email: info@vitalcapital.com
Internet: www.vitalcapital.com/key_invesments/natraherbal/index.htm
Address: C/- Mr S Friedmann, Vital Capital
Limited Level 2
90 William Street
Melbourne, VIC, 3000
Australia

Profile: Natraherbal Pty Ltd is developing nutritional products, including superior quality garlic powder and
antioxidants, for the global health and supplements markets.

Natraherbal has the exclusive worldwide marketing rights to elite varieties of French garlic,
believed to produce some of the world’s highest levels of alliin. Alliin is one of the compounds in
garlic which give it its reputation of being beneficial to health by preventing infections, coughs and
colds, lowering cholesterol levels, and acting as a natural antibiotic. Natraherbal has already
patented a commercial-scale process that maximises alliin levels in powdered garlic. The powder
retains most of the benefits of fresh garlic, but is more easily made into tablets and can be stored
longer.

Natraherbal is also identifying commercial sources of, and production methods for, the compounds
glutathione and coenzyme Q10 (CoQ10). Glutathione is one of the most important self-generated
antioxidants, and Natraherbal is researching precursors that can be easily absorbed into the
human bloodstream and converted into glutathione. CoQ10 helps produce energy within cells. It
functions as an antioxidant and is claimed to decrease heart problems and strengthen the immune
system. Natraherbal is researching food-based sources and devising ways to produce it through
fermentation.

Natraherbal is also evaluating the therapeutic value of selected peptides extracted from milk, or by
fermentation. The applications potentially include treatments of diarrhoea and constipation, and in
the dental industry. The Company's research into peptides may also benefit from water-solubility
research being conducted by Tocovite Pty Ltd [see separate entry].

Natraherbal was established in 1999 as a key investment for Melbourne-based Vital Capital
Limited, which as of May 2001 owns 40% of Natraherbal.

Neurosciences Victoria Limited ACN 56 094 548 973

Contact: Prof William Hart, CEO

Phone: +61 3 8344 1800 Fax: +61 3 9347 9543
Email: info@neurosciencesvic.com.au
Internet: www.neurosciencesvic.com.au
Address: National Neuroscience Facility
Level 2, 161 Barry St
Parkville, VIC, 3010
Australia

Profile: Neurosciences Victoria Limited (NSV) has scientific and technological capabilities to support
research in the field of neuroscience. We act to promote commercialisation of neuroscience
research from our seven Member Institutes. NSV manages IP legal and commercialisation issues
through a common multi-Institute IP management policy. NSV also provides administrative and
communication infrastructure. NSV's current capitalisation is AUD$66 million, committed over five
years.
 Norwood Abbey Ltd ACN 085 162 456

Contact: Mr Bernie Romanin, Director of Marketing

Phone: +61 3 9782 7333 Fax: +61 3 9782 7334
Email: Bromanin@norwoodabbey.com.au
Internet: www.norwoodabbey.com
Address: 63 Wells Road
Chelsea Heights, VIC, 3196
Australia

Profile: OverviewNorwood Abbey Limited is a biotechnology and medical instruments company.

Norwood’s strategy is to develop and commercialise: Transdermal and cellular technologies; and
Potential therapies of the thymic function.The Company has with three proprietary delivery
platforms in various stages of commercialization and development. Its delivery technologies
include laser-assisted delivery, micro-needle arrays, needle-less injection system and pressure
wave technology for the transfer of both drugs and genetic material.TechnologyTransdermal drug
delivery
Laser Assisted Delivery (LAD) - The LAD enhances the penetration of topical anaesthetics
providing faster onset of dermal anaesthesia:

• Safety and efficacy demonstrated;

• Painlessly alters the 10-20 micron outer barrier of the skin;
• Faster onset of dermal anaesthesia – 3-5 minutes;
• TGA approved;
• FDA (510k) clearance;
• Hand-held and portable;
• Hygienic single use disposable tip; and
• Smart engineering ensuring simple and safe operation.Microneedles

Norwood's Microneedle transdermal technology is a very safe and sophisticated platform designed
to deliver a controlled amount of drug (both with respect to volume and time) to a specific depth
below the skin:

• Drug delivery with no pain or bleeding;

• Microprocessor controller allowing dosage programming and varying rate and time of delivery;
• Needles thinner than human hair; and
• Wafer-thin, lightweight and comfortable.Needleless Injection Technology

Norwood is developing a needle-less injection technology, in the form of a portable, handheld

device aimed at injecting drugs in a similar manner to a syringe but without the use of a needle.

• Potential applications in both human and veterinary markets;

• Fast and powerful fibre-activated pump penetrating into the skin without using a needle;
• Controlled dosage delivery;
• Delivery of a single drug; delivery of multiple drugs at the one time; and for rapid repeat
deliveries of vaccines;
• Silent; and
• Hygienic disposable drug vials.Cellular Drug DeliveryGene Transfer Technology

Norwood’s Gene Transfer Technology uses pressure waves, which provides the opportunity for
efficient, non-toxic delivery of genetic material into cells both ex vivo and in vivo:

• Safety in deliver;
• Low toxicity to cells;
• Permeation of cellular and nuclear membranes
• Efficiency of deliver; and
• Mechanisable.ImmunologyNorwood’s Immunology Project is aimed at:
(a) Rebuilding the immune system by triggering the regrowth of the human thymus gland to induce
the production of new white blood cells (T-cells) to treat life-threateneing diseases.
(b) Growing a completely new, fully-functional thymus from stem cells. Potential therapeutic areas
include:
• Cancer; Viral infections, Auto-immune diseases; and Vaccinations and transplantation (both
organ, bone marrow and stem cells).

Novachem Proprietary Limited ACN 16 005 116 521

Contact: Dr David Waluka, Manager
Phone: +61 3 9826 4400 Fax: +61 3 9826 8422
Email: sales@novachem.com.au
Internet: www.novachem.com.au
Address: 50 Garden Street
South Yarra, VIC, 3141
Australia

Profile: Novachem is an Australian supplier of consumables for research in the chemical, physical and
biological sciences, specialising in stable isotopes and standards for environmental analysis.
Among its product range are deuterated solvents, NMR tubes, labelled compounds, stable
isotopes, certified reference materials, environmental standards, reagents for molecular biology,
media for affinity chromatography, and synthetic peptides. Novachem sources these and other
lines from a worldwide supplier network, and is known for providing hard-to-find chemicals.
Suppliers include Cambridge Isotope Laboratories, AccuStandard, Dr. Ehrenstorfer GmbH,
Resource Technology Corporation, Promochem, Wako Pure Chemical Industries, and Millipore.

Novachem was incorporated in 1975. For five years it engaged in the development, manufacture
and marketing of formulated consumer and industrial products. In 1980, the company underwent a
radical transformation to become a specialist supplier of consumables for research in the
chemical, physical and biological sciences. These include supplies for use in wide variety of fields,
such as nuclear magnetic resonance; radiolabelling applications; forensic toxicology; biochemistry,
molecular biology and immunology; peptide synthesis; and environmental analysis.
Nufarm Limited ACN 80 004 377 780

Contact: Dr Mike Dalling, Group General Manager, R&D

ASX: NUF
Phone: +61 3 9282 1000 Fax: +61 3 9282 1001
Email: corporate.information@au.nufarm.com
Internet: www.nufarm.com
Address: 103-105 Pipe Road
Laverton North, VIC, 3026
Australia

Profile: Nufarm is a science-based company involved in the manufacture and supply of agricultural,
industrial and specialty chemicals. The company has production and marketing operations
throughout Australasia, Asia, Europe and North America. Nufarm is a public company with its
primary listing on the Australian Stock Exchange (NUF).

Nufarm is a global leader in the supply of phenoxy herbicides (2,4-D, MCPA) and has a significant
position in a range of other agricultural chemicals. Through its ag-chemical operations, Nufarm
has proprietary technology relating to manufacturing and formulation of products. The company
has entered into strategic alliances with a number of major ag-chemical companies, including
Monsanto, Novartis, DuPont, Dow AgroSciences, and Aventis. These alliances involve joint
marketing rights to particular products, R&D collaborations and manufacturing joint ventures. The
company also has a strategic position in biotechnology via its activities relating to the genetic
improvement of plants, through its subsidiary, Florigene [see separate entry]. Nufarm is also a
major shareholder in Nugrain, a joint venture involving Wesfarmers and Australia's major grain
handling organisations, which is introducing quality control systems for the introduction of biotech
enhanced crops into Australia [see separate entry].

The company has increased spending on R&D - mainly associated with the Australian
biotechnology program of the recently acquired Florigene business- and incurred higher costs
associated with market development and expansion activity, particularly in North America.
 Nugrain Pty Ltd ACN 31 085 901 604

Contact: Mr Barry Cox, General Manager

Phone: +61 3 9282 1184 Fax: +61 3 9282 1148
Email: barry.cox@nugrain.com.au
Internet: www.nufarm.com
Address: 103-105 Pipe Road
Laverton North, VIC, 3026
Australia

Profile: Nugrain Pty Ltd was established in 1999, as a joint venture involving Nufarm Limited, a science-
based company involved in the manufacture and supply of agricultural, industrial and specialty
chemicals; Australia's three largest grain handling companies - GrainCorp (incorporating
VicGrain), AusBulk (formerly SACBH) and CBH; and Wesfarmers Landmark, a leading Australian
agribusiness. The mission of the company is the responsible delivery of conventionally bred and
genetically modified plant varieties to Australian farmers, end customers and consumers.

Nugrain aims to foster the Australian grain industry's use of new plant breeding technology. The
company plans to achieve this through direct participation in the accelerated development and
release of proprietary conventionally bred and genetically manipulated plant varieties, which
possess attributes important to the grower, processor and consumer. Nugrain aims to assist in the
development of this technology throughout Australia via the implementation of accredited quality
assurance programs for the management of new technologies and products, and regular
participation in scientific debate to promote the uptake of new plant varieties and their successful
utilisation by farmer, end user and consumer. [See separate profile for Nufarm Limited].
Nutrasense Australia Pty Ltd ACN 23 081 455 094

Contact: Mr Alistair Cumming, Managing Director

Phone: +61 3 5973 4888 Fax: +61 3 5973 4188
Email: info@nutrasense-australia.com
Internet: www.arkopharma.com
Address: Unit 30, Postal PO Box 324
1140 Nepean Highway Address: Mt Eliza, VIC, 3931
Mornington, VIC, 3931 Australia
Australia

Profile: Nutrasense Australia Pty Ltd, formed in 1998, is now part of the Arkopharma Laboratories
nutraceuticals group, based in Europe. Nutrasense Australia has its head office based on
Victoria's Mornington Peninsula. Currently, Nutrasense Australia manufactures and markets a
range of arthritis and osteoarthritis treatments, including ARTHRO-AID™ Capsules, for temporary
relief from painful flare ups in the hand, knee, ankle or hip joints, back, or any other localised area
of the body; and ARTHRO-AID DIRECT™ Arthritis Cream, using the Fusome™ delivery system
for enhanced transfer of nutrients through the dermal layer. ARTHRO-AID DIRECT contains
glucosamine, a vital, naturally occurring building block of normal cartilage, and shark cartilage, a
naturally occurring source of glycosaminoglycans.

Now, as part of the Arkopharma group, Nutrasense Australia will be expanding its product range. It
is through Arkopharma’s mission to provide a comprehensive approach to health and well-being
that Nutrasense Australia aims to grow and become a leader in the field of complementary
medicine. New products of natural origin are planned for a range of conditions, including
menopause, weight control, headache and stress, and skin disorders.

Products recently launched in Australia include Phyto Soya (for menopause) based on soy bean,
and Exolise (slimming) based on green tea extract, AR25® Catechol.
 Nutrihealth Pty Ltd ACN 85 091 021 813

Contact: Mr Paul Raff, Commercial Manager

Phone: +61 3 9931 1118 Fax: +61 3 9369 4922
Email: paul.raff@nutrihealth.com.au
Internet: www.nutrihealth.com (under construction)
Address: 10 Ives Road
Altona North, VIC, 3025
Australia

Profile: Nutrihealth Pty Ltd's primary business is the marketing of seed and a range of products derived
from the processing of a specialised strain of canola called Monola® Oil (Monola). Nutrihealth has
exclusive rights to Monola through an agreement with Ag-Seed Research Pty Ltd. In terms of the
end product, Monola enjoys superior characteristics in both health (has the lowest level of
saturated fats of all commonly used frying oils) and stability in the frying process (equal to palm oil
and tallow) over all commonly used soft oils.

Canola is one of the major success stories for field production in Australia with approximately 1.9
million tones produced per annum. Canada produces approximately 6 times the volume of
Australia and has developed a similar product to Monola, namely, Canadian Low Linolenic canola.
The demand for this product is well established and growing in the Asian markets. Monola is
currently achieving a more efficient yield profile against standard canola than the Canadian variety.
In terms of end user demand, estimates by the respective Councils in both Australia and Canada
show that Monola and the Canadian Low Linolenic varieties can reach one-third of the production
of standard canola over the next 10 years.
Nutrition Care Pharmaceuticals Pty Ltd ACN 72 007 064 066

Contact: Dr Ian Brighthope, Managing Director

Phone: +61 3 9769 0811 Fax: +61 3 9769 0822
Email: webmaster@nutritioncare.com.au
Internet: www.nutritioncare.com.au
Address: 25-27 Keysborough Avenue
Keysborough, VIC, 3173
Australia

Profile: Nutrition Care Pharmaceuticals Pty Ltd specialises in nutrition and environmental medicine, and its
products are used extensively by the healing professions. They are specialists in plant extractions
and preparations, and also use essential fatty acids and oils to create professional supplements.
The Nutrition Care product range is exclusive to practitioners and available by professional
prescription only. Nutrition Care products are designed to fulfil a number of aims, such as the
prevention of specific diseases or complications; detoxification; stimulation of regeneration and
repair processes; and functional improvements in the individual (eg IQ or sports performance).
Ongoing research is conducted by and for Nutrition Care to spearhead better products.

Nutrition Care has a state-of-the-art TGA-licensed manufacturing facility. The company is

innovative and is involved in the design and implementation of clinical studies, with a particular
emphasis on the use of trace elements in various formulations to influence the process of
inflammation and carcinogenesis. Nutrition Care was one of the first Australian companies to
recognise and clinically develop probiotics for human health maintenance and various disease
conditions.

Nutrition Care is very active in expanding its export markets and relationships with international
companies. It has had significant growth into the Asian-Pacific marketplace and some minor
penetration into Europe and the Americas. Nutrition Care uses low-allergy excipents in all
formulations. The company sources its raw materials internationally, and wherever possible,
Australian ingredients are used, especially with respect to organically grown herbs. Most
formulations are free from added sugars, salt, yeast, starches, gluten, wheat, corn, cereals, dairy
products, preservatives, artificial colours and flavours. Through a START grant funded project with
Monash University, Nutrition Care developed a grape seed extract rich in OPC (oligomeric
proanthocyanidins).

O'Shea and Associates ACN 007 196 376

Contact: Ms Anne O'Shea, Principal Consultant
Phone: +61 3 9576 1500 Fax: +61 3 9576 1955
Email: oshea@bigpond.net.au
Address: Level 2
61 Station St
Malvern, VIC, 3144
Australia

Profile: O'Shea and Associates provides clinical trial management, including protocol preparation and
submission to Ethics Committees (CTX/CTN). The firm also reviews and compiles registration
dossiers, including bibliographic submissions and preparation of clinical/technical reports. Other
services include strategic planning in clinical research, regulatory affairs, pharmacoeconomics and
new business development. Medical information services including preparation of product
information, consumer medicine information and literature reviews
Ocean Wave Seafoods Pty Ltd ACN 34 081 236 875

Contact: Mr Peter Rankin, Managing Director

Phone: +61 3 5282 5350 Fax: +61 3 5282 5354
Email: peterrankin@msn.com.au
Address: 295 Dandos Road Postal PO Box 190
Lara, VIC, 3212 Address: Lara, VIC, 3212
Australia Australia

Profile: Ocean Wave Seafoods Pty. Ltd. is engaged in abalone, shellfish and finfish aquaculture
production, and also aquaculture development consultancy. The company operates a multispecies
hatchery, nursery and grow-out facilities at Lara, near Geelong, Victoria.

Consultancy services are offered in the fields of aquaculture technology, animal husbandry and
hatchery production and aquaculture business development and management.

Oncomab Ltd ACN 101 431 814

Contact: Mr Marcus Clark, CEO

Phone: (03) 9854 5700 Fax: (03) 9854 5777
Email: enquires@primabiomed.com.au
Internet: www.primabiomed.com.au
Address: Unit 7
79-83 High Street
Kew, VIC, 3101
Australia

Profile: Development of anti-cancer antibodies as diagnostics and therapeutics

 Optiscan Imaging Limited ACN 81 077 771 987

Contact: Mr Matthew Barnett, CEO

ASX: OIL
Phone: +61 3 9538 3333 Fax: +61 3 9562 7742
Email: info@optiscan.com
Internet: www.optiscan.com
Address: 15 - 17 Normanby Road Postal PO Box 1066
Notting Hill, VIC, 3168 Address: Mount Waverley MDC, VIC, 3149
Australia Australia

Profile: Optiscan Imaging Limited is using its patented platform technology to develop a miniaturised
flexible microscope for assisting diagnosis - internally in the gastrointestinal tract and the cervix,
and externally for detection of skin cancer and determining the severity of burns. The microscope,
technically a confocal endomicroscope, combines optical fibre and laser technologies to provide
clear high-magnification images of living tissue cells. Digital images of cells appear in real time on
a computer screen and can be sent via the Internet to pathologists in diagnostic centres. With the
initial development of the platform technology virtually complete, Optiscan is now researching
different applications of the technology. The company has made positive headway with its skin
cancer trials, being conducted in Queensland, and has widened its clinical trials to include
applications in gastroenterology. The gastroenterology development is being accelerated by
Optiscan’s collaboration with Japanese endoscope manufacturer Pentax, with a view to Pentax
including confocal microscopy as part of their product offering in the future. Optiscan recently
received notification from the US Food and Drug Administration (FDA) that its miniaturised hand-
held microscope, the Optiscan Stratum, has been cleared for sale in the US market. Optiscan
Imaging Limited was formed in 1994, listed on the Australian Stock Exchange in August 1997, and
was given a further boost in June 1998 with an R & D Start grant from the Federal Government.
The Melbourne company already markets a system for research applications, and has also
granted non-exclusive licences to the world's six largest microscope manufacturers for certain
other applications of the confocal microscope.
Orica Limited ACN 24 004 145 868

Contact: Mr James Fazzino, Investor and analyst enquiries

ASX: ORI
Phone: +61 3 9665 7111 Fax: +61 3 9665 7937
Email: companyinfo@orica.com hung.nguyen@orica.com
Internet: www.orica.com.au
Address: 1 Nicholson Street Postal GPO Box 4311
Melbourne, VIC, 3000 Address: Melbourne, VIC, 3001
Australia Australia

Profile: Orica Limited is a publicly owned chemical company listed on the Australian Stock Exchange
(ORI). Orica employs around 9000 staff across approximately 30 countries. The company's core
business includes the manufacture and supply of commercial explosives and mining chemicals;
agricultural chemicals and fertilisers; industrial and speciality chemicals including products for
water care; and paints and paint preparation products.

Subsidiary company Orica Australia Pty Ltd has an interest in pesticide bioremediation, and
received a Commonwealth Government Biotechnology Innovation Fund grant in September 2001
of $250,000 for "Enzymatic Bioremediation of Pesticides". If successful, the project will result in the
fast-tracked commercialisation of a range of formulated enzyme products capable of degrading
major organochlorine, organophosphate, carbamate and pyrethroid pesticides. The major
outcomes will be a significant reduction in pesticide levels in broadacre run-off and effluent
generated from rinsing food produce and pesticide spray equipment.
 Orphan Australia Pty Ltd ACN 11 067 189 342

Contact: Mr Gennaro D'Alessandro, Manager - New Products

Phone: +61 3 9769 5744 Fax: +61 3 9769 5944
Email: info@orphan.com.au
Internet: www.orphan.com.au
Address: 48 Kangan Drive
Berwick, VIC, 3806
Australia

Profile: Orphan Australia is a privately owned pharmaceutical company based in Melbourne, providing
niche products to Australia, New Zealand and selected South East Asian countries. Orphan
Australia specializes in the development, marketing and distribution of 'orphan drugs' - typically
used by specialists to treat serious and/or life threatening disorders where current therapy is either
unavailable or inadequate, and which affect relatively small patient populations. Among recent
advances achieved by the company in Australia are: - Orphan Australia's treatment for kidney
stones (UROCIT®-K, potassium citrate) tablets accepted for release - agreement for future
distribution with United Therapeutics Corporation (USA) for a subcutaneous prostacyclin therapy
for the treatment of late-stage pulmonary hypertension, UT-15 (with the pending name of Uniprost)
- Ursofalk (ursodeoxycholic acid) now available on the Pharmaceutical Benefits Scheme (PBS) for
Primary Biliary Cirrhosis (licensed from Dr Falk Pharma GmbH) - ReVia (naltrexone HCI) now
available Authority Listed on the PBS for use within a comprehensive treatment programme for
alcohol dependence (licensed from Du Pont Pharmaceuticals) Orphan Australia is part of an
international network of orphan pharmaceutical companies, and began operations in 1995. The
company actively seeks new licensing opportunities with international companies.
Ortho-Clinical Diagnostics ACN 85 000 160 403

Contact: Mr Cameron Ridley, National Sales Manager

Phone: +61 3 8540 0400 Fax: +61 3 8540 0440
Email: cridley@ocdau.jnj.com; bconnors@ocdau.jnj.com
Internet: www.orthoclinical.com
Address: 31 Hardner Road
Mt Waverley, VIC, 3149
Australia

Profile: Ortho-Clinical Diagnostics, a Johnson & Johnson company, provides high-value diagnostic
products and services for the global health care community. For more than half a century, the
company has been committed to providing accurate, timely, and cost-effective solutions for
screening, diagnosing, monitoring and confirming diseases.

Ortho-Clinical Diagnostics combines ongoing investment in technological innovation and product

quality with a focus on customer service and support. The company’s patented MicroSlide™ and
enhanced chemiluminescence technologies have transformed the way that clinical laboratories
perform testing. Ortho-Clinical Diagnostics is headquartered in Raritan, New Jersey, while the
Australian headquarters is in Melbourne. Ortho Clinical Diagnostics supports research in
Australian laboratories on the use of products in certain clinical conditions or as part of pre-market
evaluation.

The company maintains a leadership position in two major market segments: transfusion medicine
and clinical laboratories. In transfusion medicine, Ortho-Clinical Diagnostics has developed and
commercialised instrument systems and reagents that screen blood for AIDS and hepatitis, aimed
at ensuring the safety of the world's blood supply. For blood typing, Ortho-Clinical Diagnostics
supplies instrumentation and reagent systems.

For the clinical laboratory, Ortho-Clinical Diagnostics has patented MicroSlide™ technology and
systems for use in stat and routine random-access in-vitro diagnostic testing. The company offers
basic metabolites, classical chemistries, special chemistries, proteins, toxicology and therapeutic
drug monitoring tests. Immunodiagnostics include enhanced chemiluminescence technology and
systems offering immunoassay testing capabilities across menu categories of thyroid function,
reproductive endocrinology, cardiology, anemia, metabolism, oncology and infectious diseases.

Oxoid Australia Pty Limited ACN 79005422659

Contact: Mr Greg Ashworth, Sales and Marketing Manager
Phone: +61 3 9458 1311 Fax: +61 3 9458 4759
Email: info@oxoid.com.au
Internet: www.oxoid.com.au
Address: 104 Northern Road Postal PO Box 220
West Heidelberg, Vic, 3081 Address: West Heidelberg, Vic, 3081
Australia Australia

Profile: Oxoid is one of the world's leading manufacturers and distributors of microbiological culture media
and other diagnostic products. The corporate headquarters in Basingstoke, Hampshire is the main
production and administrative site, supported by a network of wholly owned sales and distribution
companies in Europe, North and South America and Australia. The Oxoid range of products is
used in clinical and industrial laboratories to isolate and identify the bacteria or other organisms
causing disease or spoilage.
Pacific Medical Pty Ltd

Contact: Mr William Crothers, Chief Executive Officer

Phone: +61 3 8416 0333 Fax: +61 3 8416 0355
Email: support@pacificmedical.com.au
Internet: www.pacificmedical.com.au
Address: Level 1, 263 Mary Street
Richmond, VIC, 3121
Australia

Profile: Pacific Medical Pty Ltd was established in 1989 in Victoria to market and distribute the Laryngeal
Mask Airway (LMA) throughout Australasia and the Asia-Pacific region.

Since that time the product range has expanded to now include orthopaedic, ear/nose/throat and
head & neck products, plus additional airway management products.

The head office is in Melbourne and there are two regional offices in Singapore and Korea. These
three locations also service New Zealand, Indonesia, Malaysia, Philippines, Papua New Guinea,
China, Japan, Taiwan, Vietnam, Laos and Cambodia.

Pacific Medical also distributes an extensive range of ear/nose/throat and head & neck products,
including Atos laryngectomy, rhinology and otology products; Boston Medical surgical and
respiratory products; the Mucosal Atomization Device (MAD™); artificial larynxes; Passy-Muir
tracheostomy and ventilator speaking valves; and Tracoe tracheostomy tubes. As well, Pacific
Medical distributes Orthofix orthopaedic products and USBiomaterials PerioGlas® bone graft
particulate.
 Panvax Limited ACN 23 100 033 583

Contact: Mr Marcus Clark, CEO

Phone: +61 3 9287 0637 Fax: +61 3 9287 0639
Email: enquiries@primabiomed.com.au
Internet: www.primabiomed.com.au
Address: Suite 2
1233 High Street
Armadale, VIC, 3143
Australia

Profile: Panvax Limited was formed in March 2002 to further develop and commercialise the DCtag
technology that was discovered by scientists at the Austin Research Institute (ARI). The ARI has
demonstrated that this technology can enhance immune responses to vaccines in experimental
animals and that these responses will protect those animals from disease. The technology at mid-
2002 is being evaluated in small and large animal models to confirm the preliminary data and to
prepare for clinical evaluation of the technology. DCtag has potential for applications in the control
of infectious diseases and cancer. Panvax’s business strategy focuses on strengthening the
underlying technology and commercialising the outcomes through a combination of product
development for specific disease applications, and technology licensing to increase the
penetration of the technology into the market.
Pargenex Pharmaceuticals Pty Ltd ACN 84 096 155 243

Contact: Dr Tom Cocks, Director and Chief Scientist

Phone: +61 3 8344 5678 Fax: +61 3 8344 8328
Email: t.cocks@pharmacology.unimelb.edu.au
Internet: www.pargenex.com (under construction)
Address: Level 9
Medical Building
University of Melbourne, VIC, 3010
Australia

Profile: Pargenex Pharmaceuticals Pty Ltd has been formed to develop new drugs for the treatment of
inflammatory diseases, in particular asthma and arthritis. The patented technology involves novel
ways of activating long-lasting and naturally occurring anti-inflammatory mechanisms in the body
by safe and selective compounds that stimulate barrier cell protease-activated receptors (PARs).
As their name indicates, PARs are activated by enzymes usually serine proteases like thrombin
(PAR1, PAR3 and PAR4) and trypsin (PAR2). They can, however, be activated by unique synthetic
peptides. PAR2 is the main target for Pargenex, as these receptors have been discovered to
constitute the sensory arm on airways epithelial cells of a powerful bronchoprotective mechanism,
analogous to the cytoprotective and most likely anti-ulcer role for PAR2 in the stomach and
intestine. Also, high levels of PAR2 expression are observed on synovial cells lining joints,
indicating that a similar protective system operates there too. Pargenex has now found trypsin to
be synthesised and released in a regulated manner from airways epithelium in response to
inflammatory stimuli. Pargenex has new data concerning structural requirements for active PAR2-
activating peptides. This has already generated unique peptides and will help in the design of
small molecule activators of PAR2. Pargenex will operate initially out of The University of
Melbourne and will eventually relocate to Bio21. The company aims to make safe and effective
new drugs for asthma, arthritis and possibly other important inflammatory diseases and seeks
partnerships with synergistic people and organisations.
 Perseverance Corporation Limited ACN 13 010 650 049

Contact: Mr Chris Roberts, Director

ASX: PSV
Phone: +61 3 5439 7244 Fax: +61 3 5439 7281
Email: chrisr@perseverance.com.au
Internet: www.perseverance.com.au
Address: Fosterville Gold Mine
McCormicks Road
Fosterville, VIC, 3557
Australia

Profile: Perseverance Corporation Limited is a public company which first listed on the Australian Stock
Exchange in 1987. Perseverance has more than 1,200 shareholders. The largest single
shareholder is a Scottish based company, Palmaris Capital plc, but more than half the
shareholders are Victorian, with many coming from regional Victoria. Perseverance Corporation
Limited is Victoria’s second largest gold producer, and has produced more than 385,000 ounces
valued at over A$210 million at a long term average gold price of $550/oz. From the perspective of
biotechnology, Perseverance has an interest in treating refractory gold sulphide deposits with
biological oxidation. Perseverance has now completed preparatory test work and assessed
competing technologies, selecting the most suitable for these deposits. Sulphide ore which
underlies the oxide mineralisation, and requires a different treatment process, is planned to be
treated through a bacterial oxidation plant using Goldfields Limited’s BIOX® process. In the
deeper sulphide zone, the gold occurs as fine grains contained within the sulphide minerals,
arsenopyrite and pyrite. Gold from the sulphide zone is difficult to recover in high yield using the
traditional cyanidation process, without the prior breakdown by oxidation of the sulphide minerals
to release the gold grains. The Fosterville Sulphides Project (FSP) will establish a process plant to
oxidise this ore, using naturally occurring bacteria, enabling the subsequent recovery of gold by
cyanidation techniques. A contract has been entered into with Minsaco, a subsidiary of the large
South African miner, Goldfields Limited, to permit Perseverance to utilise the BIOX® process.
Peter MacCallum Cancer Centre

Contact: Mr Jerry de la Harpe, General Manager (Research)

Phone: +61 3 9656 3723 Fax: +61 3 9656 1414
Email: j.delaharpe@pmci.unimelb.edu.au
Internet: www.petermac.org or www.pmci.unimelb.edu.au
Address: St. Andrews Place Postal Locked Bag
East Melbourne, VIC, 3002 Address: 1 A’Beckett Street
Australia Victoria, 8006
Australia

Profile: Peter MacCallum Cancer Centre is a specialist oncology centre, and Australia’s only
comprehensive cancer centre. The Cancer Institute Board was established by an Act of Parliament
in March 1949 with two major objectives: to consolidate Victoria’s radiotherapy services and to
continue research into cancer and allied diseases. The Cancer Institute Board commenced its
activities in one room of the former Queen Victoria Hospital in Melbourne. From this modest
beginning the Cancer Institute/Peter MacCallum Hospital has grown to become an internationally
recognised cancer research and treatment centre. In 1990 approval was given to move Peter Mac
to our present site in East Melbourne, in close proximity to a number of the city’s major hospitals
(public and private) and on the fringe of the business district, as well as within five minutes by car
to The University of Melbourne, with which the Institute has a strong affiliation. The Institute’s Chief
Executive Officer is Dr David Hillis and the Director of Research is Associate Professor David
Bowtell. The Centre has a long-standing history as a research body and is the largest cancer
research team in Australia, comprising some 240 research and support staff and 77 PhD and
higher degree students, located across 25 laboratories and organised into 6 programmes. Allowing
for the specialist clinical connections on the site, the Centre's Research Division is uniquely placed
to translate biological discoveries from the bench to the bedside, the essence of modern
translational research.
 PharmAction Manufacturing Pty Limited ACN 78 076 755 354

Contact: Mr David Lyon, Sales and Marketing Manager, Business Development Manager
Phone: +61 3 9278 7555 Fax: +61 3 9369 6730
Email: davidl@pharmaction.com.au
Internet: www.pharmaction.com.au
Address: 73-83 Cherry Lane
Laverton North, VIC, 3026
Australia

Profile: PharmAction Manufacturing is a contract pharmaceutical manufacturer operating in purpose

designed facilities in Melbourne, Australia. In addition to the provision of contracting services,
PharmAction has a range of innovative, over the counter (OTC) products and complementary and
alternate medicines that are available to licence.

All activities and manufacturing are consistent with the international standards of Good
Manufacturing Practice (GMP), the Medical Device Standards (ISO9002) and Good Clinical
Practice, as appropriate. The company offers a comprehensive range of services to the
pharmaceutical and health industries. These include:

(1) Contract manufacturing and packaging to a world class standard: PharmAction has a TGA
licence to manufacture sterile, or pack non-sterile, therapeutic goods and complementary and
alternate medicines for human use.

(2) A complete range of technical services to manufacturing and packaging: PharmAction has a
primary responsibility to ensure that all aspects of new and changed products are successfully
transferred to operations from PharmAction Product Development or, as a contract manufacturer,
from other pharmaceutical companies. The Technical Services/Quality Assurance Group performs
the full service quality control and quality assurance function for PharmAction.

(3) Product development: This involves the formulation, process development, and stability testing
of drug products from pre-formulation to marketing, including the development, validation and
registration of all formulations and processes and their transfer to manufacture. It also involves
analytical development, which supports the pharmaceutical development and manufacturing
activities, including the selection, development and validation of methods for drug products.

Other services include clinical trials, formulation, pilot batch manufacture, and stability testing to
support registration of products.
Pharmasafe Pty Ltd ACN 67 099 439 371

Contact: Mr Richard Li, Director

Phone: +61 3 9629 6615 Fax: +61 3 9614 1946
Email: richard.li@sino.com.au
Internet: www.sino.com.au
Address: Level 3
43-51 Queen Street
Melbourne, VIC, 3000
Australia

Profile: Pharmasafe Pty Ltd was launched in early 2002 to commercialise Chinese natural product based
medicines for several major diseases, including hepatitis B and arthritis. Pharmasafe holds the
intellectual property rights, and is responsible for manufacture or licensing the manufacture, and
for marketing and distribution of the medications throughout Australia and internationally.
Professor Tzi Chiang Lin will hold a 60% stake in Pharmasafe, with other 40% held by ASX-listed
investment service company Sino Securities International Limited (SSI). Professor Lin has been a
practitioner and researcher of Chinese medicine for close to 30 years. SSI will be providing its
investment banking services to Pharmasafe, and a related ASX-listed company, GoConnect
Limited, will handle promotion, marketing and distribution on the internet.

Pharmion Pty Limited ACN 87 097 066 512

Contact: Ms Jennifer Antonino, Sales & Marketing Director, Australia & New Zealand
Phone: +61 3 9869 8000 Fax: +61 3 9869 8099
 Email: jmcdonnell@pharmion.com
Internet: www.pharmion.com
Address: Level 1
476 St Kilda Road
Melbourne, VIC, 3004
Australia

Profile: Pharmion Pty Limited is the Melbourne-based, Australian subsidiary of the US parent, Pharmion
Corporation, which is a global pharmaceutical company.

Pharmion's aim is to provide specialised products in an ethical manner, initially in the haematology
and oncology areas, focusing on serious unmet needs. To date, two haematology products have
been licensed. Clinical trial and registration activity has commenced on a global and local scale for
these products. Further products are currently under investigation for in-licence, clinical
development and registration.

Pharmion has a well-developed global regulatory group, an innovative information technology

team and highly specialised sales and medical marketing support and utilises these core strengths
to bring improved patient care.
Phytogene Pty Ltd ACN 098 823 235

Contact: Prof German Spangenberg, -

Phone: +61 3 9479 3851 Fax: +61 3 9479 3851
Email: german.spangenberg@nre.vic.gov.au
Address: Plant Biotechnology Centre Latrobe
University
Bundoora, VIC, 3083
Australia

Profile: Phytogene Pty Ltd is a "spin-off" company wholly owned by Agriculture Victoria Services Pty Ltd,
part of the Victorian Department of Natural Resources and Environment (NRE). It was established
in 2001 with the assistance of a Federal Government Biotechnology Innovation Fund Grant.
Phytogene has developed a method for the manipulation of senescence in plant species using
gene technology. The technology has a wide range of potential applications including the
increased shelf life of leaves, fruit, flowers and tubers; reduced perishability of horticultural crops;
and increased carbon fixation in senescence retarded leaves leading to enhanced yields,
enhanced biomass production in forage plants and enhanced seed production. The company’s
focus over the ensuing two-year period will be to obtain full patent protection and establish the
proof of concept in a wide range of plant species.
 Planreal Australasia ACN 57 313 611 787

Contact: Dr Bruce Anderson, Manager

Phone: +61 (0)419 305 342 Fax: +61 3 9331 5501
Email: australasia@planreal.com, bnanderson@planreal.com
Internet: www.planreal.com
Address: 25 Garden Avenue
Keilor, VIC, 3036
Australia

Profile: Planreal AG was founded in 1977 in Lucerne, Switzerland, and provides value-adding services
into the property acquisition, divestment and redevelopment sector throughout Europe. Planreal
also offers specialist environmental biotechnology and microbiology services for the
bioremediation and restoration of contaminated land and groundwater, with an emphasis on cost-
effective microbiological methods.

Planreal uses bioremediation methods and expertise developed over several years by an
interdisciplinary international team of scientists, engineers and consultants from Australia, the
United Kingdom, Germany and France in addition to the core capabilities provided from the head
office in Switzerland. Key tools in the assessment and monitoring processes include lux-based
bacterial biosensors, radiolabelled substrate mineralization, respirometry and biogeochemical
parameter analysis and tracking.

Planreal has undertaken feasibility studies and full-scale soil and groundwater bioremediation
projects at several contaminated sites in Europe, and has recently extended operations to North
America, Brazil and Australia. Many of the project sites have been impacted with organic
hydrocarbon and chlorinated solvent contamination, and some have additional impacts from
mineral oils, pesticides and heavy metals.

A key feature in all projects is the use of environmental microbiology and biotechnology tools for
the development of a cost-effective strategy to restore and add value to industrial land, and to
minimize future economic and legal liabilities whilst minimizing risks to human health and the
environment.
Plant Biotechnology Centre - Department of Natural
Resources and Environment

Contact: Prof German Spangenberg, Institute Director

Phone: +61 3 9479 2995 Fax: +61 3 9479 3618
Email: German.Spangenberg@nre.vic.gov.au
Internet: www.nre.vic.gov.au
Address: Agriculture Victoria, DPI c/La Trobe
University
Bundoora, VIC, 3083
Australia

Profile: The Plant Biotechnology Centre is a Research Institute of Agriculture Victoria, a business of the
Victorian Department of Natural Resources and Environment. The Institute, conveniently located
at the Bundoora campus of La Trobe University, has over 60 staff and postgraduate research
students and a strong research base with skills in plant biotechnology and associated biosciences.
The Institute is focused on the development and deployment of genomics, transgenic and
molecular marker technologies for plant improvement, and is world-leader in pasture plant
biotechnology. The main Institute services are:

a) strategic research in plant gene technology, plant molecular marker technology and plant
genomics;

b) transfer of new plant biotechnologies and products to commercialization; and

c) training in plant biotechnology at postgraduate level.

Plant Cell Biology Research Centre

Contact: Prof Tony Bacic, Director
Phone: +61 3 8344 5041 Fax: +61 3 9347 1071
Email: abacic@unimelb.edu.au
Internet: www.botany.unimelb.edu.au
Address: Plant Cell Biology Research Centre,
School of Botany, University of
Melbourne
Melbourne, VIC, 3010
Australia

Profile: The Centre, within the School of Botany, was established by Professor Adrienne E. Clarke in 1982
with Special Research Centre funding from the Australian Research Council. The current Director
is Professor Tony Bacic and the Deputy Director is Dr Ed Newbigin.

Over the past twenty years the Centre has established an international reputation in the area of
plant biotechnology and molecular and cellular biology, particularly relating to the basis of cell-cell
recognition during fertilisation in higher plants and the structure, function and biosynthesis of cell
surfaces (cell walls) and secretions of both land plants and marine red algae.

Some of the discoveries from the basic research program have led to the establishment of a start-
up company, Hexima Ltd. Current research programs are focussed on agriculture, food industry
and fundamental science. Agriculture work through a joint functional genomics initiative on the
"Growth and end-use quality of cereals" with the Department of Plant Science at the University of
Adelaide (Professor Geoff Fincher and Peter Langridge) and the GRDC. Food industry initiatives
are carried out through the CRC for Bioproducts. Fundamental aspects of plant growth and
development are also studied, including the role of arabinogalactan-proteins and self-
incompatibility in flowering plants.

The Centre now has 10 postdoctoral fellows and 23 postgraduate students.

Plantic Technologies Limited ACN 71 097 524 975

Contact: Mr David MacInnes, Managing Director & Chief Executive Officer

Phone: +61 3 9691 5907 Fax: +61 3 9691 5901
Email: davidm@plantic.com.au
Internet: www.plantic.com.au
Address: Unit 2 Angliss Park Estate
227-331 Fitzgerald Road
Laverton, VIC, 3026
Australia

Profile: Plantic Technologies Limited has an exclusive worldwide licence to commercialise technology that
uses biodegradable starch based polymers as an alternative to conventional petrochemical-based
plastic packaging. This environmentally friendly technology has been developed by the Australian
Government supported Cooperative Research Centre for International Food Manufacture and
Packaging Science. TSL Group Limited [see separate entry] was instrumental in maximising the
benefits of this start-up for the CRC through preparation of business plans, establishing
infrastructure and raising venture capital.
 PlantTech Pty Ltd ACN 22 099 431 884

Contact: Mr Bruce Walker, National Production and Cultivation Manager

Phone: +61 3 9641 2400 Fax: +61 3 9641 2410
Email: bwalker@planttech.com.au
Internet: www.planttech.com.au
Address: Level 10
600 Bourke St
Melbourne, VIC, 3000
Australia

Profile: PlantTech Pty Ltd commercialises technology in agriculture. It specialises in the commercialisation
of seed and seed-related products. The company was formed in early 2002 through the merging of
Paramount Seeds and Grainco Australia Seeds and the subsequent acquisition of Seed Grain
Biotechnology Australia Pty Ltd. PlantTech is a joint venture between Elders Limited and Grainco
Australia Limited. PlantTech provides an efficient pathway to market for technology transfer to
agriculture. The organisation is structured to provide Research and Development companies with
an end-to-end service, including manufacturing and production, sales and marketing, and royalty
collection and adminstration. PlantTech has regional offices in Western Australia, South Australia,
Victoria, New South Wales and Queensland, with its head office based in Melbourne.
PPD Australia Pty Limited ACN 43 077 675 373

Contact: Ms Lesley Gerrard, Clinical Operations Manager

Phone: +61 3 9804 5211 Fax: +61 3 9804 5233
Email: Lesley.Gerrard@australia.ppdi.com
Internet: www.ppddevelopment.com
Address: Suite 1, Level 4 Illoura Plaza
424 St Kilda Road
Melbourne, VIC, 3004
Australia

Profile: PPD Australia Pty Limited is part of PPD Development, the clinical research (CRO) operating
subsidiary of PPD, Inc. With a global infrastructure of dedicated project teams, cross-functional
therapeutic units and innovative technologies, PPD Development works with a worldwide
commitment to quality, to deliver strategic solutions for preclinical programs, Phase I-IV clinical
development and market support. With more than 4,600 professionals in 47 offices and 21
countries in the key and emerging markets in Europe, the Americas, the Middle East, Africa, Asia
and the Pacific Rim, PPD Development provides local experts with well-established networks.

PPD Development expertise crosses a wide range of therapeutic arenas with extensive
experience in antiviral/anti-infective, central nervous system, gastrointestinal, respiratory,
cardiovascular, endocrinology, oncology, critical care and women’s health. These teams work
closely with clients across program management, regulatory and clinical trial management. In
addition, seamless communications between clients and PPD Development are supported by
online resources, and rigorous team training on project protocols to promote a consistent level of
quality, providing clients strategic solutions for a decided advantage.
 Prana Biotechnology Ltd ACN 37 080 699 065

Contact: Mr Dennis Cahill, Laboratory Manager

ASX: PBT
Phone: +61 3 9690 7892 Fax: +61 3 9824 8161
Email: aquick@pranabio.com; gkempler@pranabio.com
Internet: www.pranabio.com
Address: Level 1
100 Dorcas Street
South Melbourne, VIC, 3205
Australia

Profile: Prana Biotechnology Ltd, a Melbourne company which listed on the ASX in March 2000, is
developing therapeutic drugs for age-related diseases. Prana researchers believe their lead
compound PBT-1 has the potential to treat Alzheimer's Disease. PBT-1 can dissolve protein
deposits (amyloid plaques) in brain tissue believed to be related to the cause of Alzheimer's
Disease.

The key research has been done over the past 20 years by University of Melbourne scientists
Professor Colin Masters, Associate Professor Ashley Bush (based mainly at Harvard Medical
School in the USA) and their colleagues. This work, which focuses particularly on the involvement
of certain metals in the disease process, forms the basis of Prana's intellectual property portfolio.

A key Phase II human clinical trial testing PBT-1 in Alzheimer's Disease was completed in April
2002, with successful results being reported in Geneva at the 7th International Springfield
Symposium on Advances in Alzheimers Therapy. Prana has established a medicinal chemistry
laboratory at the University of Melbourne.

Prana's platform technology is applicable to other age-related and degenerative disorders,

including cataracts, involuntary repetitive muscle movement (such as that caused by prolonged
treatment with drugs used to treat schizophrenia), Parkinson's disease, and motor neuron disease
(Lou Gehrig's disease), as well as prion-related conditions such as Creutzfeldt-Jakob disease and
mad cow disease.
 Premier Bionics Limited ACN 67 099 084 143

Contact: Mr Martin Soust, Executive Director and Chief Executive Officer

ASX: PBI
Phone: +61 3 9594 5473 Fax: +61 3 9594 6330
Email: enquiries@premierbionics.com.au; martin@premierbionics.com.au
Internet: www.premierbionics.com.au
Address: C/- The Ritchie Centre, Level 5,
Monash Medical Centre
246 Clayton Road
Clayton, VIC, 3168
Australia

Profile: Premier Bionics Limited has been established to invest in and commercialise late stage 'R' and
early stage 'D' projects in the medical devices and diagnostics markets. To achieve this, it will seek
to identify and invest in high quality Australian R&D projects, as measured by a range of criteria
including market potential, strength of intellectual property, experienced management team, and
potential for significant commercial returns.

The company will focus its efforts on ensuring optimal commercial outcomes through disciplined
‘hands on’ management of R&D projects and staged financing based on achievement of technical
and commercial milestones. By bringing together its extensive scientific, commercial and project
management expertise residing in its Board, management and Scientific Advisory Panel, it will
build value and maximise the commercial potential of its investments. It will also implement
commercialisation and exit strategies from an early stage of development.

Premier Bionics expects that many of its investments will be based on technology developed in
Australian research institutes and universities.

To maintain continuity of the R&D programs the company will also secure the involvement of key
founders, scientists and inventors through appropriate incentive structures. Premier Bionics’ first
investee company is Pulmosonix Pty Ltd, a company developing medical devices utilizing
proprietary technology based on acoustics, and targeting specific human respiratory disorders
[see separate entry].
 Prima Biomed Ltd ACN 90 009 237 889

Contact: Mr Marcus Clark, Chief Executive Officer

ASX: PRR
Phone: +61 3 9854 5700 Fax: +61 3 9854 5777
Email: enquiries@primabiomed.com.au
Internet: www.primabiomed.com.au
Address: Unit 7, 79-83 High Street
Kew, VIC, 3101
Australia

Profile: Prima Biomed Ltd was formed in mid-2001 when Prima Resources Limited switched its focus from
mining to biomedical research and development. Prima focuses on the commercialisation of
biomedical research and has negotiated first rights to commercialise all technologies arising from
Melbourne’s Austin Research Institute (ARI), with the exception of Xeno Trans. This work will
initially be pursued through three project companies owned jointly by Prima Biomed (65%) and
others (35%): Arthron Limited, Cancer Vac Limited and Panvax Limited [see separate entries].
Prima provides R&D funding and its experienced management team.

Arthron aims to develop pharmaceuticals to treat inflammatory autoimmune diseases, including

rheumatoid arthritis and a bleeding disorder, immune thrombocytopenia purpura (ITP). The
strategy is to block certain receptors, found on most inflammatory white blood cells, and that are
involved in key inflammatory pathways. The objective is to develop compounds to control
autoimmune disease by blocking the receptors, thereby inhibiting the release of inflammatory
chemicals.

Cancer Vac is developing a therapeutic process for treating solid tumours. Research has indicated
that stimulation of cells "ex vivo" (temporarily removed from the patient) may generate potent
immune responses that will eliminate, arrest or retard the growth of tumours. The cell type of
interest is the dendritic cell. Reintroduction of primed dendritic cells into the body may lead to the
eradication of tumours through killing of tumour cells by cytotoxic T cells.

Panvax is developing platform technology to enhance immune responses to vaccines and other
immunotherapies. Through the DCtag technology, Panvax has discovered a mechanism for
targeting antigens to dendritic cells and subsequently enhancing both B and T cell immune
responses. This discovery is being evaluated in animal models prior to preparation for testing in
human clinical trials.
 Prince Henry’s Institute of Medical Research

Contact: Prof Evan Simpson, Director

Phone: +61 3 9594 4372 Fax: +61 3 9594 6125
Email: evan.simpson@med.monash.edu.au
Internet: www.med.monash.edu.au/phimr
Address: Level 4, Block E, Monash Medical Postal PO Box 5152
Centre Address: Clayton, Victoria, 3168
246 Clayton Rd Australia
Clayton, VIC, 3168
Australia

Profile: Prince Henry’s Institute began as the Medical Research Centre in 1960 at Prince Henry’s Hospital,
Melbourne, Australia. In 1990, the Institute moved to the Monash Health Research Precinct that
includes the Monash Medical Centre and Monash University Faculty of Medicine and the Monash
Institute of Reproduction and Development.

The Institute has developed world-standard research and clinical programs in the field of
endocrinology (the investigation of the production and function of hormones). Research at the
Institute has made substantial internationally recognised contributions to new knowledge in the
fields of ovarian, uterine and breast cancer, reproductive physiology and medicine of the male and
female. It is one of a few major research institutes that combine basic research with patient care.
The World Health Organization has recognised the work and status of the Institute by designating
it a WHO Collaborating Centre for Research in Human Reproduction - one of only two in Australia.

ProBio International Pty Ltd ACN 17 096 204 741

Contact: Mr Laith Reynolds, Executive Chairman

Phone: +61 3 9909 7050 Fax: +61 3 9909 7052
Email: info@probioinc.com
Internet: www.probioinc.com
Address: Suite 213, Level 2
530 Little Collins Street
Melbourne, VIC, 3000
Australia

Profile: ProBio licenses and develops technologies and intellectual property (IP) in animal reproduction
and modification, cell therapies, genomics and associated technologies for use in agriculture and
medicine. ProBio’s goal is to enable and ease the ready flow of knowledge, rights and rewards
within life sciences worldwide. ProBio has a significant portfolio of technologies and IP in focused
disciplines and sectors, and a sophisticated understanding of associated sciences, markets and
commercialisation. In additional to in- and out-licensing, ProBio is well placed within the Life
Sciences industry to provide standardized procedures for the identification, valuation, patenting
and marketing of scientific and medical IP. The company develops business models and plans for
IP marketing for universities, research laboratories and commercial enterprises, enabling
researchers and organisations to better benefit from their research efforts and to provide a
standardised method of licensing and managing biotech IP on their behalf. Uniquely, ProBio also
manages the rights to technological improvements generated by the licensees. ProBio is a
participant in the new Cooperative Research Centre (CRC) for Innovative Dairy Products, in
alliance with six other participants. Approved in Oct 2001, the CRC is funded in part by the
Commonwealth Government of Australia.
 Process Design and Fabrication Proprietary Limited ACN 52 004 565 137

Contact: Mr Pat Scrimizzi, Business Development Manager

Phone: +61 3 9551 3490 Fax: +61 3 9551 3590
Email: pat.scrimizzi@pdf.com.au
Internet: www.pdf.com.au
Address: 100 Fairbank Road Postal PO Box 1452
Clayton, VIC, 3169 Address: Clayton, VIC, 3169
Australia Australia

Profile: Process Design and Fabrication Proprietary Limited (Pdf) is an engineering and project
management group with offices in Melbourne, Sydney and Perth. A significant supplier of
customised process and manufacturing systems throughout Australia and South East Asia for over
40 years, Pdf has considerable experience in the integration of process technology and holds a
client list containing many high-profile pharmaceutical companies such as GlaxoSmithKline,
Schering-Plough, Novogen Industries and Merck Sharp & Dohme.

Pdf specialises in the design, construction and project management of process facilities, plant and
equipment for a range of industries, including pharmaceutical, chemical, food & beverage, and
manufacturing, pilot plants, pilot plant scale up and laboratory facilities. Pdf also provides
feasibility studies and masterplanning services. Pdf can provide assistance with FDA & TGA
approvals and validation protocols and qualifications including design, installation, operation and
process validation. Pdf will provide training, commissioning and ongoing support to operations and
maintenance.

Projects range in scope from skid-mounted packages, to large scale "turnkey" plants involving civil
and building works, infrastructure, process plant and equipment, process simulation, clean room
design, LV and HV power system design, instrument and control systems, services, Hazard and
Operability (HAZOP) studies, hazardous area installation design and dossier preparation and
Dangerous Goods Regulations audits.

Pdf was acquired in 1999 by Lycopodium Pty Ltd, a Perth-based engineering consultancy with
extensive Australian and international experience. Lycopodium further strengthens Pdf’s project
development expertise with tried and proven systems in the areas of procurement and cost
control, and project and construction management procedures. The combined organisations
employ over 200 personnel to support Australian and international engineering projects.
 ProPharma CRO Pty Ltd ACN 66 098 739 532

Contact: Mr Peter Fursdon, Office Head and Head of Data Management

ASX: NASDAQ listed (PPD Inc)
Phone: +61 3 9830 4394 Fax: +61 3 9830 0146
Email: pfursdon@propharmacro.com
Internet: www.ppdi.com
Address: Suite 202 Postal PO Box 217
991 Whitehorse Road Address: Canterbury, VIC, 3126
Box Hill, VIC, 3128 Australia
Australia

Profile: ProPharma CRO Pty Ltd is a wholly owned subsidiary of PPD Inc.

The division provides clinical data management services in support of clinical trials being
conducted in Australia and Asia. It acts as the data management hub for PPD Development’s
Asian region and works closely with PPD Development’s clinical groups which are based in
Melbourne, Singapore, Hong Kong, Taiwan, China, India and Thailand. It also specialises in stand
alone data management contracts, particularly smaller, proof of concept, Phase I/II and Phase IV
studies.

Staff are very experienced and the division is fully integrated into PPD Development’s global data
management network. It provides processing using ICH GCP compliant systems and to
international standard SOPs (Standard Operating Procedures).

Prostate Diagnostics Pty Ltd ACN 090 899 120

Contact: Prof Gail Risbridger, Chief Scientific Officer

Phone: +61 3 9594 7118
Email: Gail.risbridger@med.monash.edu.au
Address: 27-31 Wright Street Postal Monash Institute of Reproduction and
Clayton, VIC, 3168 Address: Development Monash Medical Centre
Australia 246 Clayton Road
Clayton, VIC, 3168
Australia

Profile: Prostate Diagnostics Pty Ltd has developed novel diagnostic techniques capable of distinguishing
aggressive and slow growing prostate tumours.
 Pulmosonix Pty. Ltd ACN 92 096 917 127

Contact: Dr Martin Soust, CEO

Phone: +61 3 9594 5473 Fax: +61 3 9594 6330
Email: pbinfo@premierbionics.com.au
Internet: www.premierbionics.com.au
Address: C/- The Ritchie Centre,
Level 5 Monash Medical Centre
246 Clayton Road
Clayton, VIC, 3168
Australia

Profile: Pulmosonix is a newly formed company developing platform technology based on the
transmission of audible sound through biological tissues. The company has received funding from
Premier Bionics Limited to further develop two specific applications of this technology: (1) a
monitor that will continuously and non-invasively record the inflation of the lungs in humans; and
(2) a device that will non-invasively monitor the patency of the upper airways. The first device will
have valuable application in an intensive care setting, while the second device has potential uses
in clinical sleep laboratories in the diagnosis of obstructive apnea and in the control of respiratory
support devices.

QIAGEN Pty Ltd ACN 75 072 382 944

Contact: Mr Duncan Jones, Managing Director

Phone: +61 3 9489 3666 Fax: +61 3 9489 3888
Email: qiagenaustralia@ozemail.com.au
Internet: www.qiagen.com
Address: 17 Austin Street Postal PO Box 25
Fairfield, VIC, 3078 Address: Clifton Hill, VIC, 3068
Australia Australia

Profile: QIAGEN believes it is the world’s leading provider of innovative enabling technologies and
products for separating and purifying nucleic acids (DNA and RNA). Since 1986, the company has
developed and marketed a broad range of proprietary products for the academic and industrial
research markets. More recently, increased understanding of nucleic acids’ structure and function
and the development of innovative technologies such as the polymerase chain reaction (PCR)
have rapidly expanded nucleic acid use in developing commercial markets. These markets include
genomics, DNA sequencing for gene-based drug screening, nucleic acid based molecular
diagnostics for genetic and infectious diseases, genetic vaccination, and gene therapy. With the
growing need for nucleic acid purification technologies in these markets, QIAGEN believes it is in
a strong position for continued growth and success in the future.
 QNA International Pty Ltd

Contact: Mr Graham Thurston, General Manager

Phone: +61 3 9479 3762 Fax: +61 3 9479 3764
Email: info@qna-international.com
Internet: www.qna-international.com
Address: Suite 13, TEC Building, Latrobe R&D Postal PO Box 2001
Park Address: East Ivanhoe, VIC, 3079
2 Park Drive Australia
Bundoora, VIC, 3083
Australia

Profile: QNA International Pty Ltd (QNA) was established in 1996 to create opportunities for enterprises to
commercialise and or export their technology and products. Using its expertise, experience and
international network, QNA has successfully assisted a number of clients in the introduction of
their product or technology into international markets, resulting in sales and collaborative
marketing as well as R&D assistance.

R P Scherer Holdings Pty Ltd ACN 61 007 219 990

Contact: Mrs Ronda Jacobs, General Manager

Phone: +61 3 9586 1222 Fax: +61 3 9586 1200
Email: ronda.jacobs@rpscherer.com
Internet: www.rpscherer.com
Address: 217 -221 Governor Road Postal PO Box 805
Braeside, VIC, 3195 Address: Mordialloc, VIC, 3195
Australia Australia

Profile: Originally an American based company, R P Scherer has been operating in Victoria for over 40
years and became R P Scherer Holdings Pty Ltd in 1989. As part of Cardinal Health, Inc.’s
Pharmaceutical Technology and Services group, R P Scherer offers broadbased experience,
unique and proprietary technologies and specialised services. While the company provides
innovative drug delivery solutions for a full range of therapeutic products, R P Scherer is
predominantly a TGA-licensed contract manufacturer of soft capsules, tablets, hard shell capsules,
liquids and creams for the complementary healthcare (health and nutritional) area. They also
produce many over-the-counter (OTC) and prescription products for a large number of companies,
with more than a dozen of the top 100 drug products sold using R P Scherer technologies. R P
Scherer also has a large export market with approximately 40% of all goods they manufacture
being exported.

In addition to contract manufacturing, R P Scherer provides a full complement of services

including: research, analytical and process development; stability testing; packaging; production of
clinical trial materials; assistance with regulatory affairs; and commercial manufacturing
capabilities. R P Scherer is also a licensed manufacturer of veterinary products and some food
items.
 RareCellect Ltd ACN 14 096 135 947

Contact: Mr Ian Smith, Secretary

Phone: +61 3 9417 5711 Fax: +61 3 9417 2987
Email: info@gtg.com.au
Internet: www.gtg.com.au
Address: 60 - 66 Hanover Street Postal PO Box 115
Fitzroy, VIC, 3065 Address: Fitzroy, VIC, 3065
Australia Australia

Profile: A member of the ASX-listed Genetic Technologies Limited group (GTG), RareCellect Ltd is one of
two recently formed GTG companies branching out into major new biotechnology areas.
RareCellect revolutionises testing for disease in unborn babies. RareCellect is pursuing the
development of a new procedure called RareCellect™, based on the company’s proprietary foetal
cell recovery technology. The technology is based on the discovery that a very small number of
foetal cells exist in a mother's blood stream and these foetal cells can survive in the mother's
circulation for many years. The RareCellect process uses genetic markers to differentiate between
the mother’s blood cells and those originating from the foetus. A high-speed cell sorter separates
the foetal cells, which can then be tested for abnormalities. The RareCellect process will be a
major step forward in foetal testing as it is non-invasive and so it is safer, cheaper, easier and may
be done earlier in the pregnancy.

Ratek Instruments Pty. Ltd.

Contact: Mr Ray Cutting, Managing Director

Phone: +61 3 9887 2161 Fax: +61 3 9887 2163
Email: mail@ratek.com.au, ray@ratek.com.au
Internet: www.ratek.com.au
Address: 60 Wadhurst Drive Postal PO Box 4431
Boronia, VIC, 3155 Address: Knox City, VIC, 3152
Australia Australia

Profile: Since 1979, Ratek Instruments has grown to become one of Australia's leading manufacturers of
laboratory equipment for use in the industrial, scientific and medical research fields. Operating
from a modern self-contained factory in Boronia, Melbourne, all equipment is designed and
produced in house. Components and materials used are almost entirely from local suppliers.

Ratek Instruments manufactures thermoregulators, coolers, dry block heaters, mixers and
shakers, incubators and waterbaths.

The company also has the capacity to tailor equipment to customer specifications.
 Regional Laboratory Services

Contact: Dr David Paynter, Principal Scientist

Phone: +61 3 5762 7502 Fax: +61 3 5762 7287
Email: rls@benalla.net.au
Address: Samaria Road Postal PO Box 805
Benalla, VIC, 3672 Address: Benalla, VIC, 3672
Australia Australia

Profile: Regional Laboratory Services is a privately owned laboratory providing diagnostic services in
animal health, environmental and agricultural testing. Clients include private individuals, industry,
and Government bodies. The laboratory has NATA (National Association of Testing Authorities)
accreditation for veterinary biochemistry, haematology and toxicology.

Rhodia Australia Pty Ltd ACN 72 003 502 485

Contact: Mr Leonard Lane, Manager – Dairy Applications

Phone: +61 3 9541 1000 Fax: +61 3 9548 8458
Email: leonard.lane@ap.rhodia.com
Internet: www.food.us.rhodia.com
Address: 352 Ferntree Gully Road Postal PO Box 1544
Notting Hill, VIC, 3168 Address: Clayton South, VIC, 3169
Australia Australia

Profile: Rhodia Australia, based at Notting Hill Victoria, is the Australian arm of a major multinational
speciality chemical company. Some might recognise the name Rhone Poulenc, which is where
Rhodia has its origins. Formed approximately three years ago after the merger of Rhone Poulenc
and Hoechst (now called Aventis), Rhodia became the new entity for the speciality chemicals
division. So although new in name, Rhodia has had a long association with local industry.

The Food Ingredients Division services all areas of the industry, supplying hydrocolloids and
stabiliser systems, cheese and yoghurt cultures, probiotics, bioprotectants, speciality meat
phosphates and baking phosphates, and flavourings such as vanillin and ethyl vanillin.

The local team is supported by global resources and technical centres based in Europe, America
and Asia enabling the company to respond to the varied needs and requests from Australian
customers.
 Rio Tinto Limited ACN 96 004 458 404

Contact: Dr Bruce Kelley, General Manager, Technology Development

ASX: RIO
Phone: +61 3 9242 3111 Fax: +61 3 9242 3222
Email: bruce.kelley@riotinto.com
Internet: www.riotinto.com
Address: Technical Services
1 Research Avenue
Bundoora, VIC, 3083
Australia

Profile: Rio Tinto Technical Services (TS) is a unique resource of mining industry professionals providing
assistance to Rio Tinto's head office and its operations. Over 150 technical specialists are located
in Melbourne and other cities in Australia, the UK and USA. A key area of work is monitoring and
improving the environmental performance of the Group. The TS Development wing does this by
linking an external research program with projects at RT sites, to transfer innovative technologies
to the company's operations.

One example of this is in the development and implementation of environmental biotechnologies

for mining and industrial land contamination, and treatment of waste streams. Rio Tinto's scientists
and engineers have more than 12 years' experience in this area, with successful field scale
projects in Australia, New Zealand, Europe and the USA. Site projects have ranged from initial
assessments, process evaluation (treatability) studies, technical and economic evaluations of
remedial options, and preparation of detailed engineering designs, to supervision of construction,
on site commissioning and operations, and finally validation of successful clean-ups. Processes
used successfully include landfarming, composting, biopiles, in situ bioremediation (bioventing and
biosparging) and natural attenuation. Contaminants treated include petroleum hydrocarbons
(fuels, oils and solvents), polyaromatic hydrocarbons, chlorinated solvents, cyanide, sulphate, and
metals and metalloids (manganese, copper, zinc, uranium and selenium).

Rio Tinto head office: Tel: +61 3 9283 3333; Fax: +61 3 9283 3707; 33rd Floor, 55 Collins Street,
Melbourne VIC 3000, Australia
 RMIT Drug Discovery Technologies ACN 49 781 030 034

Contact: Ms Edna Yeo, RDDT Manager

Phone: +61 3 9925 7194 Fax: +61 3 9925 7664
Email: rddt@rmit.edu.au
Internet: www.rddt.com.au
Address: Bundoora West Campus Postal PO Box 71
Building 223 Level 2 Address: Bundoora West Campus
Bundoora, VICTORIA, 3083 Australia
Australia

Profile: As one of the few drug discovery centres in Australia, RMIT Drug Discovery Technologies was
established in year 2003 to develop and provide preclinical toxicology and pharmacology services
to the biotechnology and pharmaceutical industries in Australia. Compounds generated by the
biotechnology and pharmaceutical industries require early testing and screening to minimize long-
term development costs. Inadequate toxicity data often leads to: costly development of
unfavourable compounds, drug withdrawals during clinical trials or after licensing, therapeutic
failure and toxicity in clinical use, or mortality. This would directly benefit the consumers in the long
run with much more affordable drugs and less therapeutic side effects.RMIT Drug Discovery
Technologies is also a research centre with an objective of developing intellectual property in drug
discovery and development technologies. Currently RMIT Drug Discovery Technologiesis in
collaboration with Victorian Partnership for Advanced Computing, Department of Computer
Science (RMIT) and Department of Chemistry (La Trobe University) developing high technology in
silico toxicology evaluations (Computational Prediction of Drug Toxicity). RMIT Drug Discovery
Technologies plays an important role in University education by developing undergraduate and
postgraduate programs with specific drug development technologies and quality management
standards as well as the opportunities for work placements.RMIT Drug Discovery Technologies
Team is managed by Ms Edna Yeo for more information please email RMIT Drug Discovery
Technologies@rmit.edu.au
 Rutherglen Research Institute - Department of Natural
Resources and Environment

Contact: Dr Garrick MacDonald, Institute Director

Phone: +61 2 6030 4500 Fax: +61 2 6030 4600
Email: garry.mcdonald@nre.vic.gov.au
Internet: www.nre.vic.gov.au
Address: Chiltern Valley Road Postal RMB 1145
Rutherglen, VIC, 3685 Address: Chiltern Valley Road
Australia Rutherglen, Victoria, 3685
Australia

Profile: DNRE-Rutherglen is a major Research Institute that is situated in a delightful rural landscape,
surrounded by an 870-hectare research farm with sheep, cattle, grain crops, wine grapes and a
400-head beef cattle feedlot. It is located 25 minutes west of the Albury-Wodonga growth centre in
the renowned Rutherglen wine-producing region.

The Institute has been well regarded for its innovative work in cropping and lamb production and
natural resource protection, and is now embracing a new lead role in DNRE for the development
of dryland agricultural ecosystems that enhance the environment.

The Institute has 66 staff, including 11 PhD holders, organised into 3 research sections:
Environmental Services, Plants in Agroecosystems and Food and Wine Production Systems.
Within these sections research is arranged into scientific programs including water and the
environment, soil resource management, alternative perennial plants (native and exotic), balanced
nutrient cycling, drivers of change in land use, and sustainable food and wine production.

The Institute's major customers and stakeholders include the State Government, Catchment
Management Authorities, Murray-Darling Basin Commission, Land and Water Australia, the Grains
Research and Development Corporation, Meat and Livestock Australia, Grape and Wine Research
and Development Corporation, CRC for Plant-Based Solutions to Dryland Salinity, CRC for
Viticulture, ACIAR and numerous corporate agribusinesses.
S 2 F Pty Ltd ACN 68 685 634 275

Contact: Ms Kirsty Hibbins, Business Development Manager

Phone: +61 3 8862 8918 Fax: +61 3 8862 8998
Email: kirhib@s2f.com.au; andkin@s2f.com.au
Internet: www.s2f.com.au
Address: 2 Domville Avenue
Hawthorn, VIC, 3122
Australia

Profile: S 2 F Pty Ltd (S2F) is a specialist consulting organisation dedicated to the delivery of project
services to the laboratory, pharmaceutical and high technology industries. S2F offers its clients an
integrated multi-disciplined team of project managers, architects, servicers and process engineers
with the experience and knowledge to provide a comprehensive facility design and delivery
service. S2F has the capacity to manage all aspects of specialist laboratory projects from the
feasibility study through master planning, cost planning, design and documentation through to
construction management, commissioning and validation.

S2F has experience in all facets of specialist laboratory facilities, including all levels of PC (BSL)
labs, as well as specialist facilities such as spectrometry and magnetic resonance imaging (MRI)
suites, specific pathogen-free (SPF) animal houses, and phenomics facilities, to the requirements
of regulatory authorities such as the Therapeutic Goods Administration (TGA), the Food and Drug
Administration, Eudralex, and the Gene Technology Regulator (OGTR).

With offices in Sydney, Melbourne, Brisbane, Philadelphia and Shanghai, S2F has the capability to
serve its clients throughout Australia, Asia and the US.
 S G E International Pty. Ltd.

Contact: Mr Reno Cerra, Business Development Manager

Phone: +61 3 9837 4200 Fax: +61 3 9874 5672
Email: rcerra@sge.com
Internet: www.sge.com.au
Address: 7 Argent Place Postal PO Box 437
Ringwood, VIC, 3134 Address: Ringwood, VIC, 3134
Australia Australia

Profile: S G E International Pty. Ltd. (SGE) began in 1966 as Scientific Glass Engineering, in a tiny garage
at the backyard of a house in Melbourne, Australia. Today, SGE has two modern facilities engaged
in developing and manufacturing chromatography and analytical products. SGE has grown
substantially, with 250 employees by April 2002, and a distribution and support network in nine
countries, including worldwide distribution partners.

SGE started solely as a syringe manufacturer, but now manufactures a vast array of products for
chromatography and mass spectroscopy. These products include GC capillary columns, GC/MS
accessories, HPLC columns, HPLC accessories, and GC retrofit instrumentation. SGE provides
the biotechnology industry with micro syringe arrays and micro fluidic handling equipment. SGE is
an ISO-accredited company. The major instrument manufacturers in these fields all rely on and
incorporate SGE-manufactured components in their systems.

The company is heavily committed to research and development, with 11 R&D employees
involved in more than 20 in-house research projects.

SGE strongly pursues environmentally sustainable activities. Many years ago SGE purchased a
substantial grazing landholding in the Otway Ranges in the South Eastern part of Australia, and
converted it to a Eucalyptus Blue Gum plantation that is now nearing maturity. SGE has produced
many times more trees specifically for paper production than the whole organisation has
consumed.

Sartorius Australia Pty. Ltd. ACN 29 007 161 462

Contact: Mr Michael Godfrey, Business Development Manager

Phone: +61 3 9590 8800 Fax: +61 3 9590 8828
Email: sartaus@sartorius.com.au
Internet: www.sartorius.com
Address: Unit 17 Postal PO Box 8004
104 Ferntree Gully Road Address: East Oakleigh, VIC, 3166
Oakleigh, VIC, 3166 Australia
Australia

Profile: Sartorius Australia is a leading supplier of equipment and consumables to the biotechnology and
pharmaceutical industries.

The Sartorius Group comprises Sartorius Separation Technology (membrane filtration, sterile
filtration, crossflow filtration, ion-exchange membranes and full validation services), BBraun
Biotech (bioreactors, fermentors and laboratory equipment) and Vivascience (proteomics,
ultrafiltration and cell culture equipment and consumables).

Sartorius Australia is the only internationally recognised bioreactor and fermentor supplier that
operates directly in Australia.

The parent company is based in Goettingen in Germany and has a long history as a driver and
innovator in filtration and separation technology. Sartorius Australia was formed in 1991 to meet
the needs of the Australasian market. The company has rapidly expanded and is now recognised
as a competent and able supplier of knowledge and expertise. The company specialises in
process development and has invested in the development of its staff as a valuable resource to
give Sartorius Australia and customers a unique competitive advantage.
 Saurin Technologies Pty. Ltd. ACN 88 091 106 946

Contact: Mr Rakesh Aggarwal, Managing Director

Phone: +61 3 9646 6771 Fax: +61 3 9646 8779
Email: sales@saurin.com.au
Internet: www.saurin.com.au
Address: 6 Westside Avenue
Port Melbourne, VIC, 3207
Australia

Profile: Specialising in plant and equipment for the food and pharmaceuticals industries, the Saurin Group
of companies has three independent divisions. Saurin Technologies Pty. Ltd. provides solutions for
the food processing industry. The Research & Development Division develops pilot plant, and is
involved in major R&D projects. Longwarry Food Park Pty. Ltd. (operating from the former Bonlac
Foods Longwarry site) provides contract spray drying and offers manufacturing facilities to food
manufacturers to enable a quick route to market.

Current R&D projects include the development of a novel twin fluid nozzle for spray drying, to
improve the high pressure equipment currently required. Saurin has already brought the first true
in-line mixer to market.

With CSIRO, Saurin is developing pulse combination technology for spray drying. Saurin has
exclusive worldwide rights to this technology. Saurin is also developing micro-encapsulation
equipment for probiotics in collaboration with the School of Food Sciences, University of Western
Sydney. Other R&D projects are being undertaken with Monash University.

Saurin’s technologies comprise mixing, dehydration, process improvement, and pilot plant design
and manufacture. Saurin can design and manufacture a wide range of process equipment, or
upgrade existing plant. Saurin can simulate a client’s manufacturing processes, design or supply
equipment, or upgrade processes on a turnkey basis. The Mini equipment range is ideal for
laboratory product testing. The Maxi range is for small production-scale operations.

Saurin exports to USA, UK and Bangladesh. Exports include high-grade equipment used for blood
purification and pharmaceutical production. Saurin earned commendation as Emerging Exporter in
the 2002 Governor of Victoria Export Awards.
 Schumacher Pharmaceuticals Pty. Ltd. ACN 30 004 547 602

Contact: Dr Monty Rudov, Joint Managing Director

Phone: +61 3 9654 8791 Fax: +61 3 9650 1205
Email: cwaves@bigpond.com
Address: 252 Collins Street
Melbourne, VIC, 3000
Australia

Profile: Schumacher Pharmaceuticals Pty. Ltd. has developed a number of herbal-based products based
on the healing properties of Secale cereale, more commonly known as rye. While the nutritional
properties of the rye grain have been known for centuries, the healing effects of the extract made
from the juvenile rye grass are only more recently beginning to be investigated. It is the extract
from rye grass, harvested when its nutritional properties are at their peak, that is the active agent
in the product originally developed by the founders of the firm, the Schumacher brothers. The
products based on the rye grass extract demonstrate profound healing properties in the human
body, effected primarily through their effects upon the immune system. These effects appear to be
mediated by particular phytoestrogens and lignans present in the rye extract, which regulate the
human immune system, hence the application of the term 'immunomodulator'.

Laboratory experiments have defined a number of molecules in the rye extract, all of which have
demonstrated immunological effects. For example, several isoflavones (a subgroup of
phytoestrogens) are present, one of whose effects is to arrest cell growth. The actions of such
molecules might provide a clue to the mechanisms underlying the remarkable results of cancer
trials, in which the cell growth in culture of five different cancer lines was significantly inhibited.
Significantly, this inhibition was not mediated by cytotoxic activity, and some intervention in DNA,
RNA or protein synthesis is suggested.

Science Traveller International ACN 006937864

Contact: Mr John Douglass, MD

Phone: +613 5441 4898
Email: info@scitrav.com
Internet: http://www.scitrav.com/wwater
Address: 125 Mollison Street Postal Box107
P.O.Box 107 Address: Australia
Bendigo, VIC, 3550
Australia

Profile: Science Traveller International (STI) is an international software company with offices in USA and
Australia. Since 1988,

our company has been developing high technology and scientific products across a wide range of
disciplines for

multi-national clients. Our scientific software is used in over 60% of laboratories around the
world.We also produce a range of software products for laboratory instrumentation, environmental
monitoring and wastewater

applications.
 Scientec Research Pty. Ltd. ACN 32 058 744 371

Contact: Dr Michael O’Donoghue, Chief Executive Officer and Principal Scientist

Fax: +61 3 9844 2076
Email: scientec@labyrinth.net.au
Address: 71 Yarra Street
Warrandyte, VIC, 3113
Australia

Profile: Scientec Research Pty Ltd is a 100% privately owned Australian scientific research and
development company formed in February 1993. Scientec’s principal area of activity has been the
development of its own technologies for controlled release drug delivery. In addition, Scientec
Research provides contract research and development services to a number of Australian
academic and industrial groups. The principal areas of service provision have been in
development of (i) controlled release drug delivery systems; (ii) drug formulations; and (iii)
manufacture processes and associated equipment.

Scientex Pty Ltd ACN 18 006 697 310

Contact: Mr Joseph Simonetti, Director

Phone: +61 3 9877 0500 Fax: +61 3 9894 3699
Email: info@scientex.com.au
Internet: www.scientex.com.au
Address: 4/109 Whitehorse Road Postal PO Box 1378
Blackburn, VIC, 3130 Address: Doncaster East, VIC, 3109
Australia Australia

Profile: Scientex Pty Ltd is exclusive distributor for a range of analytical instruments and products from
specialist manufacturers with respected brands:

Polymer Laboratories (PL) specializes in resins for chromatography and for synthesis. PL offers a
range of high quality products for solid phase synthesis and solution phase synthesis, for low
volume and scale up production. Instruments include evaporative light scattering detector and high
temperature GPC systems.

Precision Detectors offers dynamic light scattering (also known as photon correlation
spectroscopy) for determination of Rh. Molecular weight (Mw) may be determined using Raleigh
light scattering or differential viscometry (DV) as relatively inexpensive alternatives to mass
spectrometry. Viscotek holds the international patent for the four capillary bridge viscometer.

The need to separate particles has been enhanced with the Postnova field flow fractionation (FFF)
techniques. Traditional methods have included size exclusion chromatography (SEC) and
ultracentrifugation. FFF offers an elegant fast alternative to both these techniques. Picometrics
manufactures a range of laser induced fluorescence detectors (LIF) for ultra low detection of
naturally fluorescence species or those with fluorescence tags and suit HPLC, micro HPLC and
CE.

Analytical techniques include: Setaram and Rubotherm- thermal analysis, Bohlin- rheometers,
Anter- thermo-physical testing, Testometric-universal test machines. Specialist applications are
represented by the TLC/FID Iatroscan from Iatron, NIR chemical imaging from Spectral
Dimensions, particle size from PL, electronic aroma sensing from Smartnose and chiral detection
from PDR-Chiral.
 ScimaR ACN 93 449 422 808

Contact: Mr Bud Thompson

Phone: +61 3 9842 3386 Fax: +61 3 9842 3407
Email: scimar@bigpond.net.au
Address: 4 Ruskin Close
Templestowe, VIC, 3106
Australia

Profile: ScimaR is a niche distributor focused on the life sciences market. Products distributed are in the
areas of cell & molecular biology, nucleic acid research, monoclonal antibody
production/purification, yeast genetics, clinical chemistry raw materials and research biochemicals.

Scitech Pty Ltd

Contact: Mr Con Sapounas, Managing Director/Director of Sales

Phone: +61 3 9480 4999 Fax: +61 3 9416 9959
Email: cons@scitech.com.au
Internet: www.scitech.com.au
Address: 155 Plenty Road Postal PO Box 1625
Preston, VIC, 3072 Address: Preston, VIC, 3072
Australia Australia

Profile: Established in 1989, Scitech has grown to become one of Australia's leading suppliers of image
capture analysis and data acquisition products. Scitech offers innovative and leading edge
technology, service, and expertise.

Specialities include machine vision, digital imaging, microscopy, data acquisition, and high-speed
cameras.

Products used in the Life Sciences sector include a wide range of digital and video cameras,
frame grabbers, imaging software, gel documentation, microscope accessories, lighting, motorized
stages, and data acquisition and phase imaging products.

Products include the Media Cybernetics range of image analysis and 3D visualisation software,
gel documentation and analysis software, and the Array Pro Analyser for microarray data analysis.
Scitech offers the largest range of specialist digital cameras in Australia: from 1.4 to 12 million
pixels; and from low light to high speed (1000 frames per sec).

Customers include CSIRO, universities, major hospitals, the Defence Science and Technology
Organisation (DSTO), leading manufacturers, and microscope suppliers.

Scitech is a member of the Scientific Suppliers Association and the Australian Society for
Biochemistry and Molecular Biology (ASBMB).
 SDA Biotech Pty Ltd ACN 22 061 715 384

Contact: Ms Paris Brooke, Managing Director

Phone: +61 3 9629 9917 Fax: +61 3 9629 9099
Email: info@sdabiotech.com.au
Internet: www.sdabiotech.com.au
Address: Level 8
460 Collins Street
Melbourne, VIC, 3000
Australia

Profile: SDA Biotech Pty Ltd is a team of strategists, communicators and educators assisting
biotechnology awareness and commercialisation. SDA Biotech provides strategic communication
advice to maximise potential, build value and enhance visibility and credibility. The company
assists national and international clients in effective management of their communication across
all sectors, to strengthen commercial positioning in the market. Its role is as the communication
core for corporate, financial, business, government, media and scientific communities. SDA
Biotech provides counsel to shareholders, opinion leaders, analysts, investors, industry
collaborators, journalists, healthcare providers and consumers.

SeerPharma Pty Ltd ACN 28 096 346 173

Contact: Mrs Sue Cox, Office Manager

Phone: +61 3 9897 1990 Fax: +61 3 9897 1984
Email: sue.cox@seerpharma.com
Internet: www.seerpharma.com.au
Address: Suite 3, Level 1
818 Whitehorse Road
Box Hill, VIC, 3128
Australia

Profile: SeerPharma Pty Ltd is the product of a merger of Pharma Systems International and Seer
Solutions, two Australian consultancies specialising in Quality Assurance, good manufacturing
practice (GMP) compliance and information technology in the pharmaceutical, medical devices
and biologicals industries.

Pharma Systems was started in 1989 to provide professional products and services in GMP
Compliance, Quality Assurance and Training. Seer Solutions was formed in 1994 to provide
innovative computer systems to satisfy the pharmaceutical regulatory requirements and to bridge
the communication gap between information technology and pharmaceutical specialists.

The two companies worked together for some time prior to their merger in 2001. The merged
company is better able to remain current with international trends. It aims to grow both nationally
and internationally. SeerPharma’s head office is in Melbourne, and the company has other offices
in Sydney, the UK, and Singapore.
 Servier Laboratories (Aust.) Pty. Ltd. ACN 54 004 838 500

Contact: Mr Barry Young, Managing Director

Phone: +61 3 8823 7333 Fax: +61 3 9822 7517
Email: barry.young@au.netgrs.com
Internet: www.servier.com
Address: 8 Cato Street
Hawthorn, VIC, 3122
Australia

Profile: Servier Laboratories (Aust.) Pty. Ltd. (Servier Australia) is the local affiliate of a privately owned
Paris-based parent company. Servier is a research-based manufacturer of human pharmaceutical
products – the main areas of focus being cardiovascular and metabolic diseases. Servier Australia
distributes this range of products.

Australia is designated an International Centre for Therapeutic Research within the group.
Preclinical, Phase II and Phase III research and development work is undertaken in Australia on
behalf of the parent company.
Shimadzu Australia Manufacturing Pty Ltd

Contact: Mr Brian Godden, Manufacturing Manager

Phone: +61 3 9767 4488 Fax: +61 3 9793 7733
Email: briang@sam.shimadzu.co.jp
Internet: www.shimadzu.com.au
Address: 7 Monterey Road
Dandenong, VIC, 3175
Australia

Profile: Melbourne-based Shimadzu Australia Manufacturing Pty Ltd (SAM) is part of the Shimadzu Group,
one of the world’s largest manufacturers of analytical instrumentation. SAM’s facility at Dandenong
is one of the Group’s major manufacturing plants. Shimadzu combines its worldwide pool of
dedicated expertise to design, manufacture and market its solutions-based product range, which
includes:
HPLC - high performance liquid chromatography systems, including the fully integrated LC-2010 -
high throughput HPLC system

- LC-MS - mass spectrometry detection for liquid chromatography

- GC - gas chromatograph range, including fast GC
- GC-MS - gas chromatograph/mass spectrometers
- UV-visible, fluorescence, FTIR and atomic absorption spectrophotometers,
- Total organic carbon and thermal analyzers, and the Shimadzu Biotech range of instrumentation
specifically designed for the life science/biotechnology industries.

Shimadzu emphasises innovative thinking, painstaking design and development, meticulous

manufacture and stringent testing, to ensure that its products meet the toughest international
standards of excellence.

SAM and sister companies Shimadzu Medical Systems and Shimadzu Scientific Instruments now
employ over 200 people in Australia and New Zealand. The Group’s parent company, Shimadzu
Corporation, is based in Tokyo, Japan. Shimadzu Corporation has ISO-9001 certification and SAM
has ISO-9002.

SAM has manufactured approximately 50 different types of high-tech instruments, including

analytical instruments, medical equipment, environmental measuring instruments, and testing
machines. Annual turnover is in excess of A$50 million and production continues to expand.
Staffing levels have been steadily increasing and over 150 people are now employed. Most of the
instruments produced are exported to Japan, USA, Europe and Asia. The same instruments are
provided to the Australasian market through sister companies in Australia and New Zealand.
 Sigma Pharmaceuticals Pty Ltd ACN 88 004 118 594

Contact: Ms Louise Leone, Executive Assistant to CEO

Phone: +61 3 9839 2800 Fax: +61 3 9839 2801
Email: louise.leone@signet.com.au
Internet: www.sigmaco.com.au
Address: 96 Merrindale Drive Postal Locked Bag 268
Croydon, VIC, 3136 Address: Croydon, VIC, 3136
Australia Australia

Profile: The Sigma Group of companies (ASX SIG) is engaged in the manufacture and wholesale
distribution of pharmaceutical and allied healthcare products in Australia. It is the largest Australian
contract manufacturer for Australian and international pharmaceutical companies and the leading
Australian antibiotic manufacturer, with other core business being the manufacture and marketing
of company branded products and brand acquisition and development.

Since it began manufacturing in 1942 in Victoria, the group's manufacturing subsidiary, Sigma
Pharmaceuticals Pty Ltd, has become one of the largest Australian-owned pharmaceutical
manufacturers, and has developed a wide range of quality Australian over-the-counter and
prescription products through in-house development, acquisition and licensing agreements. Sigma
is also a significant contract manufacturer, producing pharmaceutical products for a number of
domestic and international pharmaceutical companies. It has the ability to manufacture liquids,
creams, ointments, tablets, capsules, lozenges, injectibles and other sterile products. It has now
established itself as an international contract manufacturer, having been awarded a major 7-year
supply contract in Japan, and others with several pharmaceutical multinationals, increasing
contract turnover to A$150 million.

Other recent initiatives have included the purchase of Aventis’ Baulkham Hills (NSW) plant,
together with a minimum 7-year manufacturing contract; the purchase of the branded products
range from Glaxo Wellcome Hong Kong; increased market share in both the prescription and OTC
markets in Australia; and a more recent acquisition of a number of branded pharmaceuticals from
Wyeth Australasia.

Silbase Scientific Services Pty. Ltd. ACN 22 080 724 027

Contact: Mr Ian Smith, Director

Phone: +61 3 9417 2400 Fax: +61 3 9416 3808
Email: silbase@genetype.com.au
Address: 60-66 Hanover St Postal PO Box 115
Fitzroy, VIC, 3065 Address: Fitzroy, VIC, 3065
Australia Australia

Profile: Silbase Scientific Services Pty. Ltd. is part of the ASX-listed Melbourne-based group Genetic
Technologies Limited (GTG). The company carries out DNA paternity testing and minor forensic
work. Largely sourcing referrals from New South Wales for analysis at the Victorian headquarters
of GTG, Silbase Scientific Services has been has been operating as a specialist parentage testing
laboratory since 1986. Silbase is accredited by the National Association of Testing Authorities
(NATA) and is thereby authorised to perform parentage testing under the Family Law Act. Only
reports from an accredited lab can be used in family law proceedings. These reports are also
accepted by the Registry of Births, Deaths and Marriages, and the Department of Immigration.
Silbase offers parentage testing, DNA analysis, and testing for forensic investigation, immigration
matters, family reunions, estate-kinship disputes, and twins and sibship analysis. [See separate
entry for Genetic Technologies Limited].
 Silliker Microtech Pty. Ltd. ACN 94 006 462 335

Contact: Mr Stephen Jay, Director

Phone: +61 3 9877 8222 Fax: +61 3 9877 8444
Email: sales@sillikermicrotech.com
Internet: www.sillikermicrotech.com
Address: 20 King Street
Blackburn, VIC, 3130
Australia

Profile: Silliker Microtech offers consulting and laboratory analysis in industrial microbiology and chemistry
and related areas. Major areas of expertise include the food, pharmaceutical, medical device,
antimicrobial, preservation, cosmetic, toiletry, and water industries. Specific consulting experience
encompasses Hazard Analysis and Critical Control Point (HACCP), factory hygiene, food safety
plans and management, food shelf life studies, good manufacturing practice (GMP), good
laboratory practice (GLP), sterilisation validation, product stability studies and laboratory method
validation.

Established in 1985 and known as Microtech Laboratories until October 2001, the company in
June 2000 joined the Silliker Group, based in Illinois, USA. Silliker comprises a worldwide network
of 29 laboratories and technical consultancy teams providing industrial microbiology and chemistry
analytical services, technical consulting and auditing, product stability assessment, applied
research, and staff training for the food industry. Food Safety Solutions is now also part of Silliker
Microtech, and its expanded food safety consulting team operates from both Melbourne and
Sydney. The food industry is one of the company’s largest markets.

Silliker Microtech employs approximately 110 personnel nationally and services a wide range of
industries. It will maintain its broad ranging accreditation with Australian regulatory authorities
NATA, TGA and NRA. Silliker Microtech has offices and laboratories in Melbourne and at a new
site in Regents Park, Sydney, and all Australian states and international areas are serviced.

Simons GeneType Diagnostics Pty. Ltd. ACN 13 007 279 736

Contact: Mr Ian Smith, Director

Phone: +61 3 9417 5711 Fax: +61 3 9416 4076
Email: ians@genetype.com.au
Address: 60-66 Hanover Street Postal PO Box 115
Fitzroy, VIC, 3065 Address: Fitzroy, VIC, 3065
Australia Australia

Profile: Simons GeneType Diagnostics Pty Ltd is part of the ASX-listed Melbourne based group Genetic
Technologies Limited (GTG) [see separate entry]. Simons GeneType specialises in DNA
parentage, individuality, and forensic laboratory analysis. The Company was formed in 1989 and is
accredited by the National Association of Testing Authorities (NATA) to perform parentage testing
under the Family Law Act. Only reports from an accredited laboratory can be used in family law
proceedings. These reports can also be accepted by the Registry of Births, Deaths and Marriages.
Some of the laboratory's more publicly known activities include the acquittal of Lindy Chamberlain,
the identification of the person responsible for the bombing of the Turkish consulate in South
Yarra, Victoria, and the identification of crew members lost from the yacht "Great Expectations".
 Solagran Limited ACN 085 675 323

Contact: Dr Vagif Soultanov, Chairman

ASX: SLA.AX
Phone: +61 3 9820 2699 Fax: +61 3 9820 3155
Email: info@solagran.com
Internet: www.solagran.com and www.lazure.com.au
Address: Level 11
492 St Kilda Road
Melbourne, VIC, 3004
Australia

Profile: Solagran Limited, based in Melbourne, owns all the intellectual property pertaining to technology
for manufacture and applications of products collectively known as Bioeffectives®. Bioeffectives®
are natural biologically active substances obtained via specialized technology which allows their
isolation as balanced, synergistic complexes with predefined therapeutic properties. Bioeffectives
are the results of over 72 years of fundamental research and clinical trials undertaken in Russia
and NIS countries, and have a wide range of applications in the prevention and treatment of
illness. For example, Bioeffective® R, a member of the polyprenols group, has shown extremely
promising results in Level I and II hepatitis, HIV and multiple sclerosis clinical trials. Other
Bioeffectives are marketed for their antimicrobial, tissue-regenerative, wound and burn healing,
anti-inflammatory and immunomodulating properties. Solagran is currently seeking regulatory
approval for several Bioeffectives® from the Therapeutic Goods Administration. Solagran’s
extraction technology can be tuned to virtually any plant or tree source, including local Australian
species.

St. Vincent’s Institute of Medical Research

Contact: Prof Thomas Kay, Director

Phone: +61 3 9288 2480 Fax: +61 3 9416 2676
Email: svimr@medstv.unimelb.edu.au
Internet: www.svimr.unimelb.edu.au
Address: 9 Princes Street Postal 41 Victoria Parade
Fitzroy, VIC, 3065 Address: Fitzroy, Victoria, 3065
Australia Australia

Profile: St. Vincent’s Institute of Medical Research was established in 1957, initially through a bequest
from the late John Holt. It is an independent health and medical research institute affiliated with
the University of Melbourne and St. Vincent’s Hospital. The current Director is Professor T.J.
Martin AO FRS. The Institute, which has a Faculty of 14 laboratory heads and a total staff of 100,
including 10 post graduate research students, regularly hosts visiting international students and
scientists. Staffing and research support is funded by peer-reviewed grants from national and
international bodies, Trusts, charities and donations, and industry collaborations, with
infrastructure support from the State government.
 Starpharma Pooled Development Limited ACN 20 078 532 180

Contact: Dr John Raff, Chief Executive Officer

ASX: SPL
Phone: +61 3 8532 2704 Fax: +61 3 9510 5955
Email: john.raff@starpharma.com
Internet: www.starpharma.com
Address: Level 1, Old Baker Building Postal PO Box 6535
Prahran, VIC, 3081 Address: St Kilda Road Central, VIC, 8008
Australia Australia

Profile: Starpharma is an Australian-owned Research and Development group consisting of 4 subsidiary

companies operating under a parent funding entity set up as a Pooled Development Fund (PDF).
It was established to commercialise novel polyvalent compound technology discovered at the
Biomolecular Research Institute in Melbourne, Australia, to which Starpharma has acquired
exclusive world-wide rights. The technology is protected by broad patents and comprises a class
of high molecular weight, branch-like chemicals (dendrimers) and other polyvalent compounds
with demonstrated activity against a broad range of viruses and other human diseases for which
current therapies are inadequate. To fund new research opportunities and to exploit the wide
range of activity shown by the polyvalent compounds, Starpharma Pooled Development Fund
raised additional capital through a public float on the Australian Stock Exchange (ASX) in
September 2000.

Starpharma has been concentrating its resources to date on developing two priority programs to
the point of showing efficacy in humans (phase II clinical trials), prior to licensing to a major
pharmaceutical company. In March 2001, it was reported that one of these projects, the sexually
transmitted disease (STD) prevention project, has advanced to full preclinical development. The
company also announced that it has been issued with a key patent for its biotechnology and has
obtained further funding from the US based National Institutes of Health (NIH). The second of the
priority projects, an anticancer application (Angiogenesis Inhibitor Program) is currently in the
preclinical development phase.

The platform technology has further demonstrated a broad range of activity in a number of other
disease applications. Starpharma’s polyvalent compounds have shown potential as drugs active
against toxins, HIV and AIDS related viruses, hepatitis B virus infection and related liver cancer,
malaria, respiratory viruses, and exotic viral diseases.
 Stem Cell Sciences Limited ACN 93 063 293 130

Contact: Dr Peter Mountford, Chief Executive Officer

Phone: +61 3 9804 5505 Fax: +61 3 9804 5520
Email: peter.mountford@stemcellsciences.com.au
Internet: www.stemcellsciences.com.au
Address: Level 1
28 Riddell Parade
Elsternwick, VIC, 3185
Australia

Profile: Stem Cell Sciences Ltd (SCS) was established in 1994 to realize the potential of Embryonic Stem
(ES) cells in human medicine. ES cells retain the ability to form all cell types found in the body
even following extensive growth in culture.

Stem Cell Sciences, in an exclusive alliance a recognised world-leading institute in ES cell

research, the Centre for Genome Research (CGR, Edinburgh University), has developed
proprietary ES cell-based technologies to provide an unlimited supply of highly purified cells
including neurons, heart and blood cells for immediate application in the company's cell-based
gene and drug screening business and future application in human cell-based gene and tissue
therapies. Stem Cell Sciences' patented technologies enable the growth and selection of stem
cells and their application in new drug discovery. In the future, the Company aims to develop cell-
based therapies for currently incurable diseases such as Parkinson's disease and diabetes.

Stem Cell Sciences' discovery platform has attracted equity investments and research and
licensing agreements with international biopharmaceutical companies including GlaxoSmithKline,
Hoechst Marion Rousell, BioTransplant Inc., Genentech Inc., and Aventis. In March 2001, Stem
Cell Sciences announced the creation of a wholly-owned UK subsidiary, Stem Cell Sciences (UK)
Ltd, and will continue to expand its Australian operations. Stem Cell Sciences is seeking to
accelerate the growth of its business through venture capital investment.
 Sun 2000 Pty. Ltd. ACN 41 080 045 316

Contact: Miss Debbie Monet, National Sales and Marketing Manager

Phone: +61 3 9550 1598 Fax: +61 3 9545 1033
Email: monet@sun2000.com.au
Internet: www.sun2000.com.au
Address: 490 Wellington Road
Mulgrave, VIC, 3170
Australia

Profile: Sun 2000 Pty. Ltd. established its "Sun 2000" natural product purfication and cosmetic business in
1998. Based on holistic health care principals, Sun 2000 has pioneered a range of herbal skin
care and body care products designed to protect and nourish the skin. Sun 2000 has also added a
unique product range with the first UV (Encapsulations) products.

Sun 2000 recognised the need for a highly active herbal skin care range as a natural alternative to
other products. The product range incorporates the latest innovative technology, encapsulation in
a beeswax emollient. Encapsulation is a unique process where the chemicals are locked-in to a
natural substance to prevent the absorption of impurities and active ingredients into the skin.
Active ingredients like octyl methoxycinnamate and zinc oxide are "locked in", blocking the
chemicals from the skin interaction, which can adversely affect the condition and function of the
skin. The encapsulation process enables the ingredients to be transported in a natural emollient
derived from beeswax, thus providing a protective film over the skin that allows certain herbal
ingredients to absorb fully into the underlying tissue.

Monne International Pty. Ltd. is the parent company of Sun 2000 Pty. Ltd. Both are based in
Melbourne, Australia and Sun 2000's product range is 100% Australian developed and
manufactured. Sun 2000 distributes nationally throughout department stores, and selected
pharmacies, health food stores, beauty salons, hairdressers and sporting outlets, and exports into
five countries: Germany, Hong Kong, Iceland, South Africa and the United Kingdom.

Swinburne Centre for Biomedical Instrumentation

Contact: Dr Andrew Wood, Director

Phone: +61 3 9214 8867 Fax: +61 3 9819 0856
Email: andrewwood@swin.edu.au
Address: Swinburne University Postal PO Box 218
School of Biophysical Science and Address: Mail 31
Electrical Engineering Hawthorn, Victoria, 3122
Hawthorn, VIC, 3122 Australia
Australia

Profile: It provides a focus for research and consulting activities related to medical & physiological
instrumentation. The centre draws on the strengths in biophysics, psychophysiology and
instrumentation within the School. It acts as an umbrella organisation to coordinate
instrumentation aspects of other centres within Swinburne.
 Syngene Ltd. ACN 78 006 161 753

Contact: Mr Graeme Kaufman, Managing Director

Phone: +61 3 9826 0399 Fax: +61 3 9824 0083
Email: graeme.kaufman@circadian.com.au
Internet: www.circadian.com.au/syngene.htm
Address: Level 1 Postal PO Box 23
10 Wallace Avenue Address: Toorak, VIC, 3142
Toorak, VIC, 3142 Australia
Australia

Profile: Syngene Ltd. holds DNA-based diagnostic patents which underpin a technique to locate gene
expression precisely within tissues, already being used in research, with potential for diagnostic
applications. Syngene’s patent in the USA expires in 2014. In the research applications of its
diagnostic patent, Syngene has granted a non-exclusive worldwide licence to Roche Diagnostics
in respect of its diagnostic technology, and additional projects and potential collaborations are
being evaluated. Several diagnostic companies are seeking to develop genetically-based
diagnostics for application to human disease prognosis as a result of the increasing knowledge of
the connections between genes and disease. Syngene has also established a research project to
develop new delivery technologies for oligonucleotides.

Syngene’s major sharehoders are Circadian Technologies Limited (42%) [see separate entry],
Howard Florey Institute of Experimental Physiology (20%), and Casthree Pty Ltd (an entity
controlled by Consolidated Press Holdings Limited) which subscribed for a 20% interest in
February 2000.

Syngenta Seeds

Contact: Mr Peter Gerner, Managing Director

Phone: (03) 9706 3033
Email: steve.lonie@syngenta.com
Address: 36 Newson Street Postal Locked Bag 1335
Keysborough, VIC, 3173 Address: Dandenong South, Victoria, 3164
Australia Australia

Profile:
 The Gribbles Group Limited ACN 66 091 000 225

Contact: Mr Wallace Cameron, Group Managing Director

ASX: GGL
Phone: +61 3 9538 6777 Fax: +61 3 9538 6765
Email: liaison@gribbles.com.au
Internet: www.gribbles.com.au
Address: 1868 Dandenong Road Postal Private Bag 4444
Clayton, VIC, 3168 Address: Clayton, VIC, 3169
Australia Australia

Profile: The Gribbles Group is a medical, scientific and technical testing company. It is a leading provider
of high-quality diagnostic and analytical information services, in Australia and overseas.

Beginning in 1936, with the first private medical laboratory in South Australia, Gribbles has grown
to encompass human and veterinary pathology, analytical and environmental testing, radiology,
medical and day surgery centres. The group employs over 1500 staff in Australia and over 400
internationally.

In Australia, Gribbles operates over 35 laboratories and 175 pathology collection centres providing
testing services to over 2.5 million patients and organisations; while the international businesses
have grown rapidly since 1996 and now operate in Malaysia, Indonesia, Brunei, New Zealand.
Gribbles has recently commenced a joint venture in India. The Malaysian organisation has grown
to be the largest private pathology provider in Malaysia, while in India plans are for 27 laboratories
and 270 collection centres over the next 3 years.

Recent acquisitions in Australia include GM laboratories and AMDEL, which will significantly
strengthen Gribbles' position in provision of environmental and analytical testing.

The Gribbles Group is committed to growth through excellence and innovation. It is an

organisation with an increasingly international focus, while remaining strongly Australian in its core
philosophies and business approach.
 Thermo Trace Ltd ACN 47 002 634 442

Contact: Mr Tony Bigum, CEO

Phone: +61 3 9790 4100 Fax: +61 3 9790 4155
Email: trace@thermotrace.com.au
Internet: www.thermotrace.com.au
Address: 189-199 Browns Road Postal PO Box 700
Noble Park, VIC, 3174 Address: Noble Park, VIC, 3174
Australia Australia

Profile: Thermo Trace Ltd (formerly Trace Scientific) was established in 1983 and consolidated operations
in Melbourne in early 1999. Thermo Trace manufactures and markets globally diagnostic reagents
for automated instrument platforms; innovative speciality diagnostic tests; and cell and tissue
culture products. Thermo Trace also sells a range of associated analytical instruments.

Thermo Trace's patented stabilisation technology (Dynamic Stabilisation Technology) has helped
the firm capture business with global diagnostic players and has facilitated the uptake of Trace
diagnostic reagents throughout the world.

Thermo Trace manufactures premium grade cell, tissue and organ media, media components,
media supplements and ancillary products. Trace Foetal Bovine Serum and related blood products
for cell and tissue culture are made from Australian or New Zealand sourced raw material. Each
product is traceable through the collection facility to the farm and herd of origin.

The products are manufactured in ISO 9001 accredited facilities to the relevant regulatory
guidelines (USFDA, USDA, NRA or TGA). Many of these guidelines have been, or are being,
harmonized with Emark guidelines and therefore comply with European requirements.

Thermo Trace Ltd is a business unit of Thermo Electron Corporation, based in Massachusetts
USA.

Thorgard Pharmaceuticals (Aust.) Pty Ltd ACN 23 098 254 516

Contact: Mr Joseph Vella, Chief Executive Officer and Managing Director

Phone: +61 3 9670 7966 Fax: +61 3 9670 7933
Email: josephv@thorgard.com.au
Internet: www.Thorgard.com.au
Address: Level 2, 250 Queens Street
Melbourne, VIC, 3000
Australia

Profile: Thorgard Pharmaceuticals (Aust.) Pty Ltd is an Australian owned pharmaceutical company with
overseas alliances that has been performing extensive research and development work in the
area of generic conjugated estrogens that are derived from pregnant mares' urine (PMU). These
generic conjugated estrogens are used in the women’s health industry (hormone replacement
therapy) and in the areas of osteoporosis and ischaemic heart diseases.

Thorgard's R & D involves the internationally patented inventions that relate to the collection
systems used on the pregnant mares to collect uncontaminated urine. Thorgard has also
developed estrogen extraction essays that are used for commercial purposes. Additionally,
Thorgard has set up commercial natural estrogen collection farms (NECS) in Australia to collect
the pregnant mares' urine which is then sold (in gel or powder form) to other major pharmaceutical
companies around the world.
 Tridan Limited ACN 006 785 217

Contact: Dr Richard Thwaites, Business Manager, CRC for Biopropducts

Phone: +61 3 9396 8749 Fax: +61 3 9396 8729
Email: rthwaites@albright.com.au
Address: 295 Whitehall Street Postal PO Box 20
Yarraville, VIC, 3013 Address: Yarraville, VIC, 3013
Australia Australia

Profile: In 1994, Albright & Wilson (Australia) Ltd, a large chemical manufacturer, formed a partnership
with Tridan Limited, a small R&D investment company, to establish a state-of-the-art biotechnology
fermentation scale-up facility at Yarraville, and together with the University of Melbourne and Food
Science Australia, became major participants in what has now become the CRC for Bioproducts.
The three participants have an equal share in the intellectual property.

The CRC for Bioproducts has a focus on developing commercially valuable materials produced by
plants and other living organisms - such as natural colours, nutraceuticals including the active
components in herbal remedies, pharmaceutical intermediates, and biopolymers. It aims to
establish new industries based on these novel bioproducts and bioprocesses, and also use the
skills developed by the Centre to improve the efficiency and profitability of existing industries
involved in the production and use of bioproducts.

The research program has three facets: cell culture and fermentation of novel plant cell lines;
extraction of novel and useful compounds from agricultural waste, seaweed and other biomass
sources; and applied physico-chemical studies of macromolecules in solutions and gels, relevant
to products in a range of industries. The resources of the Centre include a pilot scale fermentation
facility (up to 10,000 litres) used primarily for production of materials from plant cells, laboratories
equipped for functional testing of biopolymers and food ingredients, and state-of-the-art facilities
for carbohydrate chemistry and plant molecular biology.

TSL Group Limited

Contact: Mr Ross Dobinson, Managing Director

Phone: +61 3 3 9691 5900 Fax: +61 3 9691 5901
Email: info@tslgroup.com.au
Address: Level 34
360 Collins Street
Melbourne, Vic, 3000
Australia

Profile: TSL Group Limited (TSL) is the leading provider of expert commercial advisory services to
Australia's life sciences sector. Our primary focus is on optimising the commercial value of
intellectual property generated from Australia's strong scientific research base. At the same time
we aim to build significant value for investors.

We have a well-informed understanding of the research, development and innovation

environment. A key strength is our extensive national and international networks within the
scientific and commercial arenas developed over 20 years.

TSL has a proven track record in identifying promising technologies and structuring these
effectively to achieve successful commercial outcomes. We have the expertise to assist
companies and research organisations with all stages of their development, from seed to maturity.
We also advise investors in the life sciences sector on strategies to reduce risk and maximise
returns.
 UCB Pharma (a division of UCB Australia Pty Ltd) ACN 48 005 799 208

Contact: Mr Grant Fraser

Phone: +61 3 9303 0600 Fax: +61 3 9303 0689
Email: Grant.Fraser@UCB-Group.com
Internet: www.ucb-group.com
Address: 19 Potter Street Postal PO Box 341
Craigieburn, VIC, 3064 Address: Craigieburn, VIC, 3064
Australia Australia

Profile: The UCB Group, headquartered in Belgium, is a multinational pharmaceutical and chemical group.
Formed under the name of Union Chimique Belge in 1928, the Group has its origins in the 18th
century.

The business areas of the Group are currently centered around three industrial fields : the Pharma
Sector, the Chemical Sector and the Film Sector. Globally, each sector has a decentralised
organisation, with profit centres by type of market or activity. UCB is a Group which currently
comprises the parent company, UCB SA, together with about one hundred and forty subsidiaries
and associated companies, mainly in Western Europe but also in the Americas and Asia, in
countries with rapid growth. UCB also covers the world through its agents, distributors and
licensees and its products are sold in virtually every country. The Group employs more than 8,000
people, of whom around half are in the Pharma Sector. UCB Pharma is a research and
development pharmaceutical company.

The Melbourne office of UCB Pharma is responsible for business development and the marketing
activities supporting key products in the therapeutic areas of the Central Nervous System, and
Allergy. The major products of UCB Pharma are Zyrtec® (cetirizine), Nootropil® (piracetam) and
Keppra® (levetiracetam).

Uniseed Pty Limited ACN 63 094 466 752

Contact: Mr Gareth Dando, Chief Executive Officer

Phone: +61 3 9362 5804 Fax: +61 3 9347 5888
Email: enquiries@uniseed.com
Internet: www.uniseed.com
Address: 215 Grattan Street
Parkville, VIC, 3052
Australia

Profile: Uniseed Pty Limited is a pre-seed and seed stage venture capital fund designed to bridge the gap
between the research in Australian universities and the commercial venture capital and investment
community. Uniseed has twin headquarters, in Melbourne, Victoria and Brisbane, Queensland. It
was established in 2000 as a joint venture between the commercial arms of the University of
Queensland and the University of Melbourne, with initial funding of A$20 million. It primarily invests
in opportunities connected with these universities and their affiliated institutions. Over half of
Uniseed’s investments to date have been in the biotechnology, bioscience and biomedical area. As
of November 2002, investments included six Victorian companies profiled in this Directory –
Hatchtech Pty Limited, Chirogen Pty Ltd, Cryptopharma Pty Ltd, Pargenex Pharmaceuticals Pty
Ltd, Calibre Biotechnology Pty Limited and Hepitope Pty Ltd – as well as 10 interstate companies.
 Valley Seeds Proprietary Limited ACN 68 004 950 396

Contact: Mr Donald Coles, Managing Director

Phone: +61 3 5797 6203 Fax: +61 3 5797 6307
Email: dcoles@valleyseeds.com
Internet: www.valleyseeds.com
Address: 295 Maroondah Link Highway
Alexandra, VIC, 3714
Australia

Profile: Alexandra-based company Valley Seeds Proprietary Limited specializes in breeding grasses that
have drought tolerance, winter growth and other desirable traits, for forage, pasture, turf and lawn
use. The company supplies the Australian market, in part through its strategic alliance with Yates
Limited, and exports widely, including to major South American markets through Uruguay-based
partner Fadisol SA. (Valley Seeds has formed a spin-off, Access Genetics - see separate entry).

Since 1993, Valley Seeds has been working with researchers from the University of Melbourne in
an innovative genetics project to eliminate the misery caused by grass pollen. Asthma and
allergies are frequently triggered by plant pollen, particularly grass pollen. The Melbourne team,
led by Dr. Prem Lata Bhalla and Professor Mohan Bir Singh, isolated the genes in grass pollen
that cause asthma and hay fever, and worked out how to switch off the allergy-causing genes in
ryegrass and other grasses. Valley Seeds will be incorporating the allergy-free characteristic into
new varieties of grasses whose pollen does not cause asthma and hay fever. The company
expects that the major benefit from the introduction of these genetically modified varieties will be to
the end-consumer and the general public.
Varian Australia Pty Ltd ACN 67 004 559 540

Contact: Mr Philip Binns, Marketing Manager

Phone: +61 3 9566 1101 Fax: +61 3 9566 1196
Email: philip.binns@varianinc.com
Internet: www.varianinc.com
Address: 679 Springvale Road
Mulgrave, VIC, 3170
Australia

Profile: Varian Australia Pty Ltd is the Australian research, manufacturing and marketing arm of US-based
Varian, Inc., a major supplier of scientific instruments, vacuum technologies, and contract
manufacturing. Varian Australia's 4-hectare manufacturing plant at Mulgrave employs around 400
people, and exports over A$100 million in scientific instruments to over 60 countries worldwide.
The main instruments manufactured in Victoria are targeted towards applications in biotechnology,
health, pharmaceutical, environmental and material science industries. Specifically, these
instruments include UV-Vis spectrophotometers for molecular studies, and atomic absorption,
inductively coupled plasma and mass spectrometry for the study of elemental species in most
substances.

Varian, Inc. (Nasdaq: VARI) is a world leader in providing key tools and technologies that enable
advances in the life sciences and health care, semiconductor processing, and telecommunications
industries. Varian serves life science, health care, chemical, environmental, and industrial
customers, totalling more than 20,000 customers annually, and global sales in 2000 were US$749
million, 12% accounted for by the Asia-Pacific region. The company manufactures in 13 locations
on three continents; operates sales and service offices in North America, Europe, and the Pacific
Rim; and employs some 4,100 people. It is organized into three segments: Scientific Instruments,
Vacuum Technologies, and Electronics Manufacturing.

Although Varian, Inc. was formed in 1999, it has a rich technological heritage dating back more
than 50 years, and was spun off from Varian Associates, Inc., a pioneering Silicon Valley company.
Among many other innovations, Varian was the first to commercialize the NMR spectrometer. The
VacIon pump, invented by Varian for producing ultra-high vacuum environments, paved the way
for many important endeavours, including semiconductor manufacturing and space science
research.
 Victoria Institute of Biotechnology

Contact: Prof Mark Hogarth, Chief Executive Officer

Phone: +61 3 9287 0666 Fax: +61 3 9287 0601
Email: pm.hogarth@ari.unimelb.edu.au
Internet: www.ari.unimelb.edu.au/vib
Address: Victoria University
Hoppers Lane
Werribee, VIC, 3030
Australia

Profile: The VIB will be established as a world-class R&D and business for discovery, structure based
rational design and development of novel therapeutics and drugs. A facility for work at each step of
the drug development pathway; the development of an integrated facility for structure-based
design of new therapies and drugs. This will help create the depth, critical mass and coordination
of Victorian capability so essential to value adding to Australian discoveries and their accelerated
entry into international clinical trails.

It will use leading edge technologies to develop therapeutics for the treatment of both human and
animal diseases.

It will enable researchers from academe and small and large companies to use information from
their own sources or from the various Genome Projects (Human, Animal and Parasite) to generate
new therapeutic candidates. VIB’s intention is to become a key research participant locally and an
essential asset holder by occupying a vital technical and expertise niche in Victoria’s overall
bioscience infrastructure.

It will be part of wider consortia nationally and internationally, dedicated to developing human skills
and in efficient use of resources in advancing these technologies and in developing new therapies.
The VIB will thus provide expertise to, and draw expertise from, wider State-based consortia of
R&D enterprises and so directly addresses both perceived gaps i.e. integrated therapy/drug
discovery and design and (ii) development of all pre-clinical expertise, thereby strongly leveraging
off Victoria’s unique and long-standing basic biomedical R&D excellence.
 Victoria University of Technology

Contact: Dr Paul Chambers, Senior Lecturer, School of Life Sciences

Phone: +61 3 9216 8271 Fax: +61 3 9216 8284
Email: paul.chambers@vu.edu.au
Internet: www.vu.edu.au
Address: School of Life Sciences Werribee Postal School of Life Sciences Werribee
Campus Victoria University of Address: Campus Victoria University of
Technology Technology PO Box 14428
Werribee, VIC, 3030 Melbourne, Victoria, 8001
Australia Australia

Profile: Biotechnology activities at Victoria University of Technology are conducted primarily by the School
of Life Sciences and Technology in the Faculty of engineering and Science. The School is involved
in biotechnology education, training and research programs offering BSc degrees in biotechnology,
and Nutrition and Food Science. We also offer Honours, Masters and Doctorate degrees by
research.

Biotechnology research activities are coordinated primarily through the School of Life Sciences.
Biotechnology research is conducted in gene discovery, microbial and enzyme technologies,
forensic molecular biology, bioremediation, cancer genetics, yeast biotechnology, food science and
technology and animal technologies relating to fertility and productivity.
Victorian Chemical Company Proprietary Limited ACN 36 004 188 863

Contact: Dr Bob Killick, Managing Director

Phone: +61 3 9429 8277 Fax: +61 3 9429 6404
Email: bobkillick@vicchem.com
Internet: www.vicchem.com
Address: 37 Appleton Street Postal PO Box 71
Richmond, VIC, 3121 Address: Richmond, VIC, 3121
Australia Australia

Profile: The Victorian Chemical Company is a manufacturer and marketer of specialty agricultural and
industrial oleo-chemicals. Established in 1933 near the centre of Melbourne, Australia, the
company has built a world-wide reputation for the design and production of customised products.
In the early years, Victorian Chemicals concentrated on serving the textile and tanning industries
that were booming in the inner city.

The company's first agricultural product ( Voullaire's™ EE-MULS-OYLE™ ) was developed during
the late 1930s in conjunction with local grape growers and the CSIRO to dry grapes to sultanas.
Voullaire's is now the leading product for drying grapes in Australia and is used in several other
countries under the Victoria™ brand.

In 1983, the company was purchased by the Killick family, and shortly after several other
agricultural products were developed including bloat control products for cattle and insecticidal
spray oils for horticulture. During the 1990s, development work focused on adjuvants for
broadacre applications. HASTEN is the key product to be commercialised from this work that is
now distributed in many countries. HASTEN is based on ethyl oleate and improves the
effectiveness of herbicides.

Other products include sulfonated esters and oils, fatty esters and emulsifying esters, speciality
wetting agents, fatty alkanolamides, textile lubricants, degreasers, chemical intermediates, and
speciality blends. Victorian Chemicals manufactures their range of oleo-chemicals according to the
international quality standard ISO 9002.

Victorian Chemicals remains committed to the development of new innovative products, and is
exploring the development of technology in areas such as plant growth hormonal regulation.
 Victorian Infectious Diseases Reference Laboratory ACN 73 802 706 972

Contact: Dr Michael Catton, Medical Director

Phone: +61 3 9342 2600 Fax: +61 3 9342 2660
Email: vidrl@mh.org.au
Internet: www.vidrl.org.au
Address: 10 Wreckyn Street Postal Locked Bag 815
North Melbourne, VIC, 3051 Address: Carlton South, VIC, 3053
Australia Australia

Profile: The Victorian Infectious Diseases Reference Laboratory (VIDRL) is Victoria’s largest public health
reference laboratory, with core expertise in virology and mycobacteriology. Key activities are:

(i) Providing laboratory capacity for infectious diseases outbreak investigations by the Department
of Human Services, Victoria.

(ii) Undertaking reference laboratory testing, disease surveillance, applied research and test
development, maintaining reference collections and providing expert advice in major program
areas. The major program areas are:

- Victorian HIV Reference Laboratory (State Reference Laboratory)

- Mycobacterium Reference Laboratory
- Vaccine Preventable and Related Diseases
- Viral Gastroenteritis
- Respiratory Pathogens
- Blood-Borne Viruses and Sexually Transmitted Infections

(iii) Providing diagnostic pathology services for the Melbourne Sexual Health Centre.

VIDRL holds three Australian national designations, namely the National Poliovirus Reference
Laboratory, the National Measles Reference Laboratory, and the National High Security
Quarantine Laboratory (NHSQL). VIDRL holds World Health Organisation (WHO) Collaborating
Centre designations in Virus Reference and Research and in Biosafety in Microbiology. VIDRL is a
WHO Regional Poliovirus Reference Laboratory and the WHO Regional Measles Reference
Laboratory for the Western Pacific Region. VIDRL is also a WHO National Influenza Centre.
VIDRL undertakes a diverse range of research projects. These include studies on the mechanism
of antiviral drug resistance, transmission of hepatitis B and C viruses, the role of enteric pathogens
in disease outbreaks and molecular aspects of Mycobacterium tuberculosis. Investigations of the
epidemiology of infectious agents of public health significance, and the development of potential
new laboratory technology are also important areas of study. Research is undertaken in all
program areas, but blood borne viruses are of particular interest.
 Victorian Institute for Dryland Agriculture

Contact: Dr Chris Korte, Acting Institute Director VIDA

Phone: +61 3 5362 2111 Fax: +61 3 5362 2187
Email: chris.korte@nre.vic.gov.au
Internet: www.nre.vic.gov.au/vida
Address: Natimuk Road Postal Private Bag 260
Horsham, VIC, 3400 Address: Natimuk Road
Australia Horsham, Victoria, 3401
Australia

Profile: The core activity of VIDA is breeding of broad acre cereal (wheat, barley), pulse (field peas,
chickpeas and lentils) and oilseed (Brassica napus and Brassica juncea) crops. The ‘traditional’
breeding programs are now supported by biotechnologies to increase the rate of genetic gain in
yield, agronomic properties and end-use characteristics, and enhance the competitiveness of
Victoria’s crop improvement program.

The Institute has a molecular marker laboratory which leads Australia in the implementation of
markers in wheat, barley and pulse breeding; houses the Australian Temperate Field Crops
Collection (ATFCC), the Australian genetic resource centre for pulses and oilseeds; routinely uses
doubled haploids for cereal and oilseed improvement; has unique facilities (glasshouses, field
nurseries to enable growth of two generations of crops per year) to fast-track the release of new
varieties to meet the needs of industry; and has a grain quality research program which leads
Australia in the use of NIR technology to predict grain quality for all crops.

VIDA’s Mallee Research Station, located in the central Victorian Mallee, is a second campus of the
Institute. The Station is well equipped to evaluate crops for adaptation to low rainfall environments,
in conjunction with national and international research programs. Developing crops with genetic
attributes to perform in cropping systems of the marginal environments in Southern Australia is an
essential role of the Institute.
Victorian Institute of Animal Science

Contact: Dr Chris Langford, Director

Phone: +61 3 9217 4200 Fax: +61 3 9217 4299
Email: Chris.Langford@nre.vic.gov.au
Internet: www.nre.vic.gov.au/agvic/vias
Address: 475 Mickleham Rd
Attwood, VIC, 3049
Australia

Profile: The Victorian Institute of Animal Science (VIAS) is the leading animal research institute of the
Department of Natural Resources and Environment's Agriculture Victoria. VIAS is located across
three campuses: Attwood, Werribee and Frankston. The staff of the Victorian Institute of Animal
Science are committed to the delivery of quality animal science services and innovative products
and solutions to our customers, in support of industry competitiveness, product safety and the
environment The Victorian Institute of Animal Science has research activities that cover animal
production, animal health and biological science. With an international reputation it has always
been at the forefront of technological innovation. VIAS is building on its core capabilities in areas
such as molecular biology, DNA analysis, genomics, transgenics and many other strategic areas.
This enhanced capacity builds on existing strengths in diagnostic technologies, quantitative
genetics and animal physiology. VIAS plays a key role in the education of the science leaders of
the future through its post graduate research programs, there being about 40 students at any one
time. VIAS also boasts a modern conference facility comprising a 150 seat theatre and meeting
rooms only a few minutes drive from Melbourne's Tullamarine airport.
 Viralstar Ltd ACN 083 205 421

Contact: Dr John Raff, CEO

Phone: (03) 8532 2700 Fax: (03) 9510 5955
Address: Level 1 Old Baker Building
Prahan, VIC, 3181
Australia

Profile: Viralstar Limited has agreed to provide research funding for further development of the Technology
in the field of antiviral therapeutics. Viralstar may become involved in the commercialisation
process of this area of the Technology.

Virax Holdings Limited ACN 56 006 569 106

Contact: Mr David Beames, Chief Executive Officer

ASX: VHL
Phone: +61 3 9854 6230 Fax: +61 3 9853 5134
Email: virax@virax.com.au
Internet: www.virax.com.au/html/home.html
Address: Suite 220, Kew Junction Tower
89 High Street
Kew, VIC, 3101
Australia

Profile: Virax Holdings Limited is a publicly listed (ASX:VHL) early stage biopharmaceutical company
focusing on the development of immunotherapeutics for the treatment of autoimmune disorders,
HIV/AIDS, cancers and infectious diseases. Virax has established a specialised Good
Manufacturing Practice (GMP) manufacturing facility for vaccines and delivery vectors.

Virax is developing vaccines using their platform technology, Co-X-Gene™, which derives from
innovative work at the John Curtin School of Medical Research and CSIRO Livestock Industries in
Geelong. The initial target for these vaccines is to treat people already infected with HIV with
candidate vaccine VIR201, the Phase I/IIa trial having commenced. Virax has received an
AusIndustry R&D Start Grant in respect of this trial. A program to develop a prostate cancer
immunotherapeutic has commenced in collaboration with Royal Adelaide Hospital. Future
applications of Co-X-Gene™ include therapeutic or preventative vaccines against other cancer
targets, infectious and autoimmune diseases.

Virax is also a key member of an Australian consortium that will receive A$27m from the US
National Institutes of Health (NIH) to accelerate development of vaccines to prevent infection by
HIV/AIDS. Other Victoria-based members are the University of Melbourne and CSIRO Livestock
Industries, with the project being managed by the Institute of Drug Technology Australia Limited
[see separate entry]. The team will fast track the development and testing of a ‘prime and boost’
vaccine, designed to stimulate the body to make special white blood cells to find and destroy any
newly HIV-infected cells. The prime vaccine will be DNA based, while the boost vaccine will be
based on fowlpox virus utilising Virax technology.
 Viridans Pty. Ltd. ACN 054 535 929

Contact: Ms Wendy Opie, Executive Director

Phone: +61 3 9596 8592 Fax: +61 3 9596 8612
Email: viridans@bigpond.com
Internet: www.viridans.com.au
Address: Suite 4
614 Hawthorn Road
Brighton East, VIC, 3187
Australia

Profile: Viridans Pty Ltd is a privately owned company which specialises in biocomputing - software
platforms concerning ecological and biological databases. The databases are created for use by
local government, universities and ecological consultants, and provide information such as a guide
to various flora and fauna, where certain species can be found, and whether they are endangered
or not. Specific databases have been created for use in government departments such as the
Department of Natural Resources and Environment in Victoria, and the Department for
Environment and Heritage in South Australia.

Viridans professional Flora and Fauna Database software is used in Australia on some of the
country's largest biological databases, such as the Victorian Flora Information System, which
contains approximately 1.5 million plant records; the Victorian Fauna Display System which
contains more than 2.1 million records of zoological data; and the South Australian Flora and
Fauna Database (SAFFD), which contains over 550,000 records of botanical and zoological data.
In addition, Viridans software is used to maintain smaller databases such as the Victorian Butterfly
Information System (VBIS), the Mallee Parks Grazing Monitoring System (MPGMS), the Ballarat
Regional Flora Information System (BALFIS), and the Mallee Mandatory Monitoring database.

The Viridans public access CD-Rom products are subsets of larger, more complex professional
biological databases. These systems are designed specifically for the storage, retrieval, analysis
and display of taxonomic and geographic flora and fauna data.

Vision BioSystems Limited ACN 72 008 582 401

Contact: Dr Owen Wright, Sales Director

Phone: +61 3 9211 7400 Fax: +61 3 9265 8401
Email: owen.wright@vision-bio.com
Internet: www.vision-bio.com
Address: 495 Blackburn Road Postal Private Bag 18
Mount Waverley, VIC, 3149 Address: Mount Waverley, VIC, 3149
Australia Australia

Profile: Vision BioSystems, a wholly owned subsidiary of the publicly owned company Vision Systems
Limited [see separate entry], is a global supplier of a range of automated biomedical instruments
known for their quality and innovation excellence. Vision BioSystems has been manufacturing
innovative, quality proven laboratory instruments for in excess of 16 years.

Its products cover a range of segments including histopathology, haemotology, clinical diagnosis
and electron microscopy. For histopathology, the tissue preparation products manufactured by
Vision BioSystems are world leaders. For haemotology, automated blood smear preparation and
staining delivers key sample preparation steps. Toward a better understanding of the link between
genes and diseases, a number of instrument systems are in development.

Vision Systems acquired the monoclonal antibody company Novocastra Laboratories Ltd (UK) in
mid 2002 and sells these products through Vision BioSystems.
 Vision Systems Limited ACN 45 008 582 401

Contact: Dr Owen Wright, Sales Director

ASX: VSL
Phone: +61 3 9211 7000 Fax: +61 3 9211 7001
Email: duncan.jones@vision-bio.com
Internet: www.vsl.com.au
Address: 495 Blackburn Road
Mount Waverley, VIC, 3149
Australia

Profile: Vision Systems Ltd is a technology based manufacturing and services company which markets
high value products, contract engineering and technology based services worldwide. Vision
Systems Ltd is listed on the Australian Stock Exchange and employs over 600 people at Feb
2002. The company has grown tenfold over the last five years and continues to achieve annual
growth rates in excess of 25%.

The Vision Systems Group manufactures a range of high value products, including video-based
surveillance and security systems under the ADPRO® brand, fire protection systems based
around aspirated smoke detection (which achieves high sensitivity and very early fire detection)
sold under the VESDA® brand, and automated laboratory instruments for the histopathology,
haematology and clinical chemistry markets through their subsidiary company, Vision BioSystems
(formerly Vision Instruments) [see separate entry].

The objective of the company is to continue to grow international sales in key markets with
innovative products and services driven by ongoing investment in the company's technology base.
In 2002-03, Vision Systems will be releasing two second generation biomedical instruments - an
immunohistochemistry stainer, and an in-situ hybridisation stainer. Other projects are in
development.
Vita Life Sciences Limited ACN 35 003 190 421

Contact: Mr Mark Greenwood, Managing Director

ASX: VLS
Phone: +61 3 9867 2713 Fax: +61 3 9867 5437
Email: enquiries@vitalifesciences.com.au
Internet: www.vitalifesciences.com
Address: Level 5
432 St Kilda Road
Melbourne, VIC, 3004
Australia

Profile: Vita Life Sciences, listed on the Australian Stock Exchange (ASX), is a pharmaceutical and
healthcare company focusing on two market segments: 1. Vita Medical - research and
development, innovation, and distribution of proprietary medical and healthcare equipment in
nuclear medicine, specialising in the areas of lung diagnostics and cardiac stress testing; and 2.
Vita Health - development, manufacture and distribution of prescription and over-the-counter
medicines, as well as complementary and alternative medicines, dietary supplements and health
foods. The company has also recently formed ViMed Bio Sciences Pty Ltd to develop novel
imaging technologies. Vita Medical’s main product, Technegas, has a market share of 78% and
30% respectively in its key markets of Australasia and Europe. Technegas is used for diagnosis of
various lung diseases. Vita Medical commenced operations in 1976 to develop and manufacture
medical and health care equipment for nuclear medicine. Vita Medical’s manufacturing plant for
Technegas equipment is adjacent to Australia’s major nuclear research establishment near
Sydney. Expanded applications of the technetium-based biomedical technology include an
encapsulation technology to deliver an ultrafine radio-pharmaceutical for medical applications.
Potential applications extend to other isotopes for diagnostic/therapeutic products. Further projects
include PVDS for delivery of Technegas for patients with breathing difficulties; and ThromboTrace
for diagnosis of Deep Vein Thrombosis. Vita Health, with origins in Singapore in 1947, has more
than 545 registered products, many developed and formulated at its Sydney laboratory, and
exports to over 30 countries.
 Vital Life Sciences ACN 86 085 968 341

Contact: Dr Andrew Vizard, Chairman

Phone: +61 3 9605 5900 Fax: +61 3 9605 5999
Email: info@vitalcapital.com
Internet: www.vitalcapital.com/key_invesments/tocovite/index.htm
Address: C/- Mr S Friedmann, Vital Capital
Limited, Level 2
90 William St
Melbourne, VIC, 3000
Australia

Profile: Tocovite is developing products for the dietary and health care markets. Among these is a process
to produce water-soluble forms of fat-soluble nutrients - initially vitamin E, and potentially other
natural and synthetic compounds. The objective is increasing the compatibility of vitamin E and
other nutrients, such as coenzyme Q10 and vitamin K1, as additives to everyday food, drinks, and
water-based cosmetics. Water-soluble nutrients are more easily absorbed and used by the human
body. Tocovite plans to market and distribute water-soluble vitamin E as a natural cosmetic
emulsifier.

Tocovite is also developing a method of extracting tocotrienols from palm oil distillate. These
vitamin E precursors are themselves a valuable source of antioxidants, and can delay the onset of
certain chronic and degenerative diseases. Tocotrienols have not previously been commercially
extractable in sufficient quantities, and Tocovite's process should provide cost-effective supplies
for the first time. Other projects being researched include methods of extracting natural vitamin E
from palm oil. This promises to yield a 'natural' and premium product at a low cost.

Tocovite’s technology is also applicable to a large number of pharmaceutical drugs, and fourteen
patents have been lodged. The company has identified eight classes of drugs for its first round of
research into changing the properties of selected compounds, with the view to improving their
transdermal, intravenous and oral delivery, as well as their systemic transport and bioavailability.

Tocovite is in the process of splitting into two companies to better commercialise its technology.
Vital Capital will retain its equity in each company. Australian-based Vital Health Sciences will
develop applications for personal care, human nutrition and animal nutrition. US-based Vital
Biosciences will focus on the development and commercialisation of pharmaceutical applications.
 Vitapharm Research Pty. Ltd. ACN 48 082 174 918

Contact: Mr Peter Wilson, Business Development Manager International

Phone: +61 3 9764 1555 Fax: +61 3 9764 1554
Email: bizdev@vitapharm.com.au
Internet: www.vitalbiotech.com
Address: 20 Kingsley Close
Rowville, VIC, 3178
Australia

Profile: Vitapharm Research is a member of the Vital Biotech Group which has a proven profitable track
record in developing, manufacturing and distributing pharmaceutical products. Vitapharm is
responsible for the new down-stream, value-adding technology development and early stage
concepts of biological formulations that offer patient friendly delivery of effective, yet affordable,
products. Commercialisation occurs through Vital Biotech with its extensive marketing network,
regulatory approval expertise and manufacturing and distributing capability in China (PRC).

In a strategy to be close to this commercial activity, the organisation was the first Australian
biotechnology company to list successfully on the Hong Kong Stock Exchange.

The PSD platform technology developed by Vitapharm replaces freeze drying of biologicals to
yield room temperature stabilised products for non-injection delivery. It can be applied to proteins,
enzymes, vaccines, probiotics and potentially, many other biopharmaceutical products.

Vitapharm has established a unique business model in the pharmaceutical/ biotechnology industry
where Australian technology is combined with the Chinese market to efficiently create and
commercialise biopharmaceuticals with low risk, low cost and immediate returns. Pharmaceutical
and biotechnology companies can partner with Vitapharm Research to incorporate their new and
existing biologicals into the PSD platform technology and gain quick and easy access to the fast
and growing Chinese market. Using this approach, Vitapharm Research grows with its
international partners achieving technological and commercialisation advantages with:

- low production cost through freeze-drying replacement

- commercially viable and patient friendly delivery systems
- non-refrigerated stable biological products
- extended patent protection
- expanded product clinical indications
- differentiation from competitor/generic products
- access to the PRC market
 Walter and Eliza Hall Institute of Medical Research

Contact: Mr Brad Allan, Community Relations Manager

Phone: +61 3 9345 2345 Fax: +61 3 9345 2329
Email: allan@wehi.edu.au
Internet: www.wehi.edu.au
Address: 1G Royal Parade
Parkville, VIC, 3050
Australia

Profile: The Walter and Eliza Hall Institute is Melbourne's - and Australia's - oldest and most respected
medical research institute. It resides at the hub of one of the world's great biomedical research
precincts, the 'Parkville strip', just north of the city's centre. A great tradition of excellence, honed
over an eighty year history, has secured for the Hall Institute an outstanding international
reputation. Indeed, it is one of an elite group of medical research centres acknowledged around
the world as the powerhouses of 20th century medical research. Key discoveries emerging from
the Institute include colony-stimulating factors, SOCS proteins and novel genes regulating
apoptosis.

Founded in 1915, using funds from a trust established by Walter Hall, grazier and miner and his
wife Eliza, the Institute is now an innovative organisation of over 500 people, housed in an
ultramodern building, with close links to the neighbouring Royal Melbourne Hospital and University
of Melbourne. The Hall Institute attracts some of the best and brightest young biomedical
researchers from around Australia and overseas. Institute staff are at the cutting edge of their
research fields, many in constant demand as invited speakers at international research
conferences. Its graduates are held in high regard at home and abroad; many go on to post-
doctoral studies in leading overseas centres such as the Whitehead Institute; Harvard Medical
School; the University of California at Berkeley; the Medical Research Institute at Mill Hill; Imperial
Cancer Research Fund; and the European Molecular Biology Laboratory. Institute researchers
seek to understand the basic mechanisms of disease, motivated by the knowledge that exposing
the underlying genetic and molecular processes will lead to the new therapies, drugs and vaccines
needed for longer, healthier lives.

The principal focus of the Institute remains the blood cell system and its diseases, but there are
growing programs in development and neurobiology, genetic susceptibility to disease; and
bioinformatics. The Institute's pioneering exploration of the immune system continues apace,
alongside vigorous investigations of auto-immune disorders, particularly insulin-dependent
diabetes and arthritis. Exciting discoveries being made about two major parasitic diseases, malaria
and leishmaniasis, are aiding the search for protective vaccines and new drugs. The identification
of mutations that cause cancer remains a key objective, with a particular emphasis on those
responsible for chromosome translocation in leukemia and lymphoma, those that lead to breast
cancer and those that perturb cell survival and cell cycling.

Aided by the node of Australian Genome Research Facility recently established within the Hall
Institute, great progress is being made in looking for genes that make people susceptible to
diabetes, the eye disease glaucoma and the brittle-bone disorder osteoporosis. Cancer - and
malaria - susceptibility genes are also being sought. The research laboratories are organised as
eight divisions/groups: Cancer and Haematology; Molecular Genetics of Cancer; Immunology;
Autoimmunity and Transplantation; Infection and Immunity; Development and Neurobiology;
Genetics and Bioinformatics; and Structural Biology.
 Whatman Asia Pacific

Contact: Mr John Sestanovich, Area Sales Manager

Phone: 03 9787 7830 Fax: 03 9787 7092
Email: john.sestanovich@whatman.com
Internet: www.whatman.com
Address: PO Box 1245 Postal PO Box 1245
Mornington, Vic, 3931 Address: Mornington, Vic, 3931
Australia Australia

Profile: Whatman Asia pacific is a global company with operations in Europe , North America and Asia,
and sales in more than 140 countries world wide.

We specialise in separations technology to provide the latest in laboratory filtration and

processing, microplates for high throughput screening applications, media for the manufacture of
medical and diagnostic devices, as well as range of products employing our patented FTA
technology for the collection, transport, purification and archiving of DNA from a wide variety of
biological sources, all at room temperature.

Whatman continues to innovate to the meet the needs of life science.

Wilkore Pty. Ltd. ACN 13 668 230 908

Contact: Mr Michael Wilkinson, Managing Director

Phone: +61 3 9764 2033 Fax: +61 3 9763 9867
Email: michaelwilkinson@wilkore.com.au
Internet: www.caribbeanpark.com
Address: 1 Dalmore Drive
Caribbean Park
Scoresby, VIC, 3179
Australia

Profile: Wilkore is a design and construction company based in Melbourne, Australia, specialising in the
pharmaceutical and bioscience industries. Wilkore's expertise is in the provision of a broad range
of design, management and construction skills to facilitate the construction of new buildings and
the refurbishment of existing ones. Over the past 15 years, Wilkore has established a reputation
for building large, high-quality industrial, commercial and pharmaceutical projects. Wilkore's direct
fields of expertise include design and construction, project planning, quality assurance,
commissioning and validation, cost management, and contract management for pharmaceutical
and biotechnology projects. Among Wilkore’s recent projects was the design and construction of
major new manufacturing facilities and a new head office/warehouse complex for the Institute of
Drug Technology Australia Limited [see separate Directory entry]. Some of Wilkore’s other clients
include Sigma, Amrad, Becton Dickinson and Arrow Phamaceuticals. Wilkore is also an integral
partner in the business and technology precinct at the 490-acre Caribbean Park, situated at the
demographic centre of Melbourne. At the core of Caribbean Park is the proposed MiniFAB project
which brings together biotechnology, nanotechnology and microtechnology in an open-access
incubator and prototyping facility.
 Xeno Trans Limited ACN 74 097 283 166

Contact: Prof Ian McKenzie, Chief Executive Officer

Phone: +61 3 9287 0681 Fax: +61 3 9287 0601
Email: i.mckenzie@ari.unimelb.edu.au
Internet: www.ari.unimelb.edu.au
Address: 359 Brunswick Road
Brunswick, VIC, 3056
Australia

Profile: Xeno Trans Limited, formed in mid-2001 as a spin-off of the Austin Research Institute, is creating
transgenic pigs whose kidneys will not be rejected by a transplant recipient. The Austin research
group that developed the technology successfully implanted a kidney into a baboon in South Africa
during 2001, with rejection held off for 30 days. The company is, at mid-2002, seeking $2 million a
year for three years to develop a second batch of transgenic pigs suitable for transplant into
baboons. The use of animal organs (such as pig) for human organ transplantation is known as
xenotransplantation. The demand for such organs is caused by a chronic shortage of organ
donors. In the USA alone, around 40,000 patients per year fail to receive transplanted organs.
Xeno Trans has an especially interesting target - the particular sugar on the surfaces of pig organ
cells which stimulates the immune system of the human to generate a massive response leading
to organ rejection. The Austin Research Institute characterised and patented the crucial gene
responsible for the sugar to blame. This gene codes for a enzyme (a specific galactosyl
transferase) which catalyses the key step in assembling the sugar. Knocking out the gene so it
cannot function is one strategy being used to breed pigs which make organs suitable for
transplantation into a human. The organs, not displaying the offending sugar, are more likely to
survive rejection.
 XRT Limited ACN 25 076 348 000

Contact: Mr Grant Dow, Managing Director

Phone: +61 3 8545 2000 Fax: +61 3 8545 2050
Email: info@xrt.com.au
Internet: www.xrt.com.au
Address: 86 Peters Avenue
Melbourne, VIC, 3170
Australia

Profile: XRT Limited (XRT) is a leader in the field of x-ray phase contrast imaging. The images have visual
and data content superior to those produced using existing technology, and the technology
delivers contrast and resolution not previously available from commercial x-ray instruments.
Formed in 1996 to capture the commercial potential of patented discoveries made by researchers
at the CSIRO, XRT acquired the technology and is now commercialising on the basis of its strong
intellectual property position. Prior to the CSIRO's scientific work, the basic principles underlying
conventional x-ray technology had not changed significantly since their inception 105 years ago.
The standard x-ray radiograph in use today only records the fraction of x-rays which pass through
an object. Phase contrast imaging differs in that it not only measures the absorption but also the
interference caused by refraction of the x-ray wave after passing through an object. The
applications of the technology are very diverse. Structures not discernable with the older
technology may be seen in exceptional detail. It also offers new approaches for the development
of computer chip products, quality control in manufacturing, inspection of aircraft components, and
in the study of biology, pathology, minerals and other complex structures. A key investor is BioTech
Capital Limited, which for a A$4-million investment, holds 20% of the company at the start of June
2001.
 Yakult Australia Pty. Ltd. ACN 97 055 486 443

Contact: Mr Greg Jerram, Manager of Personnel and Public Relations

Phone: +61 3 9793 2045 Fax: +61 3 9793 2468
Email: info@yakult.com.au
Internet: www.yakult.com.au
Address: 10 Monterey Road
Dandenong, VIC, 3175
Australia

Profile: Yakult, the fermented milk drink, has been manufactured in Australia since 1994. However, it has a
long and interesting history overseas that spans over 60 years. Yakult has been available in Japan
since it was developed by Dr Minora Shirota, a medical practitioner in Japan in 1935. Dr Shirota
founded the Yakult Honsha Company in Japan in 1955. Since then, the number and type of
products manufactured by Yakult has increased. Yakult is now available in a total of 24 countries
world-wide. The emphasis for the distribution of the product remains based upon the company’s
philosophy of assisting all peoples of the world to better health through the promotion of sound
health practices, and effective use of probiotics. Yakult Australia Pty. Ltd. is a wholly-owned
subsidiary of an international company, Yakult Honsha, and was incorporated in 1992. The Yakult
factory, which is located in Dandenong, Victoria, was built in 1993. Production and marketing
commenced in January 1994 and Yakult was officially launched in Melbourne on 1 February 1994.
Yakult is produced in a technologically advanced manufacturing plant with an on-site
biotechnology laboratory and modern office complex. The multi-million dollar plant will be the only
plant in Australia, and has the capacity to supply all of the Australian market. Yakult has sales
branch offices in all major states of Australia.